{"PMC7194934": [], "69f672bab4f554ef50f8df67ddfedda8a8d8c052": [["INTRODUCTIONIn January 2020, Chinese health authorities reported several cases of a new acute respiratory illness arising in December 2019 in the city of Wuhan, Hubei province.", [["respiratory", "ANATOMY", 94, 105], ["respiratory illness", "DISEASE", 94, 113], ["a new acute respiratory illness", "PROBLEM", 82, 113], ["new", "OBSERVATION_MODIFIER", 84, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory", "ANATOMY", 94, 105], ["illness", "OBSERVATION", 106, 113]]], ["[1] [2] [3] [4] Symptoms of this novel illness are typical of respiratory infections of viral origin; fever, fatigue, myalgia and dry cough are commonly observed.", [["respiratory", "ANATOMY", 62, 73], ["illness", "DISEASE", 39, 46], ["respiratory infections", "DISEASE", 62, 84], ["fever", "DISEASE", 102, 107], ["fatigue", "DISEASE", 109, 116], ["myalgia", "DISEASE", 118, 125], ["dry cough", "DISEASE", 130, 139], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["Symptoms", "PROBLEM", 16, 24], ["this novel illness", "PROBLEM", 28, 46], ["respiratory infections of viral origin", "PROBLEM", 62, 100], ["fever", "PROBLEM", 102, 107], ["fatigue", "PROBLEM", 109, 116], ["myalgia", "PROBLEM", 118, 125], ["dry cough", "PROBLEM", 130, 139], ["respiratory", "ANATOMY", 62, 73], ["infections", "OBSERVATION", 74, 84], ["viral origin", "OBSERVATION", 88, 100], ["dry", "OBSERVATION_MODIFIER", 130, 133], ["cough", "OBSERVATION", 134, 139]]], ["[2] [3] [4] [5] Although most patients experience mild to moderate symptoms and recover within a few days, some 20% of identified patients exhibit more severe forms of the disease requiring prolonged hospitalization, and in some cases acute care and ventilation.", [["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 0, 15], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 130, 138], ["mild to moderate symptoms", "PROBLEM", 50, 75], ["the disease", "PROBLEM", 168, 179], ["prolonged hospitalization", "TREATMENT", 190, 215], ["acute care", "TREATMENT", 235, 245], ["ventilation", "TREATMENT", 250, 261], ["mild", "OBSERVATION_MODIFIER", 50, 54], ["moderate", "OBSERVATION_MODIFIER", 58, 66], ["symptoms", "OBSERVATION", 67, 75], ["more severe", "OBSERVATION_MODIFIER", 147, 158], ["disease", "OBSERVATION", 172, 179]]], ["6 The exact mortality rate is difficult to assess, as varying proportions of asymptomatic or presymptomatic cases have been reported, and broad serosurveys to understand the true burden of disease have been hampered by a variety of logistic and scientific issues.", [["The exact mortality rate", "TEST", 2, 26], ["asymptomatic or presymptomatic cases", "PROBLEM", 77, 113], ["disease", "PROBLEM", 189, 196], ["disease", "OBSERVATION", 189, 196]]], ["7 However, the detailed study of Wu and McGoogan, reporting on 72 314 suspected cases from the Chinese Center for Disease Control and Prevention, including 44 672 confirmed cases, provides an estimated case fatality rate of 2.3%.", [["Disease Control", "TREATMENT", 114, 129], ["fatality rate", "TEST", 207, 220]]], ["6 Simultaneously to the primary reports of cases of COVID-19, a virus was isolated from bronchoalveolar lavage fluids of affected patients.", [["bronchoalveolar lavage fluids", "ANATOMY", 88, 117], ["bronchoalveolar lavage fluids", "ORGANISM_SUBSTANCE", 88, 117], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["COVID", "TEST", 52, 57], ["a virus", "PROBLEM", 62, 69], ["bronchoalveolar lavage fluids", "TREATMENT", 88, 117], ["bronchoalveolar lavage", "OBSERVATION", 88, 110]]], ["Characterization of the virus and elucidation of the nucleotide sequence of its genome identified an enveloped, non-segmented positive single-stranded RNA virus, a novel member of the betacoronavirus family, subfamily Orthocoronaviridae.", [["nucleotide", "CHEMICAL", 53, 63], ["nucleotide", "CHEMICAL", 53, 63], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 184, 199], ["Orthocoronaviridae", "GENE_OR_GENE_PRODUCT", 218, 236], ["betacoronavirus family", "PROTEIN", 184, 206], ["Orthocoronaviridae", "PROTEIN", 218, 236], ["the virus", "PROBLEM", 20, 29], ["the nucleotide sequence", "TEST", 49, 72], ["non-segmented positive single-stranded RNA virus", "PROBLEM", 112, 160], ["subfamily Orthocoronaviridae", "TREATMENT", 208, 236], ["virus", "OBSERVATION", 24, 29], ["enveloped", "OBSERVATION_MODIFIER", 101, 110]]], ["This new virus, referred to by the acronym SARS-CoV-2, shares 79.6% genomic sequence identity with severe acute respiratory syndrome coronavirus (SARS-CoV).", [["acute respiratory syndrome coronavirus", "DISEASE", 106, 144], ["SARS-CoV)", "DISEASE", 146, 155], ["SARS-CoV-2", "ORGANISM", 43, 53], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 99, 144], ["SARS-CoV", "ORGANISM", 146, 154], ["SARS-CoV", "SPECIES", 43, 51], ["severe acute respiratory syndrome coronavirus", "SPECIES", 99, 144], ["SARS-CoV", "SPECIES", 146, 154], ["This new virus", "PROBLEM", 0, 14], ["CoV", "TEST", 48, 51], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 99, 144], ["virus", "OBSERVATION", 9, 14], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["acute", "OBSERVATION_MODIFIER", 106, 111], ["respiratory syndrome coronavirus", "OBSERVATION", 112, 144]]], ["2, 8 The latter is a coronavirus that was responsible for an outbreak of a severe acute respiratory syndrome which affected several countries in 2003.", [["coronavirus", "DISEASE", 21, 32], ["acute respiratory syndrome", "DISEASE", 82, 108], ["coronavirus", "ORGANISM", 21, 32], ["a coronavirus", "PROBLEM", 19, 32], ["a severe acute respiratory syndrome", "PROBLEM", 73, 108], ["coronavirus", "OBSERVATION", 21, 32], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["acute", "OBSERVATION_MODIFIER", 82, 87], ["respiratory syndrome", "OBSERVATION", 88, 108]]], ["That outbreak was successfully managed through strict confinement of infected individuals and quarantine of their contacts.INTRODUCTIONDuring that outbreak, there was no evidence of transfusion transmission.", [["transfusion transmission", "PROBLEM", 182, 206], ["no evidence of", "UNCERTAINTY", 167, 181], ["transfusion transmission", "OBSERVATION", 182, 206]]], ["9 Conversely, SARS-CoV-2 rapidly spread on a broad scale as a result of air travel and the relative ease by which the virus is transmitted by respiratory droplets from coughing and sneezing.", [["respiratory droplets", "ANATOMY", 142, 162], ["SARS", "DISEASE", 14, 18], ["coughing", "DISEASE", 168, 176], ["sneezing", "DISEASE", 181, 189], ["SARS-CoV-2", "ORGANISM", 14, 24], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["a broad scale", "TREATMENT", 43, 56], ["air travel", "PROBLEM", 72, 82], ["the virus", "PROBLEM", 114, 123], ["respiratory droplets", "PROBLEM", 142, 162], ["coughing", "PROBLEM", 168, 176], ["sneezing", "PROBLEM", 181, 189], ["air travel", "OBSERVATION", 72, 82], ["virus", "OBSERVATION", 118, 123], ["respiratory droplets", "OBSERVATION", 142, 162], ["coughing", "OBSERVATION", 168, 176], ["sneezing", "OBSERVATION", 181, 189]]], ["On March 11, 2020, the World HealthAccepted ArticleOrganization (WHO) officially declared that COVID-19, the disease acronym caused by SARS-CoV-2 infection, had reached the pandemic level.", [["COVID-19", "CHEMICAL", 95, 103], ["SARS-CoV-2 infection", "DISEASE", 135, 155], ["SARS-CoV-2", "ORGANISM", 135, 145], ["CoV-2", "SPECIES", 140, 145], ["SARS-CoV-2", "SPECIES", 135, 145], ["COVID", "TEST", 95, 100], ["the disease acronym", "PROBLEM", 105, 124], ["SARS", "PROBLEM", 135, 139], ["CoV-2 infection", "PROBLEM", 140, 155], ["disease", "OBSERVATION", 109, 116], ["infection", "OBSERVATION", 146, 155]]], ["10 As of June 30, 2020, more than 10.4 million cases of SARS-CoV-2 infection, and more than 509 000 deaths from COVID-19, have been reported worldwide.", [["SARS-CoV-2 infection", "DISEASE", 56, 76], ["deaths", "DISEASE", 100, 106], ["COVID-19", "CHEMICAL", 112, 120], ["SARS-CoV-2", "ORGANISM", 56, 66], ["CoV-2", "SPECIES", 61, 66], ["SARS-CoV-2", "SPECIES", 56, 66], ["SARS", "PROBLEM", 56, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["COVID", "TEST", 112, 117], ["infection", "OBSERVATION", 67, 76]]], ["[11] [12] [13] The emergence of this novel infectious agent has forced blood component suppliers to raise their level of awareness and to quickly assess the potential risk to blood safety.", [["blood", "ANATOMY", 71, 76], ["blood", "ANATOMY", 175, 180], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["this novel infectious agent", "PROBLEM", 32, 59], ["forced blood component suppliers", "PROBLEM", 64, 96], ["blood safety", "TEST", 175, 187], ["infectious", "OBSERVATION", 43, 53]]], ["This article aims to evaluate the available evidence on the theoretical risk of SARS-CoV-2 transmission by transfusion, including attempts at determining infectiousness of blood components.SEARCH STRATEGYThe PubMed public biomedical literature database (https://pubmed.ncbi.nlm.nih.gov/) was searched for references that pertain to the risk of transmission of COVID-19/SARS-CoV-2 by transfusion.", [["blood", "ANATOMY", 172, 177], ["SARS", "DISEASE", 80, 84], ["CoV-2", "ORGANISM", 85, 90], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["COVID-19", "ORGANISM", 360, 368], ["SARS-CoV-2", "ORGANISM", 369, 379], ["SARS", "PROBLEM", 80, 84], ["transfusion", "TREATMENT", 107, 118], ["infectiousness of blood components", "PROBLEM", 154, 188], ["COVID", "TEST", 360, 365], ["CoV", "TEST", 374, 377], ["transfusion", "TREATMENT", 383, 394]]], ["More specifically, PubMed was interrogated with a series of queries aimed at identifying references that relate to COVID-19/SARS-CoV-2 and the detection of viral genomic material in blood, plasma, or serum.", [["blood", "ANATOMY", 182, 187], ["plasma", "ANATOMY", 189, 195], ["serum", "ANATOMY", 200, 205], ["SARS-CoV-2", "ORGANISM", 124, 134], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["plasma", "ORGANISM_SUBSTANCE", 189, 195], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["COVID", "TEST", 115, 120], ["SARS", "TEST", 124, 128], ["CoV", "TEST", 129, 132], ["the detection", "TEST", 139, 152], ["viral genomic material", "PROBLEM", 156, 178], ["plasma", "TEST", 189, 195], ["serum", "TEST", 200, 205], ["viral genomic material", "OBSERVATION", 156, 178]]], ["As this enveloped virus would not be expected to survive the fractionation process, key words associated with purified plasma products were not included in the search.", [["plasma", "ANATOMY", 119, 125], ["plasma", "ORGANISM_SUBSTANCE", 119, 125], ["purified plasma products", "PROTEIN", 110, 134], ["this enveloped virus", "PROBLEM", 3, 23], ["purified plasma products", "TREATMENT", 110, 134]]], ["Queries were built from a basic search scriptAccepted ArticleFrom this core script, queries focused on the detection of viral genomic material in blood were built.Accepted ArticleQueries and their respective search results are shown in Table 1 .", [["blood", "ANATOMY", 146, 151], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["viral genomic material in blood", "PROBLEM", 120, 151], ["viral genomic material", "OBSERVATION", 120, 142]]], ["Titles and abstracts from the nonoverlapping 734 references from searches #2 and #5 (equivalent to search #4) were examined.", [["#5", "DNA", 81, 83]]], ["From this screen, 23 references reporting any data or stating any information on the detection of SARS-CoV-2 genomic material in human blood, plasma, or serum, were selected ( Table 2) .Accepted ArticleWhile examining the above 734 references, some references pertaining to in vitro or animal models of SARS-CoV-2 infectivity were intercepted and saved.", [["blood", "ANATOMY", 135, 140], ["plasma", "ANATOMY", 142, 148], ["serum", "ANATOMY", 153, 158], ["SARS", "DISEASE", 98, 102], ["SARS", "DISEASE", 303, 307], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["human", "ORGANISM", 129, 134], ["blood", "ORGANISM_SUBSTANCE", 135, 140], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["SARS-CoV-2", "ORGANISM", 303, 313], ["human", "SPECIES", 129, 134], ["SARS-CoV", "SPECIES", 98, 106], ["human", "SPECIES", 129, 134], ["SARS-CoV", "SPECIES", 303, 311], ["this screen", "TEST", 5, 16], ["the detection", "TEST", 81, 94], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["human blood", "TEST", 129, 140], ["plasma, or serum", "TEST", 142, 158], ["SARS", "PROBLEM", 303, 307], ["CoV", "TEST", 308, 311]]], ["Additional searches specifically targeting the in vitro infectivity of blood, plasma, or serum samples were performed to complete the list of references on that topic.Accepted ArticleAdditional searches were performed to identify references pertaining to COVID-19/SARS-CoV-2 and infection of endothelial cells.", [["blood", "ANATOMY", 71, 76], ["plasma", "ANATOMY", 78, 84], ["serum samples", "ANATOMY", 89, 102], ["endothelial cells", "ANATOMY", 292, 309], ["infection", "DISEASE", 279, 288], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["serum samples", "ORGANISM_SUBSTANCE", 89, 102], ["SARS-CoV-2", "ORGANISM", 264, 274], ["endothelial cells", "CELL", 292, 309], ["endothelial cells", "CELL_TYPE", 292, 309], ["serum samples", "TEST", 89, 102], ["COVID", "TEST", 255, 260], ["SARS", "PROBLEM", 264, 268], ["CoV", "TEST", 269, 272], ["infection of endothelial cells", "PROBLEM", 279, 309], ["infection", "OBSERVATION", 279, 288], ["endothelial cells", "OBSERVATION", 292, 309]]], ["A non-exhaustive, restricted list of relevant references were selected and are discussed in the text.DETECTION OF SARS-CoV-2 GENOMIC MATERIAL IN BLOODAn exhaustive search strategy led to the identification of 23 references reporting data on the detection of SARS-CoV-2 genomic material in blood components (Table 2) .", [["blood", "ANATOMY", 289, 294], ["SARS", "DISEASE", 258, 262], ["blood", "ORGANISM_SUBSTANCE", 289, 294], ["SARS-CoV", "SPECIES", 258, 266], ["SARS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["the detection", "TEST", 241, 254], ["SARS", "PROBLEM", 258, 262], ["CoV", "TEST", 263, 266], ["2 genomic material in blood components", "PROBLEM", 267, 305]]], ["4, 8, As correctly pointed out by Huang et al., 4 the presence of SARS-CoV-2 genomic material in the blood of asymptomatic/presymptomatic individuals or COVID-19 patients should be referred to as RNAaemia, as opposed to viremia, which refers to the presence of intact, infectious virions in blood.", [["blood", "ANATOMY", 101, 106], ["virions", "ANATOMY", 280, 287], ["blood", "ANATOMY", 291, 296], ["SARS", "DISEASE", 66, 70], ["viremia", "DISEASE", 220, 227], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 66, 76], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["individuals", "ORGANISM", 138, 149], ["patients", "ORGANISM", 162, 170], ["blood", "ORGANISM_SUBSTANCE", 291, 296], ["patients", "SPECIES", 162, 170], ["SARS", "PROBLEM", 66, 70], ["CoV", "TEST", 71, 74], ["asymptomatic/presymptomatic individuals", "PROBLEM", 110, 149], ["COVID", "TEST", 153, 158], ["viremia", "PROBLEM", 220, 227], ["intact, infectious virions in blood", "PROBLEM", 261, 296], ["viremia", "OBSERVATION", 220, 227], ["intact", "OBSERVATION", 261, 267], ["infectious", "OBSERVATION", 269, 279]]], ["First, RNAaemia, when present, is close to the limit of detection of rRT-qPCR, with cycle threshold (Ct) values well above 30 in the vast Accepted Article majority of cases.", [["RNAaemia", "PROTEIN", 7, 15], ["rRT", "PROTEIN", 69, 72], ["rRT", "TEST", 69, 72], ["cycle threshold", "TEST", 84, 99], ["Ct) values", "TEST", 101, 111]]], ["Second, RNAaemia tends to be associated with more severe disease.", [["RNAaemia", "PROTEIN", 8, 16], ["more severe disease", "PROBLEM", 45, 64], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["disease", "OBSERVATION", 57, 64]]], ["18, 20, 26, 28, 30, 32 Third, 18 of the 23 identified studies report on cases of patients diagnosed with COVID-19.", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["COVID", "TEST", 105, 110]]], ["Even when RNA testing is done on whole blood, plasma, or serum from a preselected cohort of COVID-19 patients, the prevalence of RNAaemia is generally low.", [["whole blood", "ANATOMY", 33, 44], ["plasma", "ANATOMY", 46, 52], ["serum", "ANATOMY", 57, 62], ["RNAaemia", "DISEASE", 129, 137], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["RNA testing", "TEST", 10, 21], ["whole blood", "TEST", 33, 44], ["plasma", "TEST", 46, 52], ["serum", "TEST", 57, 62], ["COVID", "TEST", 92, 97], ["RNAaemia", "TEST", 129, 137], ["generally", "OBSERVATION_MODIFIER", 141, 150], ["low", "OBSERVATION", 151, 154]]], ["In this context, the article of Zheng et al. (2020) 28INFECTIVITY OF BLOOD COMPONENTS AND OTHER NON-RESPIRATORY SAMPLESThe viral infectivity of a biological sample, including blood, plasma, or serum, can be determined in vitro using cells that are known to be susceptible to infection.", [["sample", "ANATOMY", 157, 163], ["blood", "ANATOMY", 175, 180], ["plasma", "ANATOMY", 182, 188], ["serum", "ANATOMY", 193, 198], ["cells", "ANATOMY", 233, 238], ["infection", "DISEASE", 275, 284], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["plasma", "ORGANISM_SUBSTANCE", 182, 188], ["serum", "ORGANISM_SUBSTANCE", 193, 198], ["cells", "CELL", 233, 238], ["BLOOD COMPONENTS", "TEST", 69, 85], ["OTHER NON-RESPIRATORY SAMPLES", "TEST", 90, 119], ["The viral infectivity", "PROBLEM", 119, 140], ["a biological sample", "TEST", 144, 163], ["blood, plasma", "TEST", 175, 188], ["serum", "TEST", 193, 198], ["infection", "PROBLEM", 275, 284], ["viral infectivity", "OBSERVATION", 123, 140], ["infection", "OBSERVATION", 275, 284]]], ["In such a cellular model, infection results in either detectable cytopathic effects, cell lysis, intracellular replication of the virus and production of viral particles in the culture supernatant, or a combination of these manifestations.", [["cellular", "ANATOMY", 10, 18], ["cell", "ANATOMY", 85, 89], ["intracellular", "ANATOMY", 97, 110], ["supernatant", "ANATOMY", 185, 196], ["infection", "DISEASE", 26, 35], ["cellular", "CELL", 10, 18], ["cell", "CELL", 85, 89], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 97, 110], ["infection", "PROBLEM", 26, 35], ["detectable cytopathic effects", "PROBLEM", 54, 83], ["cell lysis", "TREATMENT", 85, 95], ["intracellular replication", "TREATMENT", 97, 122], ["the virus", "PROBLEM", 126, 135], ["viral particles", "PROBLEM", 154, 169], ["the culture", "TEST", 173, 184], ["these manifestations", "PROBLEM", 218, 238], ["cellular model", "OBSERVATION", 10, 24], ["infection", "OBSERVATION", 26, 35], ["detectable", "OBSERVATION_MODIFIER", 54, 64], ["cytopathic", "OBSERVATION_MODIFIER", 65, 75], ["cell lysis", "OBSERVATION", 85, 95], ["viral particles", "OBSERVATION", 154, 169]]], ["Infectivity can also be demonstrated in a susceptible animal model, in which viral infection will result in signs and symptoms similar to those observed in humans.INFECTIVITY OF BLOOD COMPONENTS AND OTHER NON-RESPIRATORY SAMPLESSeveral cell lines can support SARS-CoV-2 replication.", [["SAMPLESSeveral cell lines", "ANATOMY", 221, 246], ["viral infection", "DISEASE", 77, 92], ["humans", "ORGANISM", 156, 162], ["SAMPLESSeveral cell lines", "CELL", 221, 246], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 259, 269], ["SAMPLESSeveral cell lines", "CELL_LINE", 221, 246], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162], ["Infectivity", "PROBLEM", 0, 11], ["viral infection", "PROBLEM", 77, 92], ["signs and symptoms", "PROBLEM", 108, 126], ["RESPIRATORY SAMPLESSeveral cell lines", "TREATMENT", 209, 246], ["SARS", "PROBLEM", 259, 263], ["CoV-2 replication", "TREATMENT", 264, 281], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["BLOOD", "ANATOMY", 178, 183], ["RESPIRATORY", "ANATOMY", 209, 220], ["SAMPLESSeveral cell lines", "OBSERVATION", 221, 246]]], ["[36] [37] [38] [39] In fact, any cell line which expresses the cognate angiotensin-converting enzyme 2 (ACE2) and capable of sustaining replication of the virus can be used to assess infectivity.", [["cell line", "ANATOMY", 33, 42], ["angiotensin", "CHEMICAL", 71, 82], ["[36] [37] [38] [39", "SIMPLE_CHEMICAL", 0, 18], ["cell line", "CELL", 33, 42], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 71, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["cognate angiotensin-converting enzyme 2", "PROTEIN", 63, 102], ["ACE2", "PROTEIN", 104, 108], ["any cell line", "PROBLEM", 29, 42], ["enzyme", "TEST", 94, 100], ["the virus", "PROBLEM", 151, 160], ["cell line", "OBSERVATION", 33, 42]]], ["40 Among the most commonly used cell lines are Vero and its derivatives.Accepted ArticleOriginally derived from African green monkey kidney epithelial cells, the Vero cell line is broadly used for the study of human respiratory viruses.", [["cell lines", "ANATOMY", 32, 42], ["kidney epithelial cells", "ANATOMY", 133, 156], ["Vero cell line", "ANATOMY", 162, 176], ["respiratory viruses", "DISEASE", 216, 235], ["cell lines", "CELL", 32, 42], ["Vero", "CELL", 47, 51], ["monkey", "ORGANISM", 126, 132], ["kidney epithelial cells", "CELL", 133, 156], ["Vero cell line", "CELL", 162, 176], ["human", "ORGANISM", 210, 215], ["respiratory viruses", "ORGANISM", 216, 235], ["cell lines", "CELL_LINE", 32, 42], ["African green monkey kidney epithelial cells", "CELL_TYPE", 112, 156], ["Vero cell line", "CELL_LINE", 162, 176], ["green monkey", "SPECIES", 120, 132], ["human", "SPECIES", 210, 215], ["African green monkey", "SPECIES", 112, 132], ["human", "SPECIES", 210, 215], ["cell lines", "TREATMENT", 32, 42], ["Vero and its derivatives", "TREATMENT", 47, 71], ["the Vero cell line", "TREATMENT", 158, 176], ["the study", "TEST", 197, 206], ["human respiratory viruses", "PROBLEM", 210, 235], ["cell lines", "OBSERVATION", 32, 42], ["kidney", "ANATOMY", 133, 139], ["epithelial cells", "OBSERVATION", 140, 156], ["Vero cell line", "OBSERVATION", 162, 176], ["respiratory viruses", "OBSERVATION", 216, 235]]], ["This in vitro model permitted confirmation of the infectivity of respiratory samples collected from suspected COVID-19 cases.", [["respiratory samples", "ANATOMY", 65, 84], ["respiratory samples", "CANCER", 65, 84], ["respiratory samples", "TEST", 65, 84], ["COVID", "TEST", 110, 115], ["respiratory", "ANATOMY", 65, 76]]], ["2, 8, 22 Other cell lines (Huh7, Calu3, Caco-2) have also been shown to be permissive for SARS-CoV-2 replication.", [["cell lines", "ANATOMY", 15, 25], ["Huh7", "ANATOMY", 27, 31], ["cell lines", "CELL", 15, 25], ["Huh7", "CELL", 27, 31], ["Calu3", "CELL", 33, 38], ["Caco-2", "CELL", 40, 46], ["CoV-2", "ORGANISM", 95, 100], ["cell lines", "CELL_LINE", 15, 25], ["Huh7", "CELL_LINE", 27, 31], ["Calu3", "CELL_LINE", 33, 38], ["Caco-2", "CELL_LINE", 40, 46], ["SARS-CoV", "SPECIES", 90, 98], ["Other cell lines", "TEST", 9, 25], ["Huh7", "TEST", 27, 31], ["Calu3", "TEST", 33, 38], ["Caco", "TEST", 40, 44], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["cell lines", "OBSERVATION", 15, 25]]], ["37 Various animal models of infection have also been identified and characterized.", [["infection", "DISEASE", 28, 37], ["infection", "PROBLEM", 28, 37], ["animal models", "OBSERVATION_MODIFIER", 11, 24], ["infection", "OBSERVATION", 28, 37]]], ["[41] [42] [43] As stated earlier, attempts at detecting infectivity in blood have been so far unsuccessful.", [["blood", "ANATOMY", 71, 76], ["[41] [42] [43] As", "CHEMICAL", 0, 17], ["[41] [42] [43", "SIMPLE_CHEMICAL", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["infectivity in blood", "PROBLEM", 56, 76]]], ["In fact, infectivity in biological samples outside of the respiratory tract has not been demonstrated.", [["samples", "ANATOMY", 35, 42], ["respiratory tract", "ANATOMY", 58, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 58, 75], ["infectivity in biological samples", "PROBLEM", 9, 42], ["infectivity", "OBSERVATION_MODIFIER", 9, 20], ["respiratory tract", "ANATOMY", 58, 75]]], ["Although infectivity can be detected in respiratory samples, a minimal RNA load, in terms of equivalent RNA copy number, appears to be necessary for in vitro infection of cell lines to occur.", [["respiratory samples", "ANATOMY", 40, 59], ["cell lines", "ANATOMY", 171, 181], ["infection", "DISEASE", 158, 167], ["cell lines", "CELL", 171, 181], ["cell lines", "CELL_LINE", 171, 181], ["infectivity", "PROBLEM", 9, 20], ["respiratory samples", "TEST", 40, 59], ["a minimal RNA load", "PROBLEM", 61, 79], ["cell lines", "TREATMENT", 171, 181], ["infectivity", "OBSERVATION", 9, 20], ["minimal", "OBSERVATION_MODIFIER", 63, 70], ["RNA load", "OBSERVATION", 71, 79], ["infection", "OBSERVATION", 158, 167], ["cell lines", "OBSERVATION", 171, 181]]], ["The data of La Scola et al.Accepted Article(2020) 44 suggest that individuals whose respiratory samples yield Ct values above 34 are no longer contagious.", [["respiratory samples", "ANATOMY", 84, 103], ["individuals", "ORGANISM", 66, 77], ["respiratory samples", "TEST", 84, 103], ["Ct values", "TEST", 110, 119], ["no longer", "UNCERTAINTY", 133, 142]]], ["Bullard et al.'s results support the idea that the quantitative criterion for infectivity could be even higher: their data suggest that the infectivity of samples with Ct values > 24 might be below the limit of detection of an in vitro infectivity assay.", [["samples", "ANATOMY", 155, 162], ["infectivity", "PROBLEM", 78, 89], ["the infectivity of samples", "PROBLEM", 136, 162], ["Ct values", "TEST", 168, 177], ["an in vitro infectivity assay", "PROBLEM", 224, 253]]], ["45 The recent article by Huang et al. (2020c) is consistent with these observations.", [["consistent with", "UNCERTAINTY", 49, 64]]], ["46 Given that RNAaemic blood samples generally give Ct values in the high 30's, the above reports on the relationship between RNAaemia in respiratory samples and infectivity are consistent with the idea that blood is unlikely to be an infectious source of SARS-CoV-2.SARS-CoV-2 INFECTION OF ENDOTHELIAL CELLS AND T CELLSAside from a respiratory infection, SARS-CoV-2 appears to induce systemic effects which likely contribute to the pathological mechanisms observed in the most severe cases of infection.", [["blood samples", "ANATOMY", 23, 36], ["respiratory samples", "ANATOMY", 138, 157], ["blood", "ANATOMY", 208, 213], ["respiratory", "ANATOMY", 333, 344], ["SARS", "DISEASE", 256, 260], ["SARS", "DISEASE", 267, 271], ["respiratory infection", "DISEASE", 333, 354], ["SARS", "DISEASE", 356, 360], ["infection", "DISEASE", 494, 503], ["blood samples", "ORGANISM_SUBSTANCE", 23, 36], ["RNAaemia", "GENE_OR_GENE_PRODUCT", 126, 134], ["blood", "ORGANISM_SUBSTANCE", 208, 213], ["SARS-CoV-2", "ORGANISM", 256, 266], ["SARS-CoV-2", "ORGANISM", 356, 366], ["SARS-CoV", "SPECIES", 256, 264], ["SARS-CoV", "SPECIES", 267, 275], ["SARS-CoV", "SPECIES", 356, 364], ["RNAaemic blood samples", "TEST", 14, 36], ["Ct values", "TEST", 52, 61], ["RNAaemia in respiratory samples", "TEST", 126, 157], ["infectivity", "PROBLEM", 162, 173], ["SARS", "PROBLEM", 256, 260], ["CoV", "TEST", 261, 264], ["ENDOTHELIAL CELLS", "PROBLEM", 291, 308], ["T CELLSAside", "PROBLEM", 313, 325], ["a respiratory infection", "PROBLEM", 331, 354], ["SARS", "PROBLEM", 356, 360], ["systemic effects", "PROBLEM", 385, 401], ["the pathological mechanisms", "PROBLEM", 429, 456], ["infection", "PROBLEM", 494, 503], ["respiratory samples", "OBSERVATION", 138, 157], ["consistent with", "UNCERTAINTY", 178, 193], ["unlikely to be", "UNCERTAINTY", 217, 231], ["infectious", "OBSERVATION", 235, 245], ["INFECTION", "OBSERVATION", 278, 287], ["ENDOTHELIAL CELLS", "OBSERVATION", 291, 308], ["respiratory", "ANATOMY", 333, 344], ["infection", "OBSERVATION", 345, 354], ["most severe", "OBSERVATION_MODIFIER", 473, 484], ["infection", "OBSERVATION", 494, 503]]], ["3, 4 Furthermore, some reports have suggested that the SARS-CoV-2 virus could infect endothelial cells lining the interior of blood vessels, [47] [48] [49] [50] raising the possibility that infectious virions might be present in the circulation.SARS-CoV-2 INFECTION OF ENDOTHELIAL CELLS AND T CELLSHowever, some of these findings have been challenged.", [["endothelial cells", "ANATOMY", 85, 102], ["blood vessels", "ANATOMY", 126, 139], ["virions", "ANATOMY", 201, 208], ["SARS", "DISEASE", 55, 59], ["[47] [48] [49]", "CHEMICAL", 141, 155], ["SARS-CoV-2 virus", "ORGANISM", 55, 71], ["endothelial cells", "CELL", 85, 102], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 126, 139], ["endothelial cells", "CELL_TYPE", 85, 102], ["SARS-CoV-2 virus", "SPECIES", 55, 71], ["the SARS", "TEST", 51, 59], ["CoV", "TEST", 60, 63], ["infectious virions", "PROBLEM", 190, 208], ["ENDOTHELIAL CELLS", "PROBLEM", 269, 286], ["interior", "ANATOMY_MODIFIER", 114, 122], ["blood vessels", "ANATOMY", 126, 139], ["infectious", "OBSERVATION", 190, 200], ["circulation", "ANATOMY", 233, 244], ["INFECTION", "OBSERVATION", 256, 265], ["ENDOTHELIAL CELLS", "OBSERVATION", 269, 286]]], ["51 Furthermore, these findings are based on case Accepted Article reports of COVID-19 patients or post-mortem analysis of deceased COVID-19 patients, and the presumed detection of SARS-CoV-2 virions was performed by electron microscopy and immunohistochemistry, which are prone to artifacts and misinterpretations.", [["SARS", "DISEASE", 180, 184], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 140, 148], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 180, 190], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 180, 188], ["COVID", "TEST", 77, 82], ["post-mortem analysis", "TEST", 98, 118], ["SARS", "PROBLEM", 180, 184], ["CoV-2 virions", "PROBLEM", 185, 198], ["electron microscopy", "TEST", 216, 235], ["immunohistochemistry", "TEST", 240, 260]]], ["51 In addition, two of these articles report on deceased patients that had comorbidities that were directly involved with the organ origin of the suspected observation of SARS-CoV-2 virions, namely the kidney of a kidney transplant patient 47 and the brain of a Parkinson's disease patient.", [["organ", "ANATOMY", 126, 131], ["kidney", "ANATOMY", 202, 208], ["kidney", "ANATOMY", 214, 220], ["brain", "ANATOMY", 251, 256], ["SARS", "DISEASE", 171, 175], ["Parkinson's disease", "DISEASE", 262, 281], ["patients", "ORGANISM", 57, 65], ["organ", "ORGAN", 126, 131], ["kidney", "ORGAN", 202, 208], ["kidney", "ORGAN", 214, 220], ["patient", "ORGANISM", 232, 239], ["brain", "ORGAN", 251, 256], ["patient", "ORGANISM", 282, 289], ["patients", "SPECIES", 57, 65], ["patient", "SPECIES", 232, 239], ["patient", "SPECIES", 282, 289], ["comorbidities", "PROBLEM", 75, 88], ["SARS", "PROBLEM", 171, 175], ["CoV", "TEST", 176, 179], ["a kidney transplant", "TREATMENT", 212, 231], ["a Parkinson's disease", "PROBLEM", 260, 281], ["kidney", "ANATOMY", 202, 208], ["kidney", "ANATOMY", 214, 220], ["transplant", "OBSERVATION", 221, 231], ["brain", "ANATOMY", 251, 256], ["Parkinson", "OBSERVATION", 262, 271]]], ["50 SARS-CoV-2 RNA has also been detected in five out of 104 endomyocardial biopsy samples from patients exhibiting signs of myocarditis or unexplained cardiac failure, suggesting that the virus might leach into the myocardium.", [["endomyocardial biopsy samples", "ANATOMY", 60, 89], ["cardiac", "ANATOMY", 151, 158], ["myocardium", "ANATOMY", 215, 225], ["SARS", "DISEASE", 3, 7], ["myocarditis", "DISEASE", 124, 135], ["cardiac failure", "DISEASE", 151, 166], ["CoV-2", "ORGANISM", 8, 13], ["endomyocardial biopsy samples", "TISSUE", 60, 89], ["patients", "ORGANISM", 95, 103], ["cardiac", "ORGAN", 151, 158], ["myocardium", "ORGAN", 215, 225], ["SARS-CoV-2 RNA", "RNA", 3, 17], ["patients", "SPECIES", 95, 103], ["endomyocardial biopsy samples", "TEST", 60, 89], ["myocarditis", "PROBLEM", 124, 135], ["unexplained cardiac failure", "PROBLEM", 139, 166], ["the virus", "PROBLEM", 184, 193], ["myocarditis", "OBSERVATION", 124, 135], ["cardiac", "ANATOMY", 151, 158], ["failure", "OBSERVATION", 159, 166], ["virus", "OBSERVATION", 188, 193], ["myocardium", "ANATOMY", 215, 225]]], ["52 However, Escher et al. did not report the detection of virions by electron microscopy or immunohistochemistry, nor were they able to demonstrate that the RNA, detected after \uf0b3 33 cycles of rRT-qPCR, was infectious.", [["virions", "ANATOMY", 58, 65], ["electron microscopy", "TEST", 69, 88], ["immunohistochemistry", "TEST", 92, 112], ["the RNA", "PROBLEM", 153, 160], ["rRT", "TREATMENT", 192, 195], ["infectious", "PROBLEM", 206, 216], ["infectious", "OBSERVATION", 206, 216]]], ["Thus, this observation could be a bystander detection or leaching/contamination of the biopsy sample with lung tissue.SARS-CoV-2 INFECTION OF ENDOTHELIAL CELLS AND T CELLSThere is some evidence that SARS-CoV-2 can infect human primary CD4+ T cells in culture and drive the expression of viral proteins in these cells.", [["biopsy sample", "ANATOMY", 87, 100], ["lung tissue", "ANATOMY", 106, 117], ["primary CD4+", "ANATOMY", 227, 239], ["T cells", "ANATOMY", 240, 247], ["cells", "ANATOMY", 311, 316], ["SARS", "DISEASE", 118, 122], ["biopsy sample", "MULTI-TISSUE_STRUCTURE", 87, 100], ["lung tissue", "TISSUE", 106, 117], ["SARS-CoV", "ORGANISM", 118, 126], ["SARS-CoV-2", "ORGANISM", 199, 209], ["human", "ORGANISM", 221, 226], ["CD4", "GENE_OR_GENE_PRODUCT", 235, 238], ["T cells", "CELL", 240, 247], ["cells", "CELL", 311, 316], ["CD4", "PROTEIN", 235, 238], ["T cells", "CELL_TYPE", 240, 247], ["viral proteins", "PROTEIN", 287, 301], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 221, 226], ["a bystander detection", "TEST", 32, 53], ["the biopsy sample", "TEST", 83, 100], ["lung tissue", "PROBLEM", 106, 117], ["ENDOTHELIAL CELLS", "PROBLEM", 142, 159], ["SARS", "PROBLEM", 199, 203], ["CoV", "TEST", 204, 207], ["T cells", "PROBLEM", 240, 247], ["culture", "TEST", 251, 258], ["viral proteins in these cells", "PROBLEM", 287, 316], ["lung", "ANATOMY", 106, 110], ["tissue", "OBSERVATION", 111, 117], ["ENDOTHELIAL CELLS", "OBSERVATION", 142, 159], ["viral proteins", "OBSERVATION", 287, 301]]], ["However, the relevance of these infections is not known, as these infections did not appear to be productive in terms of live viral particles.", [["infections", "DISEASE", 32, 42], ["infections", "DISEASE", 66, 76], ["these infections", "PROBLEM", 26, 42], ["these infections", "PROBLEM", 60, 76], ["live viral particles", "PROBLEM", 121, 141], ["infections", "OBSERVATION", 32, 42], ["not known", "UNCERTAINTY", 46, 55], ["infections", "OBSERVATION", 66, 76], ["productive", "OBSERVATION_MODIFIER", 98, 108], ["viral particles", "OBSERVATION", 126, 141]]], ["It is also expected that the burden of infected T cells, if it were to occur in vivo, would be substantially reduced through leukoreduction.", [["T cells", "ANATOMY", 48, 55], ["T cells", "CELL", 48, 55], ["infected T cells", "CELL_TYPE", 39, 55], ["infected T cells", "PROBLEM", 39, 55], ["leukoreduction", "TREATMENT", 125, 139], ["infected", "OBSERVATION", 39, 47]]], ["53CONCLUSIONSTo this day, there has not been a single reported case of transmission of a respiratory virus by transfusion.", [["respiratory virus", "DISEASE", 89, 106], ["a respiratory virus", "PROBLEM", 87, 106], ["transfusion", "TREATMENT", 110, 121], ["respiratory virus", "OBSERVATION", 89, 106]]], ["Accordingly, the long historical track record on the mode of transmission of respiratory viruses predicts that SARS-CoV-2 would not be transmissible by transfusion.", [["respiratory viruses", "DISEASE", 77, 96], ["SARS", "DISEASE", 111, 115], ["SARS-CoV-2", "ORGANISM", 111, 121], ["SARS-CoV", "SPECIES", 111, 119], ["respiratory viruses", "PROBLEM", 77, 96], ["transfusion", "TREATMENT", 152, 163], ["respiratory viruses", "OBSERVATION", 77, 96]]], ["So far, this hypothesis appears to be true, as there has been no documented case of transfusion-transmitted SARS-CoV-2.Accepted ArticleThis article is protected by copyright.", [["SARS", "DISEASE", 108, 112], ["transfusion", "TREATMENT", 84, 95], ["appears to be", "UNCERTAINTY", 24, 37]]], ["All rights reserved.Accepted ArticleAs stated by Katz (2020) , 54 given that some asymptomatic/presymptomatic individuals appear to be infectious (through their respiratory secretions), and that some of these individuals must have donated blood since the beginning of the pandemic, if indeed SARS-CoV-2 was hematogenous, then it is likely that some cases of transmission by transfusion would have been identified among transfused patients on a worldwide scale.", [["respiratory secretions", "ANATOMY", 161, 183], ["blood", "ANATOMY", 239, 244], ["SARS", "DISEASE", 292, 296], ["individuals", "ORGANISM", 110, 121], ["individuals", "ORGANISM", 209, 220], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["SARS-CoV-2", "ORGANISM", 292, 302], ["patients", "ORGANISM", 430, 438], ["patients", "SPECIES", 430, 438], ["SARS-CoV", "SPECIES", 292, 300], ["some asymptomatic/presymptomatic individuals", "PROBLEM", 77, 121], ["infectious", "PROBLEM", 135, 145], ["their respiratory secretions", "PROBLEM", 155, 183], ["CoV", "TEST", 297, 300], ["hematogenous", "PROBLEM", 307, 319], ["transfusion", "TREATMENT", 374, 385], ["a worldwide scale", "TREATMENT", 442, 459], ["infectious", "OBSERVATION", 135, 145]]], ["Furthermore, RNAaemia is generally associated with a more severe disease course; accordingly, the majority of RNAaemic individuals are not healthy enough to donate blood, which further reduces the theoretical risk of transmission by transfusion.", [["blood", "ANATOMY", 164, 169], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["a more severe disease course", "PROBLEM", 51, 79], ["RNAaemic individuals", "PROBLEM", 110, 130], ["transfusion", "TREATMENT", 233, 244], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 65, 72]]], ["The fact that epidemiological investigations and contact tracing indicate that new COVID-19 cases are generally related to close contacts with infected individuals, and that no cases have been linked to transfusion, is reassuring from a blood safety standpoint.Accepted ArticleThis article is protected by copyright.", [["blood", "ANATOMY", 237, 242], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["epidemiological investigations", "TEST", 14, 44], ["contact tracing", "TEST", 49, 64], ["new COVID-19 cases", "PROBLEM", 79, 97], ["transfusion", "TREATMENT", 203, 214]]]], "PMC6681324": [], "6368593d2407292cdfa50cd3747bd3dc6ccad171": [["IntroductionCanine distemper (CD) is a contagious multisystem disease in dogs caused by canine distemper virus (CDV), classified in the Morbillivirus genus of the Paramyxoviridae (Greene and Appel, 1998) .IntroductionTargets for CDV infection are mainly mucous membranes and lymphoid tissues.", [["mucous membranes", "ANATOMY", 254, 270], ["lymphoid tissues", "ANATOMY", 275, 291], ["distemper", "DISEASE", 19, 28], ["CD", "DISEASE", 30, 32], ["multisystem disease", "DISEASE", 50, 69], ["canine distemper virus", "DISEASE", 88, 110], ["CDV infection", "DISEASE", 229, 242], ["IntroductionCanine distemper", "ORGANISM", 0, 28], ["dogs", "ORGANISM", 73, 77], ["canine distemper virus", "ORGANISM", 88, 110], ["CDV", "ORGANISM", 112, 115], ["CDV", "ORGANISM", 229, 232], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 254, 270], ["lymphoid tissues", "TISSUE", 275, 291], ["dogs", "SPECIES", 73, 77], ["canine distemper virus", "SPECIES", 88, 110], ["canine distemper virus", "SPECIES", 88, 110], ["CDV", "SPECIES", 112, 115], ["CDV", "SPECIES", 229, 232], ["a contagious multisystem disease in dogs", "PROBLEM", 37, 77], ["canine distemper virus", "PROBLEM", 88, 110], ["IntroductionTargets", "TREATMENT", 205, 224], ["CDV infection", "PROBLEM", 229, 242], ["contagious", "OBSERVATION_MODIFIER", 39, 49], ["multisystem disease", "OBSERVATION", 50, 69], ["distemper virus", "OBSERVATION", 95, 110], ["CDV", "OBSERVATION_MODIFIER", 229, 232], ["infection", "OBSERVATION", 233, 242], ["mucous membranes", "OBSERVATION", 254, 270], ["lymphoid tissues", "OBSERVATION", 275, 291]]], ["Following aerosol infection, the virus primarily replicates in lymphatic tissues of the respiratory tract and subsequently reaches various organs, e.g. the cells of the lower respiratory and gastrointestinal tracts, the lymphoid organs, the urinary bladder and the central nervous system (Appel, 1987) .", [["lymphatic tissues", "ANATOMY", 63, 80], ["respiratory tract", "ANATOMY", 88, 105], ["organs", "ANATOMY", 139, 145], ["cells", "ANATOMY", 156, 161], ["lower respiratory", "ANATOMY", 169, 186], ["gastrointestinal tracts", "ANATOMY", 191, 214], ["lymphoid organs", "ANATOMY", 220, 235], ["urinary bladder", "ANATOMY", 241, 256], ["central nervous system", "ANATOMY", 265, 287], ["aerosol infection", "DISEASE", 10, 27], ["lymphatic tissues", "TISSUE", 63, 80], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["organs", "ORGAN", 139, 145], ["cells", "CELL", 156, 161], ["lower respiratory", "ORGANISM_SUBDIVISION", 169, 186], ["gastrointestinal tracts", "MULTI-TISSUE_STRUCTURE", 191, 214], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 220, 235], ["urinary bladder", "ORGAN", 241, 256], ["central nervous system", "ANATOMICAL_SYSTEM", 265, 287], ["aerosol infection", "PROBLEM", 10, 27], ["the virus", "PROBLEM", 29, 38], ["aerosol infection", "OBSERVATION", 10, 27], ["virus", "OBSERVATION", 33, 38], ["lymphatic tissues", "OBSERVATION", 63, 80], ["respiratory tract", "ANATOMY", 88, 105], ["lower", "ANATOMY_MODIFIER", 169, 174], ["respiratory", "ANATOMY", 175, 186], ["gastrointestinal tracts", "ANATOMY", 191, 214], ["lymphoid organs", "OBSERVATION", 220, 235], ["urinary bladder", "ANATOMY", 241, 256], ["central", "ANATOMY_MODIFIER", 265, 272], ["nervous system", "ANATOMY", 273, 287]]], ["This can result in either subclinical infection or a combination of respiratory, ocular, gastrointestinal, neurologic and cutaneous signs or lesions, that appear simultaneously or sequentially (Greene and Appel, 1998) .", [["respiratory", "ANATOMY", 68, 79], ["ocular", "ANATOMY", 81, 87], ["gastrointestinal", "ANATOMY", 89, 105], ["neurologic", "ANATOMY", 107, 117], ["cutaneous", "ANATOMY", 122, 131], ["lesions", "ANATOMY", 141, 148], ["infection", "DISEASE", 38, 47], ["respiratory, ocular, gastrointestinal, neurologic and cutaneous signs", "DISEASE", 68, 137], ["lesions", "PATHOLOGICAL_FORMATION", 141, 148], ["subclinical infection", "PROBLEM", 26, 47], ["respiratory, ocular, gastrointestinal, neurologic and cutaneous signs", "PROBLEM", 68, 137], ["lesions", "PROBLEM", 141, 148], ["subclinical", "OBSERVATION_MODIFIER", 26, 37], ["infection", "OBSERVATION", 38, 47], ["respiratory", "ANATOMY", 68, 79], ["ocular", "ANATOMY", 81, 87], ["gastrointestinal", "ANATOMY", 89, 105], ["cutaneous", "ANATOMY", 122, 131], ["lesions", "OBSERVATION", 141, 148]]], ["Nervous signs may be present in the chronic form of CD along with other manifestations, or may occur without any other signs (Appel, 1987) .IntroductionA broad number of clinical parameters and laboratory assays have been suggested for definitive ante mortem diagnosis of CD.", [["Nervous signs", "DISEASE", 0, 13], ["CD", "DISEASE", 52, 54], ["CD", "DISEASE", 272, 274], ["Nervous signs", "PROBLEM", 0, 13], ["CD", "PROBLEM", 52, 54], ["other manifestations", "PROBLEM", 66, 86], ["clinical parameters", "TEST", 170, 189], ["laboratory assays", "TEST", 194, 211], ["CD", "PROBLEM", 272, 274], ["may be", "UNCERTAINTY", 14, 20], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["CD", "OBSERVATION", 52, 54]]], ["However the unpredictable and variable course of disease such as viremia duration, clinical signs, lack or delayed humoral or cellular immune response, hampers correct diagnosis of CD and makes it crucial to collect samples suitable for laboratory confirmation.", [["cellular", "ANATOMY", 126, 134], ["samples", "ANATOMY", 216, 223], ["viremia", "DISEASE", 65, 72], ["CD", "DISEASE", 181, 183], ["cellular", "CELL", 126, 134], ["disease", "PROBLEM", 49, 56], ["viremia duration", "PROBLEM", 65, 81], ["clinical signs", "TEST", 83, 97], ["delayed humoral or cellular immune response", "PROBLEM", 107, 150], ["CD", "PROBLEM", 181, 183], ["laboratory confirmation", "TEST", 237, 260], ["unpredictable", "OBSERVATION_MODIFIER", 12, 25], ["variable", "OBSERVATION_MODIFIER", 30, 38], ["course", "OBSERVATION_MODIFIER", 39, 45], ["disease", "OBSERVATION", 49, 56], ["viremia", "OBSERVATION", 65, 72], ["cellular immune response", "OBSERVATION", 126, 150]]], ["By the way, considering the great infectious potential of the disease, the detection of CDV from different biological specimens is essential for determining subsequent patient management.IntroductionRecent developments in molecular techniques revealed the suitability of these methods for diagnosis of CDV infection in dogs (Elia et al., 2006; Kim et al., 2006; Fischer et al., 2013; Li et al., 2013; Wilkes et al., 2014) .", [["specimens", "ANATOMY", 118, 127], ["CDV infection", "DISEASE", 302, 315], ["CDV", "ORGANISM", 88, 91], ["patient", "ORGANISM", 168, 175], ["CDV", "ORGANISM", 302, 305], ["dogs", "ORGANISM", 319, 323], ["patient", "SPECIES", 168, 175], ["dogs", "SPECIES", 319, 323], ["CDV", "SPECIES", 88, 91], ["CDV", "SPECIES", 302, 305], ["the disease", "PROBLEM", 58, 69], ["CDV", "PROBLEM", 88, 91], ["different biological specimens", "TEST", 97, 127], ["subsequent patient management", "TREATMENT", 157, 186], ["these methods", "TEST", 271, 284], ["CDV infection in dogs", "PROBLEM", 302, 323], ["great", "OBSERVATION_MODIFIER", 28, 33], ["infectious", "OBSERVATION", 34, 44], ["disease", "OBSERVATION", 62, 69], ["CDV infection", "OBSERVATION", 302, 315]]], ["However, the majority of those studies were carried out in dogs infected experimentally.", [["dogs", "ORGANISM", 59, 63], ["dogs", "SPECIES", 59, 63], ["those studies", "TEST", 25, 38], ["infected", "OBSERVATION", 64, 72]]], ["In other studies, on dogs infected naturally with CDV, sampling was limited to a few biological matrices and was not covering the entire period of infection (Saito et al., 2006; Fischer et al., 2013; Wilkes et al., 2014) .IntroductionIn this note, the clinical findings, the virological and serological results of natural CDV infection in two dogs from an outbreak observed in a kennel are reported.Animals and clinical samplesOn May 28 2013, two dogs, 359/13 and 360/13, referred to as A and B, respectively, were admitted to the Teaching Veterinary Hospital (isolation Unit) of University of Bari, Italy.", [["infection", "DISEASE", 147, 156], ["CDV infection", "DISEASE", 322, 335], ["dogs", "ORGANISM", 21, 25], ["CDV", "ORGANISM", 50, 53], ["natural CDV", "ORGANISM", 314, 325], ["dogs", "ORGANISM", 343, 347], ["dogs", "ORGANISM", 447, 451], ["dogs", "SPECIES", 21, 25], ["dogs", "SPECIES", 343, 347], ["dogs", "SPECIES", 447, 451], ["CDV", "SPECIES", 50, 53], ["CDV", "SPECIES", 322, 325], ["other studies", "TEST", 3, 16], ["CDV", "PROBLEM", 50, 53], ["infection", "PROBLEM", 147, 156], ["the virological", "TEST", 271, 286], ["natural CDV infection", "PROBLEM", 314, 335], ["an outbreak", "PROBLEM", 353, 364], ["infection", "OBSERVATION", 147, 156], ["natural CDV infection", "OBSERVATION", 314, 335]]], ["The dogs came from a kennel with an ongoing outbreak of CD affecting mixed bred animals aged from 2.5 months to 12 years.", [["CD", "DISEASE", 56, 58], ["dogs", "ORGANISM", 4, 8], ["dogs", "SPECIES", 4, 8]]], ["At the introduction in the shelter, the dogs were not vaccinated.", [["dogs", "ORGANISM", 40, 44], ["dogs", "SPECIES", 40, 44]]], ["Both the animals displayed clinical signs suggestive of CD.", [["CD", "DISEASE", 56, 58], ["clinical signs", "TEST", 27, 41], ["CD", "PROBLEM", 56, 58], ["suggestive of", "UNCERTAINTY", 42, 55], ["CD", "OBSERVATION", 56, 58]]], ["When CDV infection was confirmed, http://dx.doi.org/10.1016/j.jviromet.2014.12.004 0166-0934/\u00a9 2015 Elsevier B.V. All rights reserved. the owners refused the option of euthanasia proposed for dog A. Also, medical care of the animals and inclusion in this observational study was approved by the owners.", [["CDV infection", "DISEASE", 5, 18], ["CDV", "ORGANISM", 5, 8], ["dog", "ORGANISM", 192, 195], ["CDV", "SPECIES", 5, 8], ["dog A.", "SPECIES", 192, 198], ["CDV infection", "PROBLEM", 5, 18], ["euthanasia", "TREATMENT", 168, 178], ["this observational study", "TEST", 250, 274], ["infection", "OBSERVATION", 9, 18]]], ["The study was approved by the Committee for Animal Ethics of the Department of Veterinary Medicine of Bari.Animals and clinical samplesDog A was a puppy of 3 months of age with respiratory signs including ocular and nasal discharge and coughing.", [["samples", "ANATOMY", 128, 135], ["respiratory", "ANATOMY", 177, 188], ["ocular", "ANATOMY", 205, 211], ["nasal", "ANATOMY", 216, 221], ["respiratory signs", "DISEASE", 177, 194], ["ocular and nasal discharge", "DISEASE", 205, 231], ["coughing", "DISEASE", 236, 244], ["ocular", "ORGANISM_SUBDIVISION", 205, 211], ["nasal", "ORGANISM_SUBDIVISION", 216, 221], ["The study", "TEST", 0, 9], ["clinical samples", "TEST", 119, 135], ["respiratory signs", "PROBLEM", 177, 194], ["ocular and nasal discharge", "PROBLEM", 205, 231], ["coughing", "PROBLEM", 236, 244], ["respiratory", "ANATOMY", 177, 188], ["ocular", "ANATOMY", 205, 211], ["nasal", "ANATOMY", 216, 221], ["discharge", "OBSERVATION", 222, 231], ["coughing", "OBSERVATION", 236, 244]]], ["After a few days, the pup developed fever (39.5-40.0 \u2022 C), anorexia, vomiting and hemorrhagic diarrhea which resolved within 20 days, while a slight prostration persisted after recovery.", [["pup", "ANATOMY", 22, 25], ["fever", "DISEASE", 36, 41], ["anorexia", "DISEASE", 59, 67], ["vomiting", "DISEASE", 69, 77], ["hemorrhagic diarrhea", "DISEASE", 82, 102], ["pup", "ORGANISM_SUBDIVISION", 22, 25], ["fever", "PROBLEM", 36, 41], ["anorexia", "PROBLEM", 59, 67], ["vomiting", "PROBLEM", 69, 77], ["hemorrhagic diarrhea", "PROBLEM", 82, 102], ["a slight prostration", "PROBLEM", 140, 160], ["fever", "OBSERVATION", 36, 41], ["anorexia", "OBSERVATION", 59, 67], ["hemorrhagic", "OBSERVATION_MODIFIER", 82, 93], ["diarrhea", "OBSERVATION", 94, 102], ["slight", "OBSERVATION_MODIFIER", 142, 148], ["prostration", "OBSERVATION", 149, 160]]], ["One month after hospitalization, fever and progressive neurological symptoms (ataxia, paresis and paralysis) were observed, and after 9 days the animal died.Animals and clinical samplesDog B was 8 months old and presented with systemic disease, characterized by fever (39.4 \u2022 C), lethargy, nasal discharge, conjunctivitis and hyperkeratosis of nose.", [["neurological", "ANATOMY", 55, 67], ["nasal", "ANATOMY", 290, 295], ["nose", "ANATOMY", 344, 348], ["fever", "DISEASE", 33, 38], ["neurological symptoms", "DISEASE", 55, 76], ["ataxia", "DISEASE", 78, 84], ["paresis", "DISEASE", 86, 93], ["paralysis", "DISEASE", 98, 107], ["systemic disease", "DISEASE", 227, 243], ["fever", "DISEASE", 262, 267], ["lethargy", "DISEASE", 280, 288], ["conjunctivitis", "DISEASE", 307, 321], ["hyperkeratosis of nose", "DISEASE", 326, 348], ["nasal", "ORGANISM_SUBDIVISION", 290, 295], ["nose", "ORGANISM_SUBDIVISION", 344, 348], ["fever", "PROBLEM", 33, 38], ["progressive neurological symptoms", "PROBLEM", 43, 76], ["ataxia", "PROBLEM", 78, 84], ["paresis", "PROBLEM", 86, 93], ["paralysis", "PROBLEM", 98, 107], ["systemic disease", "PROBLEM", 227, 243], ["fever", "PROBLEM", 262, 267], ["lethargy", "PROBLEM", 280, 288], ["nasal discharge", "PROBLEM", 290, 305], ["conjunctivitis", "PROBLEM", 307, 321], ["hyperkeratosis of nose", "PROBLEM", 326, 348], ["progressive", "OBSERVATION_MODIFIER", 43, 54], ["systemic", "ANATOMY", 227, 235], ["disease", "OBSERVATION", 236, 243], ["fever", "OBSERVATION", 262, 267], ["nasal", "ANATOMY", 290, 295], ["conjunctivitis", "OBSERVATION", 307, 321], ["hyperkeratosis", "OBSERVATION", 326, 340], ["nose", "ANATOMY", 344, 348]]], ["However, the dog quickly recovered within one week.Animals and clinical samplesThe animals were examined daily and the clinical data relative were recorded.", [["samples", "ANATOMY", 72, 79], ["dog", "ORGANISM", 13, 16], ["animals", "ORGANISM", 83, 90], ["clinical samples", "TEST", 63, 79], ["the clinical data", "TEST", 115, 132]]], ["Whole blood, urine, rectal, nasal and conjunctival swabs were collected every four days from the animals.", [["Whole blood", "ANATOMY", 0, 11], ["urine", "ANATOMY", 13, 18], ["rectal", "ANATOMY", 20, 26], ["nasal", "ANATOMY", 28, 33], ["conjunctival swabs", "ANATOMY", 38, 56], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["rectal", "ORGANISM_SUBDIVISION", 20, 26], ["nasal", "ORGANISM_SUBDIVISION", 28, 33], ["conjunctival swabs", "ORGANISM_SUBSTANCE", 38, 56], ["Whole blood, urine", "TEST", 0, 18], ["conjunctival swabs", "TREATMENT", 38, 56], ["rectal", "ANATOMY", 20, 26], ["nasal", "ANATOMY", 28, 33], ["conjunctival swabs", "ANATOMY", 38, 56]]], ["The samples were processed for RNA extraction immediately or stored for a maximum of 48 h at \u221220 \u2022 C before use.Animals and clinical samplesSerum samples were collected weekly for evaluation of the antibody response to CDV using virus neutralization and ELISA.RNA-DNA extractionSpecimens were homogenized (10%, wt/vol) in Dulbecco's modified Eagle's medium (DMEM) and subsequently clarified by centrifuging at 2500 \u00d7 g for 10 min.", [["samples", "ANATOMY", 4, 11], ["samplesSerum samples", "ANATOMY", 133, 153], ["Animals", "ORGANISM", 112, 119], ["samplesSerum samples", "CANCER", 133, 153], ["CDV", "ORGANISM", 219, 222], ["DNA", "CELLULAR_COMPONENT", 264, 267], ["CDV", "SPECIES", 219, 222], ["The samples", "TEST", 0, 11], ["RNA extraction", "TREATMENT", 31, 45], ["clinical samplesSerum samples", "TEST", 124, 153], ["evaluation", "TEST", 180, 190], ["the antibody response", "TEST", 194, 215], ["CDV", "PROBLEM", 219, 222], ["virus neutralization", "TREATMENT", 229, 249], ["ELISA", "TEST", 254, 259], ["RNA", "TEST", 260, 263], ["DNA extractionSpecimens", "TEST", 264, 287], ["wt/vol", "TEST", 311, 317]]], ["Each sample was prepared for RNA and DNA extraction by using QIAamp cador pathogen mini kit (Qiagen S.p.A., Milan, Italy), according to the manufacturer's instructions.CDV RNA detection and quantificationReal-time RT-PCR assay was performed for detection of CDV RNA.", [["sample", "ANATOMY", 5, 11], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["CDV", "ORGANISM", 168, 171], ["CDV", "ORGANISM", 258, 261], ["CDV RNA", "RNA", 168, 175], ["CDV RNA", "RNA", 258, 265], ["CDV", "SPECIES", 168, 171], ["CDV", "SPECIES", 258, 261], ["RNA", "TREATMENT", 29, 32], ["DNA extraction", "TREATMENT", 37, 51], ["CDV RNA detection", "TEST", 168, 185], ["quantification", "TEST", 190, 204], ["RT-PCR assay", "TEST", 214, 226], ["CDV RNA", "PROBLEM", 258, 265], ["CDV RNA", "OBSERVATION", 258, 265]]], ["All RNA extracts were subjected to reverse transcription in a reaction volume of 20 l containing PCR buffer 1\u00d7 (KCl 50 mM, Tris-HCl 10 mM, pH 8.3), MgCl 2 5 mM, 1 mM of each deoxynucleotide (dATP, dCTP, dGTP, dTTP), RNase Inhibitor 1 U, MuL V reverse transcriptase 2.5 U, random hexamers 2.5 U. Synthesis of c-DNA was carried out at 42 \u2022 C for 30 min, followed by a denaturation step at 99 \u2022 C for 5 min.CDV RNA detection and quantificationReal-time PCR and thermal protocols were carried out as previously described (Elia et al., 2006) .", [["extracts", "ANATOMY", 8, 16], ["KCl", "CHEMICAL", 112, 115], ["Tris-HCl", "CHEMICAL", 123, 131], ["MgCl", "CHEMICAL", 148, 152], ["deoxynucleotide", "CHEMICAL", 174, 189], ["dATP", "CHEMICAL", 191, 195], ["dCTP", "CHEMICAL", 197, 201], ["dGTP", "CHEMICAL", 203, 207], ["dTTP", "CHEMICAL", 209, 213], ["KCl", "CHEMICAL", 112, 115], ["Tris-HCl", "CHEMICAL", 123, 131], ["deoxynucleotide", "CHEMICAL", 174, 189], ["dATP", "CHEMICAL", 191, 195], ["dCTP", "CHEMICAL", 197, 201], ["dGTP", "CHEMICAL", 203, 207], ["dTTP", "CHEMICAL", 209, 213], ["deoxynucleotide", "SIMPLE_CHEMICAL", 174, 189], ["dATP", "SIMPLE_CHEMICAL", 191, 195], ["dCTP", "SIMPLE_CHEMICAL", 197, 201], ["dGTP", "SIMPLE_CHEMICAL", 203, 207], ["dTTP", "SIMPLE_CHEMICAL", 209, 213], ["RNase Inhibitor 1 U", "GENE_OR_GENE_PRODUCT", 216, 235], ["c-", "GENE_OR_GENE_PRODUCT", 308, 310], ["DNA", "CELLULAR_COMPONENT", 310, 313], ["CDV", "ORGANISM", 404, 407], ["RNase", "PROTEIN", 216, 221], ["MuL V reverse transcriptase", "PROTEIN", 237, 264], ["c-DNA", "DNA", 308, 313], ["CDV RNA", "RNA", 404, 411], ["CDV", "SPECIES", 404, 407], ["All RNA extracts", "PROBLEM", 0, 16], ["a reaction volume", "TEST", 60, 77], ["PCR buffer", "TREATMENT", 97, 107], ["KCl", "TEST", 112, 115], ["Tris", "TEST", 123, 127], ["HCl", "TEST", 128, 131], ["pH", "TEST", 139, 141], ["MgCl", "TEST", 148, 152], ["deoxynucleotide", "TEST", 174, 189], ["dATP", "TEST", 191, 195], ["dCTP", "TEST", 197, 201], ["dGTP", "TEST", 203, 207], ["dTTP", "TEST", 209, 213], ["RNase Inhibitor", "TREATMENT", 216, 231], ["MuL V reverse transcriptase", "TREATMENT", 237, 264], ["random hexamers", "TREATMENT", 272, 287], ["Synthesis of c-DNA", "TREATMENT", 295, 313], ["a denaturation step", "PROBLEM", 364, 383], ["CDV RNA detection", "TEST", 404, 421], ["thermal protocols", "TEST", 458, 475]]], ["Briefly, the realtime was carried out in a 50 l-reaction containing 25 l of IQTM Supermix (Bio-Rad Laboratories Srl, Milan, Italy), 600 nM of primer CDV-F (5 -AGCTAGTTTCATCTTAACTATCAAATT-3 ) and CDV-R (5 -TTAACTCTCCAGAAAACTCATGC-3 ) 400 nM of probe CDV-Pb (FAM-ACCCAAGAGCCGGATACATAGTTTCAATGC-TAMRA) and 20 l of c-DNA.CDV RNA detection and quantificationDuplicates of log 10 dilutions of standard RNA were analyzed simultaneously in order to obtain a standard curve for absolute quantification.", [["CDV-Pb", "CHEMICAL", 249, 255], ["Pb", "CHEMICAL", 253, 255], ["FAM-ACCCAAGAGCCGGATACATAGTTTCAATGC-TAMRA", "CHEMICAL", 257, 297], ["CDV", "ORGANISM", 195, 198], ["CDV", "ORGANISM", 249, 252], ["CDV", "ORGANISM", 317, 320], ["CDV RNA", "RNA", 317, 324], ["CDV", "SPECIES", 317, 320], ["primer CDV", "TEST", 142, 152], ["AGCTAGTTTCATCTTAACTATCAAATT", "TEST", 159, 186], ["CDV", "TEST", 195, 198], ["TTAACTCTCCAGAAAACTCATGC", "TEST", 205, 228], ["probe CDV", "TEST", 243, 252], ["FAM-ACCCAAGAGCCGGATACATAGTTTCAATGC", "TEST", 257, 291], ["c-DNA.", "PROBLEM", 311, 317], ["CDV RNA detection", "TEST", 317, 334], ["standard RNA", "TREATMENT", 387, 399], ["a standard curve", "TEST", 448, 464], ["absolute quantification", "TEST", 469, 492]]], ["All standard dilutions and unknown samples were tested in duplicate.", [["samples", "ANATOMY", 35, 42], ["All standard dilutions", "TREATMENT", 0, 22]]], ["The following thermal protocol was used: activation of iTaq DNA polymerase at 95 \u2022 C for 10 min and 45 cycles consisting of denaturation at 95 \u2022 C for 15 s, primer annealing at 48 \u2022 C for 1 min and extension at 60 \u2022 C for 1 min.CDV genotypingReverse transcription-PCR genotyping of the hemagglutinin (H) gene (Martella et al., 2007) was used to characterize CDV the strains.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["CDV", "ORGANISM", 228, 231], ["hemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 286, 303], ["CDV", "ORGANISM", 358, 361], ["iTaq DNA polymerase", "PROTEIN", 55, 74], ["hemagglutinin (H) gene", "DNA", 286, 308], ["CDV", "SPECIES", 228, 231], ["CDV", "SPECIES", 358, 361], ["The following thermal protocol", "TREATMENT", 0, 30], ["iTaq DNA polymerase", "TREATMENT", 55, 74], ["denaturation", "TEST", 124, 136], ["CDV genotyping", "TEST", 228, 242], ["Reverse transcription", "TEST", 242, 263], ["PCR genotyping", "TEST", 264, 278], ["CDV the strains", "PROBLEM", 358, 373]]], ["Briefly, the RNA was reversed transcribed and the cDNA used for the first PCR amplification.", [["cDNA", "DNA", 50, 54], ["the cDNA", "TREATMENT", 46, 54], ["the first PCR amplification", "TREATMENT", 64, 91]]], ["The resulting amplicon was therefore used as template for the second-round PCR, using a panel of primers gives specific for different CDV genotypes.Screening for other viral pathogensThe samples were screened molecularly for common canine viral pathogens such as canine parvovirus type 2 (CPV-2) (real-time PCR) (Decaro et al., 2005a,b,c) , canine adenovirus type 1 and type 2 (CAV-1 and CAV-2) (PCR) (Hu et al., 2001) , canine coronavirus (CCoV) (real-time PCR) (Decaro et al., 2004 (Decaro et al., , 2005b , canine respiratory coronavirus (RT-PCR) (Erles et al., 2003) and reoviruses (Decaro et al., 2005a,b,c) .Serological assaysSerum samples were tested by virus neutralization and ELISA.", [["samples", "ANATOMY", 187, 194], ["assaysSerum samples", "ANATOMY", 626, 645], ["canine coronavirus", "DISEASE", 421, 439], ["respiratory coronavirus", "DISEASE", 517, 540], ["CDV", "ORGANISM", 134, 137], ["canine", "ORGANISM", 232, 238], ["canine parvovirus type 2", "ORGANISM", 263, 287], ["CPV-2", "ORGANISM", 289, 294], ["b,c", "GENE_OR_GENE_PRODUCT", 334, 337], ["canine adenovirus type 1", "ORGANISM", 341, 365], ["CAV-1", "GENE_OR_GENE_PRODUCT", 378, 383], ["CAV-2", "CELL", 388, 393], ["canine coronavirus", "ORGANISM", 421, 439], ["canine respiratory coronavirus", "ORGANISM", 510, 540], ["assaysSerum samples", "CANCER", 626, 645], ["canine", "SPECIES", 232, 238], ["canine parvovirus", "SPECIES", 263, 280], ["canine", "SPECIES", 341, 347], ["canine coronavirus", "SPECIES", 421, 439], ["canine respiratory coronavirus", "SPECIES", 510, 540], ["CDV", "SPECIES", 134, 137], ["canine", "SPECIES", 232, 238], ["canine parvovirus type 2", "SPECIES", 263, 287], ["CPV", "SPECIES", 289, 292], ["canine adenovirus type 1", "SPECIES", 341, 365], ["canine coronavirus", "SPECIES", 421, 439], ["CCoV", "SPECIES", 441, 445], ["canine respiratory coronavirus", "SPECIES", 510, 540], ["The resulting amplicon", "TREATMENT", 0, 22], ["the second-round PCR", "TREATMENT", 58, 78], ["a panel of primers", "TREATMENT", 86, 104], ["different CDV genotypes", "PROBLEM", 124, 147], ["Screening", "TEST", 148, 157], ["other viral pathogens", "PROBLEM", 162, 183], ["The samples", "TEST", 183, 194], ["common canine viral pathogens", "PROBLEM", 225, 254], ["canine parvovirus type", "TEST", 263, 285], ["CPV", "TEST", 289, 292], ["PCR", "TEST", 307, 310], ["Decaro et al.", "TEST", 313, 326], ["canine adenovirus type 1", "PROBLEM", 341, 365], ["CAV", "TEST", 378, 381], ["CAV", "TEST", 388, 391], ["PCR", "TEST", 396, 399], ["Hu et al.", "TEST", 402, 411], ["canine coronavirus (CCoV", "PROBLEM", 421, 445], ["canine respiratory coronavirus", "TEST", 510, 540], ["reoviruses", "PROBLEM", 575, 585], ["Serological assaysSerum samples", "TEST", 614, 645], ["ELISA", "TEST", 686, 691], ["canine coronavirus", "ANATOMY", 421, 439], ["respiratory coronavirus", "ANATOMY", 517, 540]]], ["For virus neutralization, twofold serial dilutions starting from 1/2 of each serum were mixed with 100 tissue culture infectious doses (TCID)50 of the CDV strain Onderstepoort in 96-well microplates.", [["serum", "ANATOMY", 77, 82], ["tissue", "ANATOMY", 103, 109], ["Onderstepoort", "CHEMICAL", 162, 175], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["CDV", "ORGANISM", 151, 154], ["CDV", "SPECIES", 151, 154], ["virus neutralization", "TREATMENT", 4, 24], ["twofold serial dilutions", "TREATMENT", 26, 50], ["each serum", "TEST", 72, 82], ["the CDV strain Onderstepoort", "TEST", 147, 175]]], ["After pre-incubation at room temperature for 60 min, 2 \u00d7 10 3 VERO cells were added to each well.", [["VERO cells", "ANATOMY", 62, 72], ["VERO cells", "CELL", 62, 72], ["VERO cells", "CELL_LINE", 62, 72], ["3 VERO cells", "TREATMENT", 60, 72]]], ["The plates were read after 3 days of incubation at 37 \u2022 C in a CO 2 incubator.", [["CO 2", "CHEMICAL", 63, 67], ["incubation", "TREATMENT", 37, 47], ["a CO 2 incubator", "TREATMENT", 61, 77]]], ["The titer of each serum was expressed as the highest serum dilution neutralizing the virus.Serological assaysFor ELISA, in-house test based on whole-virus antigen was developed, as described previously for CCoV (Pratelli et al., 2002) .", [["serum", "ANATOMY", 18, 23], ["serum", "ANATOMY", 53, 58], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["CCoV", "SPECIES", 206, 210], ["The titer of each serum", "TEST", 0, 23], ["the highest serum dilution neutralizing the virus", "PROBLEM", 41, 90], ["Serological assays", "TEST", 91, 109], ["ELISA", "TEST", 113, 118], ["-house test", "TEST", 122, 133], ["whole-virus antigen", "TEST", 143, 162]]], ["Supernatants of VERO cell cultures infected with CDV strain Ondersterpoort were used for antigen preparation.", [["Supernatants", "ANATOMY", 0, 12], ["VERO cell cultures", "ANATOMY", 16, 34], ["Ondersterpoort", "CHEMICAL", 60, 74], ["Supernatants", "CELL", 0, 12], ["VERO cell cultures", "CELL", 16, 34], ["CDV strain Ondersterpoort", "ORGANISM", 49, 74], ["VERO cell cultures", "CELL_LINE", 16, 34], ["CDV", "SPECIES", 49, 52], ["VERO cell cultures", "TEST", 16, 34], ["CDV strain Ondersterpoort", "TREATMENT", 49, 74], ["antigen preparation", "TREATMENT", 89, 108], ["VERO cell cultures", "OBSERVATION", 16, 34], ["infected", "OBSERVATION_MODIFIER", 35, 43], ["CDV strain", "OBSERVATION", 49, 59]]], ["Briefly, polysorb microtiter plates (Nunc, Milan, Italy) were coated with antigen (250 ng/well).", [["polysorb", "CHEMICAL", 9, 17], ["polysorb microtiter plates", "TREATMENT", 9, 35], ["Nunc", "TEST", 37, 41]]], ["After treatment with blocking solution (0.2% gelatin in carbonate buffer) and repeated washing, 100 l of each dog serum diluted 1:50 in PBS-Tween 20 was added in duplicate and the plates incubated at 37 \u2022 C for 90 min.", [["serum", "ANATOMY", 114, 119], ["gelatin in carbonate", "CHEMICAL", 45, 65], ["carbonate", "CHEMICAL", 56, 65], ["Tween 20", "CHEMICAL", 140, 148], ["gelatin", "SIMPLE_CHEMICAL", 45, 52], ["carbonate", "SIMPLE_CHEMICAL", 56, 65], ["dog", "ORGANISM", 110, 113], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["PBS-Tween 20", "SIMPLE_CHEMICAL", 136, 148], ["dog", "SPECIES", 110, 113], ["dog", "SPECIES", 110, 113], ["blocking solution", "TREATMENT", 21, 38], ["0.2% gelatin in carbonate buffer", "TREATMENT", 40, 72], ["repeated washing", "TREATMENT", 78, 94], ["the plates", "TEST", 176, 186]]], ["After a wash cycle, goat anti-dog IgG antibody labeled with peroxidase (Sigma-Aldrich, Milan, Italy) was added and the plates incubated for 60 min at 37 \u2022 C. After an additional three washes, ABTS [2,2 -azino-di-(3-ethylbenzothiazoline sulfonate)] substrate solution (Sigma-Aldrich, Milan, Italy) was added to each well and the plate was incubated at room temperature for 25 min.", [["ABTS", "CHEMICAL", 192, 196], ["2,2 -azino-di-(3-ethylbenzothiazoline sulfonate", "CHEMICAL", 198, 245], ["ABTS", "CHEMICAL", 192, 196], ["2,2 -azino-di-(3-ethylbenzothiazoline sulfonate)]", "CHEMICAL", 198, 247], ["goat", "ORGANISM", 20, 24], ["peroxidase", "GENE_OR_GENE_PRODUCT", 60, 70], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 72, 85], ["ABTS [2,2 -azino-di-(3-ethylbenzothiazoline sulfonate", "SIMPLE_CHEMICAL", 192, 245], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 268, 281], ["goat anti-dog IgG antibody", "PROTEIN", 20, 46], ["peroxidase", "PROTEIN", 60, 70], ["goat", "SPECIES", 20, 24], ["goat", "SPECIES", 20, 24], ["a wash cycle", "TREATMENT", 6, 18], ["goat anti-dog IgG antibody", "TEST", 20, 46], ["peroxidase", "TEST", 60, 70], ["the plates", "TREATMENT", 115, 125], ["an additional three washes", "TREATMENT", 164, 190], ["ABTS", "TEST", 192, 196], ["azino-di-(3-ethylbenzothiazoline sulfonate)", "TREATMENT", 203, 246]]], ["The optical density (OD) was read at 405 nm using an automatic ELISA reader.Serological assaysTen control negative sera were used to adjust the Elisa cut-off value (three standard deviations higher than the arithmetic mean of the absorbance of concordantly negative samples).", [["sera", "ANATOMY", 115, 119], ["samples", "ANATOMY", 266, 273], ["sera", "ORGANISM_SUBSTANCE", 115, 119], ["Serological assays", "TEST", 76, 94], ["the Elisa", "TEST", 140, 149], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19]]], ["Samples with value exceeding than 0.040 were considered to be positive.ResultsBy real-time RT-PCR, CDV infection was confirmed in both animals at the day of recovery.", [["Samples", "ANATOMY", 0, 7], ["infection", "DISEASE", 103, 112], ["CDV", "ORGANISM", 99, 102], ["CDV", "SPECIES", 99, 102], ["Samples", "TEST", 0, 7], ["value", "TEST", 13, 18], ["PCR", "TEST", 94, 97], ["CDV infection", "PROBLEM", 99, 112], ["CDV", "OBSERVATION_MODIFIER", 99, 102], ["infection", "OBSERVATION", 103, 112]]], ["In animal A, all the collected samples tested positive for CDV, while in dog B CDV was detected only in urine and rectal swab.", [["samples", "ANATOMY", 31, 38], ["urine", "ANATOMY", 104, 109], ["rectal swab", "ANATOMY", 114, 125], ["CDV", "ORGANISM", 59, 62], ["dog B CDV", "ORGANISM", 73, 82], ["urine", "ORGANISM_SUBSTANCE", 104, 109], ["rectal swab", "ORGANISM_SUBSTANCE", 114, 125], ["dog B CDV", "SPECIES", 73, 82], ["CDV", "SPECIES", 59, 62], ["dog B CDV", "SPECIES", 73, 82], ["all the collected samples", "TEST", 13, 38], ["CDV", "PROBLEM", 59, 62], ["dog B CDV", "TEST", 73, 82], ["urine", "TEST", 104, 109], ["rectal swab", "TEST", 114, 125], ["rectal", "ANATOMY", 114, 120]]], ["Sample from both animals tested negative for other viral pathogens.", [["Sample from both animals", "TEST", 0, 24], ["other viral pathogens", "PROBLEM", 45, 66], ["viral pathogens", "OBSERVATION", 51, 66]]], ["Based on the RT-PCR genotyping, the CDV strains were characterized as Arctic genotype.ResultsReal-time RT-PCR was used to screen all the collected samples.", [["samples", "ANATOMY", 147, 154], ["CDV", "ORGANISM", 36, 39], ["CDV", "SPECIES", 36, 39], ["the RT-PCR genotyping", "TEST", 9, 30], ["the CDV strains", "TEST", 32, 47], ["Arctic genotype", "PROBLEM", 70, 85], ["PCR", "TEST", 106, 109], ["Arctic genotype", "OBSERVATION", 70, 85]]], ["Dog A was found to shed virus in all the samples with consistently higher viral RNA load in urine, rectal, nasal and conjunctival swabs (Table 1) .", [["samples", "ANATOMY", 41, 48], ["urine", "ANATOMY", 92, 97], ["rectal", "ANATOMY", 99, 105], ["nasal", "ANATOMY", 107, 112], ["conjunctival swabs", "ANATOMY", 117, 135], ["Dog", "ORGANISM", 0, 3], ["urine", "ORGANISM_SUBSTANCE", 92, 97], ["rectal", "ORGANISM_SUBDIVISION", 99, 105], ["nasal", "MULTI-TISSUE_STRUCTURE", 107, 112], ["conjunctival swabs", "TISSUE", 117, 135], ["shed virus", "PROBLEM", 19, 29], ["consistently higher viral RNA load in urine", "PROBLEM", 54, 97], ["rectal, nasal and conjunctival swabs", "TEST", 99, 135], ["virus", "OBSERVATION", 24, 29], ["viral RNA load", "OBSERVATION", 74, 88], ["rectal", "ANATOMY", 99, 105], ["nasal", "ANATOMY", 107, 112], ["conjunctival swabs", "ANATOMY", 117, 135]]], ["Moreover, all the samples tested positive for CDV at all the sampling times, with a virus load higher than 1.06 \u00d7 10 4 RNA copies/L of template 37 days after hospitalization.ResultsDog B was consistently positive for CDV in urine samples until 50 days after hospitalization (Table 1) .", [["samples", "ANATOMY", 18, 25], ["urine samples", "ANATOMY", 224, 237], ["CDV", "ORGANISM", 46, 49], ["Dog B", "CELL", 181, 186], ["CDV", "ORGANISM", 217, 220], ["urine samples", "ORGANISM_SUBSTANCE", 224, 237], ["CDV", "SPECIES", 46, 49], ["CDV", "SPECIES", 217, 220], ["all the samples", "TEST", 10, 25], ["CDV", "PROBLEM", 46, 49], ["a virus load", "TEST", 82, 94], ["CDV in urine samples", "PROBLEM", 217, 237]]], ["Peaks in viral loads were recorded from 10 to 22 days after hospitalization with a mean titer of 1.47 \u00d7 10 4 RNA copies/l of template.", [["Peaks in viral loads", "PROBLEM", 0, 20], ["a mean titer", "TEST", 81, 93], ["viral loads", "OBSERVATION", 9, 20]]], ["In the remaining observation period, the mean viral load detected in urine was 7.22 \u00d7 10 2 RNA copies/l of template.", [["urine", "ANATOMY", 69, 74], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["the mean viral load", "TEST", 37, 56], ["urine", "TEST", 69, 74], ["RNA copies", "TEST", 91, 101], ["viral load", "OBSERVATION", 46, 56]]], ["Interestingly, rectal swabs resulted consistently positive from 1 to 36 days of hospitalization with the highest viral load (5.71 \u00d7 10 4 RNA copies/l of template) detected at day 10.", [["rectal swabs", "ANATOMY", 15, 27], ["rectal swabs", "ORGANISM_SUBSTANCE", 15, 27], ["rectal swabs", "TEST", 15, 27], ["the highest viral load", "TEST", 101, 123], ["RNA copies", "TEST", 137, 147], ["rectal", "ANATOMY", 15, 21]]], ["Blood, nasal and conjunctival swabs of dog B tested negative at hospitalization.", [["Blood", "ANATOMY", 0, 5], ["nasal", "ANATOMY", 7, 12], ["conjunctival swabs", "ANATOMY", 17, 35], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["nasal", "ORGANISM_SUBDIVISION", 7, 12], ["conjunctival swabs", "ORGANISM_SUBSTANCE", 17, 35], ["dog", "ORGANISM", 39, 42], ["B", "CELL", 43, 44], ["dog B", "SPECIES", 39, 44], ["Blood", "TEST", 0, 5], ["nasal and conjunctival swabs of dog B tested", "TEST", 7, 51], ["nasal", "ANATOMY", 7, 12], ["conjunctival", "ANATOMY", 17, 29]]], ["The virus was detected only occasionally and with low viral titer in the first month, while it was no longer detected after the 32nd day of hospitalization.SerologyThe animals were screened for the presence of antibodies against CDV.", [["animals", "ORGANISM", 168, 175], ["CDV", "ORGANISM", 229, 232], ["antibodies", "PROTEIN", 210, 220], ["CDV", "SPECIES", 229, 232], ["The virus", "PROBLEM", 0, 9], ["low viral titer", "PROBLEM", 50, 65], ["Serology", "TEST", 156, 164], ["antibodies", "PROBLEM", 210, 220], ["CDV", "PROBLEM", 229, 232], ["virus", "OBSERVATION", 4, 9], ["no longer", "UNCERTAINTY", 99, 108]]], ["Blood samples were collected at arrival (day 1), and then at day 15 and at day 35 of hospitalization.SerologyAntibodies against CDV were not detected in the sera collected from dog A by virus neutralization.", [["Blood samples", "ANATOMY", 0, 13], ["sera", "ANATOMY", 157, 161], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["SerologyAntibodies", "SIMPLE_CHEMICAL", 101, 119], ["CDV", "ORGANISM", 128, 131], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["dog A", "ORGANISM", 177, 182], ["CDV", "SPECIES", 128, 131], ["dog A", "SPECIES", 177, 182], ["Blood samples", "TEST", 0, 13], ["SerologyAntibodies", "TEST", 101, 119], ["CDV", "PROBLEM", 128, 131], ["the sera", "TEST", 153, 161]]], ["However, in ELISA a slightly immune response against CDV was detected with an OD value of 0.067 at day 1.", [["CDV", "ORGANISM", 53, 56], ["CDV", "SPECIES", 53, 56], ["CDV", "PROBLEM", 53, 56], ["an OD value", "TEST", 75, 86]]], ["This reactivity did not increase with time (0.071 and 0.060, at day 15 and day 35, respectively).", [["increase", "OBSERVATION_MODIFIER", 24, 32]]], ["By converse, in dog B the virus neutralization antibodies against CDV ranged from 1:320 at day 1 to 1:160 at day 15 and day 35.", [["dog B", "ORGANISM", 16, 21], ["CDV", "ORGANISM", 66, 69], ["virus neutralization antibodies", "PROTEIN", 26, 57], ["CDV", "SPECIES", 66, 69], ["the virus neutralization antibodies", "TEST", 22, 57], ["CDV", "PROBLEM", 66, 69]]], ["These results were confirmed by ELISA, with an high OD mean value of 0.245.DiscussionCD is a major disease of dog, characterized by high morbidity and mortality rates.", [["dog", "ORGANISM", 110, 113], ["ELISA", "TEST", 32, 37], ["a major disease of dog", "PROBLEM", 91, 113], ["high morbidity and mortality rates", "PROBLEM", 132, 166], ["high", "OBSERVATION_MODIFIER", 132, 136], ["morbidity", "OBSERVATION", 137, 146]]], ["In affected dogs, CDV may cause a large variety of clinical signs.", [["CDV", "DISEASE", 18, 21], ["dogs", "ORGANISM", 12, 16], ["CDV", "ORGANISM", 18, 21], ["dogs", "SPECIES", 12, 16], ["CDV", "SPECIES", 18, 21], ["affected dogs", "PROBLEM", 3, 16], ["CDV", "PROBLEM", 18, 21], ["affected", "OBSERVATION_MODIFIER", 3, 11], ["dogs", "OBSERVATION", 12, 16], ["large", "OBSERVATION_MODIFIER", 34, 39], ["variety", "OBSERVATION_MODIFIER", 40, 47]]], ["Depending on the age, the immune status of the host and the virus strain, the infection can lead to abortive, clinical or subclinical disease.", [["infection", "DISEASE", 78, 87], ["the host", "PROBLEM", 43, 51], ["the virus strain", "PROBLEM", 56, 72], ["the infection", "PROBLEM", 74, 87], ["abortive, clinical or subclinical disease", "PROBLEM", 100, 141], ["infection", "OBSERVATION", 78, 87], ["subclinical disease", "OBSERVATION", 122, 141]]], ["Many dogs do not display the classical clinical picture, thus making CD diagnosis difficult (Amude et al., 2007) .DiscussionThe cases of CD described in this study confirm the clinical variability of CDV infection and the importance of choosing appropriate biological samples for diagnosis.", [["samples", "ANATOMY", 268, 275], ["CD", "DISEASE", 69, 71], ["CD", "DISEASE", 137, 139], ["CDV infection", "DISEASE", 200, 213], ["dogs", "ORGANISM", 5, 9], ["CDV", "ORGANISM", 200, 203], ["dogs", "SPECIES", 5, 9], ["CDV", "SPECIES", 200, 203], ["CD", "PROBLEM", 137, 139], ["this study", "TEST", 153, 163], ["CDV infection", "PROBLEM", 200, 213], ["CDV infection", "OBSERVATION", 200, 213]]], ["Previous studies on CDV shedding were carried out in dogs infected experimentally.", [["CDV", "ORGANISM", 20, 23], ["dogs", "ORGANISM", 53, 57], ["dogs", "SPECIES", 53, 57], ["CDV", "SPECIES", 20, 23], ["Previous studies", "TEST", 0, 16], ["CDV shedding", "TEST", 20, 32], ["infected", "OBSERVATION", 58, 66]]], ["In this study we were able to follow the disease in dogs infected naturally, collecting different biological matrices during the entire period of infection.DiscussionDog A experienced systemic clinical signs of CD followed by a 10-days period of apparent health, during which it was difficult to suspect CD.", [["infection", "DISEASE", 146, 155], ["CD", "DISEASE", 211, 213], ["CD", "DISEASE", 304, 306], ["dogs", "ORGANISM", 52, 56], ["dogs", "SPECIES", 52, 56], ["this study", "TEST", 3, 13], ["the disease in dogs infected naturally", "PROBLEM", 37, 75], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 146, 155]]], ["However, in this phase the animal shed the virus at high titers in all the body fluids, thus posing a serious threat for other susceptible dogs in close contact with the animal.", [["body fluids", "ANATOMY", 75, 86], ["body", "ORGANISM_SUBDIVISION", 75, 79], ["dogs", "ORGANISM", 139, 143], ["dogs", "SPECIES", 139, 143], ["the virus", "PROBLEM", 39, 48], ["virus", "OBSERVATION", 43, 48]]], ["In such epidemiological circumstances, a wrong or delayed diagnosis of CDV infection may have dramatic consequences.", [["CDV infection", "DISEASE", 71, 84], ["CDV", "ORGANISM", 71, 74], ["CDV", "SPECIES", 71, 74], ["CDV infection", "PROBLEM", 71, 84], ["CDV infection", "OBSERVATION", 71, 84]]], ["As expected, in the serum samples collected from dog A, CDV-specific antibodies were not detected in virus neutralization, and were rather low in ELISA.", [["serum samples", "ANATOMY", 20, 33], ["serum samples", "ORGANISM_SUBSTANCE", 20, 33], ["dog", "ORGANISM", 49, 52], ["CDV", "ORGANISM", 56, 59], ["CDV-specific antibodies", "PROTEIN", 56, 79], ["dog A", "SPECIES", 49, 54], ["CDV", "SPECIES", 56, 59], ["the serum samples", "TEST", 16, 33], ["CDV", "TEST", 56, 59], ["specific antibodies", "TEST", 60, 79], ["virus neutralization", "PROBLEM", 101, 121]]], ["These results may be accounted for by the fact that ELISA technique can detect antibodies to all the viral proteins, including the major internal N protein that elicits the highest antibody response in morbillivirus infections (von Messling et al., 1999) .", [["morbillivirus infections", "DISEASE", 202, 226], ["morbillivirus", "ORGANISM", 202, 215], ["antibodies", "PROTEIN", 79, 89], ["viral proteins", "PROTEIN", 101, 115], ["N protein", "PROTEIN", 146, 155], ["ELISA technique", "TEST", 52, 67], ["antibodies", "PROBLEM", 79, 89], ["the viral proteins", "TEST", 97, 115], ["morbillivirus infections", "PROBLEM", 202, 226], ["morbillivirus infections", "OBSERVATION", 202, 226]]], ["This would suggest that it is better to use assays based either on the whole virion or on the N protein when evaluating CDV serological status.DiscussionDog B showed only few mild symptoms of infection and recovered completely within a week.", [["infection", "DISEASE", 192, 201], ["CDV", "ORGANISM", 120, 123], ["Dog B", "CELL", 153, 158], ["N protein", "PROTEIN", 94, 103], ["CDV", "SPECIES", 120, 123], ["the whole virion", "TREATMENT", 67, 83], ["the N protein", "TREATMENT", 90, 103], ["few mild symptoms of infection", "PROBLEM", 171, 201], ["few", "OBSERVATION_MODIFIER", 171, 174], ["mild", "OBSERVATION_MODIFIER", 175, 179], ["infection", "OBSERVATION", 192, 201]]], ["This is the typical pattern of CDV infection with dogs mounting an immune response able to clear the virus from the epithelial cells.", [["epithelial cells", "ANATOMY", 116, 132], ["infection", "DISEASE", 35, 44], ["CDV", "ORGANISM", 31, 34], ["dogs", "ORGANISM", 50, 54], ["epithelial cells", "CELL", 116, 132], ["epithelial cells", "CELL_TYPE", 116, 132], ["dogs", "SPECIES", 50, 54], ["CDV", "SPECIES", 31, 34], ["CDV infection", "PROBLEM", 31, 44], ["an immune response", "PROBLEM", 64, 82], ["the virus", "PROBLEM", 97, 106], ["CDV", "OBSERVATION_MODIFIER", 31, 34], ["infection", "OBSERVATION", 35, 44], ["epithelial cells", "OBSERVATION", 116, 132]]], ["Dog B displayed a good humoral reactivity against CDV, as observed by ELISA and virus neutralization, confirming this hypothesis.", [["Dog B", "CELL", 0, 5], ["CDV", "ORGANISM", 50, 53], ["Dog B", "PROTEIN", 0, 5], ["CDV", "SPECIES", 50, 53], ["CDV", "PROBLEM", 50, 53], ["ELISA", "TEST", 70, 75], ["virus neutralization", "TREATMENT", 80, 100], ["this hypothesis", "PROBLEM", 113, 128]]], ["At hospitalization, dog B tested positive for CDV only in the urine and rectal swab.", [["urine", "ANATOMY", 62, 67], ["rectal swab", "ANATOMY", 72, 83], ["dog", "ORGANISM", 20, 23], ["CDV", "ORGANISM", 46, 49], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["rectal swab", "ORGANISM_SUBSTANCE", 72, 83], ["CDV", "SPECIES", 46, 49], ["dog B", "TEST", 20, 25], ["CDV", "PROBLEM", 46, 49], ["the urine", "TEST", 58, 67], ["rectal swab", "TEST", 72, 83], ["urine", "ANATOMY", 62, 67], ["rectal", "ANATOMY", 72, 78]]], ["In these samples, CDV RNA was detected continuously during the entire observation period.DiscussionWhole blood, conjunctival swab and urine are usually recommended for CDV laboratory diagnosis (Saito et al., 2006; Kim et al., 2006; Shin et al., 2004; An et al., 2008) .", [["samples", "ANATOMY", 9, 16], ["blood", "ANATOMY", 105, 110], ["conjunctival swab", "ANATOMY", 112, 129], ["urine", "ANATOMY", 134, 139], ["samples", "CANCER", 9, 16], ["CDV", "ORGANISM", 18, 21], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["conjunctival swab", "ORGANISM_SUBSTANCE", 112, 129], ["urine", "ORGANISM_SUBSTANCE", 134, 139], ["CDV RNA", "RNA", 18, 25], ["CDV", "SPECIES", 18, 21], ["CDV", "SPECIES", 168, 171], ["CDV RNA", "PROBLEM", 18, 25], ["conjunctival swab and urine", "TEST", 112, 139], ["CDV RNA", "OBSERVATION", 18, 25], ["conjunctival", "ANATOMY", 112, 124], ["Shin", "ANATOMY", 232, 236]]], ["However, it is important to consider also the stage of the infection and the clinical form of the disease.", [["infection", "DISEASE", 59, 68], ["the infection", "PROBLEM", 55, 68], ["the disease", "PROBLEM", 94, 105], ["infection", "OBSERVATION", 59, 68], ["disease", "OBSERVATION", 98, 105]]], ["In this study blood and urine were found to be the samples more suitable for CDV diagnosis.", [["blood", "ANATOMY", 14, 19], ["urine", "ANATOMY", 24, 29], ["samples", "ANATOMY", 51, 58], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["urine", "ORGANISM_SUBSTANCE", 24, 29], ["CDV", "ORGANISM", 77, 80], ["CDV", "SPECIES", 77, 80], ["this study blood and urine", "TEST", 3, 29], ["the samples", "TEST", 47, 58], ["CDV diagnosis", "TEST", 77, 90]]], ["In dog A, CDV was detected by real-time PCR in blood and urine much more consistently than in the other samples (nasal and conjunctival swabs).", [["blood", "ANATOMY", 47, 52], ["urine", "ANATOMY", 57, 62], ["samples", "ANATOMY", 104, 111], ["nasal", "ANATOMY", 113, 118], ["conjunctival swabs", "ANATOMY", 123, 141], ["dog", "ORGANISM", 3, 6], ["CDV", "ORGANISM", 10, 13], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["urine", "ORGANISM_SUBSTANCE", 57, 62], ["nasal", "ORGANISM_SUBDIVISION", 113, 118], ["conjunctival swabs", "MULTI-TISSUE_STRUCTURE", 123, 141], ["CDV", "SPECIES", 10, 13], ["CDV", "PROBLEM", 10, 13], ["blood and urine", "TEST", 47, 62], ["nasal and conjunctival swabs", "TEST", 113, 141], ["nasal", "ANATOMY", 113, 118], ["conjunctival swabs", "ANATOMY", 123, 141]]], ["However only the urine tested positive in both dogs.", [["urine", "ANATOMY", 17, 22], ["urine", "ORGANISM_SUBSTANCE", 17, 22], ["dogs", "ORGANISM", 47, 51], ["dogs", "SPECIES", 47, 51], ["the urine", "TEST", 13, 22]]], ["Regardless of the clinical stage and form of the illness, urine seems to be the most appropriate sample for diagnosis.", [["urine", "ANATOMY", 58, 63], ["urine", "ORGANISM_SUBSTANCE", 58, 63], ["the clinical stage", "PROBLEM", 14, 32], ["the illness", "PROBLEM", 45, 56]]], ["Interestingly, as previously reported (Fischer et al., 2013) , both the animals were also positive in the rectal swabs, although the duration of shedding of CDV was shorter in the feces than in the urines.", [["rectal swabs", "ANATOMY", 106, 118], ["feces", "ANATOMY", 180, 185], ["urines", "ANATOMY", 198, 204], ["animals", "ORGANISM", 72, 79], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 106, 118], ["CDV", "ORGANISM", 157, 160], ["feces", "ORGANISM_SUBSTANCE", 180, 185], ["urines", "ORGANISM_SUBSTANCE", 198, 204], ["CDV", "SPECIES", 157, 160], ["the rectal swabs", "TEST", 102, 118], ["CDV", "PROBLEM", 157, 160], ["positive", "OBSERVATION", 90, 98], ["rectal swabs", "ANATOMY", 106, 118]]], ["Fecal samples are of easier collection in non-clinical settings and can also be used for parallel screening of other gastrointestinal pathogens.DiscussionSeveral recent reports suggest both the re-emergence and increased activity of CDV worldwide (Griot et al., 2003) .", [["Fecal samples", "ANATOMY", 0, 13], ["gastrointestinal", "ANATOMY", 117, 133], ["gastrointestinal pathogens", "DISEASE", 117, 143], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["gastrointestinal", "ORGANISM_SUBDIVISION", 117, 133], ["CDV", "ORGANISM", 233, 236], ["CDV", "SPECIES", 233, 236], ["Fecal samples", "TEST", 0, 13], ["easier collection", "PROBLEM", 21, 38], ["parallel screening", "TEST", 89, 107], ["other gastrointestinal pathogens", "PROBLEM", 111, 143], ["easier", "OBSERVATION_MODIFIER", 21, 27], ["collection", "OBSERVATION", 28, 38], ["gastrointestinal", "ANATOMY", 117, 133], ["pathogens", "OBSERVATION", 134, 143]]], ["Respiratory and enteric signs in CDV infected dogs may be confused with the signs caused by other respiratory and enteric pathogens, hindering early CDV diagnosis (Appel, 1970; Griot et al., 2003) .", [["respiratory", "ANATOMY", 98, 109], ["Respiratory and enteric signs", "DISEASE", 0, 29], ["CDV infected", "DISEASE", 33, 45], ["respiratory and enteric pathogens", "DISEASE", 98, 131], ["CDV", "ORGANISM", 33, 36], ["dogs", "ORGANISM", 46, 50], ["CDV", "ORGANISM", 149, 152], ["dogs", "SPECIES", 46, 50], ["CDV", "SPECIES", 33, 36], ["CDV", "SPECIES", 149, 152], ["Respiratory and enteric signs in CDV infected dogs", "PROBLEM", 0, 50], ["confused", "PROBLEM", 58, 66], ["the signs", "PROBLEM", 72, 81], ["other respiratory and enteric pathogens", "PROBLEM", 92, 131], ["enteric", "ANATOMY", 16, 23], ["respiratory", "ANATOMY", 98, 109], ["enteric", "ANATOMY", 114, 121], ["pathogens", "OBSERVATION", 122, 131]]], ["Therefore, rapid and accurate diagnosis of CDV infection would enable veterinarians to implement appropriate and timely strategies necessary to improve disease management and to prevent virus diffusion, particularly within a shelter environment.", [["CDV infection", "DISEASE", 43, 56], ["CDV", "ORGANISM", 43, 46], ["CDV", "SPECIES", 43, 46], ["CDV infection", "PROBLEM", 43, 56], ["disease management", "TREATMENT", 152, 170], ["virus diffusion", "PROBLEM", 186, 201], ["CDV infection", "OBSERVATION", 43, 56]]], ["The local and global epidemiology of CDV reinforces the importance of vaccination in dogs and the need for implementing an accurate and reliable diagnostic.", [["CDV", "DISEASE", 37, 40], ["CDV", "ORGANISM", 37, 40], ["dogs", "ORGANISM", 85, 89], ["dogs", "SPECIES", 85, 89], ["CDV", "SPECIES", 37, 40], ["vaccination in dogs", "TREATMENT", 70, 89], ["local", "OBSERVATION_MODIFIER", 4, 9]]]], "d49b66b0f13208ca89025bce31d7c437dcd554d7": [["Results: Fifty percentage of subjects reported allergy, 59% had \u22651 nasopharyngeal viruses, and 24% had \u22651 intratonsillar viruses.", [["nasopharyngeal", "ANATOMY", 67, 81], ["allergy", "DISEASE", 47, 54], ["nasopharyngeal viruses", "DISEASE", 67, 89], ["subjects", "ORGANISM", 29, 37], ["nasopharyngeal", "CANCER", 67, 81], ["allergy", "PROBLEM", 47, 54], ["\u22651 nasopharyngeal viruses", "PROBLEM", 64, 89], ["\u22651 intratonsillar viruses", "PROBLEM", 103, 128], ["nasopharyngeal", "ANATOMY", 67, 81], ["viruses", "OBSERVATION", 82, 89], ["intratonsillar viruses", "OBSERVATION", 106, 128]]], ["Tonsillar virus detection showed a strong negative association with age; especially rhinovirus or parainfluenza virus detection showed positive association with IFN-c and Tbet expressions.", [["Tonsillar virus", "ORGANISM", 0, 15], ["rhinovirus", "ORGANISM", 84, 94], ["parainfluenza virus", "ORGANISM", 98, 117], ["IFN-c", "GENE_OR_GENE_PRODUCT", 161, 166], ["Tbet", "GENE_OR_GENE_PRODUCT", 171, 175], ["IFN", "PROTEIN", 161, 164], ["Tbet", "PROTEIN", 171, 175], ["parainfluenza", "SPECIES", 98, 111], ["parainfluenza virus", "SPECIES", 98, 117], ["Tonsillar virus detection", "TEST", 0, 25], ["rhinovirus", "PROBLEM", 84, 94], ["parainfluenza virus detection", "PROBLEM", 98, 127], ["IFN", "TEST", 161, 164], ["virus", "OBSERVATION", 10, 15]]], ["IL-37 expression was positively associated with atopic dermatitis, whereas IFN-a, IL-13, IL-28, and Tbet expressions were negatively associated with allergic diseases.", [["atopic dermatitis", "DISEASE", 48, 65], ["allergic diseases", "DISEASE", 149, 166], ["IL-37", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-a", "GENE_OR_GENE_PRODUCT", 75, 80], ["IL-13", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-28", "GENE_OR_GENE_PRODUCT", 89, 94], ["Tbet", "GENE_OR_GENE_PRODUCT", 100, 104], ["IL-37", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 75, 78], ["Tbet", "PROTEIN", 100, 104], ["IL", "TEST", 0, 2], ["atopic dermatitis", "PROBLEM", 48, 65], ["IFN", "TEST", 75, 78], ["IL", "TEST", 82, 84], ["IL", "TEST", 89, 91], ["allergic diseases", "PROBLEM", 149, 166], ["positively associated with", "UNCERTAINTY", 21, 47], ["atopic dermatitis", "OBSERVATION", 48, 65], ["allergic diseases", "OBSERVATION", 149, 166]]], ["Network analyses demonstrated strongly polarized clusters of immune regulatory (IL-10, IL-17, TGF-b, FOXP3, GATA3, RORC2, Tbet) and antiviral (IFN-a, IFN-b, IL-28, IL-29) genes.", [["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-17", "GENE_OR_GENE_PRODUCT", 87, 92], ["TGF-b", "GENE_OR_GENE_PRODUCT", 94, 99], ["FOXP3", "GENE_OR_GENE_PRODUCT", 101, 106], ["GATA3", "GENE_OR_GENE_PRODUCT", 108, 113], ["RORC2", "GENE_OR_GENE_PRODUCT", 115, 120], ["Tbet", "GENE_OR_GENE_PRODUCT", 122, 126], ["IFN-a", "GENE_OR_GENE_PRODUCT", 143, 148], ["IFN-b", "GENE_OR_GENE_PRODUCT", 150, 155], ["IL-28", "GENE_OR_GENE_PRODUCT", 157, 162], ["IL-29", "GENE_OR_GENE_PRODUCT", 164, 169], ["TGF", "DNA", 94, 97], ["FOXP3", "DNA", 101, 106], ["GATA3", "DNA", 108, 113], ["RORC2", "DNA", 115, 120], ["Tbet", "DNA", 122, 126], ["antiviral (IFN-a, IFN-b, IL-28, IL-29) genes", "DNA", 132, 176], ["Network analyses", "TEST", 0, 16], ["immune regulatory", "TEST", 61, 78], ["IL", "TEST", 80, 82], ["IL", "TEST", 87, 89], ["TGF", "TEST", 94, 97], ["GATA3", "TEST", 108, 113], ["RORC2", "TEST", 115, 120], ["Tbet", "TEST", 122, 126], ["antiviral", "TREATMENT", 132, 141], ["IFN", "TEST", 143, 146], ["IFN", "TEST", 150, 153], ["IL", "TEST", 157, 159], ["IL", "TEST", 164, 166]]], ["These two clusters became more distinctive in the presence of viral infection or allergy.", [["viral infection", "DISEASE", 62, 77], ["allergy", "DISEASE", 81, 88], ["viral infection", "PROBLEM", 62, 77], ["allergy", "PROBLEM", 81, 88], ["clusters", "OBSERVATION_MODIFIER", 10, 18], ["more distinctive", "OBSERVATION_MODIFIER", 26, 42], ["viral", "OBSERVATION_MODIFIER", 62, 67], ["infection", "OBSERVATION", 68, 77]]], ["A negative correlation between antiviral cytokines and IL-10, IL-17, IL-37, FOXP3, and RORC2 was observed only in the presence of viruses, and interestingly, IL-13 strongly correlated with antiviral cytokines.", [["IL-10", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-17", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-37", "GENE_OR_GENE_PRODUCT", 69, 74], ["FOXP3", "GENE_OR_GENE_PRODUCT", 76, 81], ["RORC2", "GENE_OR_GENE_PRODUCT", 87, 92], ["IL-13", "GENE_OR_GENE_PRODUCT", 158, 163], ["antiviral cytokines", "PROTEIN", 31, 50], ["FOXP3", "PROTEIN", 76, 81], ["RORC2", "PROTEIN", 87, 92], ["IL-13", "PROTEIN", 158, 163], ["antiviral cytokines", "PROTEIN", 189, 208], ["antiviral cytokines", "TEST", 31, 50], ["IL", "TEST", 55, 57], ["IL", "TEST", 62, 64], ["IL", "TEST", 69, 71], ["FOXP3", "TREATMENT", 76, 81], ["RORC2", "TREATMENT", 87, 92], ["viruses", "PROBLEM", 130, 137], ["IL", "TEST", 158, 160], ["antiviral cytokines", "TREATMENT", 189, 208], ["negative", "OBSERVATION", 2, 10], ["viruses", "OBSERVATION", 130, 137], ["antiviral cytokines", "OBSERVATION", 189, 208]]]], "808f58f8f13279209cd4f9443798f23ddd55f8fb": [["Submitted to the \"Commentary\" sectionThe 2019 Coronavirus Disease (abbreviated COVID-19) was believed to be originated in Wuhan, China in late December, 2019.", [["Coronavirus Disease", "DISEASE", 46, 65], ["Coronavirus Disease", "PROBLEM", 46, 65], ["Coronavirus Disease", "OBSERVATION", 46, 65]]], ["This disease is rapidly transmitting to more than 200 countries, and has become a pandemic.", [["This disease", "PROBLEM", 0, 12], ["a pandemic", "PROBLEM", 80, 90], ["disease", "OBSERVATION", 5, 12], ["rapidly", "OBSERVATION_MODIFIER", 16, 23], ["pandemic", "OBSERVATION", 82, 90]]], ["With the rapid transmission of the COVID-19, Hong Kong has been confronted by the increasing number of confirmed and suspected cases daily, now exceeding 1,000 at the time of reporting.", [["rapid", "OBSERVATION_MODIFIER", 9, 14], ["increasing", "OBSERVATION_MODIFIER", 82, 92]]], ["Hong Kong people are beyond doubt in a state of anxiety, fear and helplessness.", [["anxiety", "DISEASE", 48, 55], ["helplessness", "DISEASE", 66, 78], ["people", "ORGANISM", 10, 16], ["people", "SPECIES", 10, 16], ["anxiety", "PROBLEM", 48, 55], ["helplessness", "PROBLEM", 66, 78]]], ["The latest evidence indicates that face mask helps prevent the transmission of human coronaviruses and influenza viruses from symptomatic individuals [1] and thus, an increasing number of healthcare authorities have recommended the use of face mask in public spheres for self-protection and others [1] [2] [3] .", [["influenza viruses", "DISEASE", 103, 120], ["human", "ORGANISM", 79, 84], ["coronaviruses", "ORGANISM", 85, 98], ["influenza viruses", "ORGANISM", 103, 120], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 298, 309], ["human", "SPECIES", 79, 84], ["human coronaviruses", "SPECIES", 79, 98], ["face mask", "TREATMENT", 35, 44], ["human coronaviruses", "PROBLEM", 79, 98], ["influenza viruses", "PROBLEM", 103, 120], ["symptomatic individuals", "PROBLEM", 126, 149], ["face mask", "TREATMENT", 239, 248], ["public spheres", "TREATMENT", 252, 266], ["self-protection", "TREATMENT", 271, 286]]], ["Consequently, Hong Kong people started a mass surge of surgical masks locally and nationally.", [["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["surgical masks locally", "TREATMENT", 55, 77], ["mass", "OBSERVATION", 41, 45], ["surgical masks", "OBSERVATION", 55, 69]]], ["This gives a golden opportunity to thousands of fake masks and protective gears flocking in markets ever since the pandemic [4, 5] .", [["fake masks", "TREATMENT", 48, 58]]], ["However, there is rare empirical data to unfold this condition regarding severity and prevalence.Submitted to the \"Commentary\" sectionIn accordance with ASTM F2299-03 international standard [6], our Squina International Centre for Infection Control established a system to estimate the Particle Filtration Efficiency (PFE) of face mask.", [["Infection", "DISEASE", 231, 240], ["Infection Control", "TREATMENT", 231, 248], ["the Particle Filtration Efficiency", "TREATMENT", 282, 316], ["face mask", "TREATMENT", 326, 335], ["Infection", "OBSERVATION", 231, 240]]], ["This estimation was performed to evaluate the PFE of a given face mask by comparing the artificial generated aerosols in upstream (i.e., outside mask) of the test article with the downstream (inside mask).Submitted to the \"Commentary\" sectionThe aerosols were generated by Sodium Chloride and kept in the buffer chamber until reaching an optimum test environment, including aerosol concentration between 10 7 and 10 8 particles/m 3 , humidity of 30-50% (+ 5%), and temperature of 21\u00b0C (+ 3\u00b0C).Submitted to the \"Commentary\" sectionTwo sets of Optical Particle Counter (Grimm Aerosol Spectrometer, Model 1.109) [7] were used to capture and count the aerosols with the size of 0.3 \u00b5m and 1 \u00b5m at upstream and downstream.", [["Sodium Chloride", "CHEMICAL", 273, 288], ["Sodium Chloride", "CHEMICAL", 273, 288], ["Sodium Chloride", "SIMPLE_CHEMICAL", 273, 288], ["upstream and downstream", "DNA", 693, 716], ["This estimation", "TEST", 0, 15], ["face mask", "TREATMENT", 61, 70], ["the downstream (inside mask", "TREATMENT", 176, 203], ["Sodium Chloride", "TREATMENT", 273, 288], ["the buffer chamber", "TREATMENT", 301, 319], ["aerosol concentration", "TREATMENT", 374, 395], ["humidity", "TEST", 434, 442], ["temperature", "TEST", 465, 476], ["Optical Particle Counter (Grimm Aerosol Spectrometer", "TREATMENT", 542, 594], ["size", "OBSERVATION_MODIFIER", 666, 670]]], ["Five to ten pairs of consistent data (<3% variation of particle count) were used to estimate the PFE.", [["particle count", "TEST", 55, 69]]], ["This system was validated with Automated Filter Tester (TSI Model 8130A as gold standard for 0.3 \u03bcm PFE) [8] by comparing the known 0.3 \u03bcm PFE materials from 40.33% to 99.99%.", [["Automated Filter Tester", "TREATMENT", 31, 54], ["PFE materials", "TEST", 139, 152]]], ["Results indicated that the PFE difference ranged from -6.81% to 3.85% (mean = -1.65, SD 3.47).", [["the PFE difference", "TEST", 23, 41], ["mean", "TEST", 71, 75]]], ["Concurrent validity that correlated the two set of PFE scores was also satisfactory (r = 0.99, p < 0.001).Submitted to the \"Commentary\" sectionWe tested 160 brands of masks from different sources and countries (Figure 1) .Submitted to the \"Commentary\" sectionResults showed that low-quality face masks accounted for 48.8% (i.e., 0.3 \u03bcm PFE, mean = 47%; 1 \u03bcm PFE, mean = 69%).", [["PFE scores", "TEST", 51, 61], ["masks", "TREATMENT", 167, 172], ["PFE", "TEST", 336, 339], ["mean", "TEST", 341, 345], ["PFE", "TEST", 358, 361], ["mean", "TEST", 363, 367]]], ["Approximately 42.6% of face masks claimed to achieve ASTM level 1 standard (i.e., PFE > 95% on 0.1 \u03bcm, provided with certification or printed description on box) but demonstrated insufficient filtration performance at 0.3 \u03bcm (range = 6%-94%).", [["face masks", "TREATMENT", 23, 33], ["ASTM level", "TEST", 53, 63], ["PFE", "TEST", 82, 85], ["insufficient filtration performance", "PROBLEM", 179, 214]]], ["Surprisingly, we extracted seven considerably from 38% (fake ones) to 99% (good-quality ones).Submitted to the \"Commentary\" sectionCounterfeit and fake face masks are merely the tip of the iceberg in the personal protective equipment market [9] .", [["seven", "OBSERVATION_MODIFIER", 27, 32], ["considerably", "OBSERVATION_MODIFIER", 33, 45], ["tip", "OBSERVATION_MODIFIER", 178, 181], ["iceberg", "OBSERVATION_MODIFIER", 189, 196]]], ["It is anticipated that they may face similar difficulty in examining their PPEs, N95 respirators, and surgical gown.Submitted to the \"Commentary\" sectionOur test results were alarming because using fake masks / protective gears will jeopardize the health of COVID-19 patients, suspected cases, close contacts, and vulnerable subpopulation (health professionals, older adults, patients with chronic disease, poverty).", [["chronic disease", "DISEASE", 390, 405], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 376, 384], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 376, 384], ["N95 respirators", "TREATMENT", 81, 96], ["surgical gown", "TREATMENT", 102, 115], ["fake masks / protective gears", "TREATMENT", 198, 227], ["chronic disease", "PROBLEM", 390, 405], ["similar", "OBSERVATION_MODIFIER", 37, 44], ["difficulty", "OBSERVATION", 45, 55], ["surgical gown", "OBSERVATION", 102, 115]]], ["Illegal fake mask and protective gears manufacturing may disrupt the infection prevention and control towards the COVID-19 outbreak in clinical and community settings.", [["infection", "DISEASE", 69, 78], ["Illegal fake mask", "TREATMENT", 0, 17], ["protective gears manufacturing", "TREATMENT", 22, 52], ["the infection prevention", "TREATMENT", 65, 89], ["the COVID", "TEST", 110, 119], ["fake mask", "OBSERVATION", 8, 17], ["infection", "OBSERVATION", 69, 78]]], ["Failure to curb the rapid disease transmission may transform the infectious pandemic into a new hybrid disaster (natural and man-made events).", [["Failure to curb", "PROBLEM", 0, 15], ["the rapid disease transmission", "PROBLEM", 16, 46], ["rapid", "OBSERVATION_MODIFIER", 20, 25], ["disease", "OBSERVATION", 26, 33], ["infectious", "OBSERVATION_MODIFIER", 65, 75], ["new", "OBSERVATION_MODIFIER", 92, 95]]], ["Thus, there is a pressing need for the Food and Drugs Authority (FDA) to impose stringent guidelines on proper face mask production, materials to be used, quality control, commodity labelling, distribution and recommended price range.", [["the Food and Drugs", "TREATMENT", 35, 53], ["stringent guidelines", "TREATMENT", 80, 100], ["proper face mask production", "TREATMENT", 104, 131], ["materials", "TREATMENT", 133, 142]]], ["Local and international governing bodies should strictly enact and enforce legal guidelines to forbid fake mask/ protective gears manufacturing with a serious penalty to deter those profiteers.", [["Local and international governing bodies", "TREATMENT", 0, 40]]]], "96775ec12c4441b3acb9b9743a9827cc381471cc": [["IntroductionAerosol-generating medical procedures (AGMPs) are increasingly being recognized as important sources for nosocomial transmission of emerging viruses.", [["IntroductionAerosol", "CHEMICAL", 0, 19], ["IntroductionAerosol", "TREATMENT", 0, 19], ["medical procedures (AGMPs)", "TREATMENT", 31, 57], ["emerging viruses", "PROBLEM", 144, 160]]], ["Intubation was investigated as a possible cause of Ebola virus (EBOV) transmission among health-care workers (HCWs) in the United States [1] .", [["Ebola virus (EBOV) transmission", "DISEASE", 51, 82], ["Ebola virus", "ORGANISM", 51, 62], ["EBOV", "ORGANISM", 64, 68], ["Ebola virus", "SPECIES", 51, 62], ["Ebola virus", "SPECIES", 51, 62], ["EBOV", "SPECIES", 64, 68], ["Intubation", "TREATMENT", 0, 10], ["Ebola virus", "PROBLEM", 51, 62]]], ["Additionally, the high rate of nosocomial transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) caused speculation about the role of AGMPs [2] [3] [4] [5] .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 58, 102], ["Acute Respiratory Syndrome coronavirus", "DISEASE", 125, 163], ["SARS", "DISEASE", 165, 169], ["AGMPs [2] [3] [4]", "CHEMICAL", 212, 229], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 58, 102], ["MERS-CoV", "ORGANISM", 104, 112], ["Severe Acute Respiratory Syndrome coronavirus", "ORGANISM", 118, 163], ["AGMPs [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 212, 233], ["Middle East respiratory syndrome coronavirus", "SPECIES", 58, 102], ["MERS-CoV", "SPECIES", 104, 112], ["Severe Acute Respiratory Syndrome coronavirus", "SPECIES", 118, 163], ["SARS-CoV", "SPECIES", 165, 173], ["nosocomial transmission", "TREATMENT", 31, 54], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 58, 102], ["Severe Acute Respiratory Syndrome coronavirus", "PROBLEM", 118, 163], ["nosocomial", "OBSERVATION", 31, 41], ["Middle", "ANATOMY_MODIFIER", 58, 64], ["respiratory syndrome", "OBSERVATION", 70, 90], ["Severe", "OBSERVATION_MODIFIER", 118, 124], ["Acute", "OBSERVATION_MODIFIER", 125, 130], ["Respiratory Syndrome coronavirus", "OBSERVATION", 131, 163]]], ["Crimean-Congo hemorrhagic fever orthonairovirus (CCHFV), was also associated with nosocomial infection secondary to AGMPs [6] .", [["Crimean-Congo hemorrhagic fever", "DISEASE", 0, 31], ["CCHFV", "DISEASE", 49, 54], ["infection", "DISEASE", 93, 102], ["AGMPs", "DISEASE", 116, 121], ["Crimean-Congo hemorrhagic fever orthonairovirus", "ORGANISM", 0, 47], ["CCHFV", "ORGANISM", 49, 54], ["Crimean-Congo hemorrhagic fever orthonairovirus", "SPECIES", 0, 47], ["Crimean-Congo hemorrhagic fever orthonairovirus", "SPECIES", 0, 47], ["CCHFV", "SPECIES", 49, 54], ["Crimean", "TEST", 0, 7], ["Congo hemorrhagic fever orthonairovirus", "PROBLEM", 8, 47], ["CCHFV", "PROBLEM", 49, 54], ["nosocomial infection", "PROBLEM", 82, 102], ["hemorrhagic", "OBSERVATION_MODIFIER", 14, 25], ["associated with", "UNCERTAINTY", 66, 81], ["nosocomial", "OBSERVATION_MODIFIER", 82, 92], ["infection", "OBSERVATION", 93, 102]]], ["While guidelines were developed for performing AGMPs on patients with certain viral infections, assessing and understanding the risk that specific viruses and AGMPs pose for nosocomial transmission could improve infection control practices, as well as reveal relationships in virus transmission.IntroductionDespite the perceived importance of AGMPs in nosocomial transmission of viruses and other infectious agents, scarce empirical or quantitative evidence exists [7] .", [["viral infections", "DISEASE", 78, 94], ["infection", "DISEASE", 212, 221], ["AGMPs", "CHEMICAL", 343, 348], ["patients", "ORGANISM", 56, 64], ["AGMPs", "GENE_OR_GENE_PRODUCT", 159, 164], ["AGMPs", "GENE_OR_GENE_PRODUCT", 343, 348], ["patients", "SPECIES", 56, 64], ["certain viral infections", "PROBLEM", 70, 94], ["specific viruses", "PROBLEM", 138, 154], ["nosocomial transmission", "PROBLEM", 174, 197], ["infection control practices", "TREATMENT", 212, 239], ["viruses", "PROBLEM", 379, 386], ["other infectious agents", "TREATMENT", 391, 414], ["infections", "OBSERVATION", 84, 94], ["virus", "OBSERVATION", 276, 281]]], ["In order to assess the risk that certain viruses and AGMPs create for nosocomial transmission, we first need to identify potential AGMPs and viruses.", [["AGMPs", "GENE_OR_GENE_PRODUCT", 53, 58], ["AGMPs", "GENE_OR_GENE_PRODUCT", 131, 136], ["certain viruses", "PROBLEM", 33, 48], ["nosocomial transmission", "PROBLEM", 70, 93], ["potential AGMPs and viruses", "PROBLEM", 121, 148], ["viruses", "OBSERVATION", 141, 148]]], ["The second step is then to determine the risk associated with these viruses and procedures, either through retrospective analysis, investigating the circumstances of nosocomial transmission, or through experiments, such as using air sampling during AGMPs to determine the risk of generating infectious virus-laden aerosols.", [["procedures", "TREATMENT", 80, 90], ["retrospective analysis", "TEST", 107, 129], ["nosocomial transmission", "TREATMENT", 166, 189], ["air sampling", "TEST", 229, 241], ["AGMPs", "TREATMENT", 249, 254], ["generating infectious virus", "PROBLEM", 280, 307], ["viruses", "OBSERVATION", 68, 75], ["infectious", "OBSERVATION", 291, 301]]], ["Lasers can create plumes of debris that contain infectious aerosolized virus, as well [15] .", [["Lasers", "TREATMENT", 0, 6], ["debris", "PROBLEM", 28, 34], ["infectious aerosolized virus", "PROBLEM", 48, 76], ["plumes", "OBSERVATION_MODIFIER", 18, 24], ["debris", "OBSERVATION", 28, 34], ["infectious", "OBSERVATION_MODIFIER", 48, 58], ["aerosolized virus", "OBSERVATION", 59, 76]]], ["It is important to recognize the range of AGMPs and the circumstances under which they might be performed on infected patients.", [["AGMPs", "GENE_OR_GENE_PRODUCT", 42, 47], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126]]], ["In order to associate certain AGMPs with nosocomial virus transmission, researchers need to test whether certain procedures generate aerosols with infectious virus, either through hospital sampling or laboratory procedures.", [["nosocomial virus transmission", "DISEASE", 41, 70], ["AGMPs", "GENE_OR_GENE_PRODUCT", 30, 35], ["nosocomial virus transmission", "TREATMENT", 41, 70], ["infectious virus", "PROBLEM", 147, 163], ["laboratory procedures", "TEST", 201, 222]]], ["Potential types of aerosol-generating medical procedures (AGMPs).", [["aerosol", "TREATMENT", 19, 26], ["medical procedures", "TREATMENT", 38, 56]]], ["AGMPs can be divided into procedures that induce the patient to produce aerosols and procedures that mechanically generate aerosols themselves.Emerging High-Risk VirusesKnowing the mechanisms behind different AGMPs allows us to narrow our focus of emerging viruses that could cause nosocomial transmission via AGMPs.", [["AGMPs", "SIMPLE_CHEMICAL", 0, 5], ["patient", "ORGANISM", 53, 60], ["AGMPs", "GENE_OR_GENE_PRODUCT", 209, 214], ["AGMPs", "GENE_OR_GENE_PRODUCT", 310, 315], ["AGMPs", "DNA", 209, 214], ["AGMPs", "PROTEIN", 310, 315], ["patient", "SPECIES", 53, 60], ["aerosols and procedures", "TREATMENT", 72, 95], ["emerging viruses", "PROBLEM", 248, 264], ["nosocomial transmission via AGMPs", "PROBLEM", 282, 315], ["viruses", "OBSERVATION", 257, 264]]], ["These viruses must be able to Figure 1 .", [["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["Potential types of aerosol-generating medical procedures (AGMPs).", [["aerosol", "TREATMENT", 19, 26], ["medical procedures", "TREATMENT", 38, 56]]], ["AGMPs can be divided into procedures that induce the patient to produce aerosols and procedures that mechanically generate aerosols themselves.", [["AGMPs", "SIMPLE_CHEMICAL", 0, 5], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["aerosols and procedures", "TREATMENT", 72, 95]]], ["[11] [12] [13] .Emerging High-Risk VirusesIn contrast to causing a patient to produce aerosols, AGMPs can also mechanically create and disperse respiratory aerosols through procedures such as ventilation, suctioning of the airway, or nebulizer treatment.", [["airway", "ANATOMY", 223, 229], ["AGMPs", "CHEMICAL", 96, 101], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 0, 14], ["Viruses", "ORGANISM", 35, 42], ["patient", "ORGANISM", 67, 74], ["AGMPs", "SIMPLE_CHEMICAL", 96, 101], ["airway", "MULTI-TISSUE_STRUCTURE", 223, 229], ["patient", "SPECIES", 67, 74], ["aerosols", "TREATMENT", 86, 94], ["AGMPs", "TREATMENT", 96, 101], ["respiratory aerosols", "TREATMENT", 144, 164], ["procedures", "TREATMENT", 173, 183], ["ventilation", "TREATMENT", 192, 203], ["suctioning of the airway", "TREATMENT", 205, 229], ["nebulizer treatment", "TREATMENT", 234, 253], ["Risk Viruses", "OBSERVATION", 30, 42], ["respiratory aerosols", "OBSERVATION", 144, 164], ["airway", "ANATOMY", 223, 229]]], ["Both manual ventilation, using a bag-valve-mask, and other forms of noninvasive ventilation (NIV), such as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), and high-frequency oscillatory ventilation (HFOV) are associated with SARS-CoV nosocomial transmission [11] .", [["airway", "ANATOMY", 127, 133], ["airway", "ANATOMY", 168, 174], ["SARS-CoV nosocomial transmission", "DISEASE", 263, 295], ["airway", "MULTI-TISSUE_STRUCTURE", 127, 133], ["airway", "MULTI-TISSUE_STRUCTURE", 168, 174], ["SARS-CoV", "SPECIES", 263, 271], ["Both manual ventilation", "TREATMENT", 0, 23], ["a bag-valve-mask", "TREATMENT", 31, 47], ["noninvasive ventilation", "TREATMENT", 68, 91], ["NIV)", "TREATMENT", 93, 97], ["continuous positive airway pressure (CPAP", "TREATMENT", 107, 148], ["bilevel positive airway pressure", "TREATMENT", 151, 183], ["BiPAP", "TREATMENT", 185, 190], ["high-frequency oscillatory ventilation", "TREATMENT", 197, 235], ["SARS", "PROBLEM", 263, 267], ["manual ventilation", "OBSERVATION", 5, 23], ["valve", "ANATOMY", 37, 42], ["airway pressure", "OBSERVATION", 168, 183]]], ["Although the exact mechanisms of how these procedures create virus-laden aerosols in the respiratory tract remain unknown, it is possible that forcing or removing air from the respiratory tract could generate aerosols.Emerging High-Risk VirusesWhile AGMPs are traditionally thought of in regard to the generation of respiratory aerosols, AGMPs can also aerosolize infected fluids in other regions of the human body.", [["respiratory tract", "ANATOMY", 89, 106], ["respiratory tract", "ANATOMY", 176, 193], ["body", "ANATOMY", 410, 414], ["respiratory tract", "DISEASE", 89, 106], ["AGMPs", "CHEMICAL", 338, 343], ["respiratory tract", "ORGANISM_SUBDIVISION", 89, 106], ["respiratory tract", "ORGANISM_SUBDIVISION", 176, 193], ["AGMPs", "SIMPLE_CHEMICAL", 338, 343], ["human", "ORGANISM", 404, 409], ["body", "ORGANISM_SUBDIVISION", 410, 414], ["human", "SPECIES", 404, 409], ["human", "SPECIES", 404, 409], ["virus-laden aerosols", "TREATMENT", 61, 81], ["air from the respiratory tract", "PROBLEM", 163, 193], ["respiratory aerosols", "PROBLEM", 316, 336], ["infected fluids", "PROBLEM", 364, 379], ["respiratory tract", "ANATOMY", 89, 106], ["air", "OBSERVATION", 163, 166], ["respiratory tract", "ANATOMY", 176, 193], ["respiratory aerosols", "OBSERVATION", 316, 336], ["infected", "OBSERVATION_MODIFIER", 364, 372], ["fluids", "OBSERVATION", 373, 379], ["human", "ANATOMY", 404, 409], ["body", "ANATOMY_MODIFIER", 410, 414]]], ["Surgical techniques can aerosolize blood and possibly viruses.", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Surgical techniques", "TREATMENT", 0, 19], ["blood", "PROBLEM", 35, 40], ["viruses", "PROBLEM", 54, 61], ["possibly", "UNCERTAINTY", 45, 53], ["viruses", "OBSERVATION", 54, 61]]], ["For example, infectious HIV-1 was found in the aerosols generated by surgical power tools [14] , and a tracheotomy was associated with SARS-CoV transmission [11] .", [["SARS-CoV transmission", "DISEASE", 135, 156], ["HIV-1", "ORGANISM", 24, 29], ["HIV-1", "SPECIES", 24, 29], ["HIV-1", "SPECIES", 24, 29], ["SARS-CoV", "SPECIES", 135, 143], ["infectious HIV", "PROBLEM", 13, 27], ["a tracheotomy", "TREATMENT", 101, 114], ["SARS", "PROBLEM", 135, 139], ["infectious", "OBSERVATION_MODIFIER", 13, 23], ["tracheotomy", "OBSERVATION", 103, 114]]], ["Lasers can create plumes of debris that contain infectious aerosolized virus, as well [15] .", [["Lasers", "TREATMENT", 0, 6], ["debris", "PROBLEM", 28, 34], ["infectious aerosolized virus", "PROBLEM", 48, 76], ["plumes", "OBSERVATION_MODIFIER", 18, 24], ["debris", "OBSERVATION", 28, 34], ["infectious", "OBSERVATION_MODIFIER", 48, 58], ["aerosolized virus", "OBSERVATION", 59, 76]]], ["It is important to recognize the range of AGMPs and the circumstances under which they might be performed on infected patients.", [["AGMPs", "GENE_OR_GENE_PRODUCT", 42, 47], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126]]], ["In order to associate certain AGMPs with nosocomial virus transmission, researchers need to test whether certain procedures generate aerosols with infectious virus, either through hospital sampling or laboratory procedures.Emerging High-Risk VirusesKnowing the mechanisms behind different AGMPs allows us to narrow our focus of emerging viruses that could cause nosocomial transmission via AGMPs.", [["nosocomial virus transmission", "DISEASE", 41, 70], ["AGMPs", "GENE_OR_GENE_PRODUCT", 30, 35], ["AGMPs", "GENE_OR_GENE_PRODUCT", 289, 294], ["AGMPs", "GENE_OR_GENE_PRODUCT", 390, 395], ["AGMPs", "DNA", 289, 294], ["AGMPs", "PROTEIN", 390, 395], ["nosocomial virus transmission", "TREATMENT", 41, 70], ["infectious virus", "PROBLEM", 147, 163], ["laboratory procedures", "TEST", 201, 222], ["emerging viruses", "PROBLEM", 328, 344], ["nosocomial transmission via AGMPs", "PROBLEM", 362, 395], ["viruses", "OBSERVATION", 337, 344]]], ["These viruses must be able to opportunistically infect via the aerosol route and must be present in the patient where the AGMP is taking place.", [["patient", "ORGANISM", 104, 111], ["AGMP", "GENE_OR_GENE_PRODUCT", 122, 126], ["patient", "SPECIES", 104, 111], ["These viruses", "PROBLEM", 0, 13], ["the aerosol route", "TREATMENT", 59, 76], ["viruses", "OBSERVATION", 6, 13]]], ["These two conditions fit a wide spectrum of viruses, and therefore we focus on those that are emerging and pose a high risk to HCWs performing AGMPs.", [["AGMPs", "DISEASE", 143, 148], ["AGMPs", "GENE_OR_GENE_PRODUCT", 143, 148], ["a wide spectrum of viruses", "PROBLEM", 25, 51], ["viruses", "OBSERVATION", 44, 51]]], ["Here we define high risk as both a high likelihood of infection if an aerosol is inhaled or comes into contact with a mucous membrane and a high case-fatality rate for the viral disease.", [["mucous membrane", "ANATOMY", 118, 133], ["infection", "DISEASE", 54, 63], ["viral disease", "DISEASE", 172, 185], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 118, 133], ["infection", "PROBLEM", 54, 63], ["an aerosol", "TREATMENT", 67, 77], ["a mucous membrane", "PROBLEM", 116, 133], ["the viral disease", "PROBLEM", 168, 185], ["high risk", "OBSERVATION_MODIFIER", 15, 24], ["infection", "OBSERVATION", 54, 63], ["mucous", "ANATOMY", 118, 124], ["viral disease", "OBSERVATION", 172, 185]]], ["Such viruses are those that are highly infectious and pathogenic and for which limited prophylactic or therapeutic countermeasures are available.", [["Such viruses", "PROBLEM", 0, 12], ["pathogenic", "PROBLEM", 54, 64], ["therapeutic countermeasures", "TREATMENT", 103, 130], ["viruses", "OBSERVATION", 5, 12], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["infectious", "OBSERVATION_MODIFIER", 39, 49]]], ["This includes most biosafety level 3 and 4 viruses, while it excludes viruses such as the measles, mumps, and rubella, which can infect via the aerosol route and be spread by AGMPs, but a common vaccine protects HCWs against them.", [["measles, mumps, and rubella", "DISEASE", 90, 117], ["measles", "ORGANISM", 90, 97], ["mumps", "ORGANISM", 99, 104], ["AGMPs", "GENE_OR_GENE_PRODUCT", 175, 180], ["HCWs", "ORGANISM", 212, 216], ["viruses", "PROBLEM", 70, 77], ["the measles", "PROBLEM", 86, 97], ["mumps", "PROBLEM", 99, 104], ["rubella", "PROBLEM", 110, 117], ["the aerosol route", "TREATMENT", 140, 157], ["a common vaccine", "TREATMENT", 186, 202], ["viruses", "OBSERVATION", 70, 77]]], ["Viruses such as Norwalk virus, enteroviruses, or human respiratory syncytial virus (RSV), which either cause self-limiting diseases or are primarily pathogenic in pediatric, pregnant, or immunocompromised patients, are also included.", [["enteroviruses", "DISEASE", 31, 44], ["respiratory syncytial virus (RSV)", "DISEASE", 55, 88], ["self-limiting diseases", "DISEASE", 109, 131], ["Norwalk virus", "ORGANISM", 16, 29], ["enteroviruses", "ORGANISM", 31, 44], ["human respiratory syncytial virus", "ORGANISM", 49, 82], ["RSV", "ORGANISM", 84, 87], ["patients", "ORGANISM", 205, 213], ["human", "SPECIES", 49, 54], ["respiratory syncytial virus (RSV", "SPECIES", 55, 87], ["patients", "SPECIES", 205, 213], ["Norwalk virus", "SPECIES", 16, 29], ["human respiratory syncytial virus", "SPECIES", 49, 82], ["RSV", "SPECIES", 84, 87], ["Viruses", "PROBLEM", 0, 7], ["Norwalk virus", "PROBLEM", 16, 29], ["enteroviruses", "PROBLEM", 31, 44], ["human respiratory syncytial virus", "PROBLEM", 49, 82], ["self-limiting diseases", "PROBLEM", 109, 131], ["immunocompromised patients", "PROBLEM", 187, 213], ["Norwalk virus", "OBSERVATION", 16, 29], ["respiratory syncytial", "ANATOMY", 55, 76], ["pathogenic", "OBSERVATION_MODIFIER", 149, 159]]], ["Infection control measures must be performed on these and other viruses, for other patients and hospital visitors are also at risk of nosocomial virus transmission [16] .", [["nosocomial virus transmission", "DISEASE", 134, 163], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Infection control measures", "TREATMENT", 0, 26], ["nosocomial virus transmission", "PROBLEM", 134, 163]]], ["However, here we focus on novel, high-risk viruses for HCWs performing AGMPs.Emerging High-Risk VirusesWhen considering emerging highly pathogenic viruses, we used the following criteria to assess which viruses are high risk for HCWs performing AGMPs.", [["AGMPs", "DISEASE", 71, 76], ["AGMPs", "DISEASE", 245, 250], ["AGMPs", "GENE_OR_GENE_PRODUCT", 71, 76], ["Viruses", "ORGANISM", 96, 103], ["AGMPs", "PROTEIN", 71, 76], ["emerging highly pathogenic viruses", "PROBLEM", 120, 154], ["viruses", "PROBLEM", 203, 210], ["Risk Viruses", "OBSERVATION", 91, 103], ["pathogenic", "OBSERVATION_MODIFIER", 136, 146], ["viruses", "OBSERVATION", 147, 154]]], ["(1) The virus is infectious via small or large droplet aerosols in humans or non-human primates (NHPs).", [["humans", "ORGANISM", 67, 73], ["non-human primates", "ORGANISM", 77, 95], ["NHPs", "ORGANISM", 97, 101], ["humans", "SPECIES", 67, 73], ["humans", "SPECIES", 67, 73], ["The virus", "PROBLEM", 4, 13], ["infectious", "PROBLEM", 17, 27], ["small or large droplet aerosols in humans", "PROBLEM", 32, 73], ["virus", "OBSERVATION", 8, 13], ["infectious", "OBSERVATION", 17, 27], ["small", "OBSERVATION_MODIFIER", 32, 37], ["large", "OBSERVATION_MODIFIER", 41, 46], ["droplet aerosols", "OBSERVATION", 47, 63]]], ["Although some virus-laden aerosols, specifically large droplets, could land on surfaces and cause subsequent fomite transmission, those that can infect via inhalation of aerosols or aerosol contact with the eyes or mucous membranes may have the most potential to cause nosocomial transmission through AGMPs.", [["eyes", "ANATOMY", 207, 211], ["mucous membranes", "ANATOMY", 215, 231], ["eyes", "ORGAN", 207, 211], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 215, 231], ["AGMPs", "SIMPLE_CHEMICAL", 301, 306], ["some virus", "PROBLEM", 9, 19], ["large droplets", "PROBLEM", 49, 63], ["mucous membranes", "PROBLEM", 215, 231], ["nosocomial transmission through AGMPs", "PROBLEM", 269, 306], ["virus", "OBSERVATION", 14, 19], ["laden aerosols", "OBSERVATION", 20, 34], ["large", "OBSERVATION_MODIFIER", 49, 54], ["droplets", "OBSERVATION", 55, 63], ["eyes", "ANATOMY", 207, 211], ["mucous membranes", "ANATOMY", 215, 231]]], ["(2) The virus is found in the human respiratory tract or in the respiratory tract of NHPs.", [["respiratory tract", "ANATOMY", 36, 53], ["respiratory tract", "ANATOMY", 64, 81], ["human", "ORGANISM", 30, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["NHPs", "ORGANISM", 85, 89], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["The virus", "PROBLEM", 4, 13], ["the human respiratory tract", "PROBLEM", 26, 53], ["virus", "OBSERVATION", 8, 13], ["human", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53], ["respiratory tract", "ANATOMY", 64, 81]]], ["Most AGMPs occur in the upper or lower human respiratory tract, and, therefore, if the virus is present in these locations, we expect that it has a higher likelihood of becoming aerosolized.", [["respiratory tract", "ANATOMY", 45, 62], ["AGMPs", "GENE_OR_GENE_PRODUCT", 5, 10], ["upper", "ORGANISM_SUBDIVISION", 24, 29], ["human", "ORGANISM", 39, 44], ["respiratory tract", "ORGANISM_SUBDIVISION", 45, 62], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["the virus", "PROBLEM", 83, 92], ["upper", "ANATOMY_MODIFIER", 24, 29], ["lower human", "ANATOMY", 33, 44], ["respiratory tract", "ANATOMY", 45, 62], ["aerosolized", "OBSERVATION", 178, 189]]], ["(3) There is previous evidence of nosocomial transmission or association with AGMPs.", [["AGMPs", "GENE_OR_GENE_PRODUCT", 78, 83], ["AGMPs", "PROTEIN", 78, 83], ["nosocomial transmission", "PROBLEM", 34, 57], ["AGMPs", "TREATMENT", 78, 83], ["evidence of", "UNCERTAINTY", 22, 33], ["nosocomial", "OBSERVATION", 34, 44]]], ["This third criteria identifies viruses that were associated with this type of transmission in the past; although, it may miss viruses that are emerging or do not frequently infect humans.Emerging High-Risk VirusesThe viruses that pose the highest risk to HCWs performing AGMPs may be some of the viruses that we know the least about.", [["AGMPs", "DISEASE", 271, 276], ["humans", "ORGANISM", 180, 186], ["AGMPs", "GENE_OR_GENE_PRODUCT", 271, 276], ["humans", "SPECIES", 180, 186], ["humans", "SPECIES", 180, 186], ["viruses", "PROBLEM", 31, 38], ["viruses", "OBSERVATION", 31, 38], ["Risk Viruses", "OBSERVATION", 201, 213], ["viruses", "OBSERVATION", 217, 224], ["viruses", "OBSERVATION", 296, 303]]], ["This is because many of these viruses may be emerging zoonotic viruses that rarely infect humans compared to human-adapted viruses.", [["zoonotic viruses", "DISEASE", 54, 70], ["humans", "ORGANISM", 90, 96], ["human", "ORGANISM", 109, 114], ["humans", "SPECIES", 90, 96], ["human", "SPECIES", 109, 114], ["humans", "SPECIES", 90, 96], ["human", "SPECIES", 109, 114], ["these viruses", "PROBLEM", 24, 37], ["emerging zoonotic viruses", "PROBLEM", 45, 70], ["viruses", "OBSERVATION", 30, 37]]], ["Therefore, we relied on knowledge from both human and animal viral infections to create a list of potential viruses (Table 2 ).", [["viral infections", "DISEASE", 61, 77], ["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["animal viral infections", "PROBLEM", 54, 77]]], ["We included viruses that fit at least two of the three previously mentioned classifications.", [["viruses", "PROBLEM", 12, 19]]], ["Many of these viruses are also on the World Health Organization's list of priority pathogens for research and development preparedness [17] .Emerging High-Risk VirusesThe viruses that we identify as high risk come from eight families and have diverse characteristics.", [["Viruses", "ORGANISM", 160, 167], ["viruses", "OBSERVATION", 14, 21], ["Risk Viruses", "OBSERVATION", 155, 167], ["viruses", "OBSERVATION", 171, 178]]], ["All of these viruses are emerging or re-emerging zoonotic RNA viruses.", [["zoonotic RNA viruses", "DISEASE", 49, 69], ["these viruses", "PROBLEM", 7, 20], ["viruses", "OBSERVATION", 13, 20]]], ["Initially spilling over from animal hosts into humans, these viruses can undergo subsequent human-to-human and nosocomial transmission to cause epidemics.", [["human-to-human and nosocomial transmission", "DISEASE", 92, 134], ["humans", "ORGANISM", 47, 53], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 101, 106], ["humans", "SPECIES", 47, 53], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 101, 106], ["humans", "SPECIES", 47, 53], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 101, 106], ["these viruses", "PROBLEM", 55, 68], ["nosocomial transmission", "TREATMENT", 111, 134], ["epidemics", "PROBLEM", 144, 153], ["spilling", "OBSERVATION", 10, 18], ["viruses", "OBSERVATION", 61, 68]]], ["However, unlike viruses that have evolved with human hosts, none of these viruses are endemic in human populations.", [["human", "ORGANISM", 47, 52], ["human", "ORGANISM", 97, 102], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 97, 102], ["unlike viruses", "PROBLEM", 9, 23], ["these viruses", "PROBLEM", 68, 81], ["viruses", "OBSERVATION", 16, 23], ["viruses", "OBSERVATION", 74, 81]]], ["Some of these viruses may cause stuttering chains of transmission before disappearing from human populations, while others, like Ebola virus or pandemic influenza A virus, may cause large outbreaks before being contained or establish themselves as endemic pathogens in the human population [18] .", [["stuttering", "DISEASE", 32, 42], ["Ebola virus", "DISEASE", 129, 140], ["influenza A virus", "DISEASE", 153, 170], ["human", "ORGANISM", 91, 96], ["Ebola virus", "ORGANISM", 129, 140], ["pandemic influenza A virus", "ORGANISM", 144, 170], ["human", "ORGANISM", 273, 278], ["human", "SPECIES", 91, 96], ["Ebola virus", "SPECIES", 129, 140], ["pandemic influenza A virus", "SPECIES", 144, 170], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 91, 96], ["Ebola virus", "SPECIES", 129, 140], ["pandemic influenza A virus", "SPECIES", 144, 170], ["human", "SPECIES", 273, 278], ["these viruses", "PROBLEM", 8, 21], ["stuttering chains of transmission", "PROBLEM", 32, 65], ["human populations", "PROBLEM", 91, 108], ["Ebola virus", "PROBLEM", 129, 140], ["pandemic influenza A virus", "PROBLEM", 144, 170], ["large outbreaks", "PROBLEM", 182, 197], ["endemic pathogens", "PROBLEM", 248, 265], ["viruses", "OBSERVATION", 14, 21]]], ["Viruses evolve within their hosts to maintain an optimum balance between transmission (consequently virulence) and persistence [19] .", [["Viruses", "PROBLEM", 0, 7]]], ["Because humans are not the reservoir hosts for these viruses, this equilibrium was not established.", [["humans", "ORGANISM", 8, 14], ["humans", "SPECIES", 8, 14], ["humans", "SPECIES", 8, 14], ["the reservoir hosts", "TREATMENT", 23, 42], ["these viruses", "PROBLEM", 47, 60], ["viruses", "OBSERVATION", 53, 60]]], ["Most of these high-risk viruses are highly infectious and virulent, but are not as efficient at transmitting and persisting as true human respiratory viruses.", [["respiratory viruses", "DISEASE", 138, 157], ["human", "ORGANISM", 132, 137], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["these high-risk viruses", "PROBLEM", 8, 31], ["virulent", "PROBLEM", 58, 66], ["true human respiratory viruses", "PROBLEM", 127, 157], ["risk viruses", "OBSERVATION", 19, 31], ["highly", "OBSERVATION_MODIFIER", 36, 42], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["virulent", "OBSERVATION_MODIFIER", 58, 66], ["respiratory viruses", "OBSERVATION", 138, 157]]], ["Of the high-risk viruses, those belonging to the families of coronaviruses, orthomyxoviruses, and paramyxoviruses come closest to the equilibrium of persistence and transmissibility in humans.", [["coronaviruses", "ORGANISM", 61, 74], ["humans", "ORGANISM", 185, 191], ["humans", "SPECIES", 185, 191], ["humans", "SPECIES", 185, 191], ["the high-risk viruses", "PROBLEM", 3, 24], ["coronaviruses", "PROBLEM", 61, 74], ["orthomyxoviruses", "TREATMENT", 76, 92], ["paramyxoviruses", "PROBLEM", 98, 113], ["high-risk", "OBSERVATION_MODIFIER", 7, 16], ["viruses", "OBSERVATION", 17, 24], ["coronaviruses", "OBSERVATION", 61, 74]]], ["Uncoincidentally, these viral families also contain viruses that have become endemic in human populations.", [["human", "ORGANISM", 88, 93], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 88, 93], ["viruses", "PROBLEM", 52, 59], ["viruses", "OBSERVATION", 52, 59], ["endemic", "OBSERVATION_MODIFIER", 77, 84]]], ["[20] [21] [22] ii.", [["[20] [21] [22] ii", "SIMPLE_CHEMICAL", 0, 17]]], ["Viral RNA in NHP oral and nasal swabs [24] ii.", [["oral", "ANATOMY", 17, 21], ["nasal swabs", "ANATOMY", 26, 37], ["NHP", "ORGANISM", 13, 16], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["nasal swabs", "TEST", 26, 37], ["RNA", "OBSERVATION", 6, 9], ["nasal", "ANATOMY", 26, 31]]], ["Virus isolated from human throat swabs [25] ii, iii.", [["throat swabs", "ANATOMY", 26, 38], ["Virus", "ORGANISM", 0, 5], ["human", "ORGANISM", 20, 25], ["throat", "ORGANISM_SUBDIVISION", 26, 32], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["Virus", "PROBLEM", 0, 5], ["human throat swabs", "TEST", 20, 38]]], ["Nosocomial transmission [26, 27] Lower respiratory: ii.", [["Nosocomial transmission", "TEST", 0, 23]]], ["Virus isolated from human lung [28] Hantaviridae, Nairoviridae, Phenuiviridae i.", [["lung", "ANATOMY", 26, 30], ["Virus", "ORGANISM", 0, 5], ["human", "ORGANISM", 20, 25], ["lung", "ORGAN", 26, 30], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["Virus", "PROBLEM", 0, 5], ["Hantaviridae", "TREATMENT", 36, 48], ["Nairoviridae", "TREATMENT", 50, 62], ["Phenuiviridae", "TREATMENT", 64, 77], ["lung", "ANATOMY", 26, 30]]], ["CCHF virus ii.", [["CCHF", "DISEASE", 0, 4], ["CCHF virus ii", "ORGANISM", 0, 13], ["CCHF virus", "SPECIES", 0, 10], ["CCHF virus ii", "PROBLEM", 0, 13]]], ["Rift valley fever virus i, ii, iii.", [["Rift valley fever", "DISEASE", 0, 17], ["Rift valley fever virus", "ORGANISM", 0, 23], ["Rift valley fever virus", "SPECIES", 0, 23], ["Rift valley fever virus", "SPECIES", 0, 23], ["Rift valley fever virus", "PROBLEM", 0, 23]]], ["Laboratory workers infected by inhaling aerosols [23, 29] Upper respiratory: i, iii.", [["inhaling aerosols", "TEST", 31, 48]]], ["Viral RNA in NHP nasal swabs [24] iii.", [["nasal swabs", "ANATOMY", 17, 28], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "TEST", 0, 9], ["nasal swabs", "TEST", 17, 28]]], ["Viral RNA in NHP oral swabs [24] ii.", [["oral swabs", "ANATOMY", 17, 27], ["NHP", "ORGANISM", 13, 16], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["oral swabs", "TEST", 17, 27]]], ["Viral RNA in human saliva [30] Lower respiratory:Emerging High-Risk Virusesi, ii.", [["Viral", "ORGANISM", 0, 5], ["human", "ORGANISM", 13, 18], ["saliva", "ORGANISM_SUBSTANCE", 19, 25], ["Viral RNA", "RNA", 0, 9], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["Viral RNA in human saliva", "PROBLEM", 0, 25], ["RNA", "OBSERVATION", 6, 9]]], ["Nosocomial transmission [6, 31] i.", [["Nosocomial transmission", "TEST", 0, 23]]], ["Likely association with AGMPs [6] ii.", [["AGMPs [6] ii", "CHEMICAL", 24, 36], ["AGMPs [6] ii", "SIMPLE_CHEMICAL", 24, 36]]], ["Causes human respiratory disease.", [["respiratory", "ANATOMY", 13, 24], ["respiratory disease", "DISEASE", 13, 32], ["human", "ORGANISM", 7, 12], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["human respiratory disease", "PROBLEM", 7, 32], ["respiratory disease", "OBSERVATION", 13, 32]]], ["Viral antigen in human lung [32] Coronaviridae i.", [["lung", "ANATOMY", 23, 27], ["human", "ORGANISM", 17, 22], ["lung", "ORGAN", 23, 27], ["Viral antigen", "PROTEIN", 0, 13], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["Viral antigen", "TEST", 0, 13], ["lung", "ANATOMY", 23, 27]]], ["MERS-CoV ii.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8], ["CoV ii", "OBSERVATION_MODIFIER", 5, 11]]], ["SARS-CoV ii.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["CoV ii", "OBSERVATION_MODIFIER", 5, 11]]], ["Known human-to-human aerosol transmission Upper respiratory:Emerging High-Risk Virusesii.", [["human", "ORGANISM", 6, 11], ["human", "ORGANISM", 15, 20], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 15, 20], ["Upper", "ANATOMY_MODIFIER", 42, 47], ["respiratory", "ANATOMY", 48, 59]]], ["Viral RNA in nasal/throat swabs [33] i, ii.", [["nasal", "ANATOMY", 13, 18], ["nasal", "ORGANISM_SUBDIVISION", 13, 18], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "TEST", 0, 9], ["nasal/throat swabs", "TEST", 13, 31], ["RNA", "OBSERVATION", 6, 9], ["nasal", "ANATOMY", 13, 18], ["throat", "ANATOMY", 19, 25]]], ["Nosocomial transmission [2, 11, 12] ii.", [["Nosocomial transmission", "TEST", 0, 23]]], ["Significant association with AGMPs [11] [12] [13] Lower respiratory: i, ii.", [["AGMPs", "CHEMICAL", 29, 34], ["AGMPs", "CHEMICAL", 29, 34], ["AGMPs", "SIMPLE_CHEMICAL", 29, 34], ["AGMPs", "TEST", 29, 34]]], ["Causes human respiratory disease.", [["respiratory", "ANATOMY", 13, 24], ["respiratory disease", "DISEASE", 13, 32], ["human", "ORGANISM", 7, 12], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["human respiratory disease", "PROBLEM", 7, 32], ["respiratory disease", "OBSERVATION", 13, 32]]], ["Virus isolated from lung and sputum [33, 34] Filoviridae i.", [["lung", "ANATOMY", 20, 24], ["sputum", "ANATOMY", 29, 35], ["Virus isolated from lung and sputum", "DISEASE", 0, 35], ["Virus", "ORGANISM", 0, 5], ["lung", "ORGAN", 20, 24], ["Virus", "PROBLEM", 0, 5], ["sputum", "TEST", 29, 35], ["Filoviridae", "TREATMENT", 45, 56], ["lung", "ANATOMY", 20, 24], ["sputum", "OBSERVATION", 29, 35]]], ["Marburg virus i, ii.", [["Marburg virus", "ORGANISM", 0, 13], ["Marburg virus", "SPECIES", 0, 13]]], ["NHPs infected by aerosol administration [35] Upper respiratory: i.", [["NHPs", "ORGANISM", 0, 4]]], ["Isolated from human saliva [36] ii.", [["human", "ORGANISM", 14, 19], ["saliva", "ORGANISM_SUBSTANCE", 20, 26], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19]]], ["[40] Upper respiratory: ii.", [["Upper", "ANATOMY_MODIFIER", 5, 10], ["respiratory", "ANATOMY", 11, 22]]], ["Isolated from human nasal and throat secretions [41] ii.", [["nasal", "ANATOMY", 20, 25], ["human", "ORGANISM", 14, 19], ["nasal", "ORGANISM_SUBDIVISION", 20, 25], ["throat", "ORGANISM_SUBDIVISION", 30, 36], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["Isolated from human nasal and throat secretions", "PROBLEM", 0, 47], ["nasal", "ANATOMY", 20, 25], ["throat", "ANATOMY", 30, 36]]], ["Nosocomial transmission [42] Lower respiratory: i, ii Causes human respiratory disease.i.", [["respiratory", "ANATOMY", 67, 78], ["respiratory disease", "DISEASE", 67, 86], ["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Nosocomial transmission", "TEST", 0, 23], ["human respiratory disease", "PROBLEM", 61, 86], ["respiratory disease", "OBSERVATION", 67, 86]]], ["Viral antigen in human lung [43] Considering these eight viral families, we can begin to assess the risk of particular viruses.", [["lung", "ANATOMY", 23, 27], ["human", "ORGANISM", 17, 22], ["lung", "ORGAN", 23, 27], ["Viral antigen", "PROTEIN", 0, 13], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["Viral antigen in human lung", "PROBLEM", 0, 27], ["particular viruses", "PROBLEM", 108, 126], ["lung", "ANATOMY", 23, 27], ["viruses", "OBSERVATION", 119, 126]]], ["To make a conclusive risk assessment, we need further experimental and epidemiological evidence.", [["a conclusive risk assessment", "TEST", 8, 36]]], ["We can inform these future studies by first looking at what is currently known about the viruses in each of these families in regard to AGMPs.Bunyavirales: ArenaviridaeThe family Arenaviridae, in the order Bunyavirales, contains multiple viruses that have the potential for nosocomial transmission due to AGMPs.", [["Bunyavirales", "CHEMICAL", 142, 154], ["AGMPs", "GENE_OR_GENE_PRODUCT", 136, 141], ["AGMPs", "GENE_OR_GENE_PRODUCT", 305, 310], ["AGMPs", "PROTEIN", 136, 141], ["AGMPs", "PROTEIN", 305, 310], ["these future studies", "TEST", 14, 34], ["Arenaviridae", "TREATMENT", 156, 168], ["multiple viruses", "PROBLEM", 229, 245], ["nosocomial transmission", "TREATMENT", 274, 297], ["multiple", "OBSERVATION_MODIFIER", 229, 237], ["viruses", "OBSERVATION", 238, 245]]], ["Arenaviruses spill over when humans inhale the aerosolized excreta of the rodent hosts for these viruses.", [["humans", "ORGANISM", 29, 35], ["humans", "SPECIES", 29, 35], ["rodent", "SPECIES", 74, 80], ["humans", "SPECIES", 29, 35], ["Arenaviruses spill", "PROBLEM", 0, 18], ["these viruses", "PROBLEM", 91, 104], ["spill", "OBSERVATION", 13, 18]]], ["Additionally, laboratory workers and NHPs were also infected by aerosolized arenaviruses, specifically Junin virus, Lassa virus, and Machupo virus [23] .", [["Lassa virus", "DISEASE", 116, 127], ["NHPs", "ORGANISM", 37, 41], ["arenaviruses", "ORGANISM", 76, 88], ["Junin virus", "ORGANISM", 103, 114], ["Lassa virus", "ORGANISM", 116, 127], ["Machupo virus", "ORGANISM", 133, 146], ["Junin virus", "SPECIES", 103, 114], ["Lassa virus", "SPECIES", 116, 127], ["Machupo virus", "SPECIES", 133, 146], ["Junin virus", "SPECIES", 103, 114], ["Lassa virus", "SPECIES", 116, 127], ["Machupo virus", "SPECIES", 133, 146], ["laboratory workers", "TEST", 14, 32], ["NHPs", "TEST", 37, 41], ["aerosolized arenaviruses", "PROBLEM", 64, 88], ["Junin virus", "PROBLEM", 103, 114], ["Lassa virus", "PROBLEM", 116, 127], ["Machupo virus", "TREATMENT", 133, 146], ["Junin virus", "OBSERVATION", 103, 114]]], ["Arenavirus infections can cause viral hemorrhagic fevers (VHFs) in humans.", [["Arenavirus infections", "DISEASE", 0, 21], ["viral hemorrhagic fevers", "DISEASE", 32, 56], ["VHFs", "DISEASE", 58, 62], ["VHFs", "CANCER", 58, 62], ["humans", "ORGANISM", 67, 73], ["humans", "SPECIES", 67, 73], ["Arenavirus", "SPECIES", 0, 10], ["humans", "SPECIES", 67, 73], ["Arenavirus infections", "PROBLEM", 0, 21], ["viral hemorrhagic fevers", "PROBLEM", 32, 56], ["VHFs", "PROBLEM", 58, 62], ["infections", "OBSERVATION", 11, 21], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["hemorrhagic", "OBSERVATION_MODIFIER", 38, 49], ["fevers", "OBSERVATION", 50, 56]]], ["Known nosocomial transmission has occurred from patients infected with Lassa virus and Machupo virus [26, 27] .", [["Lassa virus", "DISEASE", 71, 82], ["patients", "ORGANISM", 48, 56], ["Lassa virus", "ORGANISM", 71, 82], ["Machupo virus", "ORGANISM", 87, 100], ["patients", "SPECIES", 48, 56], ["Lassa virus", "SPECIES", 71, 82], ["Machupo virus", "SPECIES", 87, 100], ["Lassa virus", "SPECIES", 71, 82], ["Machupo virus", "SPECIES", 87, 100], ["Known nosocomial transmission", "PROBLEM", 0, 29], ["Lassa virus", "PROBLEM", 71, 82], ["Machupo virus", "TREATMENT", 87, 100], ["nosocomial", "OBSERVATION", 6, 16], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["Lassa virus", "OBSERVATION", 71, 82]]], ["Less clinical or experimental data exist for other arenaviruses, but these may have similar characteristics.", [["arenaviruses", "DISEASE", 51, 63], ["arenaviruses", "ORGANISM", 51, 63], ["experimental data", "TEST", 17, 34], ["other arenaviruses", "PROBLEM", 45, 63]]], ["Although arenaviruses are found in the respiratory tracts of humans or animal models [24, 25, 28] , there is no evidence for human-to-human airborne transmission of arenaviruses.", [["respiratory tracts", "ANATOMY", 39, 57], ["arenaviruses", "DISEASE", 165, 177], ["arenaviruses", "ORGANISM", 9, 21], ["humans", "ORGANISM", 61, 67], ["human", "ORGANISM", 125, 130], ["human", "ORGANISM", 134, 139], ["arenaviruses", "ORGANISM", 165, 177], ["humans", "SPECIES", 61, 67], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139], ["humans", "SPECIES", 61, 67], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 134, 139], ["arenaviruses", "PROBLEM", 9, 21], ["arenaviruses", "PROBLEM", 165, 177], ["arenaviruses", "OBSERVATION", 9, 21], ["respiratory tracts", "ANATOMY", 39, 57], ["no evidence for", "UNCERTAINTY", 109, 124], ["arenaviruses", "OBSERVATION", 165, 177]]], ["However, arenavirus aerosol transmission could theoretically occur when aerosols are mechanically generated through AGMPs.Bunyavirales: Hantaviridae, Nairoviridae, PhenuiviridaeLike arenaviruses, multiple other viruses within the order Bunyavirales are zoonotic and can cause VHFs.", [["Bunyavirales", "CHEMICAL", 122, 134], ["PhenuiviridaeLike arenaviruses", "DISEASE", 164, 194], ["VHFs", "DISEASE", 276, 280], ["arenavirus", "ORGANISM", 9, 19], ["AGMPs", "GENE_OR_GENE_PRODUCT", 116, 121], ["PhenuiviridaeLike arenaviruses", "ORGANISM", 164, 194], ["Bunyavirales", "GENE_OR_GENE_PRODUCT", 236, 248], ["VHFs", "PATHOLOGICAL_FORMATION", 276, 280], ["AGMPs", "PROTEIN", 116, 121], ["arenavirus aerosol transmission", "TREATMENT", 9, 40], ["Hantaviridae", "TREATMENT", 136, 148], ["Nairoviridae", "TREATMENT", 150, 162], ["PhenuiviridaeLike arenaviruses", "TREATMENT", 164, 194], ["multiple other viruses", "PROBLEM", 196, 218], ["VHFs", "PROBLEM", 276, 280], ["viruses", "OBSERVATION", 211, 218]]], ["Both Crimean-Congo hemorrhagic fever (CCHF) orthonairovirus and Andes hantavirus were associated with nosocomial transmission, with CCHF transmission occurring after AGMPs were performed without eye or respiratory protection [6, 31] .", [["eye", "ANATOMY", 195, 198], ["respiratory", "ANATOMY", 202, 213], ["Crimean-Congo hemorrhagic fever", "DISEASE", 5, 36], ["CCHF", "DISEASE", 38, 42], ["hantavirus", "DISEASE", 70, 80], ["CCHF", "DISEASE", 132, 136], ["Crimean-Congo hemorrhagic fever", "ORGANISM", 5, 36], ["eye", "ORGAN", 195, 198], ["Congo hemorrhagic fever", "SPECIES", 13, 36], ["Andes hantavirus", "SPECIES", 64, 80], ["Crimean-Congo hemorrhagic fever (CCHF) orthonairovirus", "SPECIES", 5, 59], ["Andes hantavirus", "SPECIES", 64, 80], ["Congo hemorrhagic fever", "PROBLEM", 13, 36], ["CCHF) orthonairovirus", "PROBLEM", 38, 59], ["Andes hantavirus", "PROBLEM", 64, 80], ["nosocomial transmission", "PROBLEM", 102, 125], ["CCHF transmission", "PROBLEM", 132, 149], ["AGMPs", "TEST", 166, 171], ["Crimean", "OBSERVATION_MODIFIER", 5, 12], ["Congo", "OBSERVATION_MODIFIER", 13, 18], ["hemorrhagic", "OBSERVATION_MODIFIER", 19, 30], ["fever", "OBSERVATION", 31, 36]]], ["Interestingly, other hantaviruses were aerosol transmitted to humans, either through accidentally aerosolizing the virus or through inhaling aerosolized rodent excreta [23] , but only Andes hantavirus was confirmed to transmit from person to person [31] .", [["hantavirus", "DISEASE", 190, 200], ["humans", "ORGANISM", 62, 68], ["humans", "SPECIES", 62, 68], ["rodent", "SPECIES", 153, 159], ["person", "SPECIES", 232, 238], ["person", "SPECIES", 242, 248], ["humans", "SPECIES", 62, 68], ["other hantaviruses", "PROBLEM", 15, 33], ["the virus", "PROBLEM", 111, 120], ["Andes hantavirus", "PROBLEM", 184, 200], ["hantaviruses", "OBSERVATION", 21, 33]]], ["Although hantaviruses can cause respiratory disease in humans, as in hantavirus pulmonary syndrome (HPS), and were found in the respiratory tract [30] , they do not seem to efficiently transmit between humans like typical respiratory viruses.", [["respiratory", "ANATOMY", 32, 43], ["respiratory tract", "ANATOMY", 128, 145], ["hantaviruses", "DISEASE", 9, 21], ["respiratory disease", "DISEASE", 32, 51], ["hantavirus pulmonary syndrome", "DISEASE", 69, 98], ["HPS", "DISEASE", 100, 103], ["respiratory viruses", "DISEASE", 222, 241], ["hantaviruses", "ORGANISM", 9, 21], ["humans", "ORGANISM", 55, 61], ["hantavirus", "ORGANISM", 69, 79], ["pulmonary", "ORGAN", 80, 89], ["humans", "ORGANISM", 202, 208], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 202, 208], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 202, 208], ["hantaviruses", "PROBLEM", 9, 21], ["respiratory disease in humans", "PROBLEM", 32, 61], ["hantavirus pulmonary syndrome", "PROBLEM", 69, 98], ["typical respiratory viruses", "PROBLEM", 214, 241], ["hantaviruses", "OBSERVATION", 9, 21], ["respiratory disease", "OBSERVATION", 32, 51], ["hantavirus", "OBSERVATION", 69, 79], ["pulmonary", "ANATOMY", 80, 89], ["syndrome", "OBSERVATION", 90, 98], ["respiratory tract", "ANATOMY", 128, 145], ["respiratory viruses", "OBSERVATION", 222, 241]]], ["However, similar to arenaviruses, certain bunyaviruses found in human-or animal-model respiratory tracts, including CCHF virus, hantaviruses, and Rift valley fever virus, could possibly gain the route of aerosol transmission if an AGMP is performed.CoronaviridaeThe family of Coronaviridae contains viruses that are known to transmit routinely between humans through the aerosol route.", [["respiratory tracts", "ANATOMY", 86, 104], ["arenaviruses", "DISEASE", 20, 32], ["respiratory tracts", "DISEASE", 86, 104], ["CCHF", "DISEASE", 116, 120], ["hantaviruses", "DISEASE", 128, 140], ["Rift valley fever", "DISEASE", 146, 163], ["bunyaviruses", "GENE_OR_GENE_PRODUCT", 42, 54], ["human", "ORGANISM", 64, 69], ["CCHF virus", "ORGANISM", 116, 126], ["Rift valley fever virus", "ORGANISM", 146, 169], ["AGMP", "SIMPLE_CHEMICAL", 231, 235], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 276, 289], ["humans", "ORGANISM", 352, 358], ["human", "SPECIES", 64, 69], ["CCHF virus", "SPECIES", 116, 126], ["Rift valley fever virus", "SPECIES", 146, 169], ["humans", "SPECIES", 352, 358], ["human", "SPECIES", 64, 69], ["CCHF virus", "SPECIES", 116, 126], ["Rift valley fever virus", "SPECIES", 146, 169], ["humans", "SPECIES", 352, 358], ["arenaviruses", "PROBLEM", 20, 32], ["certain bunyaviruses", "PROBLEM", 34, 54], ["human", "TEST", 64, 69], ["animal-model respiratory tracts", "PROBLEM", 73, 104], ["CCHF virus", "PROBLEM", 116, 126], ["hantaviruses", "PROBLEM", 128, 140], ["Rift valley fever virus", "PROBLEM", 146, 169], ["aerosol transmission", "TREATMENT", 204, 224], ["an AGMP", "TEST", 228, 235], ["Coronaviridae", "TREATMENT", 249, 262], ["Coronaviridae", "TREATMENT", 276, 289], ["viruses", "TREATMENT", 299, 306], ["the aerosol route", "TREATMENT", 367, 384], ["arenaviruses", "OBSERVATION", 20, 32], ["respiratory tracts", "ANATOMY", 86, 104], ["viruses", "OBSERVATION", 299, 306]]], ["Both MERS-CoV and SARS-CoV cause respiratory disease in humans and transmit via aerosols, but it is unknown whether small-droplet or large-droplet aerosols are the modes of transmission for these viruses.", [["respiratory", "ANATOMY", 33, 44], ["respiratory disease", "DISEASE", 33, 52], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["SARS-CoV", "ORGANISM", 18, 26], ["humans", "ORGANISM", 56, 62], ["humans", "SPECIES", 56, 62], ["MERS-CoV", "SPECIES", 5, 13], ["SARS-CoV", "SPECIES", 18, 26], ["humans", "SPECIES", 56, 62], ["SARS", "PROBLEM", 18, 22], ["respiratory disease in humans", "PROBLEM", 33, 62], ["transmit via aerosols", "TREATMENT", 67, 88], ["small-droplet", "PROBLEM", 116, 129], ["large-droplet aerosols", "TREATMENT", 133, 155], ["these viruses", "PROBLEM", 190, 203], ["MERS", "OBSERVATION", 5, 9], ["respiratory disease", "OBSERVATION", 33, 52], ["small", "OBSERVATION_MODIFIER", 116, 121], ["large", "OBSERVATION_MODIFIER", 133, 138], ["droplet aerosols", "OBSERVATION", 139, 155], ["viruses", "OBSERVATION", 196, 203]]], ["Significant nosocomial transmission of SARS-CoV has incited the most research regarding the role of AGMPs in nosocomial virus transmission [11] [12] [13] , while recent nosocomial transmission events of MERS-CoV warrant further research [2] [3] [4] [5] .", [["SARS", "DISEASE", 39, 43], ["AGMPs", "CHEMICAL", 100, 105], ["nosocomial virus transmission", "DISEASE", 109, 138], ["SARS-CoV", "ORGANISM", 39, 47], ["AGMPs", "GENE_OR_GENE_PRODUCT", 100, 105], ["nosocomial virus", "ORGANISM", 109, 125], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 203, 211], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 237, 252], ["SARS-CoV", "SPECIES", 39, 47], ["MERS-CoV", "SPECIES", 203, 211], ["Significant nosocomial transmission of SARS", "PROBLEM", 0, 43], ["nosocomial", "OBSERVATION", 12, 22]]], ["Therefore, AGMPs could possibly amplify an already established route of infection for these viruses.FiloviridaeFiloviruses also cause VHFs and could potentially become transmissible through AGMPs.", [["AGMPs", "CHEMICAL", 11, 16], ["infection", "DISEASE", 72, 81], ["VHFs", "DISEASE", 134, 138], ["AGMPs", "SIMPLE_CHEMICAL", 11, 16], ["FiloviridaeFiloviruses", "SIMPLE_CHEMICAL", 100, 122], ["VHFs", "PATHOLOGICAL_FORMATION", 134, 138], ["AGMPs", "GENE_OR_GENE_PRODUCT", 190, 195], ["AGMPs", "PROTEIN", 11, 16], ["AGMPs", "PROTEIN", 190, 195], ["infection", "PROBLEM", 72, 81], ["these viruses", "PROBLEM", 86, 99], ["FiloviridaeFiloviruses", "TREATMENT", 100, 122], ["VHFs", "PROBLEM", 134, 138], ["infection", "OBSERVATION", 72, 81]]], ["During outbreaks of Ebola virus disease (EVD), concerns were raised regarding airborne transmission of EBOV because of nosocomial transmission events and the discovery of the virus in the human respiratory tract [36, 38] .", [["respiratory tract", "ANATOMY", 194, 211], ["Ebola virus disease", "DISEASE", 20, 39], ["EVD", "DISEASE", 41, 44], ["EBOV", "DISEASE", 103, 107], ["Ebola virus", "ORGANISM", 20, 31], ["EBOV", "ORGANISM", 103, 107], ["human", "ORGANISM", 188, 193], ["respiratory tract", "ORGANISM_SUBDIVISION", 194, 211], ["Ebola virus", "SPECIES", 20, 31], ["human", "SPECIES", 188, 193], ["Ebola virus", "SPECIES", 20, 31], ["EBOV", "SPECIES", 103, 107], ["human", "SPECIES", 188, 193], ["Ebola virus disease", "PROBLEM", 20, 39], ["EVD", "TREATMENT", 41, 44], ["EBOV", "PROBLEM", 103, 107], ["nosocomial transmission events", "PROBLEM", 119, 149], ["the virus in the human respiratory tract", "PROBLEM", 171, 211], ["Ebola virus disease", "OBSERVATION", 20, 39], ["virus", "OBSERVATION", 175, 180], ["respiratory tract", "ANATOMY", 194, 211]]], ["Given what we know from experimental and epidemiological evidence, airborne transmission is unlikely, yet it is possible that AGMPs could create infectious EBOV-laden aerosols that could lead to nosocomial transmission [8, 44] .", [["AGMPs", "CHEMICAL", 126, 131], ["AGMPs", "SIMPLE_CHEMICAL", 126, 131], ["EBOV", "ORGANISM", 156, 160], ["EBOV", "SPECIES", 156, 160], ["infectious EBOV-laden aerosols", "PROBLEM", 145, 175], ["infectious", "OBSERVATION_MODIFIER", 145, 155]]], ["Likewise, viruses belonging to the other species of ebolaviruses that are pathogenic in humans, as well as another filovirus, Marburg virus, could share similar transmission properties.OrthomyxoviridaeThe family of viruses Orthomyxoviridae contains both human and zoonotic viruses, of which the most well-known are influenza viruses.", [["Marburg virus", "DISEASE", 126, 139], ["human and zoonotic viruses", "DISEASE", 254, 280], ["influenza viruses", "DISEASE", 315, 332], ["ebolaviruses", "GENE_OR_GENE_PRODUCT", 52, 64], ["humans", "ORGANISM", 88, 94], ["Marburg virus", "ORGANISM", 126, 139], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 185, 201], ["human", "ORGANISM", 254, 259], ["influenza viruses", "ORGANISM", 315, 332], ["humans", "SPECIES", 88, 94], ["Marburg virus", "SPECIES", 126, 139], ["human", "SPECIES", 254, 259], ["humans", "SPECIES", 88, 94], ["Marburg virus", "SPECIES", 126, 139], ["human", "SPECIES", 254, 259], ["viruses", "PROBLEM", 10, 17], ["ebolaviruses", "PROBLEM", 52, 64], ["pathogenic in humans", "PROBLEM", 74, 94], ["another filovirus", "PROBLEM", 107, 124], ["Marburg virus", "PROBLEM", 126, 139], ["Orthomyxoviridae", "TREATMENT", 185, 201], ["viruses Orthomyxoviridae", "TREATMENT", 215, 239], ["both human and zoonotic viruses", "PROBLEM", 249, 280], ["influenza viruses", "PROBLEM", 315, 332], ["viruses", "OBSERVATION", 10, 17], ["pathogenic", "OBSERVATION", 74, 84], ["zoonotic viruses", "OBSERVATION", 264, 280], ["influenza viruses", "OBSERVATION", 315, 332]]], ["While seasonal flu vaccines protect HCWs against influenza [10] .", [["influenza", "DISEASE", 49, 58], ["seasonal flu vaccines", "TREATMENT", 6, 27], ["influenza", "PROBLEM", 49, 58]]], ["However, there is variation in the efficiency of human-to-human aerosol transmission of different influenza A viruses.", [["influenza A viruses", "DISEASE", 98, 117], ["human", "ORGANISM", 49, 54], ["human", "ORGANISM", 58, 63], ["influenza A viruses", "ORGANISM", 98, 117], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 58, 63], ["influenza A viruses", "SPECIES", 98, 117], ["human aerosol transmission", "TREATMENT", 58, 84], ["different influenza A viruses", "PROBLEM", 88, 117], ["variation", "OBSERVATION_MODIFIER", 18, 27], ["different", "OBSERVATION_MODIFIER", 88, 97], ["influenza", "OBSERVATION", 98, 107]]], ["For instance, to date, there were few instances of nosocomial transmission of H7N9 or H5N1, even when protective measures were not used, while there were multiple nosocomial transmission events of pandemic H1N1 and other influenza A virus subtypes [39, [45] [46] [47] [48] [49] .", [["H5N1", "DISEASE", 86, 90], ["H1N1", "DISEASE", 206, 210], ["H5N1", "ORGANISM", 86, 90], ["influenza A virus", "ORGANISM", 221, 238], ["[45] [46", "SIMPLE_CHEMICAL", 253, 261], ["pandemic H1N1", "SPECIES", 197, 210], ["influenza A virus", "SPECIES", 221, 238], ["H7N9", "SPECIES", 78, 82], ["H5N1", "SPECIES", 86, 90], ["influenza A virus", "SPECIES", 221, 238], ["nosocomial transmission", "TREATMENT", 51, 74], ["H7N9", "PROBLEM", 78, 82], ["H5N1", "PROBLEM", 86, 90], ["protective measures", "TREATMENT", 102, 121], ["multiple nosocomial transmission events", "PROBLEM", 154, 193], ["pandemic H1N1", "PROBLEM", 197, 210], ["other influenza A virus subtypes", "TEST", 215, 247]]], ["This could be due to variation in infectivity of the virus and tissue tropism, with the pandemic H1N1 preferentially replicating in the human upper respiratory tract and the avian influenza A viruses preferentially replicating in the lower respiratory tract [50, 51] .", [["tissue", "ANATOMY", 63, 69], ["upper respiratory tract", "ANATOMY", 142, 165], ["lower respiratory tract", "ANATOMY", 234, 257], ["tissue", "TISSUE", 63, 69], ["human", "ORGANISM", 136, 141], ["upper respiratory", "ORGANISM_SUBDIVISION", 142, 159], ["tract", "ORGANISM_SUBDIVISION", 160, 165], ["avian", "ORGANISM", 174, 179], ["influenza A viruses", "ORGANISM", 180, 199], ["lower", "ORGANISM_SUBDIVISION", 234, 239], ["respiratory tract", "ORGANISM_SUBDIVISION", 240, 257], ["human", "SPECIES", 136, 141], ["avian influenza A", "SPECIES", 174, 191], ["human", "SPECIES", 136, 141], ["variation in infectivity", "PROBLEM", 21, 45], ["the virus and tissue tropism", "PROBLEM", 49, 77], ["the pandemic H1N1", "PROBLEM", 84, 101], ["the avian influenza A viruses", "PROBLEM", 170, 199], ["could be due to", "UNCERTAINTY", 5, 20], ["variation", "OBSERVATION_MODIFIER", 21, 30], ["infectivity", "OBSERVATION", 34, 45], ["pandemic", "OBSERVATION_MODIFIER", 88, 96], ["H1N1", "OBSERVATION", 97, 101], ["human", "ANATOMY_MODIFIER", 136, 141], ["upper", "ANATOMY_MODIFIER", 142, 147], ["respiratory tract", "ANATOMY", 148, 165], ["influenza", "OBSERVATION", 180, 189], ["viruses", "OBSERVATION", 192, 199], ["lower", "ANATOMY_MODIFIER", 234, 239], ["respiratory tract", "ANATOMY", 240, 257]]], ["Therefore, AGMPs have the potential to amplify or open up the route of aerosol transmission for influenza A viruses.", [["influenza A viruses", "DISEASE", 96, 115], ["AGMPs", "GENE_OR_GENE_PRODUCT", 11, 16], ["influenza A viruses", "ORGANISM", 96, 115], ["AGMPs", "PROTEIN", 11, 16], ["influenza A viruses", "SPECIES", 96, 115], ["aerosol transmission", "TREATMENT", 71, 91], ["influenza A viruses", "PROBLEM", 96, 115]]], ["Understanding the characteristics of the aerosol transmission of different influenza A viruses and subtypes could help us determine the risk of influenza A viruses for nosocomial transmission due to AGMPs.ParamyxoviridaeOf the viruses in the family Paramyxoviridae, the recently emerged Nipah and Hendra viruses pose a high risk to HCWs performing AGMPs.", [["influenza A viruses", "DISEASE", 75, 94], ["influenza A viruses", "DISEASE", 144, 163], ["nosocomial transmission", "DISEASE", 168, 191], ["Nipah and Hendra viruses", "DISEASE", 287, 311], ["AGMPs", "DISEASE", 348, 353], ["influenza A viruses", "ORGANISM", 75, 94], ["influenza A viruses", "ORGANISM", 144, 163], ["AGMPs", "GENE_OR_GENE_PRODUCT", 199, 204], ["Nipah", "ORGANISM", 287, 292], ["Hendra viruses", "ORGANISM", 297, 311], ["AGMPs", "GENE_OR_GENE_PRODUCT", 348, 353], ["AGMPs", "PROTEIN", 199, 204], ["Nipah", "SPECIES", 287, 292], ["influenza A viruses", "SPECIES", 75, 94], ["influenza A viruses", "SPECIES", 144, 163], ["Hendra viruses", "SPECIES", 297, 311], ["the aerosol transmission", "TREATMENT", 37, 61], ["different influenza A viruses", "PROBLEM", 65, 94], ["influenza", "PROBLEM", 144, 153], ["nosocomial transmission", "TREATMENT", 168, 191], ["Hendra viruses", "TREATMENT", 297, 311], ["viruses", "OBSERVATION", 227, 234]]], ["Both viruses are known to cause respiratory disease in humans, and nosocomial transmission was documented for Nipah virus [42] .", [["respiratory", "ANATOMY", 32, 43], ["respiratory disease", "DISEASE", 32, 51], ["Nipah virus", "DISEASE", 110, 121], ["humans", "ORGANISM", 55, 61], ["Nipah virus", "ORGANISM", 110, 121], ["humans", "SPECIES", 55, 61], ["Nipah virus", "SPECIES", 110, 121], ["humans", "SPECIES", 55, 61], ["Nipah virus", "SPECIES", 110, 121], ["Both viruses", "PROBLEM", 0, 12], ["respiratory disease in humans", "PROBLEM", 32, 61], ["nosocomial transmission", "TEST", 67, 90], ["Nipah virus", "PROBLEM", 110, 121], ["viruses", "OBSERVATION", 5, 12], ["known to cause", "UNCERTAINTY", 17, 31], ["respiratory disease", "OBSERVATION", 32, 51]]], ["Aerosol transmission is one of the suspected routes of transmission for Nipah virus because of evidence from contact tracing and finding the virus in human respiratory secretions [41] .", [["Nipah virus", "DISEASE", 72, 83], ["Nipah virus", "ORGANISM", 72, 83], ["human", "ORGANISM", 150, 155], ["Nipah virus", "SPECIES", 72, 83], ["human", "SPECIES", 150, 155], ["Nipah virus", "SPECIES", 72, 83], ["human", "SPECIES", 150, 155], ["Aerosol transmission", "TREATMENT", 0, 20], ["Nipah virus", "PROBLEM", 72, 83], ["contact tracing", "TEST", 109, 124], ["the virus in human respiratory secretions", "PROBLEM", 137, 178]]], ["Hendra virus spilled over from horses to humans, and no human-to-human transmission was documented, but the virus was detected in human lungs [43] .", [["lungs", "ANATOMY", 136, 141], ["Hendra virus", "ORGANISM", 0, 12], ["humans", "ORGANISM", 41, 47], ["human", "ORGANISM", 56, 61], ["human", "ORGANISM", 65, 70], ["human", "ORGANISM", 130, 135], ["lungs", "ORGAN", 136, 141], ["Hendra virus", "SPECIES", 0, 12], ["humans", "SPECIES", 41, 47], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 130, 135], ["Hendra virus", "SPECIES", 0, 12], ["humans", "SPECIES", 41, 47], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 130, 135], ["Hendra virus", "PROBLEM", 0, 12], ["the virus", "PROBLEM", 104, 113], ["virus", "OBSERVATION", 7, 12], ["lungs", "ANATOMY", 136, 141]]], ["Although henipaviruses do not seem to be as contagious through the aerosol route between people as other viruses in their family, such as measles virus, it is possible that AGMPs could contribute to the formation of infectious Nipah-and Hendra-laden aerosols that could cause nosocomial infection.Designing Experiments and Assessing RiskGiven the lack of experimental or epidemiological data on nosocomial virus transmission and AGMPs, current guidelines for infection control are based on the precautionary principle.", [["measles virus", "DISEASE", 138, 151], ["AGMPs", "CHEMICAL", 173, 178], ["nosocomial infection", "DISEASE", 276, 296], ["nosocomial virus transmission", "DISEASE", 395, 424], ["AGMPs", "DISEASE", 429, 434], ["infection", "DISEASE", 459, 468], ["people", "ORGANISM", 89, 95], ["measles virus", "ORGANISM", 138, 151], ["AGMPs", "GENE_OR_GENE_PRODUCT", 173, 178], ["Nipah", "ORGANISM", 227, 232], ["Hendra", "ORGANISM", 237, 243], ["people", "SPECIES", 89, 95], ["Nipah", "SPECIES", 227, 232], ["measles virus", "SPECIES", 138, 151], ["henipaviruses", "PROBLEM", 9, 22], ["the aerosol route", "TREATMENT", 63, 80], ["measles virus", "PROBLEM", 138, 151], ["infectious Nipah", "PROBLEM", 216, 232], ["Hendra-laden aerosols", "TREATMENT", 237, 258], ["nosocomial infection", "PROBLEM", 276, 296], ["nosocomial virus transmission", "TREATMENT", 395, 424], ["AGMPs", "TREATMENT", 429, 434], ["current guidelines", "TREATMENT", 436, 454], ["infection control", "TREATMENT", 459, 476], ["infectious", "OBSERVATION_MODIFIER", 216, 226], ["nosocomial", "OBSERVATION_MODIFIER", 276, 286], ["infection", "OBSERVATION", 287, 296]]], ["In order to have a more nuanced understanding of the risks associated with difference AGMPs and viruses, we need more research in both clinical and experimental settings.", [["difference AGMPs and viruses", "PROBLEM", 75, 103]]], ["This type of research could take two different forms, retrospective epidemiological studies or on-site sampling and experimental tests.", [["retrospective epidemiological studies", "TEST", 54, 91], ["site sampling", "TEST", 98, 111], ["experimental tests", "TEST", 116, 134]]], ["The former was used to assess the risk of AGMPs and SARS-CoV transmission [11] .", [["AGMPs", "DISEASE", 42, 47], ["SARS", "DISEASE", 52, 56], ["AGMPs", "GENE_OR_GENE_PRODUCT", 42, 47], ["SARS-CoV", "SPECIES", 52, 60], ["AGMPs", "PROBLEM", 42, 47], ["SARS", "PROBLEM", 52, 56]]], ["However, the quality of retrospective data limits these kinds of studies.", [["retrospective data", "TEST", 24, 42], ["studies", "TEST", 65, 72]]], ["Control cases are necessary to rule out other sources of nosocomial transmission besides AGMPs, such as direct patient contact and fomite transmission.", [["AGMPs", "DISEASE", 89, 94], ["AGMPs", "GENE_OR_GENE_PRODUCT", 89, 94], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["nosocomial transmission", "PROBLEM", 57, 80]]], ["Moreover, these studies rely on reporting that may be infrequent and/or unreliable.Designing Experiments and Assessing RiskAir sampling for viruses during AGMPs performed on patients would provide the most clinically relevant data.", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["these studies", "TEST", 10, 23], ["Assessing RiskAir sampling", "TREATMENT", 109, 135], ["viruses", "PROBLEM", 140, 147]]], ["Multiple air-sampling techniques for viruses now exist.", [["Multiple air-sampling techniques", "TREATMENT", 0, 32], ["viruses", "PROBLEM", 37, 44], ["viruses", "OBSERVATION", 37, 44]]], ["Researchers can use both solid and liquid impactors to sample and recover aerosolized viruses [52] .", [["both solid and liquid impactors", "TREATMENT", 20, 51], ["aerosolized viruses", "PROBLEM", 74, 93]]], ["Personally worn bioaerosal samplers and stationary room samplers were used to detect influenza A virus RNA in an emergency department [53] .", [["influenza A virus", "ORGANISM", 85, 102], ["influenza A virus RNA", "RNA", 85, 106], ["influenza A virus", "SPECIES", 85, 102], ["influenza A virus", "SPECIES", 85, 102], ["influenza", "PROBLEM", 85, 94]]], ["Researchers also used aerosol samplers to determine the amount of influenza A (H1N1) RNA in aerosols in the vicinity of patients while AGMPs were being performed [54] .", [["influenza A (H1N1)", "ORGANISM", 66, 84], ["patients", "ORGANISM", 120, 128], ["AGMPs", "SIMPLE_CHEMICAL", 135, 140], ["influenza A (H1N1) RNA", "RNA", 66, 88], ["patients", "SPECIES", 120, 128], ["influenza A (H1N1)", "SPECIES", 66, 84], ["aerosol samplers", "TREATMENT", 22, 38], ["influenza A (H1N1) RNA", "PROBLEM", 66, 88], ["influenza", "OBSERVATION", 66, 75]]], ["This allowed the authors to determine which procedures were associated with a higher concentration of viral RNA [54] .", [["viral RNA", "RNA", 102, 111], ["a higher concentration of viral RNA", "PROBLEM", 76, 111], ["viral RNA", "OBSERVATION", 102, 111]]], ["In order to determine whether viable virus is present in aerosols, virus isolation could be performed from air samples, and further quantification could occur through titrations or plaque assays [52] .", [["air samples", "ANATOMY", 107, 118], ["plaque", "ANATOMY", 181, 187], ["air samples", "ORGANISM_SUBSTANCE", 107, 118], ["viable virus", "PROBLEM", 30, 42], ["virus isolation", "TREATMENT", 67, 82], ["air samples", "TEST", 107, 118], ["further quantification", "TEST", 124, 146], ["plaque assays", "TEST", 181, 194], ["virus", "OBSERVATION", 37, 42]]], ["One group used a simulated aerosol chamber to demonstrate that viable influenza virus A could be extracted from surgical masks and N95 respirators [55] .", [["influenza virus A", "ORGANISM", 70, 87], ["influenza virus", "SPECIES", 70, 85], ["a simulated aerosol chamber", "TREATMENT", 15, 42], ["viable influenza virus", "PROBLEM", 63, 85], ["surgical masks", "TREATMENT", 112, 126]]], ["Particle sizers may also be used in experimental settings to characterize the size and dispersal of aerosols.", [["Particle sizers", "TREATMENT", 0, 15], ["may also be", "UNCERTAINTY", 16, 27], ["size", "OBSERVATION_MODIFIER", 78, 82]]], ["One group used particle sizers to measure the size and travel distance of aerosols from patients who underwent AGMPs, such as nebulizer treatment and NIV [56] .", [["NIV", "CHEMICAL", 150, 153], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["AGMPs", "TREATMENT", 111, 116], ["nebulizer treatment", "TREATMENT", 126, 145], ["NIV", "TREATMENT", 150, 153], ["size", "OBSERVATION_MODIFIER", 46, 50]]], ["Determining the quantity of viable virus expelled from certain patients during AGMPs could help determine phenomena like super-spreading events, while understanding aerosol characteristics such as particle size could elucidate mechanisms of transmission.Designing Experiments and Assessing RiskWhile on-site sampling works for current nosocomial transmission events, we can design experiments to gain prospective knowledge.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["viable virus", "PROBLEM", 28, 40], ["phenomena like super-spreading events", "PROBLEM", 106, 143], ["viable", "OBSERVATION_MODIFIER", 28, 34], ["virus", "OBSERVATION", 35, 40]]], ["Procedures such as bronchoscopy and intubation are performed on animal models of the high-risk viral diseases we identified, and air sampling during these procedures could determine whether they are aerosol-generating.", [["viral diseases", "DISEASE", 95, 109], ["bronchoscopy", "TEST", 19, 31], ["intubation", "TREATMENT", 36, 46], ["the high-risk viral diseases", "PROBLEM", 81, 109], ["air sampling", "TEST", 129, 141], ["these procedures", "TREATMENT", 149, 165], ["viral diseases", "OBSERVATION", 95, 109]]], ["Experimentally generating virus-laden aerosols of different sizes and under different environmental conditions could also help determine the risks of different viruses based on their stability in aerosols [57, 58] .", [["Experimentally generating virus", "PROBLEM", 0, 31], ["different viruses", "PROBLEM", 150, 167], ["virus", "OBSERVATION", 26, 31], ["laden", "OBSERVATION_MODIFIER", 32, 37], ["aerosols", "OBSERVATION_MODIFIER", 38, 46], ["different", "OBSERVATION_MODIFIER", 50, 59], ["sizes", "OBSERVATION_MODIFIER", 60, 65], ["viruses", "OBSERVATION", 160, 167]]], ["Researchers could then create risk models for different viruses based on aersol stability, as well as data on the quantity, concentration, travel distance, and size of aerosols formed during AGMPs.Designing Experiments and Assessing RiskMultiple environmental factors influence the viability of aerosolized viruses, including relative humidity, temperature, UV radiation, and gas composition of the air [52] .", [["aersol", "SIMPLE_CHEMICAL", 73, 79], ["AGMPs", "SIMPLE_CHEMICAL", 191, 196], ["different viruses", "PROBLEM", 46, 63], ["aerosolized viruses", "PROBLEM", 295, 314], ["relative humidity", "TREATMENT", 326, 343], ["UV radiation", "TREATMENT", 358, 370], ["viruses", "OBSERVATION", 56, 63], ["size", "OBSERVATION_MODIFIER", 160, 164], ["aerosols formed", "OBSERVATION", 168, 183]]], ["These factors affect viruses differently, and so it is important to consider the environments where emerging viruses exist and where AGMPs are being performed.", [["AGMPs", "GENE_OR_GENE_PRODUCT", 133, 138]]], ["The aforementioned AGMPs include those that are both ubiquitous, such as CPR or manual ventilation, as well as those that are limited to advanced health-care settings, such as bronchoscopy.", [["AGMPs", "SIMPLE_CHEMICAL", 19, 24], ["CPR", "TREATMENT", 73, 76], ["manual ventilation", "TREATMENT", 80, 98], ["bronchoscopy", "TEST", 176, 188]]], ["The risk of transmission from AGMPs may be very different in a field-based treatment unit than from a tertiary care hospital.", [["AGMPs", "DISEASE", 30, 35], ["AGMPs", "TREATMENT", 30, 35]]], ["Additionally, some health-care settings, such as hospitals with biocontainment units, include additional air-handling systems that can limit aerosol exposure to HCWs [59] .", [["biocontainment units", "TREATMENT", 64, 84], ["additional air-handling systems", "TREATMENT", 94, 125]]], ["Therefore, the risk of nosocomial transmission via AGMPs varies greatly based on the environment, and this must be considered when designing experiments.DiscussionDuring the 2013-2016 outbreak of EVD, the Centers for Disease Control and Prevention (CDC) updated its guidelines regarding precautions to prevent the transmission of EBOV in health-care settings [60] .", [["EVD", "DISEASE", 196, 199], ["EBOV", "DISEASE", 330, 334], ["AGMPs", "GENE_OR_GENE_PRODUCT", 51, 56], ["EBOV", "ORGANISM", 330, 334], ["EBOV", "SPECIES", 330, 334], ["nosocomial transmission", "TREATMENT", 23, 46], ["EVD", "TREATMENT", 196, 199], ["Disease Control", "TREATMENT", 217, 232], ["precautions", "TREATMENT", 287, 298], ["nosocomial", "OBSERVATION", 23, 33]]], ["The updated guidelines further emphasized proper personal protective equipment (PPE) and isolation when performing AGMPs on EVD patients.", [["AGMPs", "CHEMICAL", 115, 120], ["AGMPs", "SIMPLE_CHEMICAL", 115, 120], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["isolation", "TREATMENT", 89, 98], ["EVD patients", "TREATMENT", 124, 136]]], ["Currently, in addition to standard PPE, the CDC recommends the use of eye protection, airborne infection isolation rooms, and N95 or higher respirators when performing AGMPs on patients with VHFs, SARS-CoV, and avian or pandemic influenza A viruses [61] .", [["eye", "ANATOMY", 70, 73], ["infection", "DISEASE", 95, 104], ["AGMPs", "CHEMICAL", 168, 173], ["VHFs", "DISEASE", 191, 195], ["SARS-CoV", "DISEASE", 197, 205], ["influenza A viruses", "DISEASE", 229, 248], ["eye", "ORGAN", 70, 73], ["patients", "ORGANISM", 177, 185], ["SARS-CoV", "ORGANISM", 197, 205], ["pandemic influenza A viruses", "ORGANISM", 220, 248], ["patients", "SPECIES", 177, 185], ["pandemic influenza A", "SPECIES", 220, 240], ["SARS-CoV", "SPECIES", 197, 205], ["pandemic influenza A viruses", "SPECIES", 220, 248], ["standard PPE", "TREATMENT", 26, 38], ["eye protection", "TREATMENT", 70, 84], ["airborne infection isolation rooms", "TREATMENT", 86, 120], ["VHFs", "TREATMENT", 191, 195], ["SARS", "PROBLEM", 197, 201], ["CoV", "PROBLEM", 202, 205], ["pandemic influenza A viruses", "PROBLEM", 220, 248]]], ["The CDC made similar recommendations as an interim guidance for MERS-CoV [62] , and we were unable to find additional CDC AGMP guidelines for Nipah virus, Hendra virus, or hantaviruses.", [["Nipah virus", "DISEASE", 142, 153], ["Hendra virus", "DISEASE", 155, 167], ["hantaviruses", "DISEASE", 172, 184], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["Nipah virus", "ORGANISM", 142, 153], ["Hendra virus", "ORGANISM", 155, 167], ["Nipah virus", "SPECIES", 142, 153], ["Hendra virus", "SPECIES", 155, 167], ["MERS-CoV", "SPECIES", 64, 72], ["Nipah virus", "SPECIES", 142, 153], ["Hendra virus", "SPECIES", 155, 167], ["Nipah virus", "PROBLEM", 142, 153], ["Hendra virus", "PROBLEM", 155, 167], ["hantaviruses", "PROBLEM", 172, 184]]], ["More evidence of nosocomial transmission events of these and other viruses due to AGMPs is likely to prompt future guidelines.", [["AGMPs", "DISEASE", 82, 87], ["AGMPs", "GENE_OR_GENE_PRODUCT", 82, 87], ["nosocomial transmission events", "PROBLEM", 17, 47], ["these and other viruses", "PROBLEM", 51, 74], ["nosocomial", "OBSERVATION", 17, 27]]], ["Therefore, our understanding of the risks associated with AGMPs and nosocomial virus transmission is not static, and we must continue to improve our knowledge to develop appropriate precautions.DiscussionThe ambiguity of which procedures and viruses require additional protective measures during AGMPs may lead to breaches in protocol.", [["AGMPs", "CHEMICAL", 58, 63], ["nosocomial virus transmission", "DISEASE", 68, 97], ["AGMPs", "CHEMICAL", 296, 301], ["AGMPs", "GENE_OR_GENE_PRODUCT", 58, 63], ["nosocomial virus", "ORGANISM", 68, 84], ["AGMPs", "SIMPLE_CHEMICAL", 296, 301], ["AGMPs", "TREATMENT", 58, 63], ["nosocomial virus transmission", "PROBLEM", 68, 97], ["appropriate precautions", "TREATMENT", 170, 193], ["which procedures", "TREATMENT", 221, 237], ["viruses", "TREATMENT", 242, 249], ["additional protective measures", "TREATMENT", 258, 288], ["AGMPs", "TREATMENT", 296, 301], ["breaches in protocol", "TREATMENT", 314, 334]]], ["During many of the cited nosocomial transmission events, HCWs did not use proper eye or respiratory protection.", [["eye", "ANATOMY", 81, 84], ["respiratory", "ANATOMY", 88, 99], ["eye", "ORGAN", 81, 84], ["respiratory protection", "TREATMENT", 88, 110]]], ["Even when aware of the need for respiratory protection, HCWs may mistakenly wear surgical masks or unfitted N95 respirators, which do not provide proper protection.", [["respiratory", "ANATOMY", 32, 43], ["respiratory protection", "TREATMENT", 32, 54], ["surgical masks", "TREATMENT", 81, 95], ["N95 respirators", "TREATMENT", 108, 123]]], ["Therefore, while determining the risks of certain viruses and procedures is essential, communicating their respective precautions and providing resources is equally important.", [["certain viruses", "PROBLEM", 42, 57], ["procedures", "TREATMENT", 62, 72]]], ["Likewise, proper patient triage and diagnosis are the first steps to ensuring that precautions are undertaken when performing AGMPs.DiscussionOverall, more research and communication about the risks of certain viruses and AGMPs are necessary to resolve the uncertainty surrounding their role in nosocomial virus transmission.", [["nosocomial virus transmission", "DISEASE", 295, 324], ["patient", "ORGANISM", 17, 24], ["AGMPs", "GENE_OR_GENE_PRODUCT", 222, 227], ["nosocomial virus", "ORGANISM", 295, 311], ["AGMPs", "PROTEIN", 126, 131], ["patient", "SPECIES", 17, 24], ["precautions", "TREATMENT", 83, 94], ["certain viruses", "PROBLEM", 202, 217], ["AGMPs", "TREATMENT", 222, 227], ["nosocomial virus transmission", "TREATMENT", 295, 324], ["nosocomial virus", "OBSERVATION", 295, 311]]], ["Although we identified certain viruses and procedures that could be high risk and should be experimentally or clinically tested, emerging viruses or novel procedures may also play significant roles.", [["procedures", "TREATMENT", 43, 53], ["novel procedures", "TREATMENT", 149, 165], ["viruses", "OBSERVATION", 31, 38]]], ["If we are to design proactive infection control guidelines and understand the underlying biology of viral transmission, we must conduct collaborative clinical and scientific research on nosocomial virus transmission and AGMPs.", [["infection", "DISEASE", 30, 39], ["nosocomial virus transmission", "DISEASE", 186, 215], ["proactive infection control guidelines", "TREATMENT", 20, 58], ["nosocomial virus transmission", "TREATMENT", 186, 215]]]], "PMC7110994": [["Cells communicate with their environment via multiple mechanismsOrganisms, tissues and cells must all continuously correspond with their environment in order to best adapt to their surrounding microcosm.", [["Cells", "ANATOMY", 0, 5], ["tissues", "ANATOMY", 75, 82], ["cells", "ANATOMY", 87, 92], ["Cells", "CELL", 0, 5], ["tissues", "TISSUE", 75, 82], ["cells", "CELL", 87, 92], ["Organisms, tissues and cells", "PROBLEM", 64, 92]]], ["Classically, cells were known to secrete protein cues into extracellular space by shedding the plasma membrane with the associated protein and lipid components or by expelling a variety of vesicular particles containing a subset of the cell's protein and membrane content.", [["cells", "ANATOMY", 13, 18], ["extracellular space", "ANATOMY", 59, 78], ["plasma membrane", "ANATOMY", 95, 110], ["vesicular particles", "ANATOMY", 189, 208], ["cell", "ANATOMY", 236, 240], ["membrane", "ANATOMY", 255, 263], ["cells", "CELL", 13, 18], ["extracellular space", "CELLULAR_COMPONENT", 59, 78], ["plasma membrane", "CELLULAR_COMPONENT", 95, 110], ["cell", "CELL", 236, 240], ["membrane", "CELLULAR_COMPONENT", 255, 263], ["the associated protein and lipid components", "PROBLEM", 116, 159], ["a variety of vesicular particles", "PROBLEM", 176, 208], ["the cell's protein", "TEST", 232, 250], ["plasma membrane", "OBSERVATION", 95, 110], ["lipid components", "OBSERVATION", 143, 159], ["variety", "OBSERVATION_MODIFIER", 178, 185], ["vesicular particles", "OBSERVATION", 189, 208], ["cell", "OBSERVATION", 236, 240], ["membrane content", "OBSERVATION", 255, 271]]], ["To date the long distance transmission of signals between cells and tissues has commonly been described by protein-based signaling systems exemplified by enzymes, hormones, cytokines, and chemokines.Cells communicate with their environment via multiple mechanismsThe mode by which proteins aid cellular communication is varied and classified primarily on the basis of the \u201crange of action\u201d of the signaling molecules.", [["cells", "ANATOMY", 58, 63], ["tissues", "ANATOMY", 68, 75], ["Cells", "ANATOMY", 199, 204], ["cellular", "ANATOMY", 294, 302], ["cells", "CELL", 58, 63], ["tissues", "TISSUE", 68, 75], ["Cells", "CELL", 199, 204], ["cellular", "CELL", 294, 302], ["enzymes", "PROTEIN", 154, 161], ["cytokines", "PROTEIN", 173, 182], ["chemokines", "PROTEIN", 188, 198], ["signaling molecules", "PROTEIN", 397, 416], ["the long distance transmission of signals between cells and tissues", "PROBLEM", 8, 75], ["enzymes", "TEST", 154, 161], ["cytokines", "TREATMENT", 173, 182], ["chemokines", "TREATMENT", 188, 198], ["the signaling molecules", "PROBLEM", 393, 416], ["tissues", "ANATOMY", 68, 75], ["cellular communication", "OBSERVATION", 294, 316], ["signaling molecules", "OBSERVATION", 397, 416]]], ["For example, juxtacrine signaling (also known as contact-dependent signaling), involves actual cell-to-cell contact with the exchange of cytoplasmic materials through nanotubes or gap junctions (exemplified by the Notch signaling pathway).", [["cell", "ANATOMY", 95, 99], ["cell", "ANATOMY", 103, 107], ["cytoplasmic", "ANATOMY", 137, 148], ["gap junctions", "ANATOMY", 180, 193], ["juxtacrine", "GENE_OR_GENE_PRODUCT", 13, 23], ["cell", "CELL", 95, 99], ["cell", "CELL", 103, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 137, 148], ["gap junctions", "CELLULAR_COMPONENT", 180, 193], ["Notch", "GENE_OR_GENE_PRODUCT", 214, 219], ["juxtacrine signaling", "PROBLEM", 13, 33], ["contact-dependent signaling", "PROBLEM", 49, 76], ["cytoplasmic materials through nanotubes or gap junctions", "TREATMENT", 137, 193], ["cytoplasmic materials", "OBSERVATION", 137, 158], ["gap junctions", "OBSERVATION", 180, 193]]], ["Paracrine signaling refers to the signaling effect of released molecules in close proximity to the source/producing cell.Cells communicate with their environment via multiple mechanismsFinally in endocrine signaling, protein molecules produced by a cell are transported systemically through the blood stream to act distally, and may act either generically on all or many cells or specifically on select recipient cells containing the appropriate molecular characteristics (i.e., correct receptor, etc.).", [["cell", "ANATOMY", 116, 120], ["Cells", "ANATOMY", 121, 126], ["endocrine", "ANATOMY", 196, 205], ["cell", "ANATOMY", 249, 253], ["blood stream", "ANATOMY", 295, 307], ["cells", "ANATOMY", 371, 376], ["cells", "ANATOMY", 413, 418], ["cell", "CELL", 116, 120], ["Cells", "CELL", 121, 126], ["endocrine", "ANATOMICAL_SYSTEM", 196, 205], ["cell", "CELL", 249, 253], ["blood", "ORGANISM_SUBSTANCE", 295, 300], ["cells", "CELL", 371, 376], ["cells", "CELL", 413, 418], ["protein molecules", "PROTEIN", 217, 234], ["recipient cells", "CELL_TYPE", 403, 418], ["Paracrine signaling", "PROBLEM", 0, 19], ["released molecules", "PROBLEM", 54, 72], ["protein molecules", "PROBLEM", 217, 234], ["producing cell", "OBSERVATION", 106, 120], ["distally", "ANATOMY_MODIFIER", 315, 323]]], ["The function of such protein-based signaling cues is generally tri-phasic involving, (i) binding to a cell surface receptor, (ii) internalization into the cell, and (iii) downstream signaling that translates into a measurable response in the cell.Cells communicate with their environment via multiple mechanismsIn contrast to well-studied protein based cell-to-cell signaling discussed above, the possibility of RNA (ribonucleic acid) based cell-to-cell signaling has come to the forefront only recently.", [["cell surface", "ANATOMY", 102, 114], ["cell", "ANATOMY", 155, 159], ["cell", "ANATOMY", 242, 246], ["Cells", "ANATOMY", 247, 252], ["cell", "ANATOMY", 353, 357], ["cell", "ANATOMY", 361, 365], ["cell", "ANATOMY", 441, 445], ["cell", "ANATOMY", 449, 453], ["ribonucleic acid", "CHEMICAL", 417, 433], ["cell", "CELL", 102, 106], ["cell", "CELL", 155, 159], ["cell", "CELL", 242, 246], ["Cells", "CELL", 247, 252], ["cell", "CELL", 353, 357], ["cell", "CELL", 361, 365], ["cell", "CELL", 441, 445], ["cell", "CELL", 449, 453], ["cell surface receptor", "PROTEIN", 102, 123], ["such protein", "TEST", 16, 28], ["a cell surface receptor", "TEST", 100, 123], ["RNA (ribonucleic acid)", "TEST", 412, 434], ["based cell", "TEST", 435, 445], ["cell signaling", "PROBLEM", 449, 463], ["cell", "ANATOMY", 155, 159], ["measurable", "OBSERVATION_MODIFIER", 215, 225], ["response", "OBSERVATION_MODIFIER", 226, 234], ["cell", "ANATOMY", 242, 246]]], ["This resulted from the discovery that cell-extruded membranous bioactive vesicles called \u2018exosomes\u2019 transfer both functional protein and RNA species from one cell to another resulting in a change in the recipient cell [1], [2], [3].", [["cell", "ANATOMY", 38, 42], ["membranous bioactive vesicles", "ANATOMY", 52, 81], ["exosomes", "ANATOMY", 90, 98], ["cell", "ANATOMY", 158, 162], ["cell", "ANATOMY", 213, 217], ["cell", "CELL", 38, 42], ["vesicles", "CELLULAR_COMPONENT", 73, 81], ["cell", "CELL", 158, 162], ["cell", "CELL", 213, 217], ["RNA species", "RNA", 137, 148], ["extruded membranous bioactive vesicles", "PROBLEM", 43, 81], ["RNA species", "PROBLEM", 137, 148], ["the recipient cell", "TEST", 199, 217], ["membranous", "OBSERVATION_MODIFIER", 52, 62], ["bioactive vesicles", "OBSERVATION", 63, 81]]], ["Because of these properties, exosomes may be a rich source of stable and reproducible biomarkers in a variety of conditions.Cells communicate with their environment via multiple mechanismsThe present review provides a brief description of the biogenesis and molecular properties of exosomes as established to date.", [["exosomes", "ANATOMY", 29, 37], ["Cells", "ANATOMY", 124, 129], ["exosomes", "ANATOMY", 282, 290], ["exosomes", "CELL", 29, 37], ["Cells", "CELL", 124, 129], ["exosomes", "CELL", 282, 290], ["exosomes", "CELL_TYPE", 29, 37], ["exosomes", "CELL_TYPE", 282, 290], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["It reviews studies that have implicated functional activities of exosomes in a few model systems and finally, reviews the biomarker potential of exosomes with respect to soluble/accessible biomarkers.Discovery and biogenesis of exosomes from the endosomal system ::: ExosomesExosomes were first described in 1981 as exfoliation from monolayer cultures containing ecto-ATPase (adenosine triphosphatase) and ecto-5\u2032 exonuclease activity.", [["exosomes", "ANATOMY", 65, 73], ["exosomes", "ANATOMY", 145, 153], ["exosomes", "ANATOMY", 228, 236], ["endosomal system", "ANATOMY", 246, 262], ["monolayer cultures", "ANATOMY", 333, 351], ["exfoliation", "DISEASE", 316, 327], ["adenosine", "CHEMICAL", 376, 385], ["adenosine", "CHEMICAL", 376, 385], ["exosomes", "CELL", 65, 73], ["exosomes", "CELL", 145, 153], ["exosomes", "CELL", 228, 236], ["endosomal", "CELLULAR_COMPONENT", 246, 255], ["ExosomesExosomes", "SIMPLE_CHEMICAL", 267, 283], ["monolayer cultures", "CELL", 333, 351], ["ecto-ATPase", "GENE_OR_GENE_PRODUCT", 363, 374], ["adenosine triphosphatase", "GENE_OR_GENE_PRODUCT", 376, 400], ["ecto-5\u2032 exonuclease", "GENE_OR_GENE_PRODUCT", 406, 425], ["exosomes", "CELL_TYPE", 65, 73], ["exosomes", "CELL_TYPE", 145, 153], ["exosomes", "CELL_TYPE", 228, 236], ["monolayer cultures", "CELL_LINE", 333, 351], ["ecto-ATPase", "PROTEIN", 363, 374], ["adenosine triphosphatase", "PROTEIN", 376, 400], ["ecto-5\u2032 exonuclease", "PROTEIN", 406, 425], ["It reviews studies", "TEST", 0, 18], ["soluble/accessible biomarkers", "TEST", 170, 199], ["monolayer cultures", "TEST", 333, 351], ["ecto-ATPase (adenosine triphosphatase", "TREATMENT", 363, 400], ["ecto", "TEST", 406, 410]]], ["This suggests that they are derived from specific sub-domains of the plasma membrane [5].", [["plasma membrane", "ANATOMY", 69, 84], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84]]], ["Early research by Johnstone et al. established that such microvesicles help maturing erythrocytes get rid of transferrin receptors and other obsolete proteins [6].", [["microvesicles", "ANATOMY", 57, 70], ["erythrocytes", "ANATOMY", 85, 97], ["microvesicles", "CELL", 57, 70], ["erythrocytes", "CELL", 85, 97], ["transferrin receptors", "GENE_OR_GENE_PRODUCT", 109, 130], ["microvesicles", "CELL_TYPE", 57, 70], ["maturing erythrocytes", "CELL_TYPE", 76, 97], ["transferrin receptors", "PROTEIN", 109, 130], ["obsolete proteins", "PROTEIN", 141, 158], ["such microvesicles", "PROBLEM", 52, 70], ["maturing erythrocytes", "PROBLEM", 76, 97], ["transferrin receptors", "TREATMENT", 109, 130]]], ["Visualization by electron microscopy and correlation of the vesicle release kinetics with the well established endocytosis kinetics of markers such as the transferrin receptor (TfR), revealed that a subset of endosomal vesicles are released intact to the cell exterior in a mechanism distinct from endocytic recycling [6].Discovery and biogenesis of exosomes from the endosomal system ::: ExosomesIn a process that involves invagination of the limiting membrane to form a structure budding into the lumen of the late endosome, these exosomes are known to encapsulate material from the cell cytoplasm including RNA, protein and DNA (deoxyribonucleic acid) (Fig. 1).", [["vesicle", "ANATOMY", 60, 67], ["endosomal vesicles", "ANATOMY", 209, 227], ["cell", "ANATOMY", 255, 259], ["exosomes", "ANATOMY", 350, 358], ["endosomal system", "ANATOMY", 368, 384], ["Exosomes", "ANATOMY", 389, 397], ["membrane", "ANATOMY", 453, 461], ["lumen", "ANATOMY", 499, 504], ["late endosome", "ANATOMY", 512, 525], ["exosomes", "ANATOMY", 533, 541], ["cell cytoplasm", "ANATOMY", 585, 599], ["deoxyribonucleic acid", "CHEMICAL", 632, 653], ["vesicle", "CELLULAR_COMPONENT", 60, 67], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 155, 175], ["TfR", "GENE_OR_GENE_PRODUCT", 177, 180], ["endosomal vesicles", "CELLULAR_COMPONENT", 209, 227], ["cell", "CELL", 255, 259], ["exosomes", "CELL", 350, 358], ["endosomal", "CELLULAR_COMPONENT", 368, 377], ["Exosomes", "ORGANISM_SUBSTANCE", 389, 397], ["membrane", "CELLULAR_COMPONENT", 453, 461], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 499, 504], ["late endosome", "CELLULAR_COMPONENT", 512, 525], ["exosomes", "CELL", 533, 541], ["cell cytoplasm", "ORGANISM_SUBSTANCE", 585, 599], ["DNA", "CELLULAR_COMPONENT", 627, 630], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 632, 653], ["transferrin receptor", "PROTEIN", 155, 175], ["TfR", "PROTEIN", 177, 180], ["exosomes", "CELL_TYPE", 350, 358], ["Exosomes", "CELL_TYPE", 389, 397], ["exosomes", "CELL_TYPE", 533, 541], ["electron microscopy", "TEST", 17, 36], ["the vesicle release kinetics", "TEST", 56, 84], ["the transferrin receptor (TfR", "TEST", 151, 180], ["a subset of endosomal vesicles", "PROBLEM", 197, 227], ["DNA (deoxyribonucleic acid", "TEST", 627, 653], ["endosomal vesicles", "OBSERVATION", 209, 227], ["endocytic recycling", "OBSERVATION", 298, 317], ["lumen", "ANATOMY_MODIFIER", 499, 504], ["late endosome", "OBSERVATION", 512, 525], ["cell cytoplasm", "OBSERVATION", 585, 599]]], ["Two membrane inversions occur during the formation of an exosome from a membrane patch on the plasma membrane.", [["membrane", "ANATOMY", 4, 12], ["exosome", "ANATOMY", 57, 64], ["membrane", "ANATOMY", 72, 80], ["plasma membrane", "ANATOMY", 94, 109], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["exosome", "CELLULAR_COMPONENT", 57, 64], ["membrane patch", "CELLULAR_COMPONENT", 72, 86], ["plasma membrane", "CELLULAR_COMPONENT", 94, 109], ["exosome", "PROTEIN", 57, 64], ["Two membrane inversions", "PROBLEM", 0, 23], ["a membrane patch", "TREATMENT", 70, 86], ["the plasma membrane", "TREATMENT", 90, 109], ["membrane inversions", "OBSERVATION", 4, 23]]], ["These two membrane inversions allow exosomes to present trans membrane cargo in the same orientation relative to the cytoplasm as at the plasma membrane [7], [8].", [["membrane", "ANATOMY", 10, 18], ["exosomes", "ANATOMY", 36, 44], ["membrane cargo", "ANATOMY", 62, 76], ["cytoplasm", "ANATOMY", 117, 126], ["plasma membrane", "ANATOMY", 137, 152], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["membrane cargo", "CELLULAR_COMPONENT", 62, 76], ["cytoplasm", "ORGANISM_SUBSTANCE", 117, 126], ["plasma membrane", "CELLULAR_COMPONENT", 137, 152], ["trans membrane cargo", "PROTEIN", 56, 76], ["These two membrane inversions", "PROBLEM", 0, 29]]], ["One inversion occurs at the plasma membrane during endocytic internalization as the plasma membrane invaginates prior to budding off.", [["plasma membrane", "ANATOMY", 28, 43], ["endocytic", "ANATOMY", 51, 60], ["plasma membrane", "ANATOMY", 84, 99], ["plasma membrane", "CELLULAR_COMPONENT", 28, 43], ["plasma membrane", "CELLULAR_COMPONENT", 84, 99], ["endocytic internalization", "TREATMENT", 51, 76], ["the plasma membrane", "TREATMENT", 80, 99]]], ["The second inversion occurs as the intraluminal vesicles (ILVs) bud off into the lumen of the late endosome (Fig. 2a).Discovery and biogenesis of exosomes from the endosomal system ::: ExosomesRather than being directed into a lysosomal compartment as is the fate for a well characterized branch of the late endosome MVB population, fusion of the multivesicular bodies with the plasma membrane releases exosomes into the extracellular space.", [["intraluminal vesicles", "ANATOMY", 35, 56], ["ILVs", "ANATOMY", 58, 62], ["lumen", "ANATOMY", 81, 86], ["late endosome", "ANATOMY", 94, 107], ["exosomes", "ANATOMY", 146, 154], ["endosomal system", "ANATOMY", 164, 180], ["lysosomal compartment", "ANATOMY", 227, 248], ["endosome MVB", "ANATOMY", 308, 320], ["multivesicular bodies", "ANATOMY", 347, 368], ["plasma membrane", "ANATOMY", 378, 393], ["exosomes", "ANATOMY", 403, 411], ["extracellular space", "ANATOMY", 421, 440], ["intraluminal vesicles", "CELLULAR_COMPONENT", 35, 56], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 86], ["late endosome", "CELLULAR_COMPONENT", 94, 107], ["exosomes", "CELL", 146, 154], ["endosomal", "CELLULAR_COMPONENT", 164, 173], ["ExosomesRather", "GENE_OR_GENE_PRODUCT", 185, 199], ["late endosome", "CELLULAR_COMPONENT", 303, 316], ["MVB population", "CELLULAR_COMPONENT", 317, 331], ["multivesicular bodies", "CELLULAR_COMPONENT", 347, 368], ["plasma membrane", "CELLULAR_COMPONENT", 378, 393], ["extracellular space", "CELLULAR_COMPONENT", 421, 440], ["exosomes", "CELL_TYPE", 146, 154], ["ExosomesRather", "PROTEIN", 185, 199], ["exosomes", "CELL_TYPE", 403, 411], ["The second inversion", "PROBLEM", 0, 20], ["second", "OBSERVATION_MODIFIER", 4, 10], ["inversion", "OBSERVATION", 11, 20], ["intraluminal", "ANATOMY_MODIFIER", 35, 47], ["vesicles", "ANATOMY", 48, 56], ["lumen", "ANATOMY_MODIFIER", 81, 86], ["late endosome", "OBSERVATION", 94, 107], ["late", "OBSERVATION_MODIFIER", 303, 307], ["endosome MVB population", "OBSERVATION", 308, 331], ["multivesicular", "ANATOMY_MODIFIER", 347, 361], ["bodies", "ANATOMY_MODIFIER", 362, 368], ["plasma membrane", "OBSERVATION", 378, 393], ["extracellular space", "OBSERVATION", 421, 440]]], ["This process of directed transport relies on several components of the endocytic machinery such as the Rab GTPases (Ras-related in brain) Rab 11, Rab 27 a and b, cytoskeleton regulatory proteins, molecular motors such as myosins, and SNAREs (SNAP (soluble NSF attachment protein) receptor) for targeted fusion (Fig. 2a).Discovery and biogenesis of exosomes from the endosomal system ::: ExosomesWhile cells of the hematopoietic lineage such as B-cells, dendritic cells, mast cells, T-cells and platelets were initially characterized for exosome production, in later years non-hematopoietic cells such as various epithelial cell types, neurons, and a very wide variety of tumor cells have also been shown to produce exosomes [9].", [["brain", "ANATOMY", 131, 136], ["cytoskeleton", "ANATOMY", 162, 174], ["exosomes", "ANATOMY", 348, 356], ["endosomal system", "ANATOMY", 366, 382], ["cells", "ANATOMY", 401, 406], ["hematopoietic lineage", "ANATOMY", 414, 435], ["B-cells", "ANATOMY", 444, 451], ["dendritic cells", "ANATOMY", 453, 468], ["mast cells", "ANATOMY", 470, 480], ["T-cells", "ANATOMY", 482, 489], ["platelets", "ANATOMY", 494, 503], ["exosome", "ANATOMY", 537, 544], ["non-hematopoietic cells", "ANATOMY", 572, 595], ["epithelial cell", "ANATOMY", 612, 627], ["neurons", "ANATOMY", 635, 642], ["tumor cells", "ANATOMY", 671, 682], ["exosomes", "ANATOMY", 715, 723], ["tumor", "DISEASE", 671, 676], ["Rab", "GENE_OR_GENE_PRODUCT", 103, 106], ["Ras-related in", "GENE_OR_GENE_PRODUCT", 116, 130], ["brain", "ORGAN", 131, 136], ["Rab 11", "GENE_OR_GENE_PRODUCT", 138, 144], ["Rab 27", "GENE_OR_GENE_PRODUCT", 146, 152], ["b", "GENE_OR_GENE_PRODUCT", 159, 160], ["cytoskeleton", "CELLULAR_COMPONENT", 162, 174], ["myosins", "GENE_OR_GENE_PRODUCT", 221, 228], ["SNAREs", "GENE_OR_GENE_PRODUCT", 234, 240], ["SNAP (soluble NSF attachment protein) receptor", "GENE_OR_GENE_PRODUCT", 242, 288], ["exosomes", "CELL", 348, 356], ["endosomal", "CELLULAR_COMPONENT", 366, 375], ["ExosomesWhile cells", "CELL", 387, 406], ["hematopoietic lineage", "CELL", 414, 435], ["B-cells", "CELL", 444, 451], ["dendritic cells", "CELL", 453, 468], ["mast cells", "CELL", 470, 480], ["T-cells", "CELL", 482, 489], ["platelets", "CELL", 494, 503], ["exosome", "CELLULAR_COMPONENT", 537, 544], ["non-hematopoietic cells", "CELL", 572, 595], ["epithelial cell types", "CELL", 612, 633], ["neurons", "CELL", 635, 642], ["tumor cells", "CELL", 671, 682], ["exosomes", "CELL", 715, 723], ["Rab GTPases", "PROTEIN", 103, 114], ["Ras-related in brain) Rab 11", "PROTEIN", 116, 144], ["Rab 27 a and b", "PROTEIN", 146, 160], ["cytoskeleton regulatory proteins", "PROTEIN", 162, 194], ["molecular motors", "PROTEIN", 196, 212], ["myosins", "PROTEIN", 221, 228], ["SNAREs", "PROTEIN", 234, 240], ["SNAP", "PROTEIN", 242, 246], ["soluble NSF attachment protein) receptor", "PROTEIN", 248, 288], ["exosomes", "CELL_TYPE", 348, 356], ["ExosomesWhile cells", "CELL_LINE", 387, 406], ["hematopoietic lineage", "CELL_TYPE", 414, 435], ["B-cells", "CELL_TYPE", 444, 451], ["dendritic cells", "CELL_TYPE", 453, 468], ["mast cells", "CELL_TYPE", 470, 480], ["T-cells", "CELL_TYPE", 482, 489], ["platelets", "CELL_TYPE", 494, 503], ["non-hematopoietic cells", "CELL_TYPE", 572, 595], ["epithelial cell types", "CELL_TYPE", 612, 633], ["neurons", "CELL_TYPE", 635, 642], ["tumor cells", "CELL_TYPE", 671, 682], ["the Rab GTPases", "TEST", 99, 114], ["Rab", "TEST", 138, 141], ["Rab", "TEST", 146, 149], ["a and b, cytoskeleton regulatory proteins", "TEST", 153, 194], ["SNAREs (SNAP (soluble NSF attachment protein) receptor", "TREATMENT", 234, 288], ["targeted fusion", "TREATMENT", 294, 309], ["the hematopoietic lineage", "PROBLEM", 410, 435], ["B-cells", "PROBLEM", 444, 451], ["dendritic cells", "PROBLEM", 453, 468], ["mast cells", "PROBLEM", 470, 480], ["platelets", "TEST", 494, 503], ["exosome production", "PROBLEM", 537, 555], ["non-hematopoietic cells", "PROBLEM", 572, 595], ["various epithelial cell types", "PROBLEM", 604, 633], ["neurons", "PROBLEM", 635, 642], ["a very wide variety of tumor cells", "PROBLEM", 648, 682], ["brain", "ANATOMY", 131, 136], ["hematopoietic lineage", "OBSERVATION", 414, 435], ["dendritic cells", "OBSERVATION", 453, 468], ["mast cells", "OBSERVATION", 470, 480], ["non-hematopoietic cells", "OBSERVATION", 572, 595], ["epithelial cell types", "OBSERVATION", 612, 633], ["tumor", "OBSERVATION", 671, 676]]], ["Of particular interest are tumor cells that exhibit enhanced production of exosomes.", [["tumor cells", "ANATOMY", 27, 38], ["exosomes", "ANATOMY", 75, 83], ["tumor", "DISEASE", 27, 32], ["tumor cells", "CELL", 27, 38], ["exosomes", "CELL", 75, 83], ["tumor cells", "CELL_TYPE", 27, 38], ["exosomes", "CELL_TYPE", 75, 83], ["tumor cells", "PROBLEM", 27, 38], ["enhanced production of exosomes", "PROBLEM", 52, 83], ["tumor cells", "OBSERVATION", 27, 38], ["enhanced", "OBSERVATION_MODIFIER", 52, 60], ["production", "OBSERVATION_MODIFIER", 61, 71], ["exosomes", "OBSERVATION", 75, 83]]], ["The mechanism or need for such enhanced production of exosomes is not understood but may indicate a role for exosomes in tumor development [10].", [["exosomes", "ANATOMY", 54, 62], ["exosomes", "ANATOMY", 109, 117], ["tumor", "ANATOMY", 121, 126], ["tumor", "DISEASE", 121, 126], ["exosomes", "CELL", 54, 62], ["exosomes", "CELL", 109, 117], ["tumor", "CANCER", 121, 126], ["exosomes", "CELL_TYPE", 54, 62], ["such enhanced production of exosomes", "PROBLEM", 26, 62], ["exosomes in tumor development", "PROBLEM", 109, 138], ["tumor", "OBSERVATION", 121, 126]]], ["Since exosome production is a continuous cell function, certain cell types like platelets can be treated with agonists to induce degranulation and enhanced release of microvesicles and exosomes [11].", [["exosome", "ANATOMY", 6, 13], ["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 64, 68], ["platelets", "ANATOMY", 80, 89], ["microvesicles", "ANATOMY", 167, 180], ["exosomes", "ANATOMY", 185, 193], ["exosome", "CELLULAR_COMPONENT", 6, 13], ["cell", "CELL", 41, 45], ["cell", "CELL", 64, 68], ["platelets", "CELL", 80, 89], ["microvesicles", "CELL", 167, 180], ["platelets", "CELL_TYPE", 80, 89], ["microvesicles", "CELL_TYPE", 167, 180], ["exosomes", "CELL_TYPE", 185, 193], ["a continuous cell function", "PROBLEM", 28, 54], ["certain cell types like platelets", "PROBLEM", 56, 89], ["agonists", "TREATMENT", 110, 118], ["degranulation", "PROBLEM", 129, 142]]], ["Exosome secretion is also increased on free radical stress or UV irradiation, decreased membrane cholesterol, and increased intracellular calcium.", [["membrane", "ANATOMY", 88, 96], ["intracellular", "ANATOMY", 124, 137], ["UV", "CHEMICAL", 62, 64], ["cholesterol", "CHEMICAL", 97, 108], ["calcium", "CHEMICAL", 138, 145], ["cholesterol", "CHEMICAL", 97, 108], ["calcium", "CHEMICAL", 138, 145], ["Exosome", "GENE_OR_GENE_PRODUCT", 0, 7], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["cholesterol", "SIMPLE_CHEMICAL", 97, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 137], ["calcium", "SIMPLE_CHEMICAL", 138, 145], ["Exosome secretion", "PROBLEM", 0, 17], ["free radical stress", "TREATMENT", 39, 58], ["UV irradiation", "TREATMENT", 62, 76], ["decreased membrane cholesterol", "PROBLEM", 78, 108], ["increased intracellular calcium", "PROBLEM", 114, 145], ["secretion", "OBSERVATION", 8, 17], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["UV irradiation", "OBSERVATION", 62, 76], ["decreased", "OBSERVATION_MODIFIER", 78, 87], ["membrane cholesterol", "OBSERVATION", 88, 108], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["intracellular calcium", "OBSERVATION", 124, 145]]], ["In vivo, exosomes have been characterized in most circulating body fluids such as plasma, urine, saliva, broncheoalveolar lavage (BAL), cerebrospinal fluid (CSF), and others [12], [13].Discovery and biogenesis of exosomes from the endosomal system ::: ExosomesExosomes from different sources have a common core set of proteins that help to characterize them as endosome-derived cellular vesicles.", [["exosomes", "ANATOMY", 9, 17], ["body fluids", "ANATOMY", 62, 73], ["plasma", "ANATOMY", 82, 88], ["urine", "ANATOMY", 90, 95], ["saliva", "ANATOMY", 97, 103], ["broncheoalveolar lavage", "ANATOMY", 105, 128], ["BAL", "ANATOMY", 130, 133], ["cerebrospinal fluid", "ANATOMY", 136, 155], ["exosomes", "ANATOMY", 213, 221], ["endosomal system", "ANATOMY", 231, 247], ["endosome", "ANATOMY", 361, 369], ["cellular vesicles", "ANATOMY", 378, 395], ["exosomes", "CELL", 9, 17], ["body fluids", "ORGANISM_SUBSTANCE", 62, 73], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["saliva", "ORGANISM_SUBSTANCE", 97, 103], ["broncheoalveolar lavage", "ORGANISM_SUBSTANCE", 105, 128], ["BAL", "MULTI-TISSUE_STRUCTURE", 130, 133], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 136, 155], ["CSF", "ORGANISM_SUBSTANCE", 157, 160], ["exosomes", "CELL", 213, 221], ["endosomal", "CELLULAR_COMPONENT", 231, 240], ["ExosomesExosomes", "SIMPLE_CHEMICAL", 252, 268], ["endosome", "CELLULAR_COMPONENT", 361, 369], ["cellular vesicles", "CELLULAR_COMPONENT", 378, 395], ["exosomes", "CELL_TYPE", 9, 17], ["exosomes", "CELL_TYPE", 213, 221], ["ExosomesExosomes", "PROTEIN", 252, 268], ["plasma, urine, saliva, broncheoalveolar lavage (BAL)", "TEST", 82, 134], ["cerebrospinal fluid (CSF)", "TEST", 136, 161], ["cerebrospinal", "ANATOMY", 136, 149], ["fluid", "OBSERVATION", 150, 155], ["cellular vesicles", "OBSERVATION", 378, 395]]], ["The extent of common mRNA and miRNA content is not well established due to the limited number of global studies which have profiled both species.", [["common mRNA", "RNA", 14, 25], ["common mRNA and miRNA content", "PROBLEM", 14, 43], ["global studies", "TEST", 97, 111], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["common mRNA", "ANATOMY", 14, 25], ["miRNA content", "OBSERVATION", 30, 43]]], ["Online resources exist, such as the Exocarta compendium of all exosome based studies, which compile protein, mRNA, and miRNA data from different sources into a searchable format [14].", [["mRNA", "RNA", 109, 113], ["all exosome based studies", "TEST", 59, 84], ["mRNA", "TEST", 109, 113], ["miRNA data", "TEST", 119, 129]]], ["Additionally, the urinary exosome resource from the Knepper Lab at NIH also provides a detailed dataset of urine exosomal protein content (Urinary Exosome Protein Database).", [["urinary exosome", "ANATOMY", 18, 33], ["urine exosomal", "ANATOMY", 107, 121], ["urinary", "ORGANISM_SUBSTANCE", 18, 25], ["urine", "ORGANISM_SUBSTANCE", 107, 112], ["urine exosomal protein", "PROTEIN", 107, 129], ["urine exosomal protein content", "TEST", 107, 137], ["urinary", "ANATOMY", 18, 25], ["exosome", "OBSERVATION", 26, 33]]], ["Augmenting this core set of components, the biology of exosomes originates from the cell type and cell condition specific cargo of protein, lipid, RNA, miRNA and DNA (Fig. 1).", [["exosomes", "ANATOMY", 55, 63], ["cell", "ANATOMY", 84, 88], ["cell", "ANATOMY", 98, 102], ["exosomes", "CELL", 55, 63], ["cell type", "CELL", 84, 93], ["cell", "CELL", 98, 102], ["lipid", "SIMPLE_CHEMICAL", 140, 145], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["exosomes", "CELL_TYPE", 55, 63]]], ["This dependence of biomolecular content on cell context, and variations between normal and diseased cells, has garnered much interest in exosomes as harbors of disease biomarkers which could be thought of as a \u201cfluidome\u201d or \u201cliquid biopsies\u201d where extraction of exosomes from body fluids can provide a snapshot into the donor cell condition [15].", [["cell", "ANATOMY", 43, 47], ["cells", "ANATOMY", 100, 105], ["exosomes", "ANATOMY", 137, 145], ["exosomes", "ANATOMY", 262, 270], ["body fluids", "ANATOMY", 276, 287], ["cell", "ANATOMY", 326, 330], ["cell", "CELL", 43, 47], ["cells", "CELL", 100, 105], ["exosomes", "CELL", 137, 145], ["exosomes", "CELL", 262, 270], ["body", "ORGANISM_SUBDIVISION", 276, 280], ["cell", "CELL", 326, 330], ["normal and diseased cells", "CELL_TYPE", 80, 105], ["exosomes", "CELL_TYPE", 137, 145], ["exosomes", "CELL_TYPE", 262, 270], ["This dependence of biomolecular content", "PROBLEM", 0, 39], ["variations between normal and diseased cells", "PROBLEM", 61, 105], ["disease biomarkers", "PROBLEM", 160, 178], ["a \u201cfluidome\u201d", "TREATMENT", 208, 220], ["\u201cliquid biopsies", "TREATMENT", 224, 240], ["extraction of exosomes from body fluids", "TREATMENT", 248, 287], ["biomolecular content", "OBSERVATION", 19, 39], ["normal", "OBSERVATION", 80, 86], ["diseased cells", "OBSERVATION", 91, 105]]], ["The results obtained in such biomarker studies to date has prompted some authors to suggest that an exosome is a miniature cell in terms of healthy vs. normal status [16].Routing and sorting of cargo into exosomes ::: ExosomesExosomes arise within the cellular endosomal compartments so it is reasonable to presume that cytoplasmic cargo must be represented in exosomes.", [["exosome", "ANATOMY", 100, 107], ["cell", "ANATOMY", 123, 127], ["exosomes", "ANATOMY", 205, 213], ["cellular endosomal compartments", "ANATOMY", 252, 283], ["cytoplasmic", "ANATOMY", 320, 331], ["exosomes", "ANATOMY", 361, 369], ["exosome", "CELLULAR_COMPONENT", 100, 107], ["cell", "CELL", 123, 127], ["cargo", "CELLULAR_COMPONENT", 194, 199], ["exosomes", "CELL", 205, 213], ["ExosomesExosomes", "SIMPLE_CHEMICAL", 218, 234], ["cellular", "CELL", 252, 260], ["endosomal compartments", "CELLULAR_COMPONENT", 261, 283], ["cytoplasmic", "ORGANISM_SUBSTANCE", 320, 331], ["exosomes", "CELL", 361, 369], ["exosome", "PROTEIN", 100, 107], ["exosomes", "CELL_TYPE", 205, 213], ["ExosomesExosomes", "PROTEIN", 218, 234], ["exosomes", "CELL_TYPE", 361, 369], ["such biomarker studies", "TEST", 24, 46], ["cytoplasmic cargo", "PROBLEM", 320, 337], ["cellular", "ANATOMY_MODIFIER", 252, 260], ["endosomal compartments", "OBSERVATION", 261, 283]]], ["This is exemplified by the presence of membrane markers on the exosome like Tsg101 and Alix which are involved in MVB biogenesis.", [["membrane", "ANATOMY", 39, 47], ["exosome", "ANATOMY", 63, 70], ["MVB", "ANATOMY", 114, 117], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["exosome", "CELLULAR_COMPONENT", 63, 70], ["Tsg101", "GENE_OR_GENE_PRODUCT", 76, 82], ["Alix", "GENE_OR_GENE_PRODUCT", 87, 91], ["MVB", "CELLULAR_COMPONENT", 114, 117], ["membrane markers", "PROTEIN", 39, 55], ["exosome", "PROTEIN", 63, 70], ["Tsg101", "PROTEIN", 76, 82], ["Alix", "PROTEIN", 87, 91], ["membrane markers", "PROBLEM", 39, 55], ["membrane markers", "OBSERVATION", 39, 55], ["MVB biogenesis", "OBSERVATION", 114, 128]]], ["The mono ubiquitination of cargo and its sorting for lysosomal degradation in MVBs is a well-studied process.", [["lysosomal", "ANATOMY", 53, 62], ["MVBs", "ANATOMY", 78, 82], ["cargo", "CELLULAR_COMPONENT", 27, 32], ["lysosomal", "CELLULAR_COMPONENT", 53, 62], ["MVBs", "CELLULAR_COMPONENT", 78, 82], ["lysosomal degradation in MVBs", "PROBLEM", 53, 82], ["mono ubiquitination", "OBSERVATION", 4, 23]]], ["MVB topology serves as a sorting station where ubiquitinated cargo is directed to ILVs fated for degradation while membrane sequestration allows other proteins to be directed to the recycling compartment.Routing and sorting of cargo into exosomes ::: ExosomesEndosomal cargo can be rerouted from a recycling fate and delivered to exosomes by lateral segregation on the membrane with GPI-anchored or lipid-raft enriched micro-domains, antibody mediated higher order oligomerization, and via aggregation (Fig. 2a).", [["MVB", "ANATOMY", 0, 3], ["membrane", "ANATOMY", 115, 123], ["exosomes", "ANATOMY", 238, 246], ["Exosomes", "ANATOMY", 251, 259], ["exosomes", "ANATOMY", 330, 338], ["membrane", "ANATOMY", 369, 377], ["lipid-raft", "ANATOMY", 399, 409], ["micro-domains", "ANATOMY", 419, 432], ["MVB", "CELLULAR_COMPONENT", 0, 3], ["ILVs", "GENE_OR_GENE_PRODUCT", 82, 86], ["membrane", "CELLULAR_COMPONENT", 115, 123], ["cargo", "CELLULAR_COMPONENT", 227, 232], ["exosomes", "CELL", 238, 246], ["Exosomes", "CELL", 251, 259], ["exosomes", "CELL", 330, 338], ["membrane", "CELLULAR_COMPONENT", 369, 377], ["GPI", "SIMPLE_CHEMICAL", 383, 386], ["ILVs", "PROTEIN", 82, 86], ["exosomes", "CELL_TYPE", 238, 246], ["Exosomes", "CELL_TYPE", 251, 259], ["exosomes", "CELL_TYPE", 330, 338], ["GPI-anchored or lipid-raft enriched micro-domains", "PROTEIN", 383, 432], ["membrane sequestration", "PROBLEM", 115, 137], ["other proteins", "TREATMENT", 145, 159], ["a recycling fate", "TREATMENT", 296, 312], ["GPI", "TEST", 383, 386], ["lipid-raft enriched micro-domains", "TREATMENT", 399, 432], ["antibody", "TEST", 434, 442]]], ["Other proteins undergo a recycling or exosomal containment fate depending on the binding partners.", [["exosomal", "ANATOMY", 38, 46], ["a recycling", "TREATMENT", 23, 34], ["exosomal containment fate", "TREATMENT", 38, 63]]], ["For example, during reticulocyte maturation, decreased clathrin adaptor AP2 levels cause the transferrin receptor to associate with Hsc70 (heat shock cognate protein) and Alix rather than binding to AP2.", [["reticulocyte", "ANATOMY", 20, 32], ["reticulocyte", "CELL", 20, 32], ["clathrin", "GENE_OR_GENE_PRODUCT", 55, 63], ["AP2", "GENE_OR_GENE_PRODUCT", 72, 75], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 93, 113], ["Hsc70", "GENE_OR_GENE_PRODUCT", 132, 137], ["heat shock cognate protein", "GENE_OR_GENE_PRODUCT", 139, 165], ["Alix", "GENE_OR_GENE_PRODUCT", 171, 175], ["AP2", "GENE_OR_GENE_PRODUCT", 199, 202], ["clathrin", "PROTEIN", 55, 63], ["AP2", "PROTEIN", 72, 75], ["transferrin receptor", "PROTEIN", 93, 113], ["Hsc70", "PROTEIN", 132, 137], ["heat shock cognate protein", "PROTEIN", 139, 165], ["Alix", "PROTEIN", 171, 175], ["AP2", "PROTEIN", 199, 202], ["reticulocyte maturation", "PROBLEM", 20, 43], ["decreased clathrin adaptor AP2 levels", "PROBLEM", 45, 82], ["the transferrin receptor", "TREATMENT", 89, 113], ["Hsc70 (heat shock cognate protein)", "TREATMENT", 132, 166], ["Alix", "TREATMENT", 171, 175], ["AP2", "TEST", 199, 202], ["reticulocyte maturation", "OBSERVATION", 20, 43], ["decreased", "OBSERVATION_MODIFIER", 45, 54]]], ["Highlighting the intricacy of such a molecular balance, the same binding motif is utilized in both interactions.Routing and sorting of cargo into exosomes ::: ExosomesThere remains a significant gap in understanding the mechanisms that allow the rerouting of proteins (or possibly entire ILVs) marked for degradation to exosomes for release.", [["exosomes", "ANATOMY", 146, 154], ["Exosomes", "ANATOMY", 159, 167], ["exosomes", "ANATOMY", 320, 328], ["cargo", "CELLULAR_COMPONENT", 135, 140], ["exosomes", "CELL", 146, 154], ["Exosomes", "ORGANISM_SUBSTANCE", 159, 167], ["exosomes", "CELL", 320, 328], ["exosomes", "CELL_TYPE", 146, 154], ["Exosomes", "CELL_TYPE", 159, 167], ["ILVs", "PROTEIN", 288, 292], ["exosomes", "CELL_TYPE", 320, 328], ["a significant gap", "PROBLEM", 181, 198], ["significant", "OBSERVATION_MODIFIER", 183, 194], ["gap", "OBSERVATION", 195, 198]]], ["Exosome biology suggests the existence of separate subsets of MVBs, where some rely on ESCRT-dependent (ESCRT, endosomal sorting complex required for transport) sorting of signaling receptors.", [["MVBs", "ANATOMY", 62, 66], ["endosomal", "ANATOMY", 111, 120], ["MVBs", "CELLULAR_COMPONENT", 62, 66], ["ESCRT", "GENE_OR_GENE_PRODUCT", 87, 92], ["ESCRT", "GENE_OR_GENE_PRODUCT", 104, 109], ["endosomal", "CELLULAR_COMPONENT", 111, 120], ["ESCRT", "PROTEIN", 87, 92], ["ESCRT", "PROTEIN", 104, 109], ["endosomal sorting complex", "PROTEIN", 111, 136], ["signaling receptors", "PROTEIN", 172, 191], ["MVBs", "PROBLEM", 62, 66], ["signaling receptors", "PROBLEM", 172, 191], ["MVBs", "OBSERVATION", 62, 66]]], ["Others appear formed primarily by ceramide synthesis as a driving factor for exosome formation [7], [17] (Fig. 2a).", [["exosome", "ANATOMY", 77, 84], ["ceramide", "CHEMICAL", 34, 42], ["ceramide", "CHEMICAL", 34, 42], ["ceramide", "SIMPLE_CHEMICAL", 34, 42], ["exosome", "CELLULAR_COMPONENT", 77, 84], ["[17]", "SIMPLE_CHEMICAL", 100, 104], ["exosome formation", "PROBLEM", 77, 94]]], ["The molecular mechanisms that direct the two processes are likely to be distinct and require further elucidation.Routing and sorting of cargo into exosomes ::: ExosomesOne of the most intriguing aspects of exosome biology remains the packaging of diverse proteins and RNA into exosomes (Fig. 1, Fig. 2a).", [["exosomes", "ANATOMY", 147, 155], ["exosome", "ANATOMY", 206, 213], ["exosomes", "ANATOMY", 277, 285], ["cargo", "CELLULAR_COMPONENT", 136, 141], ["exosomes", "CELL", 147, 155], ["exosome", "CELLULAR_COMPONENT", 206, 213], ["exosomes", "CELL", 277, 285], ["exosomes", "CELL_TYPE", 147, 155], ["exosomes", "CELL_TYPE", 277, 285], ["diverse proteins", "TREATMENT", 247, 263], ["likely to be", "UNCERTAINTY", 59, 71], ["exosome", "OBSERVATION", 206, 213], ["diverse proteins", "OBSERVATION", 247, 263]]], ["Initial reports suggest that it is unlikely that exosomal content simply reflects the non-specific stoichiometric abundance of proteins and RNA throughout the cytoplasm.", [["exosomal", "ANATOMY", 49, 57], ["cytoplasm", "ANATOMY", 159, 168], ["cytoplasm", "ORGANISM_SUBSTANCE", 159, 168], ["exosomal content", "PROBLEM", 49, 65], ["the non-specific stoichiometric abundance of proteins and RNA throughout the cytoplasm", "PROBLEM", 82, 168], ["suggest that it is unlikely", "UNCERTAINTY", 16, 43], ["exosomal content", "OBSERVATION", 49, 65], ["non-specific", "OBSERVATION_MODIFIER", 86, 98], ["stoichiometric abundance", "OBSERVATION", 99, 123], ["cytoplasm", "OBSERVATION_MODIFIER", 159, 168]]], ["For example, the study from Skog et al. [3] demonstrated that glioblastoma derived microvesicles were enriched (relative to unfractionated glioblastoma cells) for several proteins, mRNAs and miRNAs that would aid tumor growth through angiogenesis, cell cycle disruption, control of translation, and immune suppression.Routing and sorting of cargo into exosomes ::: ExosomesSimilarly, \u201cstemness-imparting characteristics\u201d are enriched in stem-cell derived exosomes, demonstrating a cell context specific selection of exosomal cargo [1].", [["glioblastoma derived microvesicles", "ANATOMY", 62, 96], ["glioblastoma cells", "ANATOMY", 139, 157], ["tumor", "ANATOMY", 213, 218], ["cell", "ANATOMY", 248, 252], ["exosomes", "ANATOMY", 352, 360], ["stem-cell", "ANATOMY", 437, 446], ["exosomes", "ANATOMY", 455, 463], ["cell", "ANATOMY", 481, 485], ["exosomal", "ANATOMY", 516, 524], ["glioblastoma", "DISEASE", 62, 74], ["glioblastoma", "DISEASE", 139, 151], ["tumor", "DISEASE", 213, 218], ["glioblastoma derived microvesicles", "CELL", 62, 96], ["glioblastoma cells", "CELL", 139, 157], ["tumor", "CANCER", 213, 218], ["cell", "CELL", 248, 252], ["cargo", "CELLULAR_COMPONENT", 341, 346], ["exosomes", "CELL", 352, 360], ["stem-cell", "CELL", 437, 446], ["exosomes", "CELL", 455, 463], ["cell", "CELL", 481, 485], ["glioblastoma derived microvesicles", "CELL_TYPE", 62, 96], ["unfractionated glioblastoma cells", "CELL_TYPE", 124, 157], ["mRNAs", "RNA", 181, 186], ["exosomes", "CELL_TYPE", 352, 360], ["stem-cell derived exosomes", "CELL_LINE", 437, 463], ["the study", "TEST", 13, 22], ["glioblastoma derived microvesicles", "PROBLEM", 62, 96], ["unfractionated glioblastoma cells", "TREATMENT", 124, 157], ["several proteins, mRNAs and miRNAs", "PROBLEM", 163, 197], ["tumor growth through angiogenesis", "PROBLEM", 213, 246], ["cell cycle disruption", "PROBLEM", 248, 269], ["immune suppression", "PROBLEM", 299, 317], ["glioblastoma", "OBSERVATION", 62, 74], ["glioblastoma cells", "OBSERVATION", 139, 157], ["immune suppression", "OBSERVATION", 299, 317], ["stem", "ANATOMY", 437, 441]]], ["It is noteworthy that several molecules and adapters from the clathrin-coated pit are also found in exosomes [14], suggesting that membrane deformation and cargo selection may utilize the same molecular machinery as the plasma membrane.Routing and sorting of cargo into exosomes ::: ExosomesRecently tetraspanin proteins have been implicated in exosome cargo selection along with providing the mechanistic framework for the formulation of exosomes [18].", [["exosomes", "ANATOMY", 100, 108], ["membrane", "ANATOMY", 131, 139], ["plasma membrane", "ANATOMY", 220, 235], ["exosomes", "ANATOMY", 270, 278], ["exosome", "ANATOMY", 345, 352], ["exosomes", "ANATOMY", 439, 447], ["clathrin", "GENE_OR_GENE_PRODUCT", 62, 70], ["exosomes", "CELL", 100, 108], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["plasma membrane", "CELLULAR_COMPONENT", 220, 235], ["cargo", "CELLULAR_COMPONENT", 259, 264], ["exosomes", "CELL", 270, 278], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 300, 311], ["clathrin", "PROTEIN", 62, 70], ["exosomes", "CELL_TYPE", 270, 278], ["ExosomesRecently tetraspanin proteins", "PROTEIN", 283, 320], ["the clathrin", "TREATMENT", 58, 70], ["membrane deformation", "PROBLEM", 131, 151], ["cargo selection", "TREATMENT", 156, 171], ["ExosomesRecently tetraspanin proteins", "TREATMENT", 283, 320], ["the formulation of exosomes", "TREATMENT", 420, 447], ["several", "OBSERVATION_MODIFIER", 22, 29], ["molecules", "OBSERVATION", 30, 39], ["membrane deformation", "OBSERVATION", 131, 151], ["cargo selection", "OBSERVATION", 156, 171], ["plasma membrane", "OBSERVATION", 220, 235], ["cargo selection", "OBSERVATION", 353, 368]]], ["It's interesting to note that the ESCRT complex which has been implicated in exosome formation is also involved in selective protein sorting, e.g. binding of bicoid RNA to the ESCRT II complex allows sorting into the endosomal system [19].", [["exosome", "ANATOMY", 77, 84], ["endosomal", "ANATOMY", 217, 226], ["ESCRT", "GENE_OR_GENE_PRODUCT", 34, 39], ["exosome", "CELLULAR_COMPONENT", 77, 84], ["ESCRT II", "GENE_OR_GENE_PRODUCT", 176, 184], ["endosomal", "CELLULAR_COMPONENT", 217, 226], ["ESCRT complex", "PROTEIN", 34, 47], ["bicoid RNA", "RNA", 158, 168], ["ESCRT II complex", "PROTEIN", 176, 192], ["the ESCRT complex", "PROBLEM", 30, 47], ["selective protein sorting", "TEST", 115, 140], ["bicoid RNA", "PROBLEM", 158, 168], ["exosome formation", "OBSERVATION", 77, 94]]], ["Furthermore, a recent report that the MVB system is linked with a maturing RISC complex [20] provides an alternatively novel mechanism for the loading of RNA and miRNA species into exosomes.Routing and sorting of cargo into exosomes ::: ExosomesRecent studies indicate that a subset of plasma miRs are bound to Ago2 or LDL and this may be yet another mechanism that allows loading into exosome like vesicles exiting the cell [21], [22].", [["MVB system", "ANATOMY", 38, 48], ["exosomes", "ANATOMY", 181, 189], ["exosomes", "ANATOMY", 224, 232], ["plasma", "ANATOMY", 286, 292], ["exosome", "ANATOMY", 386, 393], ["vesicles", "ANATOMY", 399, 407], ["cell", "ANATOMY", 420, 424], ["MVB", "CELLULAR_COMPONENT", 38, 41], ["RISC", "GENE_OR_GENE_PRODUCT", 75, 79], ["exosomes", "CELL", 181, 189], ["cargo", "CELLULAR_COMPONENT", 213, 218], ["exosomes", "CELL", 224, 232], ["plasma", "ORGANISM_SUBSTANCE", 286, 292], ["miRs", "GENE_OR_GENE_PRODUCT", 293, 297], ["Ago2", "GENE_OR_GENE_PRODUCT", 311, 315], ["LDL", "GENE_OR_GENE_PRODUCT", 319, 322], ["vesicles", "CELLULAR_COMPONENT", 399, 407], ["cell", "CELL", 420, 424], ["maturing RISC complex", "PROTEIN", 66, 87], ["RNA and miRNA species", "RNA", 154, 175], ["exosomes", "CELL_TYPE", 181, 189], ["exosomes", "CELL_TYPE", 224, 232], ["plasma miRs", "PROTEIN", 286, 297], ["Ago2", "PROTEIN", 311, 315], ["LDL", "PROTEIN", 319, 322], ["the loading of RNA", "TREATMENT", 139, 157], ["miRNA species into exosomes", "PROBLEM", 162, 189], ["ExosomesRecent studies", "TEST", 237, 259], ["plasma miRs", "PROBLEM", 286, 297], ["LDL", "TEST", 319, 322]]], ["Given the variety of potential mechanisms of exosome formation and exosomal loading, there remains a clear need to establish the adaptors or sorting motifs and the lipid\u2013protein, lipid\u2013RNA/miRNA, RNA\u2013protein, miRNA\u2013protein, protein\u2013mRNA\u2013miRNA interactions that allow specific cargo packaging into exosomes.Role of exosomes in immune function ::: Functions of exosomesInterest in exosomes in immune response burgeoned in 1996 with the discovery that antigen presenting cells (APCs) enhance the immune cell response by utilizing exosomes for antigen presentation [25].", [["exosome", "ANATOMY", 45, 52], ["exosomal", "ANATOMY", 67, 75], ["exosomes", "ANATOMY", 297, 305], ["exosomes", "ANATOMY", 314, 322], ["exosomes", "ANATOMY", 359, 367], ["exosomes", "ANATOMY", 379, 387], ["antigen presenting cells", "ANATOMY", 449, 473], ["APCs", "ANATOMY", 475, 479], ["immune cell", "ANATOMY", 493, 504], ["exosomes", "ANATOMY", 527, 535], ["exosome", "CELLULAR_COMPONENT", 45, 52], ["lipid\u2013protein", "SIMPLE_CHEMICAL", 164, 177], ["lipid", "SIMPLE_CHEMICAL", 179, 184], ["RNA\u2013protein", "GENE_OR_GENE_PRODUCT", 196, 207], ["miRNA\u2013protein", "GENE_OR_GENE_PRODUCT", 209, 222], ["protein\u2013mRNA\u2013miRNA", "GENE_OR_GENE_PRODUCT", 224, 242], ["exosomes", "CELL", 297, 305], ["exosomes", "CELL", 314, 322], ["exosomes", "CELL", 359, 367], ["exosomes", "CELL", 379, 387], ["antigen presenting cells", "CELL", 449, 473], ["APCs", "CELL", 475, 479], ["immune cell", "CELL", 493, 504], ["exosomes", "CELL", 527, 535], ["sorting motifs", "PROTEIN", 141, 155], ["lipid\u2013protein", "PROTEIN", 164, 177], ["exosomes", "CELL_TYPE", 297, 305], ["exosomes", "CELL_TYPE", 379, 387], ["antigen presenting cells", "CELL_TYPE", 449, 473], ["APCs", "CELL_TYPE", 475, 479], ["exosomes", "CELL_TYPE", 527, 535], ["exosome formation", "PROBLEM", 45, 62], ["exosomal loading", "PROBLEM", 67, 83], ["RNA/miRNA", "TEST", 185, 194], ["RNA\u2013protein", "TEST", 196, 207], ["miRNA\u2013protein", "TREATMENT", 209, 222], ["protein\u2013mRNA\u2013miRNA interactions", "TREATMENT", 224, 255], ["exosome formation", "OBSERVATION", 45, 62], ["exosomal loading", "OBSERVATION", 67, 83], ["miRNA", "ANATOMY", 189, 194], ["immune cell", "OBSERVATION", 493, 504]]], ["Endosomes of APCs are enriched for MHC (major histocompatibility complex) class II molecules, MHC class II-associated chaperone Ii, and proteases that are required for Ii degradation and antigen processing [26].", [["APCs", "ANATOMY", 13, 17], ["APCs", "CELL", 13, 17], ["MHC class II", "GENE_OR_GENE_PRODUCT", 94, 106], ["Ii", "GENE_OR_GENE_PRODUCT", 128, 130], ["Ii", "GENE_OR_GENE_PRODUCT", 168, 170], ["APCs", "CELL_TYPE", 13, 17], ["MHC", "PROTEIN", 35, 38], ["major histocompatibility complex) class II molecules", "PROTEIN", 40, 92], ["MHC class II-associated chaperone Ii", "PROTEIN", 94, 130], ["proteases", "PROTEIN", 136, 145], ["Ii", "PROTEIN", 168, 170], ["proteases", "TREATMENT", 136, 145], ["Ii degradation", "PROBLEM", 168, 182]]], ["Exosomes from APCs are similarly enriched in MHC I, MHC II, and immuno-modulatory proteins.", [["Exosomes", "ANATOMY", 0, 8], ["APCs", "ANATOMY", 14, 18], ["Exosomes", "CELL", 0, 8], ["APCs", "CELL", 14, 18], ["MHC I", "GENE_OR_GENE_PRODUCT", 45, 50], ["MHC II", "GENE_OR_GENE_PRODUCT", 52, 58], ["Exosomes", "CELL_TYPE", 0, 8], ["APCs", "CELL_TYPE", 14, 18], ["MHC I", "PROTEIN", 45, 50], ["MHC II", "PROTEIN", 52, 58], ["immuno-modulatory proteins", "PROTEIN", 64, 90], ["immuno-modulatory proteins", "PROBLEM", 64, 90]]], ["A strong immunogenic response by dendritic cell (DC) exosomes (also known as dexosomes), generally relies on the presence of co-stimulatory molecules on the APC.", [["dendritic cell", "ANATOMY", 33, 47], ["DC", "ANATOMY", 49, 51], ["exosomes", "ANATOMY", 53, 61], ["dendritic cell", "CELL", 33, 47], ["DC", "CELL", 49, 51], ["exosomes", "CELL", 53, 61], ["dexosomes", "GENE_OR_GENE_PRODUCT", 77, 86], ["APC", "GENE_OR_GENE_PRODUCT", 157, 160], ["dendritic cell (DC) exosomes", "CELL_TYPE", 33, 61], ["dexosomes", "PROTEIN", 77, 86], ["co-stimulatory molecules", "PROTEIN", 125, 149], ["APC", "CELL_TYPE", 157, 160], ["the APC", "TREATMENT", 153, 160], ["strong", "OBSERVATION_MODIFIER", 2, 8], ["immunogenic response", "OBSERVATION", 9, 29], ["dendritic cell", "OBSERVATION", 33, 47]]], ["However in some cases dexosomes have been shown to stimulate a sufficient immune response dependent solely on the MHC I concentration and in the absence of APCs and corresponding co-stimulatory molecules [27].", [["APCs", "ANATOMY", 156, 160], ["dexosomes", "CANCER", 22, 31], ["MHC I", "GENE_OR_GENE_PRODUCT", 114, 119], ["APCs", "CELL", 156, 160], ["dexosomes", "PROTEIN", 22, 31], ["MHC I", "PROTEIN", 114, 119], ["APCs", "CELL_TYPE", 156, 160], ["co-stimulatory molecules", "PROTEIN", 179, 203]]], ["B-cell derived exosomes elicit an immune response by direct antigen presentation to T-cells [28].Role of exosomes in immune function ::: Functions of exosomesHowever, in the most common mechanism of exosome-stimulated immune response exosomes do not interact directly with T-cells [25].", [["B-cell", "ANATOMY", 0, 6], ["exosomes", "ANATOMY", 15, 23], ["T-cells", "ANATOMY", 84, 91], ["exosomes", "ANATOMY", 105, 113], ["exosomes", "ANATOMY", 150, 158], ["exosome", "ANATOMY", 199, 206], ["exosomes", "ANATOMY", 234, 242], ["T-cells", "ANATOMY", 273, 280], ["B-cell derived exosomes", "CELL", 0, 23], ["T-cells", "CELL", 84, 91], ["exosomes", "CELL", 105, 113], ["exosomes", "CELL", 150, 158], ["exosomes", "CELL", 234, 242], ["T-cells", "CELL", 273, 280], ["B-cell derived exosomes", "CELL_TYPE", 0, 23], ["T-cells", "CELL_TYPE", 84, 91], ["exosomes", "CELL_TYPE", 150, 158], ["exosome", "PROTEIN", 199, 206], ["T-cells", "CELL_TYPE", 273, 280], ["exosomes", "OBSERVATION", 150, 158]]], ["Immature dendritic cell-derived exosomes (immature Dex or \u201ciDex\u201d) induce an indirect T-cell activation via presentation of MHC/antigen complex to receptor DCs.", [["dendritic cell", "ANATOMY", 9, 23], ["exosomes", "ANATOMY", 32, 40], ["T-cell", "ANATOMY", 85, 91], ["DCs", "ANATOMY", 155, 158], ["Dex", "CHEMICAL", 51, 54], ["dendritic cell", "CELL", 9, 23], ["exosomes", "CELL", 32, 40], ["Dex", "CELL", 51, 54], ["iDex", "GENE_OR_GENE_PRODUCT", 59, 63], ["T-cell", "CELL", 85, 91], ["MHC/antigen complex", "GENE_OR_GENE_PRODUCT", 123, 142], ["DCs", "CELL", 155, 158], ["exosomes", "CELL_TYPE", 32, 40], ["MHC/antigen complex", "PROTEIN", 123, 142], ["receptor DCs", "CELL_TYPE", 146, 158], ["immature Dex", "TREATMENT", 42, 54], ["an indirect T-cell activation", "PROBLEM", 73, 102], ["MHC/antigen complex", "TREATMENT", 123, 142], ["receptor DCs", "TREATMENT", 146, 158], ["dendritic cell", "OBSERVATION", 9, 23]]], ["CD4+ (CD cluster of differentiation) T-cells are activated by MHC-II/antigen complex transfer to recipient DCs.", [["T-cells", "ANATOMY", 37, 44], ["DCs", "ANATOMY", 107, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["MHC-II", "GENE_OR_GENE_PRODUCT", 62, 68], ["antigen complex", "GENE_OR_GENE_PRODUCT", 69, 84], ["DCs", "CELL", 107, 110], ["CD4", "PROTEIN", 0, 3], ["T-cells", "CELL_TYPE", 37, 44], ["MHC-II", "PROTEIN", 62, 68], ["antigen complex", "PROTEIN", 69, 84], ["recipient DCs", "CELL_TYPE", 97, 110], ["CD4", "TEST", 0, 3]]], ["Similarly, MHC-I/antigen complex transfer to DCs aids polarization of Tc1 CD8+ T-cells [29], [30].", [["DCs", "ANATOMY", 45, 48], ["Tc1 CD8+ T-cells", "ANATOMY", 70, 86], ["MHC-I", "GENE_OR_GENE_PRODUCT", 11, 16], ["antigen complex", "GENE_OR_GENE_PRODUCT", 17, 32], ["DCs", "CELL", 45, 48], ["Tc1", "CELL", 70, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 74, 77], ["MHC", "PROTEIN", 11, 14], ["antigen complex", "PROTEIN", 17, 32], ["DCs", "CELL_TYPE", 45, 48], ["Tc1 CD8+ T-cells", "CELL_TYPE", 70, 86]]], ["The iDex response in vivo relies on CD8\u03b1+ DCs in a process dependent on LFA-1 (lymphocyte function-associated antigen 1) for exosome capture, and continues without exosome internalization and processing [31].Role of exosomes in immune function ::: Functions of exosomesTc1 response requires the administration of DC maturing agents like Toll like receptors TLR-3 and TLR-9 indicating the requirement for APCs in inducing the Dex response.", [["CD8\u03b1+ DCs", "ANATOMY", 36, 45], ["lymphocyte", "ANATOMY", 79, 89], ["exosome", "ANATOMY", 125, 132], ["exosome", "ANATOMY", 164, 171], ["exosomes", "ANATOMY", 216, 224], ["DC", "ANATOMY", 313, 315], ["APCs", "ANATOMY", 404, 408], ["Dex", "CHEMICAL", 425, 428], ["Dex", "CHEMICAL", 425, 428], ["iDex", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD8\u03b1", "GENE_OR_GENE_PRODUCT", 36, 40], ["LFA-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["lymphocyte function-associated antigen 1", "GENE_OR_GENE_PRODUCT", 79, 119], ["exosomes", "CELL", 216, 224], ["exosomesTc1", "GENE_OR_GENE_PRODUCT", 261, 272], ["Toll like receptors TLR-3", "GENE_OR_GENE_PRODUCT", 337, 362], ["TLR-9", "GENE_OR_GENE_PRODUCT", 367, 372], ["APCs", "CELL", 404, 408], ["Dex", "SIMPLE_CHEMICAL", 425, 428], ["iDex", "PROTEIN", 4, 8], ["CD8\u03b1", "PROTEIN", 36, 40], ["DCs", "CELL_TYPE", 42, 45], ["LFA-1", "PROTEIN", 72, 77], ["lymphocyte function-associated antigen 1", "PROTEIN", 79, 119], ["exosomesTc1", "PROTEIN", 261, 272], ["DC", "CELL_TYPE", 313, 315], ["Toll like receptors TLR-3", "PROTEIN", 337, 362], ["TLR-9", "PROTEIN", 367, 372], ["APCs", "CELL_TYPE", 404, 408], ["CD8", "TEST", 36, 39], ["DCs", "PROBLEM", 42, 45], ["LFA", "TEST", 72, 75], ["lymphocyte function", "TEST", 79, 98], ["antigen", "TEST", 110, 117], ["exosome capture", "TREATMENT", 125, 140], ["exosome internalization", "TREATMENT", 164, 187], ["DC maturing agents", "TREATMENT", 313, 331], ["TLR", "TEST", 357, 360], ["TLR", "TEST", 367, 370], ["APCs", "TREATMENT", 404, 408], ["the Dex response", "TREATMENT", 421, 437]]], ["Cytotoxic T-lymphocyte target cell recognition induces rapid polarization of both Rab-11+ recycling endosomes as well as Rab-27+ exosomes in a process mediated by hm-munc13.", [["T-lymphocyte", "ANATOMY", 10, 22], ["cell", "ANATOMY", 30, 34], ["Rab-11+ recycling endosomes", "ANATOMY", 82, 109], ["Rab-27+ exosomes", "ANATOMY", 121, 137], ["T-lymphocyte", "CELL", 10, 22], ["cell", "CELL", 30, 34], ["Rab-11", "GENE_OR_GENE_PRODUCT", 82, 88], ["endosomes", "CELLULAR_COMPONENT", 100, 109], ["Rab-27", "GENE_OR_GENE_PRODUCT", 121, 127], ["hm-munc13", "GENE_OR_GENE_PRODUCT", 163, 172], ["Rab-11", "PROTEIN", 82, 88], ["Rab-27", "PROTEIN", 121, 127], ["hm", "PROTEIN", 163, 165], ["munc13", "PROTEIN", 166, 172], ["Cytotoxic T", "TEST", 0, 11], ["cell recognition", "TEST", 30, 46], ["rapid polarization", "TEST", 55, 73], ["both Rab", "TEST", 77, 85], ["Rab", "TEST", 121, 124]]], ["This vesicle mobilization is necessary for the release of cytotoxic granules [32].", [["vesicle", "ANATOMY", 5, 12], ["granules", "ANATOMY", 68, 76], ["vesicle", "CELLULAR_COMPONENT", 5, 12], ["This vesicle mobilization", "TREATMENT", 0, 25], ["cytotoxic granules", "PROBLEM", 58, 76], ["mobilization", "OBSERVATION", 13, 25]]], ["Additionally, immature DC derived exosomes may transfer processed antigen-MHC complexes to other DCs and thus increase the effective number of APCs.Role of exosomes in immune function ::: Functions of exosomesWhile DC exosome to DC MHC-antigen presentation is common, it has also been shown that mast cell derived exosome peptide cargo may be presented on the surface of recipient B-cells and DCs [33].", [["DC", "ANATOMY", 23, 25], ["exosomes", "ANATOMY", 34, 42], ["DCs", "ANATOMY", 97, 100], ["APCs", "ANATOMY", 143, 147], ["exosomes", "ANATOMY", 156, 164], ["DC", "ANATOMY", 215, 217], ["DC", "ANATOMY", 229, 231], ["mast cell", "ANATOMY", 296, 305], ["surface", "ANATOMY", 360, 367], ["B-cells", "ANATOMY", 381, 388], ["DCs", "ANATOMY", 393, 396], ["DC", "CELL", 23, 25], ["exosomes", "CELL", 34, 42], ["antigen-MHC", "GENE_OR_GENE_PRODUCT", 66, 77], ["DCs", "CELL", 97, 100], ["APCs", "CELL", 143, 147], ["exosomes", "CELL", 156, 164], ["exosomesWhile DC exosome", "GENE_OR_GENE_PRODUCT", 201, 225], ["MHC-antigen", "GENE_OR_GENE_PRODUCT", 232, 243], ["mast cell", "CELL", 296, 305], ["surface", "CELLULAR_COMPONENT", 360, 367], ["B-cells", "CELL", 381, 388], ["DCs", "CELL", 393, 396], ["immature DC", "CELL_TYPE", 14, 25], ["exosomes", "CELL_TYPE", 34, 42], ["MHC complexes", "PROTEIN", 74, 87], ["DCs", "CELL_TYPE", 97, 100], ["APCs", "CELL_TYPE", 143, 147], ["exosomesWhile DC exosome", "PROTEIN", 201, 225], ["DC", "CELL_TYPE", 229, 231], ["MHC", "PROTEIN", 232, 235], ["recipient B-cells", "CELL_TYPE", 371, 388], ["DCs", "CELL_TYPE", 393, 396], ["mast cell", "PROBLEM", 296, 305], ["mast cell", "OBSERVATION", 296, 305]]], ["In terms of mechanisms for inducing an immune response, recent reports suggest that exosomes carry bioactive cytokines exemplified by the presence of IL-1\u03b2 and other inflammasome components [34].", [["exosomes", "ANATOMY", 84, 92], ["exosomes", "CELL", 84, 92], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 150, 155], ["exosomes", "CELL_TYPE", 84, 92], ["cytokines", "PROTEIN", 109, 118], ["IL-1\u03b2", "PROTEIN", 150, 155], ["exosomes carry bioactive cytokines", "PROBLEM", 84, 118], ["IL", "TEST", 150, 152], ["other inflammasome components", "PROBLEM", 160, 189]]], ["The concentration of tumor necrosis factor TNF-\u03b1 in dexosomes indicates that in addition to a role in adaptive immunity, exosomes could also trigger an innate immune response and in fact mediate the amplification of such a response via the cargo of protein, RNA and miRNA that it can transfer to responsive tract epithelium [35], [36].Role of exosomes in immune function ::: Functions of exosomesThere has continued to be an intensive amount of research derived on such findings and many studies have established that exosome content and functions depend on the precise maturation stage, cell lineage, and stimulation state of the parent immune cell.", [["exosomes", "ANATOMY", 121, 129], ["tract epithelium", "ANATOMY", 307, 323], ["exosomes", "ANATOMY", 343, 351], ["exosomes", "ANATOMY", 388, 396], ["exosome", "ANATOMY", 518, 525], ["cell", "ANATOMY", 588, 592], ["immune cell", "ANATOMY", 638, 649], ["tumor", "DISEASE", 21, 26], ["necrosis", "DISEASE", 27, 35], ["tumor", "CANCER", 21, 26], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 43, 48], ["dexosomes", "SIMPLE_CHEMICAL", 52, 61], ["exosomes", "CELL", 121, 129], ["tract epithelium", "TISSUE", 307, 323], ["exosomes", "CELL", 343, 351], ["exosomes", "CELL", 388, 396], ["exosome", "CELLULAR_COMPONENT", 518, 525], ["cell", "CELL", 588, 592], ["immune cell", "CELL", 638, 649], ["tumor necrosis factor TNF-\u03b1", "PROTEIN", 21, 48], ["exosomes", "CELL_TYPE", 121, 129], ["RNA", "RNA", 258, 261], ["exosomes", "CELL_TYPE", 388, 396], ["parent immune cell", "CELL_TYPE", 631, 649], ["tumor necrosis", "PROBLEM", 21, 35], ["TNF", "TEST", 43, 46], ["many studies", "TEST", 483, 495], ["exosome content", "PROBLEM", 518, 533], ["cell lineage", "PROBLEM", 588, 600], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["tumor", "OBSERVATION", 21, 26], ["necrosis", "OBSERVATION_MODIFIER", 27, 35], ["exosomes", "OBSERVATION", 388, 396], ["intensive", "OBSERVATION_MODIFIER", 425, 434], ["amount", "OBSERVATION_MODIFIER", 435, 441], ["cell lineage", "OBSERVATION", 588, 600], ["immune cell", "OBSERVATION", 638, 649]]], ["For example, immature DCs produce a larger number of MVBs and exosomes then do immature DCs; however, at the level of inducing an antigen specific T-cell response, mature DC derived exosomes show twice the potency [36].", [["DCs", "ANATOMY", 22, 25], ["MVBs", "ANATOMY", 53, 57], ["exosomes", "ANATOMY", 62, 70], ["DCs", "ANATOMY", 88, 91], ["T-cell", "ANATOMY", 147, 153], ["DC", "ANATOMY", 171, 173], ["exosomes", "ANATOMY", 182, 190], ["DCs", "CELL", 22, 25], ["MVBs", "CELLULAR_COMPONENT", 53, 57], ["exosomes", "CELL", 62, 70], ["DCs", "CELL", 88, 91], ["T-cell", "CELL", 147, 153], ["DC", "CELL", 171, 173], ["exosomes", "CELL", 182, 190], ["immature DCs", "CELL_TYPE", 13, 25], ["MVBs", "CELL_TYPE", 53, 57], ["exosomes", "CELL_TYPE", 62, 70], ["immature DCs", "CELL_TYPE", 79, 91], ["DC", "CELL_TYPE", 171, 173], ["exosomes", "CELL_TYPE", 182, 190], ["immature DCs", "PROBLEM", 79, 91], ["an antigen", "TEST", 127, 137], ["immature DCs", "OBSERVATION", 13, 25], ["larger", "OBSERVATION_MODIFIER", 36, 42]]], ["Immune functions of DC-derived exosomes can be tailored to be immunogenic or tolerizing, depending on the presence of specific molecular cargo.", [["DC", "ANATOMY", 20, 22], ["exosomes", "ANATOMY", 31, 39], ["DC", "CELL", 20, 22], ["exosomes", "CELL", 31, 39], ["DC", "CELL_TYPE", 20, 22], ["exosomes", "CELL_TYPE", 31, 39], ["DC-derived exosomes", "TREATMENT", 20, 39], ["immunogenic", "PROBLEM", 62, 73]]], ["This has increasingly found uses in creating highly specialized therapeutics termed \u2018designer dexosomes\u2019 that are utilized in cancer therapy, vaccine development, and transplant tolerance induction as recently reviewed in Viaud et al. [36].Role of exosomes in the virus life cycle ::: Functions of exosomesExosomes and viruses seem to have developed in close association prompting some virologists to suggest that they co-opted molecular machineries as they evolved.", [["cancer", "ANATOMY", 126, 132], ["exosomes", "ANATOMY", 248, 256], ["exosomesExosomes", "ANATOMY", 298, 314], ["cancer", "DISEASE", 126, 132], ["dexosomes", "SIMPLE_CHEMICAL", 94, 103], ["cancer", "CANCER", 126, 132], ["exosomes", "CELL", 248, 256], ["exosomesExosomes", "CELL", 298, 314], ["exosomes", "CELL_TYPE", 298, 306], ["Exosomes", "CELL_TYPE", 306, 314], ["cancer therapy", "TREATMENT", 126, 140], ["vaccine development", "TREATMENT", 142, 161], ["transplant tolerance induction", "TREATMENT", 167, 197], ["viruses", "PROBLEM", 319, 326], ["cancer", "OBSERVATION", 126, 132], ["exosomesExosomes", "OBSERVATION", 298, 314]]], ["Immature DCs are tasked with delivering viral antigens from the periphery to lymphoid organs and an additional mechanism significantly increases the number of virus challenged DCs.", [["DCs", "ANATOMY", 9, 12], ["periphery", "ANATOMY", 64, 73], ["lymphoid organs", "ANATOMY", 77, 92], ["DCs", "ANATOMY", 176, 179], ["DCs", "CELL", 9, 12], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 77, 92], ["DCs", "CELL", 176, 179], ["DCs", "CELL_TYPE", 9, 12], ["viral antigens", "PROTEIN", 40, 54], ["virus challenged DCs", "CELL_TYPE", 159, 179], ["Immature DCs", "PROBLEM", 0, 12], ["viral antigens", "PROBLEM", 40, 54], ["an additional mechanism", "PROBLEM", 97, 120], ["lymphoid organs", "OBSERVATION", 77, 92]]], ["This amplification involves mature DCs phagocytosing antigen-bearing DC's, or antigen-loaded exosomes produced by infected DCs.", [["DCs", "ANATOMY", 35, 38], ["DC", "ANATOMY", 69, 71], ["exosomes", "ANATOMY", 93, 101], ["DCs", "ANATOMY", 123, 126], ["DCs", "CELL", 35, 38], ["antigen", "GENE_OR_GENE_PRODUCT", 53, 60], ["DC", "CELL", 69, 71], ["antigen", "GENE_OR_GENE_PRODUCT", 78, 85], ["exosomes", "CELL", 93, 101], ["DCs", "CELL", 123, 126], ["mature DCs", "CELL_TYPE", 28, 38], ["DC", "CELL_TYPE", 69, 71], ["antigen-loaded exosomes", "CELL_TYPE", 78, 101], ["DCs", "CELL_TYPE", 123, 126], ["antigen-loaded exosomes", "TREATMENT", 78, 101], ["infected DCs", "OBSERVATION", 114, 126]]], ["The exosome antigen dissemination pathway intrinsic to DCs involves an enrichment of functional epitope\u2013MHC complexes on the exosome, and their release from the cell followed by uptake by other immune effector cells.Role of exosomes in the virus life cycle ::: Functions of exosomesSuch an exosomal packaging system allows the virus to survive within the endocytic system without lysosomal degradation, and allows subsequent trans-infection of CD4+ T-cells (Fig. 3b).", [["exosome", "ANATOMY", 4, 11], ["DCs", "ANATOMY", 55, 58], ["exosome", "ANATOMY", 125, 132], ["cell", "ANATOMY", 161, 165], ["immune effector cells", "ANATOMY", 194, 215], ["exosomes", "ANATOMY", 224, 232], ["exosomal", "ANATOMY", 290, 298], ["endocytic system", "ANATOMY", 355, 371], ["lysosomal", "ANATOMY", 380, 389], ["CD4+ T-cells", "ANATOMY", 444, 456], ["exosome antigen", "GENE_OR_GENE_PRODUCT", 4, 19], ["DCs", "CELL", 55, 58], ["epitope\u2013MHC", "GENE_OR_GENE_PRODUCT", 96, 107], ["exosome", "CELLULAR_COMPONENT", 125, 132], ["cell", "CELL", 161, 165], ["immune effector cells", "CELL", 194, 215], ["exosomes", "CELL", 224, 232], ["exosomesSuch", "GENE_OR_GENE_PRODUCT", 274, 286], ["lysosomal", "CELLULAR_COMPONENT", 380, 389], ["CD4", "GENE_OR_GENE_PRODUCT", 444, 447], ["DCs", "CELL_TYPE", 55, 58], ["epitope\u2013MHC complexes", "PROTEIN", 96, 117], ["exosome", "PROTEIN", 125, 132], ["immune effector cells", "CELL_TYPE", 194, 215], ["exosomesSuch", "PROTEIN", 274, 286], ["CD4+ T-cells", "CELL_TYPE", 444, 456], ["exosomesSuch an exosomal packaging system", "TREATMENT", 274, 315], ["the virus", "PROBLEM", 323, 332], ["lysosomal degradation", "PROBLEM", 380, 401], ["effector cells", "OBSERVATION", 201, 215], ["without", "UNCERTAINTY", 372, 379], ["lysosomal degradation", "OBSERVATION", 380, 401]]], ["HIV (human immunodeficiency virus) and other retroviruses utilize a dexosome based and predominantly MHC-II antigen complex presentation schema to trans-infect CD4+ T-cells [37].", [["CD4+ T-cells", "ANATOMY", 160, 172], ["HIV (human immunodeficiency virus", "DISEASE", 0, 33], ["HIV", "ORGANISM", 0, 3], ["human immunodeficiency virus", "ORGANISM", 5, 33], ["retroviruses", "ORGANISM", 45, 57], ["MHC-II antigen", "GENE_OR_GENE_PRODUCT", 101, 115], ["CD4", "GENE_OR_GENE_PRODUCT", 160, 163], ["MHC-II antigen complex", "PROTEIN", 101, 123], ["CD4+ T-cells", "CELL_TYPE", 160, 172], ["HIV", "SPECIES", 0, 3], ["human immunodeficiency virus", "SPECIES", 5, 33], ["HIV", "SPECIES", 0, 3], ["human immunodeficiency virus", "SPECIES", 5, 33], ["HIV (human immunodeficiency virus", "PROBLEM", 0, 33], ["other retroviruses", "PROBLEM", 39, 57]]], ["Immature DCs exhibit a budding of HIV into a structure that becomes an exosome at the stage of reverse budding in the late endosome.Role of exosomes in the virus life cycle ::: Functions of exosomesOn a per particle basis, exosome associated particles are 10-fold more infectious than cell-free virus particles [37].", [["DCs", "ANATOMY", 9, 12], ["exosome", "ANATOMY", 71, 78], ["late endosome", "ANATOMY", 118, 131], ["exosomes", "ANATOMY", 140, 148], ["exosome", "ANATOMY", 223, 230], ["cell", "ANATOMY", 285, 289], ["DCs", "CELL", 9, 12], ["HIV", "ORGANISM", 34, 37], ["late endosome", "CELLULAR_COMPONENT", 118, 131], ["exosomes", "CELL", 140, 148], ["exosomesOn", "GENE_OR_GENE_PRODUCT", 190, 200], ["exosome", "GENE_OR_GENE_PRODUCT", 223, 230], ["cell", "CELL", 285, 289], ["Immature DCs", "CELL_TYPE", 0, 12], ["exosomesOn", "PROTEIN", 190, 200], ["HIV", "SPECIES", 34, 37], ["Immature DCs", "PROBLEM", 0, 12], ["HIV", "PROBLEM", 34, 37], ["an exosome", "PROBLEM", 68, 78], ["exosome associated particles", "PROBLEM", 223, 251], ["exosome", "OBSERVATION", 71, 78]]], ["Mature DC-internalized viral particles need to compete with virion-like particles (VLP) and exosomes at the vesicle internalization stage for segregation into lipid-raft like, cholesterol enriched micro domains on the DC.", [["DC", "ANATOMY", 7, 9], ["exosomes", "ANATOMY", 92, 100], ["vesicle", "ANATOMY", 108, 115], ["lipid-raft", "ANATOMY", 159, 169], ["DC", "ANATOMY", 218, 220], ["cholesterol", "CHEMICAL", 176, 187], ["cholesterol", "CHEMICAL", 176, 187], ["DC", "CELL", 7, 9], ["virion-like particles", "GENE_OR_GENE_PRODUCT", 60, 81], ["VLP", "ORGANISM", 83, 86], ["exosomes", "CELL", 92, 100], ["vesicle", "CELLULAR_COMPONENT", 108, 115], ["cholesterol", "SIMPLE_CHEMICAL", 176, 187], ["DC", "CELL", 218, 220], ["DC", "CELL_TYPE", 7, 9], ["exosomes", "CELL_TYPE", 92, 100], ["cholesterol enriched micro domains", "PROTEIN", 176, 210], ["DC", "CELL_TYPE", 218, 220], ["internalized viral particles", "PROBLEM", 10, 38], ["virion-like particles", "TREATMENT", 60, 81], ["segregation into lipid", "PROBLEM", 142, 164], ["the DC", "TREATMENT", 214, 220], ["viral particles", "OBSERVATION", 23, 38]]], ["Glycosphingolipids from the exosome-producing cells are known to be critical for the process of VLP and exosome internalization at the mature host DC plasma membrane.", [["exosome", "ANATOMY", 28, 35], ["cells", "ANATOMY", 46, 51], ["exosome", "ANATOMY", 104, 111], ["DC plasma membrane", "ANATOMY", 147, 165], ["Glycosphingolipids", "CHEMICAL", 0, 18], ["Glycosphingolipids", "GENE_OR_GENE_PRODUCT", 0, 18], ["exosome", "GENE_OR_GENE_PRODUCT", 28, 35], ["cells", "CELL", 46, 51], ["VLP", "GENE_OR_GENE_PRODUCT", 96, 99], ["exosome", "GENE_OR_GENE_PRODUCT", 104, 111], ["plasma membrane", "CELLULAR_COMPONENT", 150, 165], ["exosome", "PROTEIN", 28, 35], ["producing cells", "CELL_TYPE", 36, 51], ["Glycosphingolipids", "TREATMENT", 0, 18], ["VLP", "TREATMENT", 96, 99], ["exosome internalization", "TREATMENT", 104, 127], ["exosome internalization", "OBSERVATION", 104, 127]]], ["This probably occurs through facilitating interaction of the exosome or viral membrane with the host [37], [38].Role of exosomes in the virus life cycle ::: Functions of exosomesConversely, as an indicator of how viruses hijack the host system to survive and propagate, the \u201cTrojan exosome hypothesis\u201d proposes that enveloped retroviruses like HIV utilize the host cell's endosomal system, including the exosome pathway, to move between APCs while searching for the best target cells (Fig. 3b) [39].", [["exosome", "ANATOMY", 61, 68], ["membrane", "ANATOMY", 78, 86], ["exosomes", "ANATOMY", 120, 128], ["exosomes", "ANATOMY", 170, 178], ["cell", "ANATOMY", 365, 369], ["endosomal system", "ANATOMY", 372, 388], ["exosome", "ANATOMY", 404, 411], ["APCs", "ANATOMY", 437, 441], ["cells", "ANATOMY", 478, 483], ["exosome", "CELLULAR_COMPONENT", 61, 68], ["exosomes", "CELL", 120, 128], ["exosomes", "CELL", 170, 178], ["enveloped retroviruses", "ORGANISM", 316, 338], ["HIV", "ORGANISM", 344, 347], ["cell", "CELL", 365, 369], ["endosomal", "CELLULAR_COMPONENT", 372, 381], ["exosome", "CELLULAR_COMPONENT", 404, 411], ["APCs", "CELL", 437, 441], ["cells", "CELL", 478, 483], ["exosome", "PROTEIN", 61, 68], ["exosomes", "CELL_TYPE", 170, 178], ["APCs", "CELL_TYPE", 437, 441], ["target cells", "CELL_TYPE", 471, 483], ["HIV", "SPECIES", 344, 347], ["HIV", "SPECIES", 344, 347], ["the exosome pathway", "TREATMENT", 400, 419], ["viral membrane", "OBSERVATION", 72, 86]]], ["It is well known that HIV viral budding occurs in an MHC II-enriched compartment similar to the MVB.Role of exosomes in the virus life cycle ::: Functions of exosomesThe generation of ILVs/exosomes result from the binding of the hepatocyte growth factor tyrosine kinase substrate (Hrs) to ubiquitinated cargo, followed by recruitment of Tsg101.", [["MVB", "ANATOMY", 96, 99], ["exosomes", "ANATOMY", 108, 116], ["exosomes", "ANATOMY", 158, 166], ["exosomes", "ANATOMY", 189, 197], ["tyrosine", "CHEMICAL", 254, 262], ["tyrosine", "CHEMICAL", 254, 262], ["HIV viral", "ORGANISM", 22, 31], ["MVB", "CELLULAR_COMPONENT", 96, 99], ["exosomes", "CELL", 108, 116], ["exosomes", "CELL", 158, 166], ["ILVs", "GENE_OR_GENE_PRODUCT", 184, 188], ["exosomes", "CELL", 189, 197], ["hepatocyte growth factor tyrosine kinase substrate", "GENE_OR_GENE_PRODUCT", 229, 279], ["Hrs", "GENE_OR_GENE_PRODUCT", 281, 284], ["Tsg101", "GENE_OR_GENE_PRODUCT", 337, 343], ["MHC II", "PROTEIN", 53, 59], ["exosomes", "CELL_TYPE", 158, 166], ["ILVs", "PROTEIN", 184, 188], ["exosomes", "CELL_TYPE", 189, 197], ["hepatocyte growth factor tyrosine kinase substrate", "PROTEIN", 229, 279], ["Hrs", "PROTEIN", 281, 284], ["ubiquitinated cargo", "PROTEIN", 289, 308], ["Tsg101", "PROTEIN", 337, 343], ["HIV", "SPECIES", 22, 25], ["HIV viral budding", "PROBLEM", 22, 39], ["ILVs/exosomes", "TREATMENT", 184, 197], ["tyrosine kinase substrate", "TREATMENT", 254, 279], ["exosomes", "OBSERVATION", 158, 166], ["hepatocyte", "ANATOMY", 229, 239]]], ["HIV-1 Gag mimics Hrs and thereby usurps Tsg101 and other components of the MVB machinery in order to facilitate viral budding.", [["MVB", "ANATOMY", 75, 78], ["HIV-1", "ORGANISM", 0, 5], ["Gag", "ORGANISM", 6, 9], ["Hrs", "GENE_OR_GENE_PRODUCT", 17, 20], ["Tsg101", "GENE_OR_GENE_PRODUCT", 40, 46], ["MVB", "CELLULAR_COMPONENT", 75, 78], ["HIV-1 Gag", "PROTEIN", 0, 9], ["Hrs", "PROTEIN", 17, 20], ["Tsg101", "PROTEIN", 40, 46], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "TEST", 0, 3], ["Tsg", "TEST", 40, 43], ["the MVB machinery", "TREATMENT", 71, 88], ["viral budding", "PROBLEM", 112, 125], ["viral budding", "OBSERVATION", 112, 125]]], ["The similarity of the exosome and viral budding pathways prompted comparative studies which indicated that viruses disguised as ILVs may be co-opted in the exosome pathway and released with the typical exosomal membrane and lipid composition.", [["exosome", "ANATOMY", 22, 29], ["exosome", "ANATOMY", 156, 163], ["exosomal membrane", "ANATOMY", 202, 219], ["exosome", "CELLULAR_COMPONENT", 22, 29], ["ILVs", "GENE_OR_GENE_PRODUCT", 128, 132], ["exosomal membrane", "CELLULAR_COMPONENT", 202, 219], ["lipid", "SIMPLE_CHEMICAL", 224, 229], ["exosome", "PROTEIN", 22, 29], ["ILVs", "PROTEIN", 128, 132], ["comparative studies", "TEST", 66, 85], ["viruses", "PROBLEM", 107, 114], ["exosome", "OBSERVATION", 22, 29], ["viral budding", "OBSERVATION", 34, 47], ["viruses", "OBSERVATION", 107, 114], ["exosomal membrane", "OBSERVATION", 202, 219], ["lipid composition", "OBSERVATION", 224, 241]]], ["In this mechanism of disguised propagation the virus is also able to conserve resources on fusion with the cell and utilizes the exosome internalization machinery to enter the host cell [40].Role in tumorigenesis via altering microenvironment (tumor growth, angiogenesis) ::: Functions of exosomesIt has been shown that part of the physiological role of exosomes is their ability to alter their micro-environment through their protein and RNA based cargo.", [["cell", "ANATOMY", 107, 111], ["exosome", "ANATOMY", 129, 136], ["cell", "ANATOMY", 181, 185], ["tumor", "ANATOMY", 244, 249], ["exosomes", "ANATOMY", 289, 297], ["exosomes", "ANATOMY", 354, 362], ["tumor", "DISEASE", 244, 249], ["cell", "CELL", 107, 111], ["cell", "CELL", 181, 185], ["tumor", "CANCER", 244, 249], ["exosomes", "CELL", 289, 297], ["exosomes", "CELL", 354, 362], ["exosomes", "CELL_TYPE", 289, 297], ["exosomes", "CELL_TYPE", 354, 362], ["the virus", "PROBLEM", 43, 52], ["fusion", "TREATMENT", 91, 97], ["the exosome internalization machinery", "TREATMENT", 125, 162], ["altering microenvironment (tumor growth", "PROBLEM", 217, 256], ["virus", "OBSERVATION", 47, 52], ["host cell", "OBSERVATION", 176, 185], ["exosomes", "OBSERVATION", 289, 297]]], ["For instance, studies on tumor derived exosomes reveal that they may perform several functions aiding tumor survival and metastasis (Fig. 3a).", [["tumor", "ANATOMY", 25, 30], ["exosomes", "ANATOMY", 39, 47], ["tumor", "ANATOMY", 102, 107], ["tumor", "DISEASE", 25, 30], ["tumor", "DISEASE", 102, 107], ["tumor", "CANCER", 25, 30], ["exosomes", "CELL", 39, 47], ["tumor", "CANCER", 102, 107], ["tumor derived exosomes", "CELL_TYPE", 25, 47], ["studies on tumor derived exosomes", "TEST", 14, 47], ["tumor survival", "PROBLEM", 102, 116], ["metastasis", "PROBLEM", 121, 131], ["tumor", "OBSERVATION", 102, 107], ["metastasis", "OBSERVATION", 121, 131]]], ["The presence of HLA-G in exosomes secreted by melanoma cells might indicate a role in creating a tumor tolerance associated response [41].", [["exosomes", "ANATOMY", 25, 33], ["melanoma cells", "ANATOMY", 46, 60], ["tumor", "ANATOMY", 97, 102], ["melanoma", "DISEASE", 46, 54], ["tumor", "DISEASE", 97, 102], ["HLA-G", "GENE_OR_GENE_PRODUCT", 16, 21], ["exosomes", "CELL", 25, 33], ["melanoma cells", "CELL", 46, 60], ["tumor", "CANCER", 97, 102], ["HLA-G", "PROTEIN", 16, 21], ["exosomes", "CELL_TYPE", 25, 33], ["melanoma cells", "CELL_TYPE", 46, 60], ["HLA", "PROBLEM", 16, 19], ["melanoma cells", "PROBLEM", 46, 60], ["a tumor tolerance", "PROBLEM", 95, 112], ["melanoma cells", "OBSERVATION", 46, 60], ["tumor", "OBSERVATION", 97, 102]]], ["Tolerogenic activity of exosomes has been associated with Fas- and TRAIL-expression in exosome membranes inducing FasL- and TRAIL-mediated apoptosis of anti-tumor T-cells [42].", [["exosomes", "ANATOMY", 24, 32], ["exosome membranes", "ANATOMY", 87, 104], ["anti-tumor T-cells", "ANATOMY", 152, 170], ["exosomes", "CELL", 24, 32], ["Fas", "GENE_OR_GENE_PRODUCT", 58, 61], ["TRAIL", "GENE_OR_GENE_PRODUCT", 67, 72], ["exosome membranes", "CELLULAR_COMPONENT", 87, 104], ["FasL", "GENE_OR_GENE_PRODUCT", 114, 118], ["TRAIL", "GENE_OR_GENE_PRODUCT", 124, 129], ["anti-tumor T-cells", "CELL", 152, 170], ["exosomes", "CELL_TYPE", 24, 32], ["Fas", "PROTEIN", 58, 61], ["TRAIL", "PROTEIN", 67, 72], ["FasL", "PROTEIN", 114, 118], ["TRAIL", "PROTEIN", 124, 129], ["anti-tumor T-cells", "CELL_TYPE", 152, 170], ["Fas", "TEST", 58, 61], ["TRAIL", "TREATMENT", 67, 72], ["exosome membranes", "TREATMENT", 87, 104], ["FasL", "TEST", 114, 118], ["exosome membranes", "ANATOMY", 87, 104]]], ["Incubation with tumor derived exosomes can disrupt the maturation of differentiating CD14+ and HLA-DRlow/neg monocyte precursors into DCs [43].", [["tumor", "ANATOMY", 16, 21], ["exosomes", "ANATOMY", 30, 38], ["HLA-DRlow/neg monocyte precursors", "ANATOMY", 95, 128], ["DCs", "ANATOMY", 134, 137], ["tumor", "DISEASE", 16, 21], ["tumor derived exosomes", "CELL", 16, 38], ["CD14", "GENE_OR_GENE_PRODUCT", 85, 89], ["HLA-DRlow", "GENE_OR_GENE_PRODUCT", 95, 104], ["tumor derived exosomes", "CELL_TYPE", 16, 38], ["CD14", "PROTEIN", 85, 89], ["HLA-DRlow/neg monocyte precursors", "CELL_LINE", 95, 128], ["DCs", "CELL_TYPE", 134, 137], ["tumor derived exosomes", "PROBLEM", 16, 38], ["CD14", "TEST", 85, 89], ["HLA", "TEST", 95, 98], ["DRlow", "TEST", 99, 104]]], ["The resulting lack of T-cell stimulatory effects on exosome co-culture is primarily due to the altered monocyte cytokine profile exemplified by inflammatory cytokines such as TNF-\u03b1, interleukin IL-6, and pro-angiogenic and immuno-suppressive factors, e.g. TGF-\u03b2, IL-8 and IL-10.Role in tumorigenesis via altering microenvironment (tumor growth, angiogenesis) ::: Functions of exosomesIn support of this result, peripheral blood of melanoma patients revealed the predicted CD14+ and HLA-DRlow/neg (MHC class II cell surface receptor) tumor growth factor TGF-\u03b2 secreting myeloid cell population which was absent in healthy individuals [44].", [["T-cell", "ANATOMY", 22, 28], ["exosome", "ANATOMY", 52, 59], ["monocyte", "ANATOMY", 103, 111], ["tumor", "ANATOMY", 331, 336], ["peripheral blood", "ANATOMY", 411, 427], ["melanoma", "ANATOMY", 431, 439], ["myeloid cell", "ANATOMY", 569, 581], ["tumor", "DISEASE", 331, 336], ["melanoma", "DISEASE", 431, 439], ["tumor", "DISEASE", 533, 538], ["T-cell", "CELL", 22, 28], ["monocyte", "CELL", 103, 111], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 175, 180], ["interleukin IL-6", "GENE_OR_GENE_PRODUCT", 182, 198], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 256, 261], ["IL-8", "GENE_OR_GENE_PRODUCT", 263, 267], ["IL-10", "GENE_OR_GENE_PRODUCT", 272, 277], ["tumor", "CANCER", 331, 336], ["exosomesIn", "GENE_OR_GENE_PRODUCT", 376, 386], ["peripheral blood", "ORGANISM_SUBSTANCE", 411, 427], ["melanoma", "CANCER", 431, 439], ["patients", "ORGANISM", 440, 448], ["CD14", "GENE_OR_GENE_PRODUCT", 472, 476], ["MHC class II cell surface receptor", "GENE_OR_GENE_PRODUCT", 497, 531], ["tumor", "CANCER", 533, 538], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 553, 558], ["myeloid cell", "CELL", 569, 581], ["cytokine", "PROTEIN", 112, 120], ["inflammatory cytokines", "PROTEIN", 144, 166], ["TNF", "PROTEIN", 175, 178], ["interleukin IL-6", "PROTEIN", 182, 198], ["immuno-suppressive factors", "PROTEIN", 223, 249], ["TGF-\u03b2, IL-8", "PROTEIN", 256, 267], ["IL", "PROTEIN", 272, 274], ["exosomesIn", "PROTEIN", 376, 386], ["CD14", "PROTEIN", 472, 476], ["HLA", "PROTEIN", 482, 485], ["MHC class II cell surface receptor", "PROTEIN", 497, 531], ["tumor growth factor TGF-\u03b2 secreting myeloid cell population", "CELL_LINE", 533, 592], ["patients", "SPECIES", 440, 448], ["T-cell stimulatory effects", "TREATMENT", 22, 48], ["exosome co-culture", "TEST", 52, 70], ["the altered monocyte cytokine profile", "PROBLEM", 91, 128], ["inflammatory cytokines", "PROBLEM", 144, 166], ["TNF", "TEST", 175, 178], ["interleukin IL", "TEST", 182, 196], ["pro-angiogenic", "TEST", 204, 218], ["immuno", "TEST", 223, 229], ["TGF", "TEST", 256, 259], ["IL", "TEST", 263, 265], ["IL", "TEST", 272, 274], ["peripheral blood of melanoma", "PROBLEM", 411, 439], ["the predicted CD14", "TEST", 458, 476], ["HLA", "TEST", 482, 485], ["DRlow", "TEST", 486, 491], ["cell surface receptor", "TEST", 510, 531], ["tumor growth", "TEST", 533, 545], ["TGF", "TEST", 553, 556], ["secreting myeloid cell population", "PROBLEM", 559, 592], ["monocyte cytokine", "OBSERVATION", 103, 120], ["inflammatory", "OBSERVATION_MODIFIER", 144, 156], ["melanoma", "OBSERVATION", 431, 439], ["secreting myeloid cell", "OBSERVATION", 559, 581]]], ["Tumor derived exosomes contain several cytokines and growth factors such as tumor necrosis factor TNF-\u03b1, IL-1\u03b2, and TGF-\u03b2 as well as functional receptors like TNFR1 and TfR2.", [["Tumor", "ANATOMY", 0, 5], ["exosomes", "ANATOMY", 14, 22], ["necrosis", "DISEASE", 82, 90], ["Tumor", "CANCER", 0, 5], ["exosomes", "CELL", 14, 22], ["tumor necrosis factor TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 76, 103], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 105, 110], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 121], ["TNFR1", "GENE_OR_GENE_PRODUCT", 159, 164], ["TfR2", "GENE_OR_GENE_PRODUCT", 169, 173], ["Tumor derived exosomes", "CELL_TYPE", 0, 22], ["cytokines", "PROTEIN", 39, 48], ["growth factors", "PROTEIN", 53, 67], ["tumor necrosis factor TNF-\u03b1, IL-1\u03b2", "PROTEIN", 76, 110], ["TGF-\u03b2", "PROTEIN", 116, 121], ["TNFR1", "PROTEIN", 159, 164], ["TfR2", "PROTEIN", 169, 173], ["Tumor derived exosomes", "PROBLEM", 0, 22], ["several cytokines", "PROBLEM", 31, 48], ["growth factors", "PROBLEM", 53, 67], ["tumor necrosis", "PROBLEM", 76, 90], ["TNF", "TEST", 98, 101], ["IL", "TEST", 105, 107], ["TGF", "TEST", 116, 119], ["several", "OBSERVATION_MODIFIER", 31, 38], ["cytokines", "OBSERVATION", 39, 48], ["tumor", "OBSERVATION_MODIFIER", 76, 81], ["necrosis", "OBSERVATION", 82, 90]]], ["Consequently, tumor derived exosomes by their very nature support neo-angiogenesis since they are enriched in tetraspanins which enhance the secretion of VEGF (vascular endothelial growth factor) and metalloproteinases from target cells [45].", [["tumor", "ANATOMY", 14, 19], ["exosomes", "ANATOMY", 28, 36], ["cells", "ANATOMY", 231, 236], ["tumor", "DISEASE", 14, 19], ["tumor derived exosomes", "CELL", 14, 36], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 110, 122], ["VEGF", "GENE_OR_GENE_PRODUCT", 154, 158], ["vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 160, 194], ["metalloproteinases", "GENE_OR_GENE_PRODUCT", 200, 218], ["cells", "CELL", 231, 236], ["tumor derived exosomes", "CELL_TYPE", 14, 36], ["tetraspanins", "PROTEIN", 110, 122], ["VEGF", "PROTEIN", 154, 158], ["vascular endothelial growth factor", "PROTEIN", 160, 194], ["metalloproteinases", "PROTEIN", 200, 218], ["target cells", "CELL_TYPE", 224, 236], ["tumor derived exosomes", "PROBLEM", 14, 36], ["VEGF (vascular endothelial growth factor", "PROBLEM", 154, 194], ["metalloproteinases from target cells", "TEST", 200, 236], ["tumor", "OBSERVATION", 14, 19], ["vascular endothelial", "ANATOMY", 160, 180]]], ["A striking result from Skog's study on glioblastoma derived microvesicles revealed that tumor derived exosomes could support cell culture based angiogenesis of HUVEC (human umbilical vein endothelial cells) to almost the same extent as extraneously added growth factors [3].Role in tumorigenesis via altering microenvironment (tumor growth, angiogenesis) ::: Functions of exosomesMelanoma exosomes were shown to induce endothelial cell spheroid formation and moved between endothelial tubule cells using tunneling nanotube structures and acting in a primarily paracrine manner [46].", [["glioblastoma derived microvesicles", "ANATOMY", 39, 73], ["tumor", "ANATOMY", 88, 93], ["exosomes", "ANATOMY", 102, 110], ["cell", "ANATOMY", 125, 129], ["HUVEC", "ANATOMY", 160, 165], ["human umbilical vein endothelial cells", "ANATOMY", 167, 205], ["tumor", "ANATOMY", 327, 332], ["Melanoma exosomes", "ANATOMY", 380, 397], ["endothelial cell spheroid", "ANATOMY", 419, 444], ["endothelial tubule cells", "ANATOMY", 473, 497], ["glioblastoma", "DISEASE", 39, 51], ["tumor", "DISEASE", 88, 93], ["tumor", "DISEASE", 327, 332], ["glioblastoma derived microvesicles", "CELL", 39, 73], ["tumor derived exosomes", "CELL", 88, 110], ["cell", "CELL", 125, 129], ["HUVEC", "CELL", 160, 165], ["human umbilical vein endothelial cells", "CELL", 167, 205], ["tumor", "CANCER", 327, 332], ["exosomesMelanoma exosomes", "CELL", 372, 397], ["endothelial cell spheroid", "CELL", 419, 444], ["endothelial tubule cells", "CELL", 473, 497], ["glioblastoma derived microvesicles", "CELL_TYPE", 39, 73], ["tumor derived exosomes", "CELL_TYPE", 88, 110], ["HUVEC", "CELL_LINE", 160, 165], ["human umbilical vein endothelial cells", "CELL_TYPE", 167, 205], ["growth factors", "PROTEIN", 255, 269], ["exosomes", "CELL_TYPE", 372, 380], ["endothelial tubule cells", "CELL_TYPE", 473, 497], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["Skog's study", "TEST", 23, 35], ["glioblastoma derived microvesicles", "PROBLEM", 39, 73], ["tumor derived exosomes", "PROBLEM", 88, 110], ["cell culture", "TEST", 125, 137], ["HUVEC (human umbilical vein endothelial cells", "TREATMENT", 160, 205], ["altering microenvironment (tumor growth", "PROBLEM", 300, 339], ["exosomesMelanoma exosomes", "PROBLEM", 372, 397], ["endothelial cell spheroid formation", "PROBLEM", 419, 454], ["endothelial tubule cells", "TREATMENT", 473, 497], ["tunneling nanotube structures", "TREATMENT", 504, 533], ["tumor", "OBSERVATION", 88, 93], ["umbilical vein", "ANATOMY", 173, 187], ["endothelial cells", "OBSERVATION", 188, 205], ["exosomesMelanoma", "OBSERVATION", 372, 388], ["endothelial cell", "OBSERVATION", 419, 435], ["spheroid formation", "OBSERVATION", 436, 454], ["endothelial tubule cells", "OBSERVATION", 473, 497], ["tunneling nanotube", "OBSERVATION", 504, 522]]], ["In an adenocarcinoma model, exosomes induced several angiogenesis related genes including von Willebrand factor, Tspan8, chemokines CXCL5 (C-X-C motif chemokine 5), MIF (macrophage migration inhibitory factor), and chemokine receptor CCR1.", [["adenocarcinoma", "ANATOMY", 6, 20], ["exosomes", "ANATOMY", 28, 36], ["adenocarcinoma", "DISEASE", 6, 20], ["adenocarcinoma", "CANCER", 6, 20], ["exosomes", "CELL", 28, 36], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 90, 111], ["Tspan8", "GENE_OR_GENE_PRODUCT", 113, 119], ["CXCL5", "GENE_OR_GENE_PRODUCT", 132, 137], ["C-X-C motif chemokine 5", "GENE_OR_GENE_PRODUCT", 139, 162], ["MIF", "GENE_OR_GENE_PRODUCT", 165, 168], ["macrophage migration inhibitory factor", "GENE_OR_GENE_PRODUCT", 170, 208], ["CCR1", "GENE_OR_GENE_PRODUCT", 234, 238], ["exosomes", "CELL_TYPE", 28, 36], ["angiogenesis related genes", "DNA", 53, 79], ["von Willebrand factor", "PROTEIN", 90, 111], ["Tspan8", "PROTEIN", 113, 119], ["chemokines", "PROTEIN", 121, 131], ["CXCL5", "PROTEIN", 132, 137], ["C-X-C motif chemokine 5", "PROTEIN", 139, 162], ["MIF", "PROTEIN", 165, 168], ["macrophage migration inhibitory factor", "PROTEIN", 170, 208], ["chemokine receptor", "PROTEIN", 215, 233], ["CCR1", "PROTEIN", 234, 238], ["an adenocarcinoma model", "PROBLEM", 3, 26], ["several angiogenesis", "PROBLEM", 45, 65], ["von Willebrand factor", "TEST", 90, 111], ["Tspan8", "TEST", 113, 119], ["chemokines CXCL5", "TEST", 121, 137], ["C", "TEST", 139, 140], ["-X-C motif chemokine", "TREATMENT", 140, 160], ["MIF (macrophage migration inhibitory factor", "TREATMENT", 165, 208], ["chemokine receptor CCR1", "TREATMENT", 215, 238], ["adenocarcinoma", "OBSERVATION", 6, 20], ["several", "OBSERVATION_MODIFIER", 45, 52], ["angiogenesis", "OBSERVATION", 53, 65]]], ["This indicated involvement of VEGF independent processes in exosome-mediated angiogenesis [47], [48].Role in tumorigenesis via altering microenvironment (tumor growth, angiogenesis) ::: Functions of exosomesA recent study showed that exosomes from a mutant KRAS allele bearing cell line have greater invasive potential than exosomes from an autologous cell line with the mutant KRAS removed by homologous recombination [10].", [["exosome", "ANATOMY", 60, 67], ["tumor", "ANATOMY", 154, 159], ["exosomes", "ANATOMY", 234, 242], ["cell line", "ANATOMY", 277, 286], ["exosomes", "ANATOMY", 324, 332], ["cell line", "ANATOMY", 352, 361], ["tumor", "DISEASE", 154, 159], ["VEGF", "GENE_OR_GENE_PRODUCT", 30, 34], ["exosome", "CELLULAR_COMPONENT", 60, 67], ["tumor", "CANCER", 154, 159], ["exosomes", "CELL", 234, 242], ["KRAS", "GENE_OR_GENE_PRODUCT", 257, 261], ["cell line", "CELL", 277, 286], ["exosomes", "CELL", 324, 332], ["cell line", "CELL", 352, 361], ["KRAS", "GENE_OR_GENE_PRODUCT", 378, 382], ["VEGF", "PROTEIN", 30, 34], ["exosome", "PROTEIN", 60, 67], ["exosomes", "CELL_TYPE", 234, 242], ["mutant KRAS allele", "DNA", 250, 268], ["exosomes", "CELL_TYPE", 324, 332], ["autologous cell line", "CELL_LINE", 341, 361], ["mutant KRAS", "DNA", 371, 382], ["VEGF independent processes", "PROBLEM", 30, 56], ["altering microenvironment (tumor growth", "PROBLEM", 127, 166], ["exosomesA recent study", "TEST", 199, 221], ["a mutant KRAS allele bearing cell line", "PROBLEM", 248, 286], ["an autologous cell line", "TREATMENT", 338, 361], ["the mutant KRAS", "TREATMENT", 367, 382], ["VEGF", "OBSERVATION", 30, 34], ["bearing cell line", "OBSERVATION", 269, 286], ["greater", "OBSERVATION_MODIFIER", 292, 299], ["invasive", "OBSERVATION_MODIFIER", 300, 308], ["autologous cell line", "OBSERVATION", 341, 361], ["KRAS", "OBSERVATION", 378, 382]]], ["Such properties could clearly aid the formation of pre-metastatic niches.", [["pre-metastatic niches", "PROBLEM", 51, 72]]], ["Exosomes also aide the spread of the human tumor Epstein Barr Virus, EBV oncogene protein called \u201clatent membrane protein 1\u201d to uninfected cells.", [["Exosomes", "ANATOMY", 0, 8], ["cells", "ANATOMY", 139, 144], ["tumor", "DISEASE", 43, 48], ["Exosomes", "CELL", 0, 8], ["human", "ORGANISM", 37, 42], ["tumor Epstein Barr Virus", "ORGANISM", 43, 67], ["EBV", "ORGANISM", 69, 72], ["latent membrane protein 1", "GENE_OR_GENE_PRODUCT", 98, 123], ["cells", "CELL", 139, 144], ["Exosomes", "CELL_TYPE", 0, 8], ["EBV oncogene protein", "PROTEIN", 69, 89], ["\u201clatent membrane protein 1", "PROTEIN", 97, 123], ["uninfected cells", "CELL_TYPE", 128, 144], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["Epstein Barr Virus", "SPECIES", 49, 67], ["EBV oncogene protein", "TEST", 69, 89], ["latent membrane protein", "TREATMENT", 98, 121], ["human", "ANATOMY", 37, 42], ["tumor", "OBSERVATION", 43, 48], ["uninfected cells", "OBSERVATION", 128, 144]]], ["EBV can enrich exosomes with proteins that are cancer associated and thus induce the enhanced cell growth, angiogenesis, and transformation of other cells.", [["exosomes", "ANATOMY", 15, 23], ["cancer", "ANATOMY", 47, 53], ["cell", "ANATOMY", 94, 98], ["cells", "ANATOMY", 149, 154], ["cancer", "DISEASE", 47, 53], ["EBV", "ORGANISM", 0, 3], ["exosomes", "CELL", 15, 23], ["cancer", "CANCER", 47, 53], ["cell", "CELL", 94, 98], ["cells", "CELL", 149, 154], ["EBV", "SPECIES", 0, 3], ["EBV", "PROBLEM", 0, 3], ["cancer", "PROBLEM", 47, 53], ["the enhanced cell growth", "PROBLEM", 81, 105], ["angiogenesis", "PROBLEM", 107, 119], ["transformation of other cells", "PROBLEM", 125, 154], ["cancer", "OBSERVATION", 47, 53], ["enhanced cell", "OBSERVATION", 85, 98], ["growth", "OBSERVATION_MODIFIER", 99, 105]]], ["They do this while evading the immune response by being encapsulated in the circulating exosomal delivery system [49].Potential role in propagating neurodegenerative diseases ::: Functions of exosomesExosomes have additional functions where they can mediate the spread of cell damage or alter the microenvironment in various metabolic and nervous system disorders [4].", [["exosomal", "ANATOMY", 88, 96], ["exosomesExosomes", "ANATOMY", 192, 208], ["cell", "ANATOMY", 272, 276], ["nervous system", "ANATOMY", 339, 353], ["neurodegenerative diseases", "DISEASE", 148, 174], ["metabolic and nervous system disorders", "DISEASE", 325, 363], ["Exosomes", "CELL", 200, 208], ["cell", "CELL", 272, 276], ["nervous", "ANATOMICAL_SYSTEM", 339, 346], ["system", "ANATOMICAL_SYSTEM", 347, 353], ["exosomes", "CELL_TYPE", 192, 200], ["Exosomes", "CELL_TYPE", 200, 208], ["propagating neurodegenerative diseases", "PROBLEM", 136, 174], ["cell damage", "PROBLEM", 272, 283], ["various metabolic and nervous system disorders", "PROBLEM", 317, 363], ["neurodegenerative diseases", "OBSERVATION", 148, 174], ["cell damage", "OBSERVATION", 272, 283]]], ["As an example, the microenvironment altering properties of exosomes have been implicated in Alzheimer's disease (AD) (Fig. 3c) and have been associated with processed Alzheimer's proteins and enzymes [50], [51], [52].", [["exosomes", "ANATOMY", 59, 67], ["Alzheimer's disease", "DISEASE", 92, 111], ["AD", "DISEASE", 113, 115], ["Alzheimer's proteins", "DISEASE", 167, 187], ["exosomes", "CELL", 59, 67], ["Alzheimer's disease", "CANCER", 92, 111], ["Alzheimer's proteins", "GENE_OR_GENE_PRODUCT", 167, 187], ["exosomes", "CELL_TYPE", 59, 67], ["Alzheimer's proteins", "PROTEIN", 167, 187], ["enzymes", "PROTEIN", 192, 199], ["Alzheimer's disease", "PROBLEM", 92, 111], ["enzymes", "TEST", 192, 199]]], ["The \u201cTrojan Exosome\u201d model of Alzheimer's (similar in concept to the Trojan Exosome model in viral infection), proposes that the initial insult of Alzheimer's may spread to surrounding cells via exosomes laden with amyloid beta (A\u03b2) peptide and other proteins and RNA associated with precipitating Alzheimer's pathogenesis.", [["cells", "ANATOMY", 185, 190], ["exosomes", "ANATOMY", 195, 203], ["Alzheimer's", "DISEASE", 30, 41], ["viral infection", "DISEASE", 93, 108], ["Alzheimer", "DISEASE", 147, 156], ["Alzheimer's pathogenesis", "DISEASE", 298, 322], ["cells", "CELL", 185, 190], ["exosomes", "CELL", 195, 203], ["amyloid beta (A\u03b2) peptide", "GENE_OR_GENE_PRODUCT", 215, 240], ["exosomes", "CELL_TYPE", 195, 203], ["A\u03b2", "PROTEIN", 229, 231], ["Alzheimer's", "PROBLEM", 30, 41], ["viral infection", "PROBLEM", 93, 108], ["Alzheimer's", "PROBLEM", 147, 158], ["amyloid beta (A\u03b2) peptide", "PROBLEM", 215, 240], ["other proteins and RNA", "PROBLEM", 245, 267], ["precipitating Alzheimer's pathogenesis", "PROBLEM", 284, 322], ["Alzheimer", "OBSERVATION", 30, 39], ["viral infection", "OBSERVATION", 93, 108]]], ["This is supported by the finding of depositions of exosome proteins in amyloid plaques in AD brains [53].", [["exosome", "ANATOMY", 51, 58], ["amyloid plaques", "ANATOMY", 71, 86], ["brains", "ANATOMY", 93, 99], ["amyloid plaques", "DISEASE", 71, 86], ["AD", "DISEASE", 90, 92], ["exosome proteins", "PROTEIN", 51, 67], ["exosome proteins", "PROBLEM", 51, 67], ["amyloid plaques in AD brains", "PROBLEM", 71, 99], ["exosome proteins", "OBSERVATION", 51, 67], ["amyloid plaques", "OBSERVATION", 71, 86]]], ["Finally, exosomes have also been associated with the spread of prion proteins indicating multiple roles for exosomes in neurodegenerative diseases.Biomarkers ::: Applications of exosomesIn terms of exosome-based applications the major facet of exosome biology that is finding utilization is the usage of cell- and condition-specific cargo as biomarkers.", [["exosomes", "ANATOMY", 9, 17], ["exosomes", "ANATOMY", 108, 116], ["exosomes", "ANATOMY", 178, 186], ["exosome", "ANATOMY", 198, 205], ["exosome", "ANATOMY", 244, 251], ["cell", "ANATOMY", 304, 308], ["neurodegenerative diseases", "DISEASE", 120, 146], ["exosomes", "CELL", 9, 17], ["prion proteins", "GENE_OR_GENE_PRODUCT", 63, 77], ["exosomes", "CELL", 108, 116], ["exosomes", "CELL", 178, 186], ["exosome", "CELLULAR_COMPONENT", 244, 251], ["cell", "CELL", 304, 308], ["exosomes", "CELL_TYPE", 9, 17], ["prion proteins", "PROTEIN", 63, 77], ["exosomes", "CELL_TYPE", 108, 116], ["exosomes", "CELL_TYPE", 178, 186], ["exosome", "PROTEIN", 198, 205], ["prion proteins", "PROBLEM", 63, 77], ["exosomes in neurodegenerative diseases", "PROBLEM", 108, 146], ["Biomarkers", "TEST", 147, 157], ["exosome-based applications", "TREATMENT", 198, 224], ["neurodegenerative diseases", "OBSERVATION", 120, 146], ["exosomes", "OBSERVATION", 178, 186], ["exosome", "OBSERVATION", 198, 205]]], ["Given that an exosomal profile reflects the cell's content, exosomes provide a means for a \u201cliquid biopsy\u201d which is minimally invasive and highly enlightening.", [["exosomal", "ANATOMY", 14, 22], ["cell", "ANATOMY", 44, 48], ["exosomes", "ANATOMY", 60, 68], ["cell", "CELL", 44, 48], ["exosomes", "CELL", 60, 68], ["exosomes", "CELL_TYPE", 60, 68], ["an exosomal profile", "TEST", 11, 30], ["a \u201cliquid biopsy", "TREATMENT", 89, 105], ["minimally invasive", "PROBLEM", 116, 134], ["minimally", "OBSERVATION_MODIFIER", 116, 125], ["invasive", "OBSERVATION", 126, 134]]], ["Table 1summarizes the main exosome derived biomarkers associated with different disease conditions and from cell culture based studies.", [["exosome", "ANATOMY", 27, 34], ["cell", "ANATOMY", 108, 112], ["cell", "CELL", 108, 112], ["different disease conditions", "PROBLEM", 70, 98], ["cell culture based studies", "TEST", 108, 134]]], ["This emerging field is still relatively young considering the vast wealth of information that emerges regularly about new exosomal content.", [["exosomal", "ANATOMY", 122, 130]]], ["For example, it has been discovered fairly recently that exosomes contain DNA.", [["exosomes", "ANATOMY", 57, 65], ["exosomes", "CELL", 57, 65], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["exosomes", "CELL_TYPE", 57, 65], ["DNA", "PROBLEM", 74, 77], ["DNA", "OBSERVATION_MODIFIER", 74, 77]]], ["This is represented by mitochondrial DNA as well as retro-transposon and amplified DNA of oncogenes in tumor cell derived exosomes [10].Biomarkers ::: Applications of exosomesThe power of exosomes as biomarkers relies on the enrichment of markers within the exosome which otherwise constitute only a very small proportion of the secretome, e.g. exosomal proteins represent less than 0.01% of the total plasma proteome.", [["mitochondrial", "ANATOMY", 23, 36], ["tumor cell", "ANATOMY", 103, 113], ["exosomes", "ANATOMY", 122, 130], ["exosomes", "ANATOMY", 167, 175], ["exosomes", "ANATOMY", 188, 196], ["exosome", "ANATOMY", 258, 265], ["secretome", "ANATOMY", 329, 338], ["exosomal", "ANATOMY", 345, 353], ["plasma", "ANATOMY", 402, 408], ["tumor", "DISEASE", 103, 108], ["mitochondrial", "CELLULAR_COMPONENT", 23, 36], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["tumor cell", "CELL", 103, 113], ["exosomes", "CELL", 167, 175], ["exosomes", "CELL", 188, 196], ["exosome", "CELLULAR_COMPONENT", 258, 265], ["plasma", "ORGANISM_SUBSTANCE", 402, 408], ["mitochondrial DNA", "DNA", 23, 40], ["retro-transposon and amplified DNA", "DNA", 52, 86], ["oncogenes", "DNA", 90, 99], ["tumor cell derived exosomes", "CELL_TYPE", 103, 130], ["exosomes", "CELL_TYPE", 167, 175], ["exosomes", "CELL_TYPE", 188, 196], ["exosome", "PROTEIN", 258, 265], ["exosomal proteins", "PROTEIN", 345, 362], ["mitochondrial DNA", "PROBLEM", 23, 40], ["retro-transposon", "TREATMENT", 52, 68], ["Biomarkers", "TEST", 136, 146], ["exosomal proteins", "TEST", 345, 362], ["the total plasma proteome", "TEST", 392, 417], ["mitochondrial DNA", "OBSERVATION", 23, 40], ["tumor cell", "OBSERVATION", 103, 113], ["exosomes", "OBSERVATION", 167, 175], ["power", "OBSERVATION_MODIFIER", 179, 184], ["exosomes", "OBSERVATION", 188, 196], ["very", "OBSERVATION_MODIFIER", 300, 304], ["small", "OBSERVATION_MODIFIER", 305, 310], ["proportion", "OBSERVATION_MODIFIER", 311, 321], ["secretome", "OBSERVATION", 329, 338]]], ["Healthy human circulating exosomes contain about 66 proteins [54] with an enrichment of cell trafficking and protein sorting related proteins reflecting the endosomal origin of exosomes (Fig. 1).", [["exosomes", "ANATOMY", 26, 34], ["cell", "ANATOMY", 88, 92], ["endosomal", "ANATOMY", 157, 166], ["exosomes", "ANATOMY", 177, 185], ["human", "ORGANISM", 8, 13], ["exosomes", "CELL", 26, 34], ["cell", "CELL", 88, 92], ["endosomal", "CELLULAR_COMPONENT", 157, 166], ["exosomes", "CELL", 177, 185], ["human circulating exosomes", "CELL_TYPE", 8, 34], ["protein sorting related proteins", "PROTEIN", 109, 141], ["exosomes", "CELL_TYPE", 177, 185], ["human", "SPECIES", 8, 13], ["human", "SPECIES", 8, 13], ["an enrichment of cell trafficking", "PROBLEM", 71, 104], ["protein sorting related proteins", "PROBLEM", 109, 141], ["cell trafficking", "OBSERVATION", 88, 104], ["endosomal origin", "OBSERVATION", 157, 173]]], ["The very highly enriched protein entities in plasma and urine will normally dampen out the minor presence of relevant biomarkers.", [["plasma", "ANATOMY", 45, 51], ["urine", "ANATOMY", 56, 61], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["plasma and urine", "TEST", 45, 61], ["protein entities", "OBSERVATION", 25, 41]]], ["The exosome biomarker strategy therefore truly exemplifies \u201cless being more\u201d since the small number of proteins and RNA nevertheless give very insightful information into a disease or pathology.Biomarkers ::: Applications of exosomesAn enrichment at source, exemplified by cargo sorting into the exosome, helps the discovery of relatively lowly expressed biomarkers that normally would go undetected.", [["exosome", "ANATOMY", 4, 11], ["exosome", "ANATOMY", 296, 303], ["exosomesAn", "GENE_OR_GENE_PRODUCT", 225, 235], ["exosome", "CELLULAR_COMPONENT", 296, 303], ["exosomesAn", "PROTEIN", 225, 235], ["exosome", "PROTEIN", 296, 303], ["a disease or pathology", "PROBLEM", 171, 193], ["Biomarkers", "TEST", 194, 204], ["exosomesAn enrichment", "TREATMENT", 225, 246], ["small", "OBSERVATION_MODIFIER", 87, 92], ["disease", "OBSERVATION", 173, 180]]], ["Several studies have shown that purification of fluid level protein and RNA can also provide biomarkers (Table 1).", [["Several studies", "TEST", 0, 15], ["fluid level protein", "PROBLEM", 48, 67], ["biomarkers", "TEST", 93, 103], ["fluid", "OBSERVATION", 48, 53]]], ["The authors suggest a practical and case-by-case based scenario where the sensitivity provided by exosome isolation may be crucial for certain diagnostics; while the biomarker differential may be high enough in other disease conditions that the isolation of exosomes can be bypassed and fluid based biomarker analysis may be sufficient.Biomarkers ::: Applications of exosomesThe multitude of secretomes converging in body fluids, and the variety of cell types contributing to the secretome can confound a fluid-based analysis system.", [["exosome", "ANATOMY", 98, 105], ["exosomes", "ANATOMY", 258, 266], ["exosomes", "ANATOMY", 367, 375], ["body fluids", "ANATOMY", 417, 428], ["cell", "ANATOMY", 449, 453], ["exosomes", "CELL", 258, 266], ["exosomes", "CELL", 367, 375], ["body", "ORGANISM_SUBDIVISION", 417, 421], ["cell", "CELL", 449, 453], ["exosomes", "CELL_TYPE", 258, 266], ["exosomes", "CELL_TYPE", 367, 375], ["the sensitivity", "TEST", 70, 85], ["exosome isolation", "TREATMENT", 98, 115], ["certain diagnostics", "TEST", 135, 154], ["the biomarker differential", "TEST", 162, 188], ["other disease conditions", "PROBLEM", 211, 235], ["the isolation of exosomes", "PROBLEM", 241, 266], ["fluid based biomarker analysis", "TEST", 287, 317], ["Biomarkers", "TEST", 336, 346], ["body fluids", "TREATMENT", 417, 428], ["a fluid-based analysis system", "TEST", 503, 532], ["exosomes", "OBSERVATION", 367, 375], ["multitude", "OBSERVATION_MODIFIER", 379, 388], ["secretomes", "OBSERVATION", 392, 402], ["cell types", "OBSERVATION", 449, 459], ["fluid", "OBSERVATION", 505, 510]]], ["For example, plasma exosomes in normal individuals originate from a variety of cell sources including red blood cells, leukocyte lineages and platelets.", [["plasma exosomes", "ANATOMY", 13, 28], ["cell", "ANATOMY", 79, 83], ["red blood cells", "ANATOMY", 102, 117], ["leukocyte lineages", "ANATOMY", 119, 137], ["platelets", "ANATOMY", 142, 151], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["exosomes", "CELL", 20, 28], ["cell", "CELL", 79, 83], ["red blood cells", "CELL", 102, 117], ["leukocyte lineages", "CELL", 119, 137], ["platelets", "CELL", 142, 151], ["plasma exosomes", "CELL_TYPE", 13, 28], ["red blood cells", "CELL_TYPE", 102, 117], ["leukocyte lineages", "CELL_TYPE", 119, 137], ["platelets", "CELL_TYPE", 142, 151], ["plasma exosomes", "TEST", 13, 28], ["red blood cells", "TEST", 102, 117], ["leukocyte lineages", "TEST", 119, 137], ["platelets", "TEST", 142, 151], ["normal individuals", "OBSERVATION", 32, 50], ["variety", "OBSERVATION_MODIFIER", 68, 75], ["cell sources", "OBSERVATION", 79, 91], ["blood cells", "OBSERVATION", 106, 117], ["leukocyte lineages", "OBSERVATION", 119, 137]]], ["Tissues that directly or indirectly contact the blood stream such as endothelial cells and large fenestrated organs like the placenta and liver also allow passage of exosome vesicles into the body fluids.", [["Tissues", "ANATOMY", 0, 7], ["blood stream", "ANATOMY", 48, 60], ["endothelial cells", "ANATOMY", 69, 86], ["organs", "ANATOMY", 109, 115], ["placenta", "ANATOMY", 125, 133], ["liver", "ANATOMY", 138, 143], ["exosome vesicles", "ANATOMY", 166, 182], ["body fluids", "ANATOMY", 192, 203], ["Tissues", "CANCER", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["endothelial cells", "CELL", 69, 86], ["organs", "ORGAN", 109, 115], ["placenta", "MULTI-TISSUE_STRUCTURE", 125, 133], ["liver", "ORGAN", 138, 143], ["exosome vesicles", "CELLULAR_COMPONENT", 166, 182], ["body fluids", "ORGANISM_SUBSTANCE", 192, 203], ["endothelial cells", "CELL_TYPE", 69, 86], ["the blood stream", "TEST", 44, 60], ["endothelial cells", "PROBLEM", 69, 86], ["large fenestrated organs like the placenta and liver", "PROBLEM", 91, 143], ["the body fluids", "TREATMENT", 188, 203], ["endothelial cells", "OBSERVATION", 69, 86], ["large", "OBSERVATION_MODIFIER", 91, 96], ["fenestrated", "OBSERVATION", 97, 108], ["placenta", "OBSERVATION", 125, 133], ["liver", "ANATOMY", 138, 143], ["exosome vesicles", "OBSERVATION", 166, 182], ["body", "ANATOMY", 192, 196]]], ["In cases where the biomarker change can be indicative of more than one condition, exosomes would be the method of choice to trace the cell lineage producing the change.Biomarkers ::: Applications of exosomesAnother advantage of using exosomes as biomarkers is the ability to immuno-isolate exosomes from particular tissue types.", [["exosomes", "ANATOMY", 82, 90], ["cell", "ANATOMY", 134, 138], ["exosomes", "ANATOMY", 199, 207], ["exosomes", "ANATOMY", 234, 242], ["exosomes", "ANATOMY", 290, 298], ["tissue", "ANATOMY", 315, 321], ["exosomes", "CELL", 82, 90], ["cell lineage", "CELL", 134, 146], ["exosomes", "CELL", 199, 207], ["exosomes", "CELL", 234, 242], ["exosomes", "CELL", 290, 298], ["tissue", "TISSUE", 315, 321], ["exosomes", "CELL_TYPE", 82, 90], ["the biomarker change", "PROBLEM", 15, 35], ["Biomarkers", "TEST", 168, 178], ["exosomes", "TREATMENT", 199, 207], ["cell lineage", "OBSERVATION", 134, 146], ["particular tissue", "OBSERVATION_MODIFIER", 304, 321]]], ["The exosomal membrane reflects a cell's plasma membrane and can therefore be immuno-isolated utilizing a significantly enriched protein on the membrane surface.", [["exosomal membrane", "ANATOMY", 4, 21], ["cell", "ANATOMY", 33, 37], ["plasma membrane", "ANATOMY", 40, 55], ["membrane surface", "ANATOMY", 143, 159], ["exosomal membrane", "CELLULAR_COMPONENT", 4, 21], ["cell", "CELL", 33, 37], ["plasma membrane", "CELLULAR_COMPONENT", 40, 55], ["membrane surface", "CELLULAR_COMPONENT", 143, 159], ["a cell's plasma membrane", "PROBLEM", 31, 55], ["exosomal membrane", "OBSERVATION", 4, 21], ["cell", "OBSERVATION", 33, 37]]], ["For example, plasma exosomes of hepatic origin can be enriched using an antibody specific to the relatively liver-specific enzyme carbamoyl phosphate synthetase 1.", [["plasma exosomes", "ANATOMY", 13, 28], ["hepatic", "ANATOMY", 32, 39], ["liver", "ANATOMY", 108, 113], ["carbamoyl phosphate", "CHEMICAL", 130, 149], ["carbamoyl phosphate", "CHEMICAL", 130, 149], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["exosomes", "CELL", 20, 28], ["hepatic", "ORGAN", 32, 39], ["liver", "ORGAN", 108, 113], ["carbamoyl phosphate synthetase 1", "GENE_OR_GENE_PRODUCT", 130, 162], ["plasma exosomes", "CELL_TYPE", 13, 28], ["liver-specific enzyme", "PROTEIN", 108, 129], ["carbamoyl phosphate synthetase 1", "PROTEIN", 130, 162], ["an antibody", "TEST", 69, 80], ["specific enzyme carbamoyl phosphate synthetase", "TREATMENT", 114, 160], ["hepatic", "ANATOMY", 32, 39], ["origin", "ANATOMY_MODIFIER", 40, 46], ["liver", "ANATOMY", 108, 113]]], ["In cell culture, A33 affinity-isolation of colorectal cancer cell line exosomes [55], and CD45 isolation of Jurkat T-cell line exosomes [56] has yielded very specific cell based signatures and holds the promise of being applied similarly to plasma exosome isolation.", [["cell culture", "ANATOMY", 3, 15], ["colorectal cancer cell line exosomes", "ANATOMY", 43, 79], ["Jurkat T-cell line exosomes", "ANATOMY", 108, 135], ["cell", "ANATOMY", 167, 171], ["plasma exosome", "ANATOMY", 241, 255], ["colorectal cancer", "DISEASE", 43, 60], ["cell", "CELL", 3, 7], ["A33", "SIMPLE_CHEMICAL", 17, 20], ["colorectal cancer cell line exosomes [55", "CELL", 43, 83], ["CD45", "GENE_OR_GENE_PRODUCT", 90, 94], ["Jurkat T-cell line exosomes", "CELL", 108, 135], ["cell", "CELL", 167, 171], ["plasma", "ORGANISM_SUBSTANCE", 241, 247], ["colorectal cancer cell line exosomes", "CELL_LINE", 43, 79], ["CD45", "PROTEIN", 90, 94], ["Jurkat T-cell line exosomes", "CELL_LINE", 108, 135], ["cell culture", "TEST", 3, 15], ["A33 affinity", "TEST", 17, 29], ["colorectal cancer", "PROBLEM", 43, 60], ["cell line exosomes", "TEST", 61, 79], ["Jurkat", "TEST", 108, 114], ["plasma exosome isolation", "TREATMENT", 241, 265], ["colorectal", "ANATOMY", 43, 53], ["cancer cell line", "OBSERVATION", 54, 70], ["Jurkat", "ANATOMY", 108, 114], ["exosome isolation", "OBSERVATION", 248, 265]]], ["In a study that compared ovarian carcinoma cell line derived exosomes vs. exosomes from malignant ascites and sera from ovarian carcinoma patients, tumor progression-related proteins like L1CAM (L1 cell adhesion molecule), CD24, and EMMPRIN (extracellular matrix metalloproteinase inducer) were found enriched on exosomes.", [["ovarian carcinoma cell line", "ANATOMY", 25, 52], ["exosomes", "ANATOMY", 61, 69], ["exosomes", "ANATOMY", 74, 82], ["malignant ascites", "ANATOMY", 88, 105], ["sera", "ANATOMY", 110, 114], ["ovarian carcinoma", "ANATOMY", 120, 137], ["tumor", "ANATOMY", 148, 153], ["exosomes", "ANATOMY", 313, 321], ["ovarian carcinoma", "DISEASE", 25, 42], ["malignant ascites", "DISEASE", 88, 105], ["ovarian carcinoma", "DISEASE", 120, 137], ["tumor", "DISEASE", 148, 153], ["ovarian carcinoma cell line derived exosomes", "CELL", 25, 69], ["exosomes", "CELL", 74, 82], ["malignant ascites", "CANCER", 88, 105], ["sera", "ORGANISM_SUBSTANCE", 110, 114], ["ovarian carcinoma", "CANCER", 120, 137], ["patients", "ORGANISM", 138, 146], ["tumor", "CANCER", 148, 153], ["L1CAM", "GENE_OR_GENE_PRODUCT", 188, 193], ["L1 cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 195, 220], ["CD24", "GENE_OR_GENE_PRODUCT", 223, 227], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 233, 240], ["extracellular matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 242, 280], ["exosomes", "CELL", 313, 321], ["ovarian carcinoma cell line", "CELL_LINE", 25, 52], ["exosomes", "CELL_TYPE", 61, 69], ["exosomes", "CELL_TYPE", 74, 82], ["L1CAM", "PROTEIN", 188, 193], ["L1 cell adhesion molecule", "PROTEIN", 195, 220], ["CD24", "PROTEIN", 223, 227], ["EMMPRIN", "PROTEIN", 233, 240], ["extracellular matrix metalloproteinase inducer", "PROTEIN", 242, 288], ["exosomes", "CELL_TYPE", 313, 321], ["patients", "SPECIES", 138, 146], ["a study", "TEST", 3, 10], ["ovarian carcinoma", "PROBLEM", 25, 42], ["malignant ascites", "PROBLEM", 88, 105], ["sera", "PROBLEM", 110, 114], ["ovarian carcinoma", "PROBLEM", 120, 137], ["tumor progression", "PROBLEM", 148, 165], ["proteins like L1CAM", "PROBLEM", 174, 193], ["L1 cell adhesion molecule", "TREATMENT", 195, 220], ["CD24", "TEST", 223, 227], ["EMMPRIN (extracellular matrix metalloproteinase inducer", "TREATMENT", 233, 288], ["ovarian", "ANATOMY", 25, 32], ["carcinoma", "OBSERVATION", 33, 42], ["cell line", "OBSERVATION", 43, 52], ["malignant", "OBSERVATION_MODIFIER", 88, 97], ["ascites", "OBSERVATION", 98, 105], ["ovarian", "ANATOMY", 120, 127], ["carcinoma", "OBSERVATION", 128, 137], ["tumor", "OBSERVATION", 148, 153], ["L1 cell", "ANATOMY", 195, 202]]], ["This study also indicated that the exosomes become systemic via the blood stream [57].Biomarkers ::: Applications of exosomesUrinary exosome profiling studies have probably been established in greatest detail owing to easy accessibility of urine samples.", [["exosomes", "ANATOMY", 35, 43], ["blood", "ANATOMY", 68, 73], ["urine samples", "ANATOMY", 240, 253], ["exosomes", "CELL", 35, 43], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["urine samples", "ORGANISM_SUBSTANCE", 240, 253], ["exosomes", "CELL_TYPE", 35, 43], ["This study", "TEST", 0, 10], ["the blood stream", "TEST", 64, 80], ["Biomarkers", "TEST", 86, 96], ["exosomesUrinary exosome profiling studies", "TEST", 117, 158], ["urine samples", "TEST", 240, 253], ["systemic", "OBSERVATION", 51, 59]]], ["Seminal work by the Knepper and Star Labs established conditions for collecting and storing samples, and optimization of design for mass spectrometry or gel chromatography based techniques for urinary exosome analysis [58], [59].", [["samples", "ANATOMY", 92, 99], ["urinary", "ANATOMY", 193, 200], ["Seminal", "ORGANISM_SUBSTANCE", 0, 7], ["urinary", "ORGANISM_SUBSTANCE", 193, 200], ["Star Labs", "TEST", 32, 41], ["collecting and storing samples", "TEST", 69, 99], ["mass spectrometry", "PROBLEM", 132, 149], ["gel chromatography", "TEST", 153, 171], ["urinary exosome analysis", "TEST", 193, 217]]], ["It has been established that urinary exosomes contain the majority of renal proteins that indicate renal cell injury including, but not limited to, aquaporins, polycystins and podocyn [60].", [["urinary exosomes", "ANATOMY", 29, 45], ["renal", "ANATOMY", 70, 75], ["renal cell", "ANATOMY", 99, 109], ["renal cell injury", "DISEASE", 99, 116], ["urinary exosomes", "ORGANISM_SUBSTANCE", 29, 45], ["renal", "ORGAN", 70, 75], ["renal cell", "CELL", 99, 109], ["aquaporins", "GENE_OR_GENE_PRODUCT", 148, 158], ["polycystins", "GENE_OR_GENE_PRODUCT", 160, 171], ["urinary exosomes", "CELL_TYPE", 29, 45], ["renal proteins", "PROTEIN", 70, 84], ["aquaporins", "PROTEIN", 148, 158], ["polycystins", "PROTEIN", 160, 171], ["urinary exosomes", "PROBLEM", 29, 45], ["renal proteins", "PROBLEM", 70, 84], ["renal cell injury", "PROBLEM", 99, 116], ["polycystins", "TREATMENT", 160, 171], ["podocyn", "TREATMENT", 176, 183], ["urinary", "ANATOMY", 29, 36], ["exosomes", "OBSERVATION", 37, 45], ["renal", "ANATOMY", 70, 75], ["proteins", "OBSERVATION", 76, 84], ["renal", "ANATOMY", 99, 104], ["cell injury", "OBSERVATION", 105, 116]]], ["Successful studies have been performed for various disease conditions where a cellular contact with urine or glomerular filtrate would be possible, e.g. acute kidney injury (AKI) models (cisplatin or ischemia-reperfusion), prostate cancer, bladder cancer, etc.Biomarkers ::: Applications of exosomesBladder cancer cell line derived exosomes contain about 350 proteins and 18 of these were also found in the urine derived exosomes from a small number of bladder cancer patients [61].", [["cellular", "ANATOMY", 78, 86], ["urine", "ANATOMY", 100, 105], ["glomerular filtrate", "ANATOMY", 109, 128], ["kidney", "ANATOMY", 159, 165], ["prostate cancer", "ANATOMY", 223, 238], ["bladder cancer", "ANATOMY", 240, 254], ["exosomesBladder cancer cell line", "ANATOMY", 291, 323], ["exosomes", "ANATOMY", 332, 340], ["urine", "ANATOMY", 407, 412], ["exosomes", "ANATOMY", 421, 429], ["bladder cancer", "ANATOMY", 453, 467], ["acute kidney injury", "DISEASE", 153, 172], ["AKI", "DISEASE", 174, 177], ["cisplatin", "CHEMICAL", 187, 196], ["ischemia", "DISEASE", 200, 208], ["prostate cancer", "DISEASE", 223, 238], ["bladder cancer", "DISEASE", 240, 254], ["Bladder cancer", "DISEASE", 299, 313], ["bladder cancer", "DISEASE", 453, 467], ["cisplatin", "CHEMICAL", 187, 196], ["cellular", "CELL", 78, 86], ["urine", "ORGANISM_SUBSTANCE", 100, 105], ["glomerular", "TISSUE", 109, 119], ["kidney", "ORGAN", 159, 165], ["cisplatin", "SIMPLE_CHEMICAL", 187, 196], ["prostate cancer", "CANCER", 223, 238], ["bladder cancer", "CANCER", 240, 254], ["exosomes", "CELL", 291, 299], ["Bladder cancer cell line derived exosomes", "CELL", 299, 340], ["urine", "ORGANISM_SUBSTANCE", 407, 412], ["exosomes", "CELL", 421, 429], ["bladder cancer", "CANCER", 453, 467], ["patients", "ORGANISM", 468, 476], ["exosomes", "CELL_TYPE", 291, 299], ["Bladder cancer cell line", "CELL_LINE", 299, 323], ["exosomes", "CELL_TYPE", 332, 340], ["urine derived exosomes", "CELL_TYPE", 407, 429], ["patients", "SPECIES", 468, 476], ["Successful studies", "TEST", 0, 18], ["various disease conditions", "PROBLEM", 43, 69], ["glomerular filtrate", "PROBLEM", 109, 128], ["acute kidney injury", "PROBLEM", 153, 172], ["AKI) models", "PROBLEM", 174, 185], ["cisplatin", "TREATMENT", 187, 196], ["ischemia", "PROBLEM", 200, 208], ["reperfusion", "TREATMENT", 209, 220], ["prostate cancer", "PROBLEM", 223, 238], ["bladder cancer", "PROBLEM", 240, 254], ["Biomarkers", "TEST", 260, 270], ["exosomesBladder cancer cell line", "TREATMENT", 291, 323], ["the urine", "TEST", 403, 412], ["bladder cancer", "PROBLEM", 453, 467], ["glomerular", "ANATOMY", 109, 119], ["filtrate", "OBSERVATION", 120, 128], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["kidney", "ANATOMY", 159, 165], ["injury", "OBSERVATION", 166, 172], ["reperfusion", "OBSERVATION_MODIFIER", 209, 220], ["prostate", "ANATOMY", 223, 231], ["cancer", "OBSERVATION", 232, 238], ["bladder", "ANATOMY", 240, 247], ["cancer", "OBSERVATION", 248, 254], ["Bladder", "ANATOMY", 299, 306], ["cancer cell line", "OBSERVATION", 307, 323], ["urine", "OBSERVATION", 407, 412], ["small", "OBSERVATION_MODIFIER", 437, 442], ["number", "OBSERVATION_MODIFIER", 443, 449], ["bladder", "ANATOMY", 453, 460], ["cancer", "OBSERVATION", 461, 467]]], ["Urine micro particles from bladder cancer patients revealed that eight proteins were elevated relative to controls, and many of these proteins were linked to the epidermal growth factor receptor (EGFR) signaling pathway [62].", [["Urine micro particles", "ANATOMY", 0, 21], ["bladder cancer", "ANATOMY", 27, 41], ["bladder cancer", "DISEASE", 27, 41], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["bladder cancer", "CANCER", 27, 41], ["patients", "ORGANISM", 42, 50], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 162, 194], ["EGFR", "GENE_OR_GENE_PRODUCT", 196, 200], ["epidermal growth factor receptor", "PROTEIN", 162, 194], ["EGFR", "PROTEIN", 196, 200], ["patients", "SPECIES", 42, 50], ["Urine micro particles", "TEST", 0, 21], ["bladder cancer", "PROBLEM", 27, 41], ["eight proteins", "PROBLEM", 65, 79], ["elevated", "PROBLEM", 85, 93], ["these proteins", "PROBLEM", 128, 142], ["signaling pathway", "TEST", 202, 219], ["micro particles", "OBSERVATION_MODIFIER", 6, 21], ["bladder", "ANATOMY", 27, 34], ["cancer", "OBSERVATION", 35, 41]]], ["Such examples suggest that the exosomal biomarker discovery approach can be \u2018topside up\u2019 or \u2018topside down\u2019.", [["exosomal", "ANATOMY", 31, 39]]], ["An initial screen in conditioned media from cultured cell lines can be used to build a predictive model for pathways over or under represented in exosomes.", [["cell lines", "ANATOMY", 53, 63], ["exosomes", "ANATOMY", 146, 154], ["cell lines", "CELL", 53, 63], ["exosomes", "CELL", 146, 154], ["cultured cell lines", "CELL_LINE", 44, 63], ["exosomes", "CELL_TYPE", 146, 154], ["An initial screen", "TEST", 0, 17], ["conditioned media", "TREATMENT", 21, 38], ["cultured cell lines", "TREATMENT", 44, 63], ["cell lines", "OBSERVATION", 53, 63]]], ["These models can then be translated to in vivo models and biological fluid sampling from a large patient cohort.Biomarkers ::: Applications of exosomesProstasomes are exosomes released from the prostate epithelium into semen or urine.", [["exosomes", "ANATOMY", 143, 151], ["exosomes", "ANATOMY", 167, 175], ["prostate epithelium", "ANATOMY", 194, 213], ["semen", "ANATOMY", 219, 224], ["urine", "ANATOMY", 228, 233], ["patient", "ORGANISM", 97, 104], ["exosomes", "CELL", 143, 151], ["Prostasomes", "GENE_OR_GENE_PRODUCT", 151, 162], ["exosomes", "CELL", 167, 175], ["prostate epithelium", "TISSUE", 194, 213], ["semen", "ORGANISM_SUBSTANCE", 219, 224], ["urine", "ORGANISM_SUBSTANCE", 228, 233], ["exosomes", "CELL_TYPE", 143, 151], ["exosomes", "CELL_TYPE", 167, 175], ["patient", "SPECIES", 97, 104], ["biological fluid sampling", "TEST", 58, 83], ["a large patient cohort", "TREATMENT", 89, 111], ["Biomarkers", "TEST", 112, 122], ["exosomesProstasomes", "TREATMENT", 143, 162], ["fluid", "OBSERVATION", 69, 74], ["large", "OBSERVATION_MODIFIER", 91, 96], ["exosomesProstasomes", "OBSERVATION", 143, 162], ["prostate", "ANATOMY", 194, 202], ["epithelium", "ANATOMY_MODIFIER", 203, 213]]], ["Analysis of urine exosome content revealed that prostate cancer patients have tumor signatures, e.g. PSA (prostate specific antigen) and PCA3 (Prostate CAncer gene 3) [63], [64].", [["urine exosome", "ANATOMY", 12, 25], ["prostate cancer", "ANATOMY", 48, 63], ["tumor", "ANATOMY", 78, 83], ["prostate", "ANATOMY", 106, 114], ["prostate cancer", "DISEASE", 48, 63], ["tumor", "DISEASE", 78, 83], ["urine", "ORGANISM_SUBSTANCE", 12, 17], ["exosome", "ORGANISM_SUBSTANCE", 18, 25], ["prostate cancer", "CANCER", 48, 63], ["patients", "ORGANISM", 64, 72], ["tumor", "CANCER", 78, 83], ["PSA", "GENE_OR_GENE_PRODUCT", 101, 104], ["prostate specific antigen", "GENE_OR_GENE_PRODUCT", 106, 131], ["PCA3", "GENE_OR_GENE_PRODUCT", 137, 141], ["Prostate CAncer gene 3", "GENE_OR_GENE_PRODUCT", 143, 165], ["urine exosome", "PROTEIN", 12, 25], ["PSA", "PROTEIN", 101, 104], ["prostate specific antigen", "PROTEIN", 106, 131], ["PCA3", "PROTEIN", 137, 141], ["patients", "SPECIES", 64, 72], ["Analysis of urine exosome content", "TEST", 0, 33], ["prostate cancer", "PROBLEM", 48, 63], ["tumor signatures", "PROBLEM", 78, 94], ["PSA", "TEST", 101, 104], ["prostate specific antigen", "TEST", 106, 131], ["PCA3 (Prostate CAncer gene", "PROBLEM", 137, 163], ["prostate", "ANATOMY", 48, 56], ["cancer", "OBSERVATION", 57, 63], ["tumor", "OBSERVATION", 78, 83], ["prostate", "ANATOMY", 106, 114], ["Prostate", "ANATOMY", 143, 151], ["CAncer", "OBSERVATION", 152, 158]]], ["PC-3 cell culture media derived exosomes and urine prostasomes both exhibit enhanced \u03b4-catenin [65].", [["PC-3 cell", "ANATOMY", 0, 9], ["exosomes", "ANATOMY", 32, 40], ["urine prostasomes", "ANATOMY", 45, 62], ["PC-3 cell", "CELL", 0, 9], ["exosomes", "CELL", 32, 40], ["urine", "ORGANISM_SUBSTANCE", 45, 50], ["exosomes", "CELL_TYPE", 32, 40], ["PC", "TEST", 0, 2], ["cell culture media", "TEST", 5, 23], ["urine prostasomes", "TEST", 45, 62]]], ["Rotavirus related gastroentitis patients display exosome associated RV antigen in stool samples [66].Biomarkers ::: Applications of exosomesIn animal models of kidney injury, exosomal Fetuin-A was identified as a marker reflecting nephrotoxic damage with a 50-fold increase over healthy animals within hours of injury and prior to the detection of the standard biomarker urine creatinine.", [["exosome", "ANATOMY", 49, 56], ["stool samples", "ANATOMY", 82, 95], ["exosomes", "ANATOMY", 132, 140], ["kidney", "ANATOMY", 160, 166], ["exosomal", "ANATOMY", 175, 183], ["urine", "ANATOMY", 371, 376], ["Rotavirus", "DISEASE", 0, 9], ["gastroentitis", "DISEASE", 18, 31], ["kidney injury", "DISEASE", 160, 173], ["Fetuin-A", "CHEMICAL", 184, 192], ["nephrotoxic", "DISEASE", 231, 242], ["creatinine", "CHEMICAL", 377, 387], ["creatinine", "CHEMICAL", 377, 387], ["Rotavirus", "ORGANISM", 0, 9], ["patients", "ORGANISM", 32, 40], ["RV antigen", "GENE_OR_GENE_PRODUCT", 68, 78], ["stool", "ORGANISM_SUBSTANCE", 82, 87], ["exosomes", "CELL", 132, 140], ["kidney", "ORGAN", 160, 166], ["Fetuin-A", "GENE_OR_GENE_PRODUCT", 184, 192], ["urine", "ORGANISM_SUBSTANCE", 371, 376], ["creatinine", "SIMPLE_CHEMICAL", 377, 387], ["exosome associated RV antigen", "PROTEIN", 49, 78], ["exosomes", "CELL_TYPE", 132, 140], ["patients", "SPECIES", 32, 40], ["Rotavirus related gastroentitis", "PROBLEM", 0, 31], ["exosome associated RV antigen", "PROBLEM", 49, 78], ["stool samples", "TEST", 82, 95], ["Biomarkers", "TEST", 101, 111], ["kidney injury", "PROBLEM", 160, 173], ["a marker", "TEST", 211, 219], ["nephrotoxic damage", "PROBLEM", 231, 249], ["injury", "PROBLEM", 311, 317], ["the detection", "TEST", 331, 344], ["the standard biomarker urine creatinine", "TEST", 348, 387], ["RV", "ANATOMY", 68, 70], ["exosomes", "OBSERVATION", 132, 140], ["kidney", "ANATOMY", 160, 166], ["injury", "OBSERVATION", 167, 173], ["nephrotoxic", "OBSERVATION_MODIFIER", 231, 242], ["damage", "OBSERVATION", 243, 249], ["50-fold", "OBSERVATION_MODIFIER", 257, 264], ["increase", "OBSERVATION_MODIFIER", 265, 273], ["injury", "OBSERVATION", 311, 317]]], ["In renal ischemia-reperfusion (I/R), decreased exosomal aquaporin-1 (AQP1) in rats correlated with decreased AQP1 levels in a person undergoing renal transplant [67].Biomarkers ::: Applications of exosomesIn a pilot study on Bartter syndrome type I patients, the sodium\u2013potassium\u2013chloride co-transporter, NKCC2 was absent in urinary exosomes.", [["renal", "ANATOMY", 3, 8], ["exosomal", "ANATOMY", 47, 55], ["renal", "ANATOMY", 144, 149], ["exosomes", "ANATOMY", 197, 205], ["urinary exosomes", "ANATOMY", 325, 341], ["renal ischemia-reperfusion", "DISEASE", 3, 29], ["Bartter syndrome type I", "DISEASE", 225, 248], ["sodium\u2013potassium\u2013chloride", "CHEMICAL", 263, 288], ["sodium\u2013potassium\u2013chloride", "CHEMICAL", 263, 288], ["renal", "ORGAN", 3, 8], ["aquaporin-1", "GENE_OR_GENE_PRODUCT", 56, 67], ["AQP1", "GENE_OR_GENE_PRODUCT", 69, 73], ["rats", "ORGANISM", 78, 82], ["AQP1", "GENE_OR_GENE_PRODUCT", 109, 113], ["renal", "ORGAN", 144, 149], ["exosomes", "CELL", 197, 205], ["patients", "ORGANISM", 249, 257], ["sodium\u2013potassium\u2013chloride co-transporter", "GENE_OR_GENE_PRODUCT", 263, 303], ["NKCC2", "GENE_OR_GENE_PRODUCT", 305, 310], ["urinary exosomes", "ORGANISM_SUBSTANCE", 325, 341], ["exosomal aquaporin-1", "PROTEIN", 47, 67], ["AQP1", "PROTEIN", 69, 73], ["AQP1", "PROTEIN", 109, 113], ["exosomes", "CELL_TYPE", 197, 205], ["sodium\u2013potassium\u2013chloride co-transporter", "PROTEIN", 263, 303], ["NKCC2", "PROTEIN", 305, 310], ["urinary exosomes", "CELL_TYPE", 325, 341], ["rats", "SPECIES", 78, 82], ["person", "SPECIES", 126, 132], ["patients", "SPECIES", 249, 257], ["renal ischemia-reperfusion", "PROBLEM", 3, 29], ["decreased exosomal aquaporin", "PROBLEM", 37, 65], ["decreased AQP1 levels", "PROBLEM", 99, 120], ["renal transplant", "TREATMENT", 144, 160], ["Biomarkers", "TEST", 166, 176], ["a pilot study", "TEST", 208, 221], ["Bartter syndrome", "PROBLEM", 225, 241], ["the sodium\u2013potassium\u2013chloride co-transporter", "TREATMENT", 259, 303], ["NKCC2", "TEST", 305, 310], ["renal", "ANATOMY", 3, 8], ["ischemia-reperfusion", "OBSERVATION", 9, 29], ["renal", "ANATOMY", 144, 149], ["transplant", "OBSERVATION", 150, 160], ["exosomes", "OBSERVATION", 197, 205], ["urinary exosomes", "ANATOMY", 325, 341]]], ["Additionally, it has been shown by Zhou et al. that transcription factors that are undetectable in whole urine could be detected in urine derived exosomes, e.g. urinary ATF3 (cyclic AMP-dependent transcription factor) might be a novel AKI renal tubular cell injury biomarker; while WT-1 (Wilms tumor protein) might be a critical biomarker for chronic kidney disease (CKD) associated with podocyte injury [68].", [["urine", "ANATOMY", 105, 110], ["urine", "ANATOMY", 132, 137], ["exosomes", "ANATOMY", 146, 154], ["urinary", "ANATOMY", 161, 168], ["renal tubular cell", "ANATOMY", 239, 257], ["kidney", "ANATOMY", 351, 357], ["podocyte", "ANATOMY", 388, 396], ["AMP", "CHEMICAL", 182, 185], ["AKI", "DISEASE", 235, 238], ["Wilms tumor", "DISEASE", 288, 299], ["chronic kidney disease", "DISEASE", 343, 365], ["CKD", "DISEASE", 367, 370], ["AMP", "CHEMICAL", 182, 185], ["urine", "ORGANISM_SUBSTANCE", 105, 110], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["exosomes", "CELL", 146, 154], ["urinary", "ORGANISM_SUBSTANCE", 161, 168], ["ATF3", "GENE_OR_GENE_PRODUCT", 169, 173], ["cyclic AMP-dependent transcription factor", "GENE_OR_GENE_PRODUCT", 175, 216], ["renal tubular cell", "CELL", 239, 257], ["WT-1", "GENE_OR_GENE_PRODUCT", 282, 286], ["Wilms tumor protein", "GENE_OR_GENE_PRODUCT", 288, 307], ["kidney", "ORGAN", 351, 357], ["podocyte", "CELL", 388, 396], ["transcription factors", "PROTEIN", 52, 73], ["urine derived exosomes", "CELL_TYPE", 132, 154], ["urinary ATF3", "PROTEIN", 161, 173], ["cyclic AMP-dependent transcription factor", "PROTEIN", 175, 216], ["WT-1", "PROTEIN", 282, 286], ["Wilms tumor protein", "PROTEIN", 288, 307], ["transcription factors", "PROBLEM", 52, 73], ["whole urine", "TEST", 99, 110], ["urine derived exosomes", "TEST", 132, 154], ["urinary ATF3", "PROBLEM", 161, 173], ["cyclic AMP-dependent transcription factor", "TREATMENT", 175, 216], ["a novel AKI renal tubular cell injury biomarker", "PROBLEM", 227, 274], ["WT", "TEST", 282, 284], ["Wilms tumor protein", "TEST", 288, 307], ["chronic kidney disease", "PROBLEM", 343, 365], ["CKD", "PROBLEM", 367, 370], ["podocyte injury", "PROBLEM", 388, 403], ["urinary ATF3", "ANATOMY", 161, 173], ["renal", "ANATOMY", 239, 244], ["tubular cell injury", "OBSERVATION", 245, 264], ["kidney", "ANATOMY", 351, 357], ["disease", "OBSERVATION", 358, 365], ["CKD", "OBSERVATION", 367, 370], ["podocyte", "ANATOMY", 388, 396], ["injury", "OBSERVATION", 397, 403]]], ["It is noteworthy that currently the biomarker perspective for CKD is a clearly unmet need with no consensus on predictive or prognostic biomarkers, particularly in the context of early detection and sensitivity.Biomarkers ::: Applications of exosomesThis discussion reflects the strength of exosomes as fluid-based, minimally invasive biomarkers but also identifies the need for larger cohort studies with well established protocols for a clinical study.", [["exosomes", "ANATOMY", 242, 250], ["exosomes", "ANATOMY", 291, 299], ["fluid", "ANATOMY", 303, 308], ["CKD", "DISEASE", 62, 65], ["exosomes", "CELL", 242, 250], ["exosomes", "CELL", 291, 299], ["exosomes", "CELL_TYPE", 242, 250], ["CKD", "PROBLEM", 62, 65], ["prognostic biomarkers", "TEST", 125, 146], ["Biomarkers", "TEST", 211, 221], ["minimally invasive biomarkers", "PROBLEM", 316, 345], ["larger cohort studies", "TEST", 379, 400], ["a clinical study", "TEST", 437, 453], ["exosomes", "OBSERVATION", 242, 250]]], ["Such studies must have built in positive and negative controls to validate the study design at various steps of sample collection, timing, storage and processing as well as the protocols for protein biomarker identification based on Western blot analysis, ELISA (enzyme linked immunosorbent assay) or FACS (fluorescence activated cell sorting) analysis.Biomarkers ::: Applications of exosomesIn the context of RNA-based biomarkers, there have been only a few studies to date.", [["sample", "ANATOMY", 112, 118], ["cell", "ANATOMY", 330, 334], ["exosomes", "ANATOMY", 384, 392], ["cell", "CELL", 330, 334], ["exosomes", "CELL", 384, 392], ["exosomes", "CELL_TYPE", 384, 392], ["Such studies", "TEST", 0, 12], ["the study", "TEST", 75, 84], ["sample collection", "TEST", 112, 129], ["protein biomarker identification", "TEST", 191, 223], ["Western blot analysis", "TEST", 233, 254], ["ELISA", "TEST", 256, 261], ["enzyme linked immunosorbent assay", "TEST", 263, 296], ["FACS", "TEST", 301, 305], ["Biomarkers", "TEST", 353, 363], ["RNA-based biomarkers", "TEST", 410, 430], ["exosomes", "OBSERVATION", 384, 392]]], ["RNA composition of the human urinary exosomes represents all regions of the nephron and the collecting duct as determined by RT-PCR [69].", [["urinary exosomes", "ANATOMY", 29, 45], ["nephron", "ANATOMY", 76, 83], ["collecting duct", "ANATOMY", 92, 107], ["human", "ORGANISM", 23, 28], ["urinary exosomes", "CELL", 29, 45], ["nephron", "MULTI-TISSUE_STRUCTURE", 76, 83], ["collecting duct", "MULTI-TISSUE_STRUCTURE", 92, 107], ["human urinary exosomes", "CELL_TYPE", 23, 45], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["RNA composition of the human urinary exosomes", "PROBLEM", 0, 45], ["RT-PCR", "TEST", 125, 131], ["human", "ANATOMY_MODIFIER", 23, 28], ["urinary", "ANATOMY", 29, 36], ["exosomes", "OBSERVATION", 37, 45], ["nephron", "ANATOMY", 76, 83], ["collecting duct", "ANATOMY", 92, 107]]], ["In a significant study on the specificity of exosomal RNA as a biomarker, urinary exosomes of the V-ATPase B1 subunit, knockout mice were found to faithfully reflect the loss of this specific subunit mRNA while normal amounts of the other V-ATPase B2 subunit and aquaporin 2 were detected [69].", [["urinary exosomes", "ANATOMY", 74, 90], ["V-ATPase B1", "GENE_OR_GENE_PRODUCT", 98, 109], ["mice", "ORGANISM", 128, 132], ["V-ATPase B2 subunit", "GENE_OR_GENE_PRODUCT", 239, 258], ["aquaporin 2", "GENE_OR_GENE_PRODUCT", 263, 274], ["exosomal RNA", "RNA", 45, 57], ["V-ATPase B1 subunit", "PROTEIN", 98, 117], ["subunit mRNA", "RNA", 192, 204], ["V-ATPase B2 subunit", "PROTEIN", 239, 258], ["aquaporin 2", "PROTEIN", 263, 274], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 128, 132], ["a biomarker", "TEST", 61, 72], ["knockout mice", "PROBLEM", 119, 132], ["ATPase B2 subunit", "TREATMENT", 241, 258], ["significant", "OBSERVATION_MODIFIER", 5, 16]]], ["Preliminary studies have shown that salivary exosome protein and miRNA content can be potentially useful to detect disease conditions such as Sjorgen's syndrome [70].Biomarkers ::: Applications of exosomesIncreased breast tumor miR-195 levels were reflected in systemic circulation exosomes [71].", [["exosomes", "ANATOMY", 197, 205], ["breast tumor", "ANATOMY", 215, 227], ["exosomes", "ANATOMY", 282, 290], ["Sjorgen's syndrome", "DISEASE", 142, 160], ["breast tumor", "DISEASE", 215, 227], ["salivary exosome", "GENE_OR_GENE_PRODUCT", 36, 52], ["exosomes", "CELL", 197, 205], ["breast tumor", "CANCER", 215, 227], ["miR-195", "GENE_OR_GENE_PRODUCT", 228, 235], ["salivary exosome protein", "PROTEIN", 36, 60], ["exosomes", "CELL_TYPE", 197, 205], ["Preliminary studies", "TEST", 0, 19], ["salivary exosome protein and miRNA content", "PROBLEM", 36, 78], ["disease conditions", "PROBLEM", 115, 133], ["Sjorgen's syndrome", "PROBLEM", 142, 160], ["Biomarkers", "TEST", 166, 176], ["breast tumor miR", "TEST", 215, 231], ["systemic circulation exosomes", "TEST", 261, 290], ["Increased", "OBSERVATION_MODIFIER", 205, 214], ["breast", "ANATOMY", 215, 221], ["tumor", "OBSERVATION", 222, 227]]], ["Glioblastoma derived exosomes contain a diagnostic set of miRs in addition to mutant EGFR vIII [3].", [["Glioblastoma", "ANATOMY", 0, 12], ["exosomes", "ANATOMY", 21, 29], ["Glioblastoma", "DISEASE", 0, 12], ["Glioblastoma derived exosomes", "CELL", 0, 29], ["EGFR", "GENE_OR_GENE_PRODUCT", 85, 89], ["Glioblastoma derived exosomes", "CELL_TYPE", 0, 29], ["miRs", "DNA", 58, 62], ["EGFR", "PROTEIN", 85, 89], ["Glioblastoma", "PROBLEM", 0, 12]]], ["Prostate cancer plasma exosomes revealed up-regulated miR-145 [64].", [["Prostate cancer plasma exosomes", "ANATOMY", 0, 31], ["Prostate cancer", "DISEASE", 0, 15], ["Prostate cancer", "CANCER", 0, 15], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["exosomes", "ORGANISM_SUBSTANCE", 23, 31], ["miR-145", "GENE_OR_GENE_PRODUCT", 54, 61], ["Prostate cancer plasma exosomes", "CELL_TYPE", 0, 31], ["miR", "DNA", 54, 57], ["Prostate cancer", "PROBLEM", 0, 15], ["plasma exosomes", "TEST", 16, 31], ["cancer", "OBSERVATION", 9, 15]]], ["Circulating levels of miR-195 and let-7a decreased in cancer patients post-operatively suggesting feasibility as a prognosis biomarker as well.", [["cancer", "ANATOMY", 54, 60], ["cancer", "DISEASE", 54, 60], ["miR-195", "GENE_OR_GENE_PRODUCT", 22, 29], ["let-7a", "GENE_OR_GENE_PRODUCT", 34, 40], ["cancer", "CANCER", 54, 60], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["Circulating levels", "TEST", 0, 18], ["miR", "TEST", 22, 25], ["a prognosis biomarker", "TEST", 113, 134], ["miR", "ANATOMY", 22, 25], ["cancer", "OBSERVATION", 54, 60]]], ["In this study, the level of certain miRs also correlated well with clinico-pathological variables like nodal status and estrogen receptor status.", [["nodal", "ANATOMY", 103, 108], ["estrogen", "CHEMICAL", 120, 128], ["estrogen", "CHEMICAL", 120, 128], ["miRs", "GENE_OR_GENE_PRODUCT", 36, 40], ["nodal", "MULTI-TISSUE_STRUCTURE", 103, 108], ["estrogen receptor", "GENE_OR_GENE_PRODUCT", 120, 137], ["miRs", "DNA", 36, 40], ["estrogen receptor", "PROTEIN", 120, 137], ["this study", "TEST", 3, 13]]], ["Significant changes to both proteins and miRNAs was also reported for circulating exosomes from patients suffering from ovarian cancers [72].", [["exosomes", "ANATOMY", 82, 90], ["ovarian cancers", "ANATOMY", 120, 135], ["ovarian cancers", "DISEASE", 120, 135], ["exosomes", "CELL", 82, 90], ["patients", "ORGANISM", 96, 104], ["ovarian cancers", "CANCER", 120, 135], ["circulating exosomes", "CELL_TYPE", 70, 90], ["patients", "SPECIES", 96, 104], ["Significant changes to both proteins and miRNAs", "PROBLEM", 0, 47], ["ovarian cancers", "PROBLEM", 120, 135], ["miRNAs", "ANATOMY", 41, 47], ["ovarian", "ANATOMY", 120, 127], ["cancers", "OBSERVATION", 128, 135]]], ["The study found that a set of 8 miRs could distinguish benign vs. malignant ovarian tumors.", [["malignant ovarian tumors", "ANATOMY", 66, 90], ["malignant ovarian tumors", "DISEASE", 66, 90], ["malignant ovarian tumors", "CANCER", 66, 90], ["miRs", "DNA", 32, 36], ["The study", "TEST", 0, 9], ["malignant ovarian tumors", "PROBLEM", 66, 90], ["benign", "OBSERVATION_MODIFIER", 55, 61], ["ovarian", "ANATOMY", 76, 83], ["tumors", "OBSERVATION", 84, 90]]], ["Peripheral blood exosomal miRs showed the same profile as the lung adenocarcinoma in stages I\u2013IV patients [73].", [["Peripheral blood exosomal", "ANATOMY", 0, 25], ["lung adenocarcinoma", "ANATOMY", 62, 81], ["lung adenocarcinoma", "DISEASE", 62, 81], ["Peripheral blood", "ORGANISM_SUBSTANCE", 0, 16], ["lung adenocarcinoma", "CANCER", 62, 81], ["patients", "ORGANISM", 97, 105], ["Peripheral blood exosomal miRs", "RNA", 0, 30], ["patients", "SPECIES", 97, 105], ["Peripheral blood exosomal miRs", "TEST", 0, 30], ["the lung adenocarcinoma", "PROBLEM", 58, 81], ["blood", "ANATOMY", 11, 16], ["exosomal miRs", "OBSERVATION", 17, 30], ["lung", "ANATOMY", 62, 66], ["adenocarcinoma", "OBSERVATION", 67, 81]]], ["The predictive capacity of exosomal miRNA was quite outstanding as exemplified by two exosomal miRNAs accurately discriminating acute lymphoid from acute myeloid leukemia.Future perspectivesThe authors propose the term \u201cfluidome\u201d to capture the complexity of secreted proteins, lipids, RNA, and DNA components that allow insight into cellular processes at a biofluid or cell culture medium level.", [["exosomal", "ANATOMY", 27, 35], ["lymphoid", "ANATOMY", 134, 142], ["acute myeloid leukemia", "ANATOMY", 148, 170], ["cellular", "ANATOMY", 334, 342], ["biofluid", "ANATOMY", 358, 366], ["cell", "ANATOMY", 370, 374], ["acute myeloid leukemia", "DISEASE", 148, 170], ["acute lymphoid", "CANCER", 128, 142], ["acute myeloid leukemia", "CANCER", 148, 170], ["lipids", "SIMPLE_CHEMICAL", 278, 284], ["DNA", "CELLULAR_COMPONENT", 295, 298], ["cellular", "CELL", 334, 342], ["cell", "CELL", 370, 374], ["exosomal miRNA", "RNA", 27, 41], ["exosomal miRNAs", "RNA", 86, 101], ["secreted proteins", "PROTEIN", 259, 276], ["The predictive capacity of exosomal miRNA", "PROBLEM", 0, 41], ["acute lymphoid", "PROBLEM", 128, 142], ["acute myeloid leukemia", "PROBLEM", 148, 170], ["the term \u201cfluidome", "TREATMENT", 210, 228], ["secreted proteins", "PROBLEM", 259, 276], ["lipids", "TREATMENT", 278, 284], ["RNA", "TREATMENT", 286, 289], ["DNA components", "TREATMENT", 295, 309], ["cell culture", "TEST", 370, 382], ["capacity", "OBSERVATION_MODIFIER", 15, 23], ["exosomal miRNA", "OBSERVATION", 27, 41], ["exosomal miRNAs", "OBSERVATION", 86, 101], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["lymphoid", "OBSERVATION", 134, 142], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["myeloid leukemia", "OBSERVATION", 154, 170]]], ["In terms of RNA content, the earliest reports of circulating RNA hypothesized that body fluid derived RNA must somehow be protected from the degradative RNAse-rich content of the body fluid.", [["body fluid", "ANATOMY", 83, 93], ["body fluid", "ANATOMY", 179, 189], ["body", "ORGANISM_SUBDIVISION", 83, 87], ["RNAse", "GENE_OR_GENE_PRODUCT", 153, 158], ["body fluid", "ORGANISM_SUBSTANCE", 179, 189], ["circulating RNA", "RNA", 49, 64], ["RNAse", "PROTEIN", 153, 158], ["RNA content", "PROBLEM", 12, 23], ["circulating RNA", "PROBLEM", 49, 64], ["body fluid derived RNA", "PROBLEM", 83, 105], ["RNA content", "OBSERVATION", 12, 23], ["body", "ANATOMY", 179, 183], ["fluid", "OBSERVATION", 184, 189]]], ["Many interesting theories have arisen over time to answer this conundrum such as the presence of a novel conformation that imparts resistance to nucleases, confinement in exosome-like vesicles and, recently, the presence of Argonaute bound and LDL bound RNA species in plasma.", [["exosome-like vesicles", "ANATOMY", 171, 192], ["plasma", "ANATOMY", 269, 275], ["exosome", "CELLULAR_COMPONENT", 171, 178], ["vesicles", "CELLULAR_COMPONENT", 184, 192], ["Argonaute", "GENE_OR_GENE_PRODUCT", 224, 233], ["LDL", "SIMPLE_CHEMICAL", 244, 247], ["plasma", "ORGANISM_SUBSTANCE", 269, 275], ["nucleases", "PROTEIN", 145, 154], ["exosome", "PROTEIN", 171, 178], ["Argonaute", "PROTEIN", 224, 233], ["LDL bound RNA species", "RNA", 244, 265], ["a novel conformation", "PROBLEM", 97, 117], ["resistance to nucleases", "PROBLEM", 131, 154], ["Argonaute bound", "PROBLEM", 224, 239], ["LDL bound RNA species in plasma", "PROBLEM", 244, 275], ["Argonaute bound", "OBSERVATION", 224, 239]]], ["Other fascinating questions in the field of exosome biology include cargo sorting mechanisms, exosome uptake specificity, and the correlation between the mRNA, miRNA and protein content of exosomes in terms of selection for expulsion as well as in the landscape of effects on the recipient cell.Future perspectivesSo far, studies have focused on these individual biologics in the exosome and there has been no dedicated effort to correlate the effect of the molecules as integrated results at the cell function level.", [["exosome", "ANATOMY", 44, 51], ["exosome", "ANATOMY", 94, 101], ["exosomes", "ANATOMY", 189, 197], ["cell", "ANATOMY", 290, 294], ["exosome", "ANATOMY", 380, 387], ["cell", "ANATOMY", 497, 501], ["exosome", "GENE_OR_GENE_PRODUCT", 44, 51], ["exosome", "CELLULAR_COMPONENT", 94, 101], ["exosomes", "CELL", 189, 197], ["recipient cell", "CELL", 280, 294], ["exosome", "CELLULAR_COMPONENT", 380, 387], ["cell", "CELL", 497, 501], ["mRNA", "RNA", 154, 158], ["exosomes", "CELL_TYPE", 189, 197], ["recipient cell", "CELL_TYPE", 280, 294], ["exosome uptake specificity", "TEST", 94, 120], ["the mRNA", "TEST", 150, 158], ["expulsion", "PROBLEM", 224, 233], ["studies", "TEST", 322, 329], ["the cell function level", "TEST", 493, 516], ["expulsion", "OBSERVATION", 224, 233], ["recipient cell", "OBSERVATION", 280, 294]]], ["Thus, it is obvious that basic research is needed to answer some of these outstanding questions on exosome biology and further strengthen the knowledge base in the field.Future perspectivesIn conclusion, with continued advancements in technology for profiling of exosomal content in a high throughput manner, combined with the elucidation of more of the basic biology of the system, exosomes provide a novel biomarker discovery and therapeutic platform with great promise.", [["exosome", "ANATOMY", 99, 106], ["exosomal", "ANATOMY", 263, 271], ["exosomes", "ANATOMY", 383, 391], ["exosomes", "CELL", 383, 391], ["exosomes", "CELL_TYPE", 383, 391], ["exosomal content", "PROBLEM", 263, 279], ["exosomal content", "OBSERVATION", 263, 279]]], ["Continued basic research will set the foundation for transition of exosome-based diagnostic and prognostic biomarkers to the clinic and a better understanding of the molecular mechanisms of disease pathogenesis.", [["exosome", "ANATOMY", 67, 74], ["prognostic biomarkers", "TEST", 96, 117], ["disease pathogenesis", "PROBLEM", 190, 210], ["disease", "OBSERVATION", 190, 197]]]], "789c5adcc87ecc0ed7e92afba5ecb938f1605bb7": [["Europe's failure to manage a bold, common response would further increase divergence, strengthen anti-European forces and fuel populism.", [["Europe's failure", "PROBLEM", 0, 16], ["a bold", "PROBLEM", 27, 33], ["strengthen anti-European forces", "TREATMENT", 86, 117], ["fuel populism", "OBSERVATION", 122, 135]]], ["The debate about the fi nancing of the euro safety net (e.g. coronabonds versus the European Monetary Mechanism, ESM) has already been very bruising and has created the impression of disregarding European solidarity.", [["bruising", "DISEASE", 140, 148], ["very bruising", "PROBLEM", 135, 148], ["very", "OBSERVATION_MODIFIER", 135, 139], ["bruising", "OBSERVATION", 140, 148]]]], "e3a237bc5435c636e63c746be7db5c3df6d4f1dd": [["IntroductionThe Coronavirus Disease 19 pandemic has presented unusual challenges to genetic and virological analyses [Fauci et al. 2020; Na Zhu et al. 2020; Qun et al. 2020 ].", [["Coronavirus Disease 19 pandemic", "DISEASE", 16, 47], ["Na", "CHEMICAL", 137, 139], ["Coronavirus Disease 19", "ORGANISM", 16, 38], ["The Coronavirus Disease", "PROBLEM", 12, 35], ["virological analyses", "TEST", 96, 116], ["Coronavirus Disease", "OBSERVATION", 16, 35]]], ["One of the major scientific problems confronted with by the SARS-CoV-2 pandemic lies in our limited understanding of the interactions between the viral and the human host genomes and the latter's defense mechanisms against this pathogen.", [["SARS", "DISEASE", 60, 64], ["SARS-CoV-2", "ORGANISM", 60, 70], ["human", "ORGANISM", 160, 165], ["human host genomes", "DNA", 160, 178], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["the viral and the human host genomes", "PROBLEM", 142, 178], ["this pathogen", "PROBLEM", 223, 236]]], ["The frequency of new mutations in viral genomes depends on a multitude of viral and host factors which determine mutant selection.", [["viral genomes", "DNA", 34, 47], ["viral and host factors", "PROTEIN", 74, 96], ["new mutations in viral genomes", "PROBLEM", 17, 47], ["viral and host factors", "PROBLEM", 74, 96], ["mutant selection", "PROBLEM", 113, 129], ["new", "OBSERVATION_MODIFIER", 17, 20], ["mutations", "OBSERVATION", 21, 30], ["viral genomes", "OBSERVATION", 34, 47]]], ["Nucleic acid sequence and the presence of repair mechanisms in the viral genome, the secondary and tertiary structures of the viral genome; the intensity of viral replication, the host's genetically determined defense mechanisms, environmental factors, like ambient temperature, UV radiation, among many unidentified factors, all contribute to the stability or instability of viral genomes.IntroductionSARS-CoV-2, like Sars- CoV-1 (2003 /2004 ), and MERS-CoV (2012 , which were also responsible for human severe acute lung diseases, belongs to the group of beta-coronaviruses.", [["lung", "ANATOMY", 518, 522], ["Nucleic acid", "CHEMICAL", 0, 12], ["UV", "CHEMICAL", 279, 281], ["acute lung diseases", "DISEASE", 512, 531], ["CoV-2", "ORGANISM", 407, 412], ["Sars- CoV-1", "ORGANISM", 419, 430], ["MERS-CoV", "ORGANISM", 450, 458], ["human", "ORGANISM", 499, 504], ["lung", "ORGAN", 518, 522], ["beta-coronaviruses", "CANCER", 557, 575], ["viral genome", "DNA", 67, 79], ["viral genome", "DNA", 126, 138], ["viral genomes", "DNA", 376, 389], ["human", "SPECIES", 499, 504], ["Sars- CoV-1", "SPECIES", 419, 430], ["MERS-CoV", "SPECIES", 450, 458], ["human", "SPECIES", 499, 504], ["Nucleic acid sequence", "TEST", 0, 21], ["repair mechanisms", "TREATMENT", 42, 59], ["the viral genome", "PROBLEM", 63, 79], ["the viral genome", "PROBLEM", 122, 138], ["viral replication", "TREATMENT", 157, 174], ["ambient temperature", "TREATMENT", 258, 277], ["UV radiation", "TREATMENT", 279, 291], ["instability of viral genomes", "PROBLEM", 361, 389], ["IntroductionSARS", "TEST", 390, 406], ["CoV", "TEST", 407, 410], ["CoV", "TEST", 425, 428], ["human severe acute lung diseases", "PROBLEM", 499, 531], ["repair", "OBSERVATION", 42, 48], ["viral genome", "OBSERVATION", 67, 79], ["secondary", "OBSERVATION_MODIFIER", 85, 94], ["tertiary", "OBSERVATION_MODIFIER", 99, 107], ["viral genome", "OBSERVATION", 126, 138], ["viral replication", "OBSERVATION", 157, 174], ["viral genomes", "OBSERVATION", 376, 389], ["severe", "OBSERVATION_MODIFIER", 505, 511], ["acute", "OBSERVATION_MODIFIER", 512, 517], ["lung", "ANATOMY", 518, 522], ["diseases", "OBSERVATION", 523, 531]]], ["Human beta-coronaviruses OC43 or HKU1 cause less severe seasonal upper respiratory tract infections.", [["upper respiratory tract", "ANATOMY", 65, 88], ["HKU1", "CHEMICAL", 33, 37], ["upper respiratory tract infections", "DISEASE", 65, 99], ["Human", "ORGANISM", 0, 5], ["beta-coronaviruses OC43", "ORGANISM", 6, 29], ["HKU1", "GENE_OR_GENE_PRODUCT", 33, 37], ["upper", "ORGANISM_SUBDIVISION", 65, 70], ["respiratory tract", "ORGANISM_SUBDIVISION", 71, 88], ["Human", "SPECIES", 0, 5], ["Human beta-coronaviruses OC43", "SPECIES", 0, 29], ["Human beta-coronaviruses OC43", "PROBLEM", 0, 29], ["HKU1", "PROBLEM", 33, 37], ["less severe seasonal upper respiratory tract infections", "PROBLEM", 44, 99], ["less", "OBSERVATION_MODIFIER", 44, 48], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["seasonal", "OBSERVATION_MODIFIER", 56, 64], ["upper", "ANATOMY_MODIFIER", 65, 70], ["respiratory tract", "ANATOMY", 71, 88], ["infections", "OBSERVATION", 89, 99]]], ["Coronaviruses carry plus-strand RNA genomes of between 26,000 and 32,000 nucleotides in length, the largest genomes among RNA viruses [Helmy et al. 2020; Coronavirus disease pandemic, 2020] .", [["Coronavirus disease pandemic", "DISEASE", 154, 182], ["nucleotides", "CHEMICAL", 73, 84], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["plus-strand RNA genomes", "DNA", 20, 43], ["Coronaviruses carry", "TEST", 0, 19], ["strand RNA genomes", "TEST", 25, 43], ["nucleotides in length", "TEST", 73, 94], ["Coronavirus disease pandemic", "PROBLEM", 154, 182], ["largest", "OBSERVATION_MODIFIER", 100, 107], ["RNA viruses", "OBSERVATION", 122, 133]]], ["During viral replication, a virus-encoded exonuclease and additional non-structural proteins form a replication complex with the viral RNA-dependent-RNA polymerase (RdRp) to generate new virion-packaged genomes [Hartenian et al. 2020; Subissi et al. 2014; Wang et al. 2020 ].", [["exonuclease", "GENE_OR_GENE_PRODUCT", 42, 53], ["virus-encoded exonuclease", "PROTEIN", 28, 53], ["non-structural proteins", "PROTEIN", 69, 92], ["replication complex", "PROTEIN", 100, 119], ["viral RNA-dependent-RNA polymerase", "PROTEIN", 129, 163], ["RdRp", "PROTEIN", 165, 169], ["viral replication", "PROBLEM", 7, 24], ["a virus", "PROBLEM", 26, 33], ["encoded exonuclease", "TREATMENT", 34, 53], ["additional non-structural proteins", "TREATMENT", 58, 92], ["a replication complex", "PROBLEM", 98, 119], ["the viral RNA", "TEST", 125, 138], ["RNA polymerase (RdRp", "TREATMENT", 149, 169], ["viral replication", "OBSERVATION", 7, 24], ["viral RNA", "OBSERVATION", 129, 138]]], ["This complex functions in proof-reading and corrects copying errors by the viral RdRp [Subissi et al. 2014] .", [["viral RdRp", "PROTEIN", 75, 85], ["corrects copying errors", "PROBLEM", 44, 67], ["the viral RdRp", "PROBLEM", 71, 85], ["viral RdRp", "OBSERVATION", 75, 85]]], ["For SARS-CoV-2, this proof reading mechanism is still under study.", [["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8]]], ["The debate that during SARS-CoV-2 RNA replication the generation of mutants remains low in comparison to other plus-strand RNA viruses, has not been resolved.", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "ORGANISM", 23, 33], ["SARS", "TEST", 23, 27], ["CoV-2 RNA replication", "TREATMENT", 28, 49], ["mutants remains low", "PROBLEM", 68, 87], ["strand RNA viruses", "PROBLEM", 116, 134], ["low", "OBSERVATION_MODIFIER", 84, 87], ["strand RNA viruses", "OBSERVATION", 116, 134], ["resolved", "OBSERVATION_MODIFIER", 149, 157]]], ["However, for our understanding of this epidemic, it will be more relevant to research how efficiently SARS-CoV-2 RNA mutants are selected and become dominant in the course of the COVID-19 pandemic.", [["SARS-CoV-2", "ORGANISM", 102, 112], ["SARS-CoV-2 RNA mutants", "DNA", 102, 124], ["CoV", "TEST", 107, 110], ["the COVID", "TEST", 175, 184], ["pandemic", "PROBLEM", 188, 196], ["dominant", "OBSERVATION", 149, 157]]], ["Mutations affecting the secondary and tertiary structures of SARS-CoV-2 RNA might be the most relevant ones when considering selection for viral survival among human populations.IntroductionThere are unique aspects of SARS-CoV-2 genetics and mutagenesis in that the virus managed to jump very recently from mammalian to human hosts and thereafter expanded with unprecedented speed among a world population of almost 8 billion who live under vastly different geographic and socioeconomic conditions.", [["SARS", "DISEASE", 218, 222], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 61, 71], ["human", "ORGANISM", 160, 165], ["human", "ORGANISM", 320, 325], ["SARS-CoV-2 RNA", "RNA", 61, 75], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 320, 325], ["SARS-CoV", "SPECIES", 61, 69], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 320, 325], ["Mutations", "PROBLEM", 0, 9], ["the secondary and tertiary structures of SARS", "PROBLEM", 20, 65], ["viral survival among human populations", "PROBLEM", 139, 177], ["SARS", "PROBLEM", 218, 222], ["mutagenesis", "TREATMENT", 242, 253], ["the virus", "PROBLEM", 262, 271], ["secondary", "OBSERVATION_MODIFIER", 24, 33]]], ["The growing distance from that critical animal-to-human transition point and the chance for rapid propagation under an ensemble of environmental factors and human genetic backgrounds has enabled SARS-CoV-2 genomes to select for replication-efficient mutations.", [["human", "ORGANISM", 50, 55], ["human", "ORGANISM", 157, 162], ["SARS-CoV-2 genomes", "DNA", 195, 213], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["SARS-CoV", "SPECIES", 195, 203], ["rapid propagation", "PROBLEM", 92, 109], ["human genetic backgrounds", "TEST", 157, 182], ["SARS", "PROBLEM", 195, 199], ["CoV", "TEST", 200, 203], ["efficient mutations", "PROBLEM", 240, 259], ["growing", "OBSERVATION_MODIFIER", 4, 11], ["distance", "OBSERVATION_MODIFIER", 12, 20]]], ["The plasticity of the SARS-CoV-2 genome has enabled us to study the frequency of occurrence, the types of nucleotide exchanges and the selection of hotspot mutations in 570 SARS-CoV-2 genomes from isolates that were collected on different continents between December 2019 and the end of May 2020.", [["SARS", "DISEASE", 22, 26], ["nucleotide", "CHEMICAL", 106, 116], ["nucleotide", "CHEMICAL", 106, 116], ["SARS-CoV-2 genome", "DNA", 22, 39], ["570 SARS-CoV-2 genomes", "DNA", 169, 191], ["SARS-CoV", "SPECIES", 22, 30], ["the SARS", "PROBLEM", 18, 26], ["nucleotide exchanges", "TREATMENT", 106, 126], ["hotspot mutations", "PROBLEM", 148, 165], ["SARS", "TEST", 173, 177], ["CoV", "TEST", 178, 181], ["isolates", "PROBLEM", 197, 205]]], ["Most observed mutations were point mutations and were found once or a few times among a large number of isolates and may not be significant.", [["Most observed mutations", "PROBLEM", 0, 23], ["may not be", "UNCERTAINTY", 117, 127]]], ["There arose, however, strongly selected mutations which show predominant representation and increase in frequency as SARS-CoV-2 explosively replicates in human populations with different geographic, socioeconomic, climatic, and genetic backgrounds.Source of Sequences and Statistical Methods employed in the Viral Mutation AnalysisThe 570 SARS-CoV-2 genome sequences, which were analyzed for sequence variations, were randomly selected from the NCBI Databank \"SARS-CoV-2 (Severe Acute Respiratory J o u r n a l P r e -p r o o f Syndrome Coronavirus-2) Sequences\"(https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2seqs/).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["human", "ORGANISM", 154, 159], ["SARS-CoV-2", "DNA", 117, 127], ["570 SARS-CoV-2 genome sequences", "DNA", 335, 366], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["SARS-CoV", "SPECIES", 339, 347], ["Severe Acute Respiratory J o u r n a l P r e -p r o o f Syndrome Coronavirus-2", "SPECIES", 472, 550], ["strongly selected mutations", "PROBLEM", 22, 49], ["increase in frequency as SARS", "PROBLEM", 92, 121], ["Statistical Methods", "TEST", 272, 291], ["the Viral Mutation Analysis", "TEST", 304, 331], ["SARS", "TEST", 339, 343], ["CoV", "TEST", 344, 347], ["sequence variations", "TEST", 392, 411], ["SARS-CoV", "TEST", 460, 468], ["Severe Acute Respiratory J", "PROBLEM", 472, 498], ["Syndrome", "PROBLEM", 528, 536], ["Coronavirus", "PROBLEM", 537, 548], ["predominant", "OBSERVATION_MODIFIER", 61, 72], ["representation", "OBSERVATION_MODIFIER", 73, 87], ["increase", "OBSERVATION_MODIFIER", 92, 100], ["Severe", "OBSERVATION_MODIFIER", 472, 478], ["Acute", "OBSERVATION_MODIFIER", 479, 484], ["Respiratory J", "OBSERVATION", 485, 498]]], ["The nucleotide sequences included in the comparisons shown in Tables S1 to S6 had been deposited in the data bank as follows: Table S1 -China: December 23, 2019 to March 18, 2020 Table S2 -Europe: January 01 to May 30, 2020 Table S3 -Germany: February to March 23, 2020 Table S4 -USA I: February 29 to April 26, 2020 Table S5 -USA II: June 12 to July 07, 2020 Table S6 -India: January 27 to May 27, 2020 Nucleotide sequences from China, Europe, the US and India were compared to the reference genome of the SARS-CoV-2 isolate form Wuhan-Hu-1, NCBI Reference Sequence: NC_045512.2.", [["nucleotide", "CHEMICAL", 4, 14], ["SARS", "DISEASE", 507, 511], ["nucleotide", "CHEMICAL", 4, 14], ["S6", "GENE_OR_GENE_PRODUCT", 75, 77], ["SARS-CoV-2", "ORGANISM", 507, 517], ["S6", "PROTEIN", 75, 77], ["SARS-CoV-2 isolate form Wuhan-Hu-1, NCBI Reference Sequence", "DNA", 507, 566], ["SARS-CoV", "SPECIES", 507, 515], ["Wuhan-Hu-1", "SPECIES", 531, 541], ["The nucleotide sequences", "TEST", 0, 24], ["the US", "TEST", 445, 451], ["the SARS", "TEST", 503, 511], ["CoV", "TEST", 512, 515]]], ["The program Vector NTI Advance\u2122 11 (Invitrogen\u2122), Tool Align X was used for the alignment of sequences from the US and Germany.", [["Invitrogen\u2122", "DNA", 36, 47], ["Tool Align X", "DNA", 50, 62], ["The program Vector NTI", "TREATMENT", 0, 22], ["the US", "TEST", 108, 114]]], ["Nucleotide sequences of isolates from China, India, and Europe were analyzed with the program Snapgene (GSL Biotech) by using the algorithm MUSCLE (MUltiple Sequence Comparison by Log-Expectation).", [["Nucleotide sequences", "TEST", 0, 20], ["MUSCLE", "ANATOMY", 140, 146]]], ["Amino acid sequences were also analyzed with the program Snapgene.", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["Amino acid sequences", "TEST", 0, 20], ["the program Snapgene", "TREATMENT", 45, 65]]], ["DNA sequence analyses of reverse-transcripts of an RNA genome will have to be considered with oversight.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["RNA genome", "DNA", 51, 61], ["DNA sequence analyses", "TEST", 0, 21], ["an RNA genome", "TREATMENT", 48, 61], ["RNA genome", "OBSERVATION", 51, 61]]], ["Errors could have been introduced at several steps, e.g., by preferred reading mistakes of the reverse transcriptase due to specific sequence or structural properties of SARS-CoV-2 RNA.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 170, 180], ["reverse transcriptase", "PROTEIN", 95, 116], ["SARS-CoV-2 RNA", "RNA", 170, 184], ["the reverse transcriptase", "TREATMENT", 91, 116], ["specific sequence", "TEST", 124, 141], ["SARS", "PROBLEM", 170, 174]]], ["We have tried to overcome this obvious complication by analyzing a large number of genomes.", [["this obvious complication", "PROBLEM", 26, 51], ["large", "OBSERVATION_MODIFIER", 67, 72], ["number", "OBSERVATION_MODIFIER", 73, 79]]], ["More specifically, the absence of the distinct hotspot mutations in the majority of sequences from samples isolated in China, convincingly argues against the possibility of technical problems during the generation of SARS-CoV-2 nucleotide sequences.Source of Sequences and Statistical Methods employed in the Viral Mutation AnalysisIn some of the statistical investigations on the data presented, notably comparisons of mutation frequencies between sample collections USA-I and USA-II, the permutation test as well as the Kolmogorov-Smirnov test were applied.Source of Sequences and Statistical Methods employed in the Viral Mutation AnalysisAll sequence alignments performed in our laboratory have been stored and are available to inspection on request.", [["samples", "ANATOMY", 99, 106], ["SARS", "DISEASE", 217, 221], ["nucleotide", "CHEMICAL", 228, 238], ["nucleotide", "CHEMICAL", 228, 238], ["SARS-CoV-2 nucleotide sequences", "DNA", 217, 248], ["SARS-CoV", "SPECIES", 217, 225], ["the distinct hotspot mutations", "PROBLEM", 34, 64], ["technical problems", "PROBLEM", 173, 191], ["SARS", "TEST", 217, 221], ["CoV-2 nucleotide sequences", "TEST", 222, 248], ["Statistical Methods", "TREATMENT", 273, 292], ["the Viral Mutation", "PROBLEM", 305, 323], ["the statistical investigations", "TEST", 343, 373], ["mutation frequencies", "PROBLEM", 420, 440], ["sample collections", "TEST", 449, 467], ["the permutation test", "TEST", 486, 506], ["the Kolmogorov-Smirnov test", "TEST", 518, 545], ["Statistical Methods", "TEST", 583, 602], ["the Viral Mutation Analysis", "TEST", 615, 642], ["All sequence alignments", "TEST", 642, 665], ["distinct", "OBSERVATION_MODIFIER", 38, 46], ["hotspot mutations", "OBSERVATION", 47, 64]]], ["The alignments are also accessible via \"google drive\" [https://drive.google.com/drive/folders/1fUoqJV_cD_gCeAiWH3iIQ6gWwSJfOqOI?usp=sha ring].ResultsWe have investigated whether and to what extent mutants of the SARS-CoV-2 RNA sequence of 29,903 nucleotides are selected as the virus spreads around the world. and predominate in human populations with different geographic, societal, and genetic backgrounds At the time of beginning our analyses, about 2.500 nucleotide sequences of SARS-CoV-2 had been published of which 570 were randomly selected and compared to the reference sequence of the Wuhan isolate from late 2019 (NCBI Reference Sequence: NC_045512.2).", [["SARS", "DISEASE", 212, 216], ["nucleotide", "CHEMICAL", 459, 469], ["SARS", "DISEASE", 483, 487], ["nucleotides", "CHEMICAL", 246, 257], ["nucleotide", "CHEMICAL", 459, 469], ["SARS-CoV-2", "ORGANISM", 212, 222], ["human", "ORGANISM", 329, 334], ["SARS-CoV-2 RNA sequence", "DNA", 212, 235], ["2.500 nucleotide sequences", "DNA", 453, 479], ["human", "SPECIES", 329, 334], ["SARS-CoV", "SPECIES", 212, 220], ["human", "SPECIES", 329, 334], ["SARS-CoV", "SPECIES", 483, 491], ["the SARS", "TEST", 208, 216], ["CoV-2 RNA sequence", "TEST", 217, 235], ["nucleotides", "TREATMENT", 246, 257], ["the virus", "PROBLEM", 274, 283], ["nucleotide sequences", "TEST", 459, 479], ["SARS", "TEST", 483, 487], ["CoV", "TEST", 488, 491]]], ["Figure 1 was reproduced here as an example of part of the SARS-CoV-2 nucleotide sequence at around position 28800 and displays 38 viral isolates from different geographic regions (lines 2-38).", [["SARS", "DISEASE", 58, 62], ["nucleotide", "CHEMICAL", 69, 79], ["nucleotide", "CHEMICAL", 69, 79], ["SARS-CoV-2 nucleotide sequence", "DNA", 58, 88], ["SARS-CoV", "SPECIES", 58, 66], ["the SARS", "TEST", 54, 62], ["CoV", "TEST", 63, 66], ["nucleotide sequence", "TEST", 69, 88], ["38 viral isolates", "PROBLEM", 127, 144]]], ["This sequence was aligned for comparison with the sequence of the Wuhan SARS-CoV-2 isolate (line 1).", [["Wuhan SARS-CoV", "SPECIES", 66, 80], ["the Wuhan SARS", "TEST", 62, 76], ["CoV", "TEST", 77, 80]]], ["In 12 of 37 selected sequences, the GGG sequence of the Wuhan sequence (in blue) was mutated to AAC (in white).", [["GGG sequence", "DNA", 36, 48], ["Wuhan sequence", "DNA", 56, 70], ["AAC", "DNA", 96, 99], ["the GGG sequence", "TEST", 32, 48], ["the Wuhan sequence", "TEST", 52, 70], ["AAC", "PROBLEM", 96, 99]]], ["Additionally, in sequence positions 28854 and 28863 a few C \u2192 T point mutations were apparent.", [["C \u2192 T", "GENE_OR_GENE_PRODUCT", 58, 63], ["a few C \u2192 T point mutations", "PROBLEM", 52, 79]]], ["As in this example, all mutations described in this report were identified by inspection and comparison of individual sequences to the Wuhan reference.", [["all mutations", "PROBLEM", 20, 33]]], ["The results of all sequence comparisons were presented as Supplemental Materials in Tables S1 to S6 and summarized in Table 1 .", [["S6", "PROTEIN", 97, 99], ["all sequence comparisons", "TEST", 15, 39]]], ["We hypothesize that signal hotspot mutations, in particular those identically noted in different populations, have functional significance and have been selected for advantages during active viral replication.", [["signal hotspot mutations", "PROBLEM", 20, 44], ["active viral replication", "TREATMENT", 184, 208], ["hotspot mutations", "OBSERVATION", 27, 44]]], ["The possible impact of these mutations on heightened pathogenicity will require further study.ChinaAccording to the best information available, the world-wide spread of SARS-CoV-2 originated from Wuhan, China, officially in late 2019 [Fauci et al. 2020; Helmy et al. 2020; Na Zhu et al. 2020; Qun et al. 2020 ].", [["SARS", "DISEASE", 169, 173], ["Na", "CHEMICAL", 273, 275], ["SARS-CoV-2", "ORGANISM", 169, 179], ["SARS-CoV", "SPECIES", 169, 177], ["these mutations", "PROBLEM", 23, 38], ["heightened pathogenicity", "PROBLEM", 42, 66], ["further study", "TEST", 80, 93], ["SARS", "PROBLEM", 169, 173], ["possible", "UNCERTAINTY", 4, 12], ["mutations", "OBSERVATION", 29, 38]]], ["In Table S1 (Supplemental Materials), the comparison of nucleotide sequences from 99 Sars-CoV-2 isolates from China with the Wuhan standard sequence revealed a total of 228 deviations from the Wuhan reference.", [["nucleotide", "CHEMICAL", 56, 66], ["nucleotide", "CHEMICAL", 56, 66], ["Sars-CoV-2", "ORGANISM", 85, 95], ["Wuhan standard sequence", "DNA", 125, 148], ["nucleotide sequences", "TEST", 56, 76], ["Sars", "TEST", 85, 89], ["CoV", "TEST", 90, 93], ["the Wuhan standard sequence", "TEST", 121, 148], ["S1", "ANATOMY", 9, 11]]], ["Most notably, in sequence positions 8782 and 28144, the point mutations CC to TC and TA to CA, respectively, were observed in 29 isolates out of the 99 sequences examined.", [["CC", "CHEMICAL", 72, 74], ["CA", "GENE_OR_GENE_PRODUCT", 91, 93], ["CA", "DNA", 91, 93]]], ["Single cytidine (C) to thymine (T) transitions, which were often seen only 1/99, occasionally 2 to 5 times in the 99 sequences, were noted in many different sequence locations.", [["cytidine", "CHEMICAL", 7, 15], ["thymine", "CHEMICAL", 23, 30], ["cytidine", "CHEMICAL", 7, 15], ["thymine", "CHEMICAL", 23, 30], ["cytidine", "SIMPLE_CHEMICAL", 7, 15], ["C", "SIMPLE_CHEMICAL", 17, 18], ["thymine", "SIMPLE_CHEMICAL", 23, 30], ["Single cytidine (C)", "TREATMENT", 0, 19]]], ["The frequent cytidine-to-uracil (C \u2192 T) transitions, as demonstrated here, might be caused by one of the cellular APOBEC (apolipoprotein B mRNA editing enzyme) cytidine deaminases attempting to restrict viral propagation [DiGiorgio et al. 2020 ].", [["cellular", "ANATOMY", 105, 113], ["cytidine", "CHEMICAL", 13, 21], ["uracil", "CHEMICAL", 25, 31], ["cytidine", "CHEMICAL", 160, 168], ["cytidine", "CHEMICAL", 13, 21], ["uracil", "CHEMICAL", 25, 31], ["cytidine", "CHEMICAL", 160, 168], ["cytidine-to-uracil", "SIMPLE_CHEMICAL", 13, 31], ["cellular", "CELL", 105, 113], ["apolipoprotein B mRNA editing enzyme) cytidine deaminases", "GENE_OR_GENE_PRODUCT", 122, 179], ["cellular APOBEC", "PROTEIN", 105, 120], ["apolipoprotein B mRNA editing enzyme", "PROTEIN", 122, 158], ["cytidine deaminases", "PROTEIN", 160, 179], ["The frequent cytidine", "TREATMENT", 0, 21], ["uracil (C \u2192 T) transitions", "TREATMENT", 25, 51], ["the cellular APOBEC (apolipoprotein B mRNA editing enzyme", "TREATMENT", 101, 158], ["cytidine deaminases", "TREATMENT", 160, 179], ["viral propagation", "TREATMENT", 203, 220]]], ["The high frequency of C to T transitions and its evolutionary implications had been pointed out earlier by Simmonds (2020) .", [["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Among these C to T transitions, 4 originated from CG dinucleotides in sequence positions 204, 9967, 25156, and 29095.", [["dinucleotides", "CHEMICAL", 53, 66], ["CG dinucleotides", "DNA", 50, 66]]], ["Such mutations can possibly be attributed to the oxidative deamination of a presumptive 5-methyl-C nucleotide (5-mC) to Uracil (U).", [["5-methyl-C nucleotide", "CHEMICAL", 88, 109], ["5-mC", "CHEMICAL", 111, 115], ["Uracil", "CHEMICAL", 120, 126], ["5-methyl-C nucleotide", "CHEMICAL", 88, 109], ["5-mC", "CHEMICAL", 111, 115], ["Uracil", "CHEMICAL", 120, 126], ["5-methyl-C nucleotide", "SIMPLE_CHEMICAL", 88, 109], ["5-mC", "SIMPLE_CHEMICAL", 111, 115], ["Uracil", "SIMPLE_CHEMICAL", 120, 126], ["U", "SIMPLE_CHEMICAL", 128, 129], ["Such mutations", "PROBLEM", 0, 14], ["the oxidative deamination", "PROBLEM", 45, 70], ["methyl-C nucleotide", "TREATMENT", 90, 109]]], ["It is unknown whether 5-mC occurs in SARS-CoV-2 RNA.", [["SARS", "DISEASE", 37, 41], ["5-mC", "SIMPLE_CHEMICAL", 22, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["SARS-CoV-2 RNA", "RNA", 37, 51], ["SARS", "PROBLEM", 37, 41]]], ["Single nucleotide mutations, other than C to T transitions, which also occurred only in 1/99 isolates or were present 2 to 7 times were also documented among the 99 isolates.", [["nucleotide", "CHEMICAL", 7, 17], ["Single nucleotide mutations", "PROBLEM", 0, 27]]], ["The functional meaning of these very rare sequence alterations can be considered questionable, unless the frequency of sequence alterations in a certain spot expands with time and/or at certain geographic locations.ChinaSome of the hotspot mutations discovered in isolates from locations other than China, like in positions 3037, 14408, 28854, and 28881, were only seen each in 2/99 isolates from China (see Table 1 ).", [["3037, 14408, 28854, and 28881", "CHEMICAL", 324, 353], ["these very rare sequence alterations", "PROBLEM", 26, 62], ["sequence alterations", "PROBLEM", 119, 139], ["the hotspot mutations", "PROBLEM", 228, 249], ["hotspot mutations", "OBSERVATION", 232, 249]]], ["Thus, the frequency of mutations in these locations strongly increased when the virus massively replicated in regions outside China (see below).", [["mutations", "PROBLEM", 23, 32], ["the virus", "PROBLEM", 76, 85], ["mutations", "OBSERVATION", 23, 32], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["This was also true for the presumably important GGG \u2192 AAC mutation in position 28881 which was found expanded particularly in isolates from Europe (see below and Discussion section).", [["GGG", "SIMPLE_CHEMICAL", 48, 51], ["the presumably important GGG \u2192 AAC mutation", "PROBLEM", 23, 66], ["AAC mutation", "OBSERVATION", 54, 66]]], ["Table S2 presents analyses of 99 nucleotide sequences in SARS-CoV-2 isolates from European countries (Czech Republic, Finland, France, Greece, Italy, Netherlands, Poland, Serbia, Spain, and Sweden).", [["nucleotide", "CHEMICAL", 33, 43], ["nucleotide", "CHEMICAL", 33, 43], ["99 nucleotide sequences", "DNA", 30, 53], ["SARS-CoV", "SPECIES", 57, 65], ["nucleotide sequences", "TEST", 33, 53], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65]]], ["Compared to the Wuhan reference sequence, five signal hotspot mutations were (5/99), 9477 (5/99), 11083 (8/99), 14805 (8/99), 20268 (9/99), 25563 (7/99), 26144 (7/99), 28144 (5/99) and others, mutations were also found, though much less frequently.EuropeThe mutation in position 28881 comprised three nucleotides, GGG to AAC in 35/98 of the analyzed sequences.", [["nucleotides", "CHEMICAL", 301, 312], ["Wuhan reference sequence", "DNA", 16, 40], ["position 28881", "DNA", 270, 284], ["five signal hotspot mutations", "TEST", 42, 71], ["GGG", "TEST", 314, 317], ["AAC", "TEST", 321, 324]]], ["This mutation affected the open reading frame for the nucleocapsid phosphoprotein N, altered the original sequence AGG GGA to AAA CGA (see Table 2 ), and led to a change in amino acid sequence positions 50 and 51 from Arg-Gly (RG) to Lys-Arg (KR) and thus juxtaposed two very polar basic amino acids.GermanyPossibly due to the strictly implemented lockdown early in the pandemic and by good luck, this country has so-far been spared excessive fatalities, although more recently (September 2020) there has been an increasing number of COVID-19 cases.", [["amino acid", "CHEMICAL", 173, 183], ["Arg-Gly", "CHEMICAL", 218, 225], ["Lys-Arg", "CHEMICAL", 234, 241], ["amino acids", "CHEMICAL", 288, 299], ["fatalities", "DISEASE", 443, 453], ["amino acid", "CHEMICAL", 173, 183], ["Arg-Gly", "CHEMICAL", 218, 225], ["Lys-Arg", "CHEMICAL", 234, 241], ["amino acids", "CHEMICAL", 288, 299], ["nucleocapsid phosphoprotein N", "GENE_OR_GENE_PRODUCT", 54, 83], ["amino acid", "AMINO_ACID", 173, 183], ["Arg-Gly", "AMINO_ACID", 218, 225], ["Lys-Arg", "AMINO_ACID", 234, 241], ["KR", "AMINO_ACID", 243, 245], ["amino acids", "AMINO_ACID", 288, 299], ["open reading frame", "DNA", 27, 45], ["nucleocapsid phosphoprotein N", "PROTEIN", 54, 83], ["KR", "PROTEIN", 243, 245], ["This mutation", "PROBLEM", 0, 13], ["the nucleocapsid phosphoprotein N", "PROBLEM", 50, 83], ["AAA CGA", "TEST", 126, 133], ["amino acid sequence positions", "TEST", 173, 202], ["Lys", "TEST", 234, 237], ["COVID", "TEST", 534, 539], ["amino acids", "OBSERVATION", 288, 299], ["increasing", "OBSERVATION_MODIFIER", 513, 523], ["number", "OBSERVATION_MODIFIER", 524, 530]]], ["Some of the previously identified mutation hotspots were confirmed at nucleotide numbers 1059 (21/62), 3037 (41/62), 14408 (39/62), 25563 (21/62), and 28881 (9/62).", [["nucleotide", "CHEMICAL", 70, 80], ["mutation hotspots", "PROBLEM", 34, 51], ["nucleotide numbers", "TEST", 70, 88]]], ["There were two additional hotspot mutations in positions 1440 (GC \u2192 AC, 15/62) and 2891 (GC \u2192 AC, 15/62).", [["GC \u2192 AC", "TEST", 63, 70], ["GC", "TEST", 89, 91], ["AC", "TEST", 94, 96], ["hotspot mutations", "OBSERVATION", 26, 43]]], ["In positions 241 and 23403, the high mutation rates in samples from Europe (Table S2) were not observed in the samples from Germany.GermanyIn this context, it will be interesting to compare the results from the published Munich study [B\u00f6hmer et al. 2020] , in which sequences of 14 isolates from patients were described.", [["samples", "ANATOMY", 55, 62], ["samples", "ANATOMY", 111, 118], ["patients", "ORGANISM", 296, 304], ["patients", "SPECIES", 296, 304], ["the high mutation rates", "PROBLEM", 28, 51], ["the published Munich study", "TEST", 207, 233]]], ["They had contracted COVID-19 in January 2020, and their SARS-CoV-2 infection could reportedly be tracked to a single conference attendee from China in the Munich area.", [["SARS", "DISEASE", 56, 60], ["infection", "DISEASE", 67, 76], ["SARS-CoV-2", "ORGANISM", 56, 66], ["SARS-CoV", "SPECIES", 56, 64], ["their SARS", "PROBLEM", 50, 60], ["CoV-2 infection", "PROBLEM", 61, 76], ["infection", "OBSERVATION", 67, 76]]], ["In the Munich patient cohort, only sequence positions 241 (14/14), 3037 (14/14), and 23403 (14/14) showed high mutation frequencies, whereas others failed to be represented (data included in synopsis Table 1 ).", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["sequence positions", "TEST", 35, 53], ["high mutation frequencies", "PROBLEM", 106, 131]]], ["Moreover, position 6446 presented with a mutation frequency of 10/14 which did not register in samples from China or any other country.", [["a mutation frequency", "PROBLEM", 39, 59]]], ["In the samples from China chosen for our analyses (Table S1), the high frequency mutations from the Munich study were altogether absent or (at nucleotide 3037) present at a low frequency of 2/99.", [["samples", "ANATOMY", 7, 14], ["nucleotide 3037", "CHEMICAL", 143, 158], ["nucleotide", "CHEMICAL", 143, 153], ["our analyses", "TEST", 37, 49], ["the high frequency mutations", "PROBLEM", 62, 90], ["the Munich study", "TEST", 96, 112]]], ["Notably, the mutation in position 28881 was absent from the Munich list, although it was found at 2/99 in the samples from China (Table S1 ).", [["samples", "ANATOMY", 110, 117], ["Munich list", "DNA", 60, 71]]], ["Of course, there might have been mutations in Chinese SARS-CoV-2 isolates not represented in the 99 sequences we analyzed (Table S1 ).USA -IThe data on the analyses of 112 isolates from the US confirmed the steady rise in mutation frequencies as SARS-CoV-2 spread to different parts of the world (Table S4 ).", [["SARS", "DISEASE", 54, 58], ["Chinese SARS-CoV-2", "ORGANISM", 46, 64], ["99 sequences", "DNA", 97, 109], ["Chinese SARS-CoV", "SPECIES", 46, 62], ["SARS-CoV", "SPECIES", 246, 254], ["mutations", "PROBLEM", 33, 42], ["Chinese SARS", "TEST", 46, 58], ["CoV", "TEST", 59, 62], ["the analyses", "TEST", 152, 164], ["the US", "TEST", 186, 192], ["mutation frequencies", "PROBLEM", 222, 242], ["SARS", "TEST", 246, 250], ["CoV", "TEST", 251, 254]]], ["These samples from the US were collected before the more recent (June/July 2020) recurrence of COVID-19 in several parts of the US ( Table S6) .", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13], ["the US", "TEST", 19, 25], ["COVID", "TEST", 95, 100], ["the US", "TEST", 124, 130]]], ["Some of the mutations annotated in Tables S1 (China) and S2 (Europe) were found even more frequently in this US cohort, like in SARS-CoV-USA -IIThe USA, unfortunately, has become the most severely SARS-CoV-2-hit country in the world with 6.54 million COVID-19 cases and has tallied about 194,000 deaths (census September 18).", [["SARS", "DISEASE", 128, 132], ["deaths", "DISEASE", 296, 302], ["SARS-CoV-USA", "ORGANISM", 128, 140], ["SARS-CoV", "SPECIES", 128, 136], ["the mutations", "PROBLEM", 8, 21], ["S2", "ANATOMY", 57, 59]]], ["We therefore analyzed an additional 97 SARS-CoV-2 RNA sequences from the most severely affected states Arizona (AZ), California (CA), Florida (FL) and Texas (TX) (Tables 1 and S5) .", [["SARS-CoV-2 RNA sequences", "DNA", 39, 63], ["CoV", "TEST", 44, 47], ["RNA sequences", "TEST", 50, 63], ["California (CA)", "TREATMENT", 117, 132], ["Florida (FL)", "TREATMENT", 134, 146], ["Texas (TX)", "TREATMENT", 151, 161]]], ["The inspected sequences (Table S5 ) had been deposited between June 12 and July 07, 2020.", [["The inspected sequences", "TEST", 0, 23]]], ["The sequences discussed here had not been included in Table S4 .", [["The sequences", "TEST", 0, 13]]], ["In Table 1 , the USA-I and USA-II analyses were juxtaposed and demonstrate that the previously identified hotspot mutations were still represented at about the same frequencies as shown in Table S4 .", [["the USA", "TEST", 13, 20], ["the previously identified hotspot mutations", "PROBLEM", 80, 123]]], ["The mutations at intermediate frequencies (12/97) in positions 17747, 17858, and 18060 registered at frequencies between 8/112 and 9/112 at slightly lower frequencies in Table S4 .", [["The mutations", "PROBLEM", 0, 13]]], ["We tested the hypothesis of differential distribution of mutation frequencies in the sequences from time point 1 (USA-I) and time point 2 (USA-II) using a permutation test as well as Kolmogorov-Smirnov test and failed to reject the null hypothesis of equivalent distributions, p > 0.6, suggesting that there is no significant difference in hotspot mutation frequencies between the two different time periods of sequence analyses from the US.IndiaIn Table S6 , mutation analyses in nucleotide sequences of isolates from India have been summarized.", [["nucleotide", "CHEMICAL", 481, 491], ["S6", "PROTEIN", 455, 457], ["mutation frequencies", "PROBLEM", 57, 77], ["a permutation test", "TEST", 153, 171], ["Kolmogorov-Smirnov test", "TEST", 183, 206], ["significant difference in hotspot mutation frequencies", "PROBLEM", 314, 368], ["sequence analyses", "TEST", 411, 428], ["the US", "TEST", 434, 440], ["mutation analyses", "TEST", 460, 477], ["nucleotide sequences", "TEST", 481, 501], ["mutation frequencies", "OBSERVATION", 57, 77], ["equivalent", "OBSERVATION_MODIFIER", 251, 261], ["distributions", "OBSERVATION_MODIFIER", 262, 275], ["no", "UNCERTAINTY", 311, 313], ["significant", "OBSERVATION_MODIFIER", 314, 325], ["difference", "OBSERVATION_MODIFIER", 326, 336]]], ["Some of the hotspot mutations documented in isolates from the US were found in RNA samples from India as well, partly at increased frequencies, at sequence In the samples studied here, the SARS-CoV-2 sequences from India showed the largest number (7) of hotspot mutations, which also had the highest occurrence (up to 82/99, i.e. 83%) of mutation at a given nucleotide position ( Table S6) .IndiaAs SARS-CoV-2 infections find susceptible populations around the world, and as the rate of viral replication shoots up in these populations, the number of new hotspots of mutation and the frequencies of mutations in individual hotspots were found increased.", [["samples", "ANATOMY", 83, 90], ["samples", "ANATOMY", 163, 170], ["SARS", "DISEASE", 189, 193], ["infections", "DISEASE", 410, 420], ["nucleotide", "CHEMICAL", 358, 368], ["SARS-CoV-2", "ORGANISM", 399, 409], ["SARS-CoV-2 sequences", "DNA", 189, 209], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV-2", "SPECIES", 399, 409], ["the hotspot mutations", "PROBLEM", 8, 29], ["the US", "TEST", 58, 64], ["increased frequencies", "PROBLEM", 121, 142], ["the SARS-CoV-2 sequences", "TEST", 185, 209], ["hotspot mutations", "PROBLEM", 254, 271], ["mutation", "PROBLEM", 338, 346], ["2 infections", "PROBLEM", 408, 420], ["susceptible populations", "PROBLEM", 426, 449], ["viral replication shoots", "PROBLEM", 487, 511], ["mutation", "PROBLEM", 567, 575], ["mutations in individual hotspots", "PROBLEM", 599, 631], ["largest", "OBSERVATION_MODIFIER", 232, 239], ["hotspot mutations", "OBSERVATION", 254, 271], ["highest", "OBSERVATION_MODIFIER", 292, 299], ["viral replication", "OBSERVATION", 487, 504], ["new", "OBSERVATION_MODIFIER", 551, 554], ["increased", "OBSERVATION_MODIFIER", 643, 652]]], ["Permitting the virus to replicate with growing efficiency might render its genome better adapted and increasingly dangerous to human health.", [["human", "ORGANISM", 127, 132], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["the virus", "PROBLEM", 11, 20], ["growing efficiency", "PROBLEM", 39, 57], ["virus", "OBSERVATION", 15, 20]]], ["Alternatively, the possibility has to be considered that the lack of J o u r n a l P r e -p r o o f deleterious effects on the host and its tolerance might have favored the selection of mutants.", [["deleterious effects", "PROBLEM", 100, 119]]], ["Moreover, repeated bottlenecks in the replication of viruses have been shown in the case of vesicular stomatitis virus to reduce its fitness (so called Muller's ratchet) [Duarte et al. 1992] .", [["vesicular stomatitis", "DISEASE", 92, 112], ["vesicular stomatitis virus", "ORGANISM", 92, 118], ["vesicular stomatitis virus", "SPECIES", 92, 118], ["repeated bottlenecks", "PROBLEM", 10, 30], ["viruses", "PROBLEM", 53, 60], ["vesicular stomatitis virus", "PROBLEM", 92, 118], ["vesicular stomatitis", "ANATOMY", 92, 112]]], ["Lastly, accumulation of mutants during the world-wide spread of SARS-CoV-2 might eventually decrease its virulence.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-2", "ORGANISM", 64, 74], ["SARS-CoV", "SPECIES", 64, 72], ["accumulation of mutants", "PROBLEM", 8, 31], ["SARS", "PROBLEM", 64, 68], ["mutants", "OBSERVATION_MODIFIER", 24, 31], ["virulence", "OBSERVATION_MODIFIER", 105, 114]]], ["Hence, the consequences of an increase in the number of viral mutations on its pathogenicity will be very difficult to predict.", [["an increase", "PROBLEM", 27, 38], ["viral mutations", "PROBLEM", 56, 71], ["its pathogenicity", "PROBLEM", 75, 92], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["viral mutations", "OBSERVATION", 56, 71]]], ["Eventually, a possible decrease in virulence might turn out to set a limit to SARS-CoV-2's pandemic potential.RussiaSo far, we have inspected the available seven SARS-CoV-2 sequences from Russia and found mutation hotspots identical to the ones predominant in Europe (data not shown)BrazilAs yet, not enough SARS-CoV-2 RNA sequences have been deposited to allow a meaningful analysis.", [["SARS", "DISEASE", 78, 82], ["CoV-2", "ORGANISM", 83, 88], ["SARS-CoV-2 sequences", "DNA", 162, 182], ["SARS-CoV-2 RNA sequences", "DNA", 308, 332], ["SARS-CoV", "SPECIES", 78, 86], ["decrease in virulence", "PROBLEM", 23, 44], ["SARS", "TEST", 78, 82], ["CoV", "TEST", 83, 86], ["mutation hotspots", "PROBLEM", 205, 222], ["RNA sequences", "TEST", 319, 332], ["a meaningful analysis", "TEST", 362, 383], ["possible", "UNCERTAINTY", 14, 22], ["decrease", "OBSERVATION_MODIFIER", 23, 31]]], ["The majority of de novo mutation hotspots arose after SARS-CoV-2 had been transmitted to regions outside China and been allowed active replication in different environments (Tables S1 to S6).", [["SARS-CoV-2", "DNA", 54, 64], ["S6", "PROTEIN", 187, 189], ["de novo mutation hotspots", "PROBLEM", 16, 41], ["SARS", "PROBLEM", 54, 58]]], ["The mutations in positions 8782 and 28144 with frequencies 29/99 in sequences from China (Table S1) were found outside China only in the US I and II samples, though with moderate frequencies (15/97 or 15/112) and at even lower frequencies in the Indian samples (7/99) ( Table 1) .", [["samples", "ANATOMY", 149, 156], ["samples", "ANATOMY", 253, 260], ["The mutations in positions", "TEST", 0, 26], ["frequencies", "TEST", 47, 58], ["moderate frequencies", "PROBLEM", 170, 190], ["moderate", "OBSERVATION_MODIFIER", 170, 178]]], ["Hence most of the world-wide mutation hotspots described here (Tables S1 to S6) must have originated and been selected in the course of massive replication of SARS-CoV-2 in its world-wide expansion.Nucleotide exchangesA challenging aspect arose from the identification of SARS-CoV-2 mutants in 14 COVID-19 patients from the Munich, Germany area in January 2020 [B\u00f6hmer et al. 2020 ].", [["SARS", "DISEASE", 159, 163], ["S6", "GENE_OR_GENE_PRODUCT", 76, 78], ["SARS-CoV-2", "ORGANISM", 159, 169], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 272, 282], ["patients", "ORGANISM", 306, 314], ["S6", "PROTEIN", 76, 78], ["SARS-CoV-2 mutants", "DNA", 272, 290], ["patients", "SPECIES", 306, 314], ["SARS-CoV", "SPECIES", 159, 167], ["SARS-CoV", "SPECIES", 272, 280], ["wide mutation hotspots", "PROBLEM", 24, 46], ["SARS", "PROBLEM", 159, 163], ["CoV", "TEST", 164, 167], ["Nucleotide exchangesA", "TREATMENT", 198, 219], ["SARS", "PROBLEM", 272, 276], ["CoV", "TEST", 277, 280], ["COVID", "TEST", 297, 302], ["massive", "OBSERVATION_MODIFIER", 136, 143], ["replication", "OBSERVATION", 144, 155], ["SARS", "OBSERVATION", 159, 163], ["wide", "OBSERVATION_MODIFIER", 183, 187], ["expansion", "OBSERVATION_MODIFIER", 188, 197]]], ["After the visitor had returned to China, she fell ill with Covid-19, and her contacts in the Munich area also came down with the disease.", [["Covid", "TEST", 59, 64], ["the disease", "PROBLEM", 125, 136], ["disease", "OBSERVATION", 129, 136]]], ["A comparison of the occurrence and frequencies of the mutants in positions 241, 3037 and 23403 in all 14 patients in the Munich report [B\u00f6hmer et al. 2020 ] to those in all other parts of the world (Table 1) , does not render the Chinese traveler the most plausible source for SARS-CoV-2 in the Munich area.", [["SARS", "DISEASE", 277, 281], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["SARS-CoV", "SPECIES", 277, 285], ["SARS", "PROBLEM", 277, 281], ["CoV", "TEST", 282, 285]]], ["These very mutations, however, are frequent hotspots in Europe, Germany, the US (I and II) and India.", [["These very mutations", "PROBLEM", 0, 20], ["the US", "TEST", 73, 79], ["mutations", "OBSERVATION", 11, 20]]], ["Of course, it will have to be investigated whether the hotspot mutations apparent in the isolates from the Munich cohort might have been present, J o u r n a l P r e -p r o o f though infrequently, among Chinese isolates, in particular in the Munich visitor (patient 0) from China.Nucleotide exchangesMutations in sequence positions 3037 -14408 -23403 or 25563 occurred at low frequency or were absent in samples from China, but expanded to levels up to 75/111 (68%) and 81/99 (82%) in the US and in India, respectively ( Table 1) .", [["samples", "ANATOMY", 405, 412], ["3037 -14408 -23403 or 25563", "CHEMICAL", 333, 360], ["Nucleotide", "CHEMICAL", 281, 291], ["patient", "ORGANISM", 259, 266], ["patient", "SPECIES", 259, 266], ["the hotspot mutations", "PROBLEM", 51, 72], ["Nucleotide exchangesMutations in sequence positions", "TEST", 281, 332], ["levels", "TEST", 441, 447], ["the US", "TEST", 486, 492], ["low frequency", "OBSERVATION_MODIFIER", 373, 386]]], ["Increases in the number of hotspot mutations and the heightened percentage of sequences altered in a given hotspot in samples from Europe, and even more so from the US and India, suggested that these increases were tied to the intense replication of SARS-CoV-2 in these countries upon its spreading from China in the course of just a few months.", [["samples", "ANATOMY", 118, 125], ["SARS", "DISEASE", 250, 254], ["SARS-CoV-2", "ORGANISM", 250, 260], ["SARS-CoV", "SPECIES", 250, 258], ["hotspot mutations", "PROBLEM", 27, 44], ["the US", "TEST", 161, 167], ["SARS", "PROBLEM", 250, 254]]], ["It will be interesting to investigate whether SARS-CoV-2 spreading to and massively replicating in constantly new, immunologically na\u00efve populations furthers the selection of viral mutants, in particular of those with heightened pathogenicity.Nucleotide exchangesThe comparison of the number and frequency of hotspot mutations between samples from the USA I (34 States) ( Table S4 ) and USA II (AZ, CA, FL, TX only) cohorts (Table S5 ) revealed no differences ( Table 1 , see above), as corroborated by statistical analyses (see above).Nucleotide exchangesIn an earlier report [Pachetti et al. 2020] , the authors analyzed 220 genomic sequences derived from patients infected by SARS-CoV-2 between December 2019 and mid-March 2020 and found eight mutations of SARS-CoV-2, located at positions 1397, 2891, 14408, 17746, 17857, 18060, 23403 and 28881 .", [["samples", "ANATOMY", 335, 342], ["Nucleotide", "CHEMICAL", 243, 253], ["SARS-CoV-2", "ORGANISM", 46, 56], ["patients", "ORGANISM", 658, 666], ["SARS-CoV-2", "ORGANISM", 679, 689], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 760, 770], ["220 genomic sequences", "DNA", 623, 644], ["SARS-CoV-2", "DNA", 760, 770], ["patients", "SPECIES", 658, 666], ["SARS-CoV", "SPECIES", 679, 687], ["SARS-CoV", "SPECIES", 760, 768], ["SARS", "PROBLEM", 46, 50], ["immunologically na\u00efve populations", "PROBLEM", 115, 148], ["viral mutants", "PROBLEM", 175, 188], ["heightened pathogenicity", "PROBLEM", 218, 242], ["Nucleotide exchanges", "TREATMENT", 243, 263], ["hotspot mutations", "PROBLEM", 309, 326], ["CA, FL, TX", "TREATMENT", 399, 409], ["genomic sequences", "TEST", 627, 644], ["CoV", "TEST", 684, 687], ["SARS", "TEST", 760, 764], ["CoV", "TEST", 765, 768], ["viral mutants", "OBSERVATION", 175, 188], ["heightened", "OBSERVATION_MODIFIER", 218, 228], ["pathogenicity", "OBSERVATION", 229, 242], ["no", "UNCERTAINTY", 445, 447]]], ["Their results are interesting in that the mutations in sequence positions 1397, 17746, 17857, and 18060 did not show up in our analyses, whereas mutations in positions 2891, 14408, 23403, and 28881 were found in our collection as well ( Table 1) .", [["the mutations in sequence positions", "TEST", 38, 73]]], ["Since their sequence selection anteceded ours by several months, it is conceivable that the non-common mutations might have been counter-selected as the pandemic spread throughout the world.", [["the non-common mutations", "PROBLEM", 88, 112]]], ["Of course, the less likely possibility existed that by chance their group and ours worked on non-overlapping sequences in the data bank.", [["less likely possibility", "UNCERTAINTY", 15, 38]]], ["Furthermore, in a preprint deposit [Laamarti et al. 2020 ], the authors analyzed 3,067 SARS-CoV-2 genomes isolated from 59 countries during the first three months of the pandemic and found 716 site mutations distributed in six genes of the SARS-CoV-2 genome.", [["SARS", "DISEASE", 87, 91], ["SARS", "DISEASE", 240, 244], ["SARS-CoV-2", "ORGANISM", 240, 250], ["SARS-CoV-2 genomes", "DNA", 87, 105], ["SARS-CoV-2 genome", "DNA", 240, 257], ["SARS-CoV", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 240, 248], ["SARS", "TEST", 87, 91], ["CoV", "TEST", 92, 95], ["the pandemic", "PROBLEM", 166, 178], ["site mutations", "PROBLEM", 193, 207], ["the SARS", "PROBLEM", 236, 244]]], ["These mutations belonged to certain genotypes which appeared to be specific to certain geographic regions.", [["These mutations", "PROBLEM", 0, 15]]], ["Table 2 summarizes the amino acid exchanges due to sequence alterations in hotspot mutations identified in this study (Table 1) .", [["amino acid", "CHEMICAL", 23, 33], ["amino acid", "CHEMICAL", 23, 33], ["amino acid", "AMINO_ACID", 23, 33], ["the amino acid exchanges", "TREATMENT", 19, 43], ["sequence alterations in hotspot mutations", "PROBLEM", 51, 92], ["this study", "TEST", 107, 117]]], ["Mutations in sequence positions 241, 3037, 8782, 18877, 22444, 25563 , and 26735 did not cause amino acid exchanges and were not included in Table 2 .", [["amino acid", "CHEMICAL", 95, 105], ["amino acid", "CHEMICAL", 95, 105], ["amino acid", "AMINO_ACID", 95, 105], ["Mutations in sequence positions", "TEST", 0, 31], ["amino acid exchanges", "PROBLEM", 95, 115]]], ["Aside from the possible functional and structural alterations in proteins altered by either codon-neutral or codon-affecting mutations, any mutation in SARS-CoV-2 RNA can impinge upon the structure of the single-stranded viral RNA molecule itself with consequences for important viral RNA-protein interactions.Amino acid exchangesIn sequence position 28881, the mutation AGG GGA \u2192 AAA CGA changes the amino acid sequence of the nucleoprotein N in positions 50 and 51 from Arg-Gly (RG) to Lys-Arg (KR) ( Table 2) .", [["SARS", "DISEASE", 152, 156], ["Amino acid", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 401, 411], ["Arg-Gly", "CHEMICAL", 472, 479], ["Amino acid", "CHEMICAL", 310, 320], ["amino acid", "CHEMICAL", 401, 411], ["Arg-Gly", "CHEMICAL", 472, 479], ["Lys-Arg", "CHEMICAL", 488, 495], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["Amino acid", "AMINO_ACID", 310, 320], ["amino acid", "AMINO_ACID", 401, 411], ["Arg-Gly", "AMINO_ACID", 472, 479], ["Lys-Arg", "AMINO_ACID", 488, 495], ["SARS-CoV-2 RNA", "RNA", 152, 166], ["single-stranded viral RNA molecule", "PROTEIN", 205, 239], ["amino acid sequence", "PROTEIN", 401, 420], ["nucleoprotein N", "PROTEIN", 428, 443], ["KR", "PROTEIN", 497, 499], ["functional and structural alterations in proteins", "PROBLEM", 24, 73], ["codon", "TEST", 92, 97], ["neutral or codon-affecting mutations", "PROBLEM", 98, 134], ["any mutation in SARS", "PROBLEM", 136, 156], ["CoV", "TEST", 157, 160], ["Amino acid exchanges", "TREATMENT", 310, 330], ["the mutation AGG GGA", "TEST", 358, 378], ["AAA CGA", "TEST", 381, 388], ["the amino acid sequence", "TEST", 397, 420], ["Lys", "TEST", 488, 491], ["viral RNA molecule", "OBSERVATION", 221, 239], ["acid exchanges", "OBSERVATION", 316, 330]]], ["The frequency of this mutation was found in isolates from different countries to be 2/99 (China), 35/99 (Europe), 9/62 (Germany), 3/112 (US I), 6/97 (US II) and 2/99 (India).", [["this mutation", "PROBLEM", 17, 30]]], ["The mutant amino acid sequence in nucleocapsid protein N between positions 29 to 35 (KKPRQKR) and 49 to 54 (RKRPEQ) ( Table 2 ) raises questions about the possible generation of a nuclear localization signal [Kalderon et al. 1984 ] and strong DNA-binding motifs in protein N. For SARS-CoV-2 very little is known about activities in the nuclei of infected cells.", [["nuclear", "ANATOMY", 180, 187], ["nuclei", "ANATOMY", 336, 342], ["cells", "ANATOMY", 355, 360], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "AMINO_ACID", 11, 21], ["nucleocapsid protein N", "GENE_OR_GENE_PRODUCT", 34, 56], ["nuclear", "CELLULAR_COMPONENT", 180, 187], ["DNA", "CELLULAR_COMPONENT", 243, 246], ["nuclei", "CELLULAR_COMPONENT", 336, 342], ["cells", "CELL", 355, 360], ["mutant amino acid sequence", "PROTEIN", 4, 30], ["nucleocapsid protein N", "PROTEIN", 34, 56], ["KKPRQKR", "PROTEIN", 85, 92], ["RKRPEQ", "PROTEIN", 108, 114], ["DNA-binding motifs", "PROTEIN", 243, 261], ["infected cells", "CELL_TYPE", 346, 360], ["SARS-CoV", "SPECIES", 280, 288], ["The mutant amino acid sequence", "TEST", 0, 30], ["nucleocapsid protein", "TEST", 34, 54], ["a nuclear localization signal", "PROBLEM", 178, 207], ["strong DNA", "PROBLEM", 236, 246], ["SARS", "PROBLEM", 280, 284], ["CoV", "TEST", 285, 288], ["infected cells", "OBSERVATION", 346, 360]]], ["One publication reports cell cycle-dependent nucleolar, not nuclear, localization of protein N, although for non-SARS coronaviruses [Cawood et al. 2007 ].", [["cell", "ANATOMY", 24, 28], ["nucleolar", "ANATOMY", 45, 54], ["nuclear", "ANATOMY", 60, 67], ["cell", "CELL", 24, 28], ["nucleolar", "CELLULAR_COMPONENT", 45, 54], ["nuclear", "CELLULAR_COMPONENT", 60, 67], ["protein N", "PROTEIN", 85, 94], ["cell cycle-dependent nucleolar", "PROBLEM", 24, 54], ["non-SARS coronaviruses", "PROBLEM", 109, 131], ["cell cycle-dependent nucleolar", "OBSERVATION", 24, 54]]], ["It is presently unknown whether a mutated N protein might fundamentally alter the biology and pathogenicity of this SARS-CoV-2 mutant.", [["SARS", "DISEASE", 116, 120], ["SARS-CoV-2 mutant", "ORGANISM", 116, 133], ["N protein", "PROTEIN", 42, 51], ["SARS-CoV-2 mutant", "PROTEIN", 116, 133], ["SARS-CoV", "SPECIES", 116, 124], ["a mutated N protein", "PROBLEM", 32, 51], ["this SARS", "TEST", 111, 120], ["CoV", "TEST", 121, 124]]], ["It is also interesting to ponder how the Wuhan sequence in position 28881 GGG was altered to AAC.", [["Wuhan sequence", "DNA", 41, 55], ["AAC", "PROBLEM", 93, 96]]], ["Could RNA-RNA recombination have played a role?Amino acid exchangesSeveral of the mutants affect virus-encoded proteins with functions in the replication of SARS-CoV-2, like non-structural proteins (nsp 2, nsp 3) and the helicase.", [["Amino acid", "CHEMICAL", 47, 57], ["SARS", "DISEASE", 157, 161], ["Amino acid", "CHEMICAL", 47, 57], ["Amino acid", "AMINO_ACID", 47, 57], ["SARS-CoV-2", "ORGANISM", 157, 167], ["nsp 2", "GENE_OR_GENE_PRODUCT", 199, 204], ["nsp 3", "GENE_OR_GENE_PRODUCT", 206, 211], ["virus-encoded proteins", "PROTEIN", 97, 119], ["non-structural proteins", "PROTEIN", 174, 197], ["nsp 2", "PROTEIN", 199, 204], ["nsp 3", "PROTEIN", 206, 211], ["helicase", "PROTEIN", 221, 229], ["SARS-CoV", "SPECIES", 157, 165], ["Amino acid exchanges", "TREATMENT", 47, 67], ["the mutants affect virus", "PROBLEM", 78, 102], ["SARS", "PROBLEM", 157, 161], ["CoV", "TEST", 162, 165], ["non-structural proteins", "TEST", 174, 197], ["nsp", "TEST", 199, 202], ["nsp", "TEST", 206, 209], ["the helicase", "TREATMENT", 217, 229], ["acid exchanges", "OBSERVATION", 53, 67]]], ["The important surface glycoprotein and the nucleocapsid phosphoprotein were also affected by codon changes.", [["surface", "ANATOMY", 14, 21], ["surface glycoprotein", "GENE_OR_GENE_PRODUCT", 14, 34], ["nucleocapsid phosphoprotein", "GENE_OR_GENE_PRODUCT", 43, 70], ["surface glycoprotein", "PROTEIN", 14, 34], ["nucleocapsid phosphoprotein", "PROTEIN", 43, 70], ["The important surface glycoprotein", "TREATMENT", 0, 34], ["the nucleocapsid phosphoprotein", "TREATMENT", 39, 70], ["surface glycoprotein", "OBSERVATION_MODIFIER", 14, 34]]], ["Evidence has been adduced that the D614G mutation of the SARS-CoV-2 spike protein bestows advantages on viral replication both in patients and in cell culture (Korber et al. 2020) .", [["cell", "ANATOMY", 146, 150], ["SARS", "DISEASE", 57, 61], ["D614G", "GENE_OR_GENE_PRODUCT", 35, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["patients", "ORGANISM", 130, 138], ["cell", "CELL", 146, 150], ["SARS-CoV-2 spike protein", "PROTEIN", 57, 81], ["patients", "SPECIES", 130, 138], ["the SARS", "PROBLEM", 53, 61], ["CoV", "TEST", 62, 65], ["protein bestows", "TREATMENT", 74, 89], ["viral replication", "TREATMENT", 104, 121], ["cell culture", "TEST", 146, 158]]], ["In a preprint deposit [Isabel et al. 2020 ], a SARS-CoV-2 this D614G spike protein mutation has also been described.Amino acid exchangesAmong the 19 mutants listed in Table 1 , 17 were transitions, 2 transversions, 12 led to amino acid changes in the proteins they were coding for, 7 were synonymous mutations.", [["SARS", "DISEASE", 47, 51], ["Amino acid", "CHEMICAL", 116, 126], ["amino acid", "CHEMICAL", 225, 235], ["Amino acid", "CHEMICAL", 116, 126], ["amino acid", "CHEMICAL", 225, 235], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["D614G", "GENE_OR_GENE_PRODUCT", 63, 68], ["Amino acid", "AMINO_ACID", 116, 126], ["amino acid", "AMINO_ACID", 225, 235], ["D614G spike protein", "PROTEIN", 63, 82], ["a SARS", "TEST", 45, 51], ["CoV", "TEST", 52, 55], ["this D614G spike protein mutation", "PROBLEM", 58, 91], ["Amino acid exchanges", "TREATMENT", 116, 136], ["amino acid changes", "PROBLEM", 225, 243], ["synonymous mutations", "PROBLEM", 289, 309], ["acid exchanges", "OBSERVATION", 122, 136]]], ["Of the transitions, 12 were C to T (U) mutations.", [["T (U)", "GENE_OR_GENE_PRODUCT", 33, 38]]], ["So far, we have not detected any insertions or deletions in the sequences analyzed.", [["any insertions or deletions in the sequences", "PROBLEM", 29, 73]]], ["A deletion in the SARS-CoV-2 genome with evolutionary implications has been recently described [Su et al. 2020 ].Amino acid exchangesIt will now be important to correlate the identified hotspot mutations with the course and outcome of individual infections in humans.", [["SARS", "DISEASE", 18, 22], ["Amino acid", "CHEMICAL", 113, 123], ["infections", "DISEASE", 246, 256], ["Amino acid", "CHEMICAL", 113, 123], ["SARS-CoV-2", "ORGANISM", 18, 28], ["Amino acid", "AMINO_ACID", 113, 123], ["humans", "ORGANISM", 260, 266], ["SARS-CoV-2 genome", "DNA", 18, 35], ["humans", "SPECIES", 260, 266], ["humans", "SPECIES", 260, 266], ["A deletion", "PROBLEM", 0, 10], ["the SARS", "PROBLEM", 14, 22], ["CoV", "PROBLEM", 23, 26], ["Amino acid exchanges", "TREATMENT", 113, 133], ["the identified hotspot mutations", "PROBLEM", 171, 203], ["individual infections in humans", "PROBLEM", 235, 266], ["deletion", "OBSERVATION", 2, 10], ["acid exchanges", "OBSERVATION", 119, 133], ["infections", "OBSERVATION", 246, 256]]], ["This demanding problem has not yet been tackled.", [["This demanding problem", "PROBLEM", 0, 22]]], ["Hopefully, the results of our study will provide a platform for those in SARS-CoV-2 research who take care of patients with SARS-CoV-2 infections.", [["SARS-CoV-2 infections", "DISEASE", 124, 145], ["patients", "ORGANISM", 110, 118], ["SARS-CoV-2", "ORGANISM", 124, 134], ["patients", "SPECIES", 110, 118], ["our study", "TEST", 26, 35], ["SARS", "PROBLEM", 124, 128], ["CoV-2 infections", "PROBLEM", 129, 145], ["infections", "OBSERVATION", 135, 145]]], ["SARS-CoV-2 has the ability to mutate and, in its course of world-wide dissemination, to select for distinct signal hotspot mutations depending on high rates of genome replication and complex environmental and genetic conditions in newly invaded territories of the world.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["distinct signal hotspot mutations", "PROBLEM", 99, 132], ["genome replication", "PROBLEM", 160, 178], ["complex environmental and genetic conditions", "PROBLEM", 183, 227]]], ["During its intercontinental journey, the exposure of SARS-CoV-2 to the 21 st century's repertoire of medical resources may have been an additional selective force.", [["SARS", "DISEASE", 53, 57], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "TEST", 53, 57], ["CoV", "TEST", 58, 61]]], ["The impact of an increase in hotspot SARS-CoV-2 mutations on immunogenesis and the prospects for vaccine development [Jackson et al. 2020 ] might be experienced and will have to be examined in the future.Author contributionsS.W. carried out all work involving sequence selection and formal analyses, was involved in the conceptualization of the project and in the analysis and interpretation of data.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["an increase in hotspot SARS", "PROBLEM", 14, 41], ["immunogenesis", "TREATMENT", 61, 74], ["sequence selection", "TEST", 260, 278], ["formal analyses", "TEST", 283, 298], ["the analysis", "TEST", 360, 372], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["W.D. initiated the project, was involved in the conceptualization of the project and in the analysis and interpretation of data and wrote the manuscript.", [["the analysis", "TEST", 88, 100]]], ["Yes, I will be a co-author on the paper.J o u r n a l P r e -p r o o fTables S1 to S6 -Presentation of all data in detail.", [["S6", "PROTEIN", 83, 85]]], ["In these Tables all alterations of SARS-CoV-2 RNA/DNA reverse transcript nucleotide sequences in comparison to the Wuhan sequence have been compiled.", [["SARS", "DISEASE", 35, 39], ["nucleotide", "CHEMICAL", 73, 83], ["nucleotide", "CHEMICAL", 73, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 35, 45], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["SARS-CoV-2 RNA", "RNA", 35, 49], ["DNA reverse transcript nucleotide sequences", "DNA", 50, 93], ["Wuhan sequence", "DNA", 115, 129], ["SARS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["RNA/DNA reverse transcript nucleotide sequences", "TREATMENT", 46, 93], ["the Wuhan sequence", "TEST", 111, 129]]], ["Sequence positions between 1 to 29,903, nucleotide alteration, and frequency of mutations in individual positions were listed.", [["nucleotide", "CHEMICAL", 40, 50], ["Sequence positions", "TEST", 0, 18], ["nucleotide alteration", "PROBLEM", 40, 61], ["mutations", "PROBLEM", 80, 89]]]]}